WorldWideScience

Sample records for 125i permanent implant

  1. Three-dimensional verification of 125I seed stability after permanent implantation in the parotid gland and periparotid region

    International Nuclear Information System (INIS)

    To evaluate seed stability after permanent implantation in the parotid gland and periparotid region via a three-dimensional reconstruction of CT data. Fifteen patients treated from June 2008 to June 2012 at Peking University School and Hospital of Stomatology for parotid gland tumors with postoperative adjunctive 125I interstitial brachytherapy were retrospectively reviewed in this study. Serial CT data were obtained during follow-up. Mimics and Geomagic Studio software were used for seed reconstruction and stability analysis, respectively. Seed loss and/or migration outside of the treated area were absent in all patients during follow-up (23–71 months). Total seed cluster volume was maximized on day 1 post-implantation due to edema and decreased significantly by an average of 13.5 % (SD = 9.80 %; 95 % CI, 6.82–17.68 %) during the first two months and an average of 4.5 % (SD = 3.60 %; 95 % CI, 2.29–6.29 %) during the next four months. Volume stabilized over the subsequent six months. 125I seed number and location were stable with a general volumetric shrinkage tendency in the parotid gland and periparotid region. Three-dimensional seed reconstruction of CT images is feasible for visualization and verification of implanted seeds in parotid brachytherapy

  2. Nursing care for elderly lung cancer patients treated with CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil

    International Nuclear Information System (INIS)

    Objective: To investigate the specific measures and effect of the nursing care for elderly lung cancer patients who were receiving the treatment of CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil. Methods: Active care, including adequate preoperative preparation, proper support during operation and postoperative nursing,was carried out for fifty-three elderly patients with lung cancer during their treatment course of CT-guided permanent interstitial brachytherapy with co-implantation of 125I seeds and slow-released fluorouracil. Results: In order to ensure accurate puncture and the smooth particle implantation, the possible conditions which might happen after the procedure were informed to the patients before the surgery and useful advice was given to patients to guide their daily activities. All 53 patients showed no obvious fear before surgery and made good cooperation during the procedure, moreover, they well responded to the therapy and recovered pretty soon. Conclusion: CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil is a safe, minimally-invasive and newly-developed technique with reliable effect, which is especially suitable for aged patients. Active and adequate nursing care is essential during the whole therapeutic course. (authors)

  3. Implant quality and acute urinary toxicity with 125I permanent seed implantation for clinically localized prostate cancer. Results of the first 30 patients treated at PMCC

    International Nuclear Information System (INIS)

    It is widely recognized that a steep learning curve exists for departments initiating a prostate low-dose radiation (LDR) implant service. Appropriate team credentialing, willingness to accept mentoring and attention toward ongoing QA initiatives are required to ensure that both clinical and dosimetric endpoints consistently achieve standards deemed appropriate. The department of urological services began a prostate seed service in 4/2002. All participating staff were suitably trained in Seattle, Washington with unit protocols based on standard trans-rectal sonographic pre-planning, modified peripheral loading, prescription dose 145Gy and 4 week CT based post implant dosimetry. Patient eligibility paralleled federal medicare guidelines with men presenting with favorable risk disease, gland volumes 15ml/sec) considered potential candidates. a) Presenting Demographics: (n=30) Median age 62 (41-73), T stage 1c:2a:2b:2c = 18:10:1:1, Median PSA 6.3ng/ ml (5.1ng/ml - 11.1ng/ml), Median IPSS 5 (0-12), Mean Qmax 18ml/s (10ml/s -35ml/s).; b) Acute toxicity: No significant peri-procedural complications. One patient developed urinary retention day 3 and was successfully trialed day 10. All patients experienced some degree of sub-acute urinary irritation although three patients followed for at least 12 months have returned to their baseline level of functioning. c) Post implant Dosimetry: Median D90 139Gy (104Gy - 190Gy). 3 Patients received a D90 < 90% with one at 104Gy receiving additional 'top-up' external beam radiation (20Gy). A definable improvement in implant quality was observed over the 12 month study interval. Although acute toxicity was considered acceptable, patients do experience a sub-acute period of low grade albeit persistent urinary irritation and need to be cautioned appropriately. A high level of implant quality was achieved in the majority of patients. Despite 5 years HDR brachytherapy experience, considerable refinement in technique and approach was

  4. Customized planning for radioactive 125I seed implantation

    International Nuclear Information System (INIS)

    Objective: To customize the optimal plans for radioactive 125I seeds volumetric implants in selected regular target volumes. Methods: 125I seeds were symmetrically and uniformly implanted into 3 spherical targets with the diameters of 1, 2 and 3 cm and 7 ellipsoidal targets with the 3 dimensions of 1 cm×1 cm×2 cm, 1 cm×1 cm×3 cm, 1 cm×2 cm×2 cm, 1 cm×2 cm×3 cm, 1 cm ×3 cm ×3 cm, 2 cm×2 cm×3 cm and 2 cm×3 cm×3 cm. The activity and inter-space of seeds were adjusted to obtain the conformal and uniform dose distribution, with the prescribed D90 (the dose delivered to 90% of the targets) greater than 145 Gy. The inter-space of seeds was changed from 1 cm to 0.75 cm, to improve the conformity and uniformity of dose distribution. Plan quality was assessed using homogeneity index (HI), external index (EI) and conformal index (CI). The activity and number of seeds implanted were also recorded and compared. Results: For the spherical target with the diameter of 1 cm, when seeds were implanted with the inter-space of 1 cm and 0.75 cm, the HI were 40.0% and 55.9%, the EI were 98.3% and 95.1%, the CI were 0.44 and 0.44, respectively. For the spherical target with the diameter of 3 cm and the target with the 3 dimensions of 1 cm × 2 cm × 2 cm, the implant with the inter-space of 1 cm provided better indices of HI, EI and CI than those with the inter-space of 0.75 cm. For the other targets, the implants with the inter-space of 0.75 cm provided better indices of EI and CI than those with the inter-space of 1 cm, although they displayed a little worse homogeneity in terms of HI. The activity per seed was 17.0-27.8 MBq and 30.0-58.8 MBq in the implants with the inter-spaces of 0.75 cm and 1 cm, respectively. 2-10 more seeds were needed in the implants with the inter-space of 0.75 cm. Conclusions: For the studied targets except the spherical targets with the diameter of 1 cm and 3 cm and the ellipsoidal target with the dimension of 1 cm × 2 cm × 2 cm, 125I seeds

  5. Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer

    International Nuclear Information System (INIS)

    Lung cancer is the most common primary malignant tumor. Because most sufferers have already been in later stage in their first diagnosis, the lump body infringing upon the important organs often influences the excision of tumor. 125I seeds permanent implantation is a new method for tumor brachytherapy, which contributes to kill the tumor completely, ensures the normal physiological functions of organs,reduces tissue injuries and treatment of complications, and raises the survival rate of sufferers. The rapid promotion of this technique is also followed by radiation risks in the treatment. Currently, the researches of 125I seeds implantation is limited to the aspects of treatment means and effects, with no detailed study in intraoperative usage, disinfection and protection. Although a satisfactory curative effect is the key in the treatment,the studies in protection principles, means and technological upgradation are also too important to be ignored. (authors)

  6. Clinical efficacy of CT-guided 125I seed implantation therapy for advanced pancreatic cancer

    International Nuclear Information System (INIS)

    Objective: To discuss the clinical efficacy of CT-guided radioactive 125I seed implantation treatment for unresectable pancreatic cancer. Methods: Forty patients with inoperable pancreatic cancer were enrolled in this study, including 25 males and 15 females with an median age of 69 years (38-89 years). Treatment planning system (TPS) was used to reconstruct 3-dimensional images of pancreatic tumor and to define the quantity and distribution of 125I seeds. The radioactivity of 125I seeds was 0.5 - 0.8 mCi / seed. The seeds were implanted into pancreatic tumor under CT guidance at intervals of 1 cm and were kept away from vessels, pancreatic duct and other adjacent important organs. The tumor matched peripheral dose (MPD) was 60-140 Gy. The median amount of implanted 125I seeds was 36 (18-68) in number. CT scan was performed immediately after the procedure to check the quality of the seeds. In addition, 10 patients received concurrent chemotherapy with arterial infusion of gemcitabin and 5-fluororacil (5-Fu) for 3 to 4 therapeutic courses. Results: The median diameter of the tumors was 4.9 cm. The follow-up period was 2 to 28 months. After the treatment the refractory pain was significantly relieved (P 125I seed implantation is a safe, effective and minimally-invasive brachytherapy for unresectable pancreatic cancer with reliable short-term efficacy. It has an excellent anti-pain effect. The curative results can be further improved when chemotherapy is employed together. However, its long-term efficacy needs to be observed. (authors)

  7. CT-guided 125I Radioactive Seed Implantation on Regional Lymph Node Metastasis after Gastrectomy

    Institute of Scientific and Technical Information of China (English)

    Shi Liangrong; Wu Jun; Jiang Jingting; Wu Changping

    2013-01-01

    Objective:To evaluate the safety and short-term effect of CT-guided 125I radioactive seed implantation on regional lymph node metastasis after gastrectomy. Methods:Twenty-three patients with regional lymph node metastasis after gastrectomy received CT-guided 125I radioactive seed implantation from June, 2007 to July, 2011 in our hospital. The overall activity and amount of radioactive seeds were calculated by simulating source distribution of radioactive seed implantation plan system before operation. 125I seeds were implanted under the guidance of CT. Effective rate was evaluated according to RECIST criterion, 1, 2 and 3 years of survival rates were calculated by life table method, the effect of relative factors on survival was tested by univariate COX model, and the survival differences between subgroups were compared to draw survival curve by log-rank method. Additionally, systemic therapies were given to 20 patients based on lfuorouracil drugs. Results:No severe complications was observed in all study subjects with 14 complete remission (60.9%), 5 particle remission (21.7%) and 4 progressive diseases (17.4%), while 1, 2 and 3 years of survival rates as well as median survival time being (87±7)%,(47±11)%, (13±9)% and (22.1±5.1) months, respectively. Univariate COX analysis showed that the maximum diameter of tumor could badly inlfuence the prognosis (χ2=9.752, P=0.002), and the subgroups analysis relieved the signiifcant difference (χ2=5.828, P=0.016, log-rank test) with 3 cm being the cut-off value. Conclusion:CT-guided 125I radioactive seed implantation has high local control rate with small trauma and slight complications.

  8. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    Directory of Open Access Journals (Sweden)

    Mazeron Renaud

    2012-03-01

    Full Text Available Abstract Purpose To evaluate predictive factors for PSA bounce after 125I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. Materials and methods Men treated with exclusive permanent 125I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF was defined using the criteria of the Phoenix conference: nadir +2 ng/ml. Results 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50. Bounce amplitude was 0.6 ng/ml (0.2-5.1, and duration was 13.6 months (4.0-44.9. In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007. In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p Conclusion High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF.

  9. CT guided radioactive seed 125I implantation in treating hilar hepatic tumor and metastatic lymph nodes

    International Nuclear Information System (INIS)

    Objective: To investigate the clinical value of CT guided radioactive seed 125I implantation in treating hilar hepatic tumor and metastatic lymph nodes. Methods: 32 patients with pancreatic cancer accepted CT guided radioactive seeds 125I implantation were enrolled in this study. The average tumor dimension was 4.2 cm. In this series, there were 8 cases of hepatocellular carcinoma, 12 cases of hilar cholangio carcinoma, 6 cases of hepatic metastasis and 6 of hepatic hilar tumor and metastatic lymph nodes. Among these patients, 14 cases had cholangiectasis and 22 cases had cirrhosis. Under CT guidance, 125I seeds of 0.6-0.9 mCi were implanted into the pancreatic cancer at a distance of 1.0-1.5 cm according to TPS. Results: Two cases died on account of metastasis and three died through liver function failure. Among CT followed-up of 32 patients in 2 months, 2 obtained CR, 20 obtained PR, 5 NC and 5 PD. The responsive rate was 68.8%. The side effects occurred during the procedure including pneumothorax in 1 case with lung compression less than 30%; 7 seeds migration in liver and 3 seeds in lung. WBC decreased slightly in 1 cases during 2 months follow up. No massive bleeding, biliary fistula, intestinal fistula, intestinal hemorrhage, acute pancreatitis, enterorrhagia and intra-abdominal abscess were encountered. Conclusions: CT guided radioactive seed 125I implantation procedure is a safe and effective method in treating hilar hepatic tumor and metastatic lymph nodes with good clinical effects of minimal damage and few complications. (authors)

  10. 125I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents

    International Nuclear Information System (INIS)

    Background and purpose: There is a lack of optimal treatment strategies for managing salivary gland cancers in children and adolescents. This study is aimed at assessing the effect of 125I seed implantation for the treatment of parotid cancers in children and adolescents. Patients and methods: A total of 12 patients younger than 16 years with parotid gland malignant tumors underwent 125I seed implant brachytherapy between October 2003 and November 2008. All patients were assessed after treatment and at the local tumor control appointments. Facial nerve function, maxillofacial development, and radioactive side-effects were assessed. Results: The follow-up period ranged from 41-104 months. One patient with T4b died of pulmonary metastasis. The other patients were alive during the follow-up period. There were no serious radiation-related complications. The treatment did not affect facial nerve function and dentofacial growth in any of the children. Conclusion: For parotid gland cancers in children, 125I seed implant brachytherapy may be an acceptable treatment without serious complications and with satisfactory short-term effects. (orig.)

  11. Pathological impairments induced by interstitial implantation of 125I Seeds in spinal canal of banna mini-pigs

    Directory of Open Access Journals (Sweden)

    Yang Zuozhang

    2012-03-01

    Full Text Available Abstract Background Use a banna mini-pig to set up 125I implantation model, and investigate the consequence of radiation-related impairments. Methods In present study, 125I seeds were implanted into spinal canal of T13 level of spine in banna mini-pigs. After operation, the pigs were raised up to 8 months, behavior changes were recorded within this period. After 8 months, spinal cords were collected for pathological analysis. Results In this study, a 125I brachytherapy animal model had been successfully established, in the model group, the banna pigs' Tarlov scale decreased from 5 to 2.57 ± 0.36, significant cellular impairments were noted by pathological analysis. Conclusions Without any protection and operation improvement, 125I implantation can cause serious histological impairments and moving difficulty for banna mini-pigs; this present research provides an alternative tool to study spinal 125I brachytherapy.

  12. Linear 125I seeds strand implantation combined with biliary stenting for the treatment of malignant biliary obstruction

    International Nuclear Information System (INIS)

    Objective: To evaluate the therapeutic efficacy of linear 125I seeds strand implantation combined with biliary stenting in treating malignant biliary obstruction. Methods: Linear 125I seeds strand implantation combined with biliary stenting was carried out in 28 patients with malignant biliary obstruction. The technical success rate, the clinical efficacy, the postoperative complications and the survival rate were analyzed. Results: Both biliary stenting and 125I seeds strand implantation were successfully accomplished in all patients. No serious complications occurred. After the procedure the biliary obstruction symptoms were markedly improved and the bilirubin level was significantly reduced (P125I seeds strand implantation together with biliary stenting is safe and effective although its long-term efficacy needs to be further studied. (authors)

  13. The clinical application of TACE together with RFA and 125I seed implantation in treating hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Objective: to assess the clinical value of the combined treatment of transcatheter arterial chemoembolization (TACE), CT-guided radiofrequency ablation (RFA) and radioactive 125I seed implantation for hepatocellular carcinoma (HCC). Methods: During the period from March 2008 to Dec. 2010, 15 patients with HCC were admitted to the hospital. A total of 25 hepatic lesions were detected with the size of 1-8 cm. TACE was carried out first, which was followed by CT-guided RFA and radioactive 125I seed implantation. With the help of treat plan system (TPS), the radioactive 125I seed implantation was conducted to make additional management for the same lesion when RFA was finished, or the radioactive 125I seeds were directly implanted into the areas where RFA could not reach. The radioactive dose was 60-100 Gy. All the patients were followed up and were kept under observation for the signs of related complications. The therapeutic results were evaluated. Results: The combined treatment was successfully accomplished in all patients. All patients were followed up for 3-28 months (mean of 10.6 months). The complete necrosis rate of the tumor was 96%. No serious complications occurred except the immigration of 125I seeds in 1 case. Conclusion: The combined treatment of TACE and CT-guided RFA together with 125I seed implantation is a safe, reliable and effective therapy for HCC with excellent short-term result. (authors)

  14. Clinical application of CT-guided 125I seed interstitial implantation for local recurrent rectal carcinoma

    International Nuclear Information System (INIS)

    The present study aimed to explore the safety profile and clinical efficacy of CT-guided radioactive seed implantation in treating local recurrent rectal carcinoma. CT-guided 125I seed implantation was carried out in 20 patients with locally recurrent rectal carcinoma. 14 of the 20 patient had prior adjuvant external-beam radiation therapy (EBRT). The treatment planning system (TPS) was used preoperatively to reconstruct three dimensional images of the tumor and to calculate the estimated seed number and distribution. The median matched peripheral dose (MPD) was 120 Gy (range, 100-160 Gy). Of the 20 patients, 12 were male, 8 were female, and ages ranged from 38 to 78, with a median age of 62. Duration of follow-up was 3-34 months. The response rate of pain relief was 85% (17/20). Repeat CT scan 2 months following the procedure revealed complete response (CR) of the tumor in 2 patients, partial response (PR) in 13 patients, stable disease (SD) in 3 patients, and progressive disease (PD) in 2 patients. 75% of patients had either CR or PR. Median survival time was 18.8 months (95% CI: 3.5-22.4 months). 1 and 2 year survival rates were 75% and 25%, respectively. 4 patients died of recurrent tumor; 4 patients died of distant metastases; 9 patients died of recurrent tumor and distant metastases. 3 patients survived after 2 year follow up. Two patients were found to have mild hematochezia, which was reversible with symptomatic management. CT-guided 125I seed implantation appeared to be a safe, useful and less complicated interventional treatment option for local recurrent rectal carcinoma

  15. Treatment of Central Type Lung Cancer by CT Guided Percutaneous Implants of 125I Radioisotopes

    Institute of Scientific and Technical Information of China (English)

    Xiaokun Hu; Mingyou Wang; Zhiguo Yang; Chundong Qiu; Dongfang Lü; Xiaodong Li; Taiyang Zuo

    2005-01-01

    OBJECTIVE To discuss the method, safety and effectiveness of the treatment for central-type carcinoma of the lungs by CT guided percutaneous implants of 125I radioisotopes in tissues.METHODS Twenty-two cases of central-type lung cancer located by plain and /or enhanced CT scans were retrospectively analyzed, among which 18cases were verified pathologically using a CT guided percutaneous puncture and biopsy before treatment. The CT guided treatment was conducted immediately after the pathological results were obtained. The number of the radioisotopes used was seven to 16. The intensities of radioactivity for 125I radioisotopes were 22, 26, 30 and 33 MBq per particle.The total intensity of radioactivity was 181 to 355 MBq. The puncture point was only one. The frequency for adjustment of needling direction was two to five times. The punctures were conducted through the anterior chest wall in eight cases, through the lateral chest wall in eight cases and thruogh the posterior chest wall in six cases. Six of the 22 cases were given intravenous chemotherapy.RESULTS Of the 22 cases, 20 were followed-up for more than one month, 16over two months, ten over three months and three cases for six months. In the 20 cases which were followed-up for one month, the diameters of the tumors were reduced by 50% or more in 18 cases, showed no change in two cases with none showing enlargement. In the 16 cases followed-up for more than two months, the diameters of tumors were reduced by 50% or more in 15cases, one case showed no change and none enlarged. In the ten cases with three months of follow-up, the tumor diameters were diminished by 50%or more in eight cases, showed no change in one case and enlarged in one case. In the three cases followed-up for six months, the diameters of tumors were reduced by 50% or more in all the cases. Of the 22 cases, atelectasis occurred in 12 before therapy. The lungs expanded again in nine cases in the follow-up after treatment. Symptoms after

  16. Nursing care for patients with local recurrent rectal cancer after CT-guided 125I seed implantation therapy

    International Nuclear Information System (INIS)

    Objective: To discuss the nursing care strategy for patients with local recurrent rectal cancer who has been treated with CT-guided 125I seed implantation therapy. Methods: Twenty patients with local recurrent rectal cancer received a series of nursing interventions, including comfort care and pain care. The clinical results were observed and analyzed. Results: The therapy was smoothly accomplished in all patients. The pain was remarkably relived and the anxiety was alleviated. No displacement of implanted 125I seed occurred. Conclusion: For patients with local recurrent rectal cancer occurred after CT-guided 125I seed implantation therapy, careful nursing can effectively relieve the pain and anxiety feeling,and the living quality can also be markedly improved. (authors)

  17. Implantation of 125I seeds for the treatment of non-small cell lung cancer: evaluation of short-term effect

    International Nuclear Information System (INIS)

    Objective: To assess the short-term effect, feasibility and safety of 125I seeds implantation in treating non-small cell lung cancer. Methods: During the period from June 2010 to December 2012 a total of 353 patients with lung cancer were admitted to authors' hospital, of whom 56 met the study standards. The 56 cases were divided into study group (n=24) and control group (n=32). Bronchial artery chemotherapy with subsequent 125I seeds implantation was carried out in the patients of study group, while only bronchial artery chemotherapy was performed in the patients of control group. The median survival time was compared between the two groups. Results: The median survival time of the study group and the control group was (22.8±1.9) months and (14.2±1.3) months respectively. The median survival time of the study group was significantly higher than that of the control group (P=0.006). Conclusion: Compared with simple bronchial artery chemotherapy, permanent implantation of 125I seeds combined with bronchial artery chemotherapy can significantly improve the quality of life and prolong the survival time as well. Therefore, this technique is an effective therapy for advanced lung cancer and should be recommended in clinical practice. (authors)

  18. Study on Treating Glioblastoma with 125I Seed Implantation during Operations

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    OBJECTIVE To evaluate the therapeutic efficacy of treating glioblastoma with interstitial irradiation using radioactive seeds.METHODS First, the tumor was removed as completely as possible under an operating microscope. Then 125I seeds which had been selected were implanted in the tumor bed followed by routine radiotherapy after the operation. The time of progression (TTP) and overall survival (OS) of the patients were recorded, and statistically compared with patients who had received only surgery and radiotherapy for glioblastoma during the same period.RESULTS Nineteen patients, who were diagnosed with glioblastoma for the first time, with a mean age of 51.2 years, were involved in this study.Radioactive seeds (8~20) were implanted into the tumor bed after tumorectomy with a mean surrounding therapeutic dose of 31.6 Gy, followed by an external irradiation dose of 42~54 Gy. The average TTP in the group with implanted seeds was 42.1±2.4 w (95% confidence interval, 37.2~46.5 w), and 27.1±2.7 w (95% confidence interval, 24.3~31.8 w) in the control group. The average OS was 66.3±3.2 w (95% confidence interval, 61.9~70.4 w) and 47.7±2.6 w (95% confidence interval, 44.4~50.5 w), respectively. Statistical analysis showed there was a significant difference between two groups.CONCLUSION The survival time of patients with glioblastoma can be prolonged through radioactive seed implantation at the time of operation.This therapeutic method can rapidly reduce the tumor volume with a minimum number of seeds to avoid excessive radiation exposure. Because of some shortcomings of this study, such as a small number of patients, and because implantation was performed under the naked eye so that the seed alignment could not be verified accurately, the experience of combining implantation of seeds with external irradiation needs to be investigated further.

  19. Radiation protective nursing intervene of 125I seed implantation in non-small cell lung carcinoma guided by CT

    International Nuclear Information System (INIS)

    Objective: To research radiation protective nursing intervene and important notice of 125I seeds minimally invasive implantation in non-small cell lung carcinoma (NSCLC) by CT. Methods: Under the system of therapy planning system (TPS) and posologic validation, 125I seeds were implanted in 89 cases of NSCLC patients. The consistent radiation protective nursing intervene was used in perioperative period management. The operative successful rate, therapeutic effect and complication rate, therapeutic effect and complication rate was observed. Results: The scientific radiation protective nursing intervene can ensure that the radioactive dose distribution of 125I seed implantation brachytherapy is consistent with the principles of effective and minimally invasive. The operative successful rate was 100%. The local control rate and 1 year survival rate respectively was 97.4% and 92.2%. But the early and later incidence rate of radioactive damaging effect was 14.6% and 1.1% respectively. Leakage of radioactive contamination has not occurred. Conclusion: The consistent TPS and posologic validation 125I seeds implantation integrated scientific radiation protective nursing intervene. It is very important to improve the therapeutic effect of NSCLC and reduce the incidence of complications. (authors)

  20. Treatment of Metastatic Spinal Tumors by Percutaneous Vertebroplasty versus Percutaneous Vertebroplasty Combined with Interstitial Implantation of 125I Seeds

    Energy Technology Data Exchange (ETDEWEB)

    Zuozhang Yang; Lin Xie; Yunchao Huang; Hongpu Sun; Pengjie Liu; Zhongxiong Wu (Dept. of Orthopedics, Tumor Hospital of Yunnan Province, Third Affiliated Hospital of Kunming Medical College, Kunming, Yunnan (China)). e-mail. yangzuozhang@163.com; Dakuan Yang (Second Affiliated Hospital of Kunming Medical College, Kunming Yunnan (China)); Yuqing Sun (Dept. of Orthopedic Oncology, Beijing Jishuitan Hospital, Beijing (China))

    2009-12-15

    Background: As the most frequent bone metastasis, spinal metastases cause severe pain and damage to vertebral bodies such as spinal osteolytic destruction and compression fractures. To avoid the trauma and complications of open surgery, a minimally invasive procedure, percutaneous vertebroplasty (PVP), has recently been developed to treat metastatic spinal tumors. Purpose: To analyze the treatment outcomes of metastatic spinal tumors by percutaneous vertebroplasty (PVP) alone or PVP combined with interstitial implantation of 125I seeds. Material and Methods: 80 patients with metastatic spinal tumors were randomized to receive PVP alone (40 cases) or PVP combined with 125I seed implantation (40 cases). Digital subtraction angiography (DSA)-guided vertebroplasty was performed under local anesthesia, and acrylic bone cement was injected into the vertebra through a bone trocar to the center of the lesion, with or without simultaneous interstitial implantation of 125I seeds. Results: At 6-month follow-up, PVP combined with 125I seed implantation resulted in zero cases with complete relief (CR), 36 with partial relief (PR), four with no changes (NC), and zero with progression of disease (PD), while PVP alone without seed implantation resulted in 0 CR, 31 PR, 7 NC, and 2 PD. While the combined-treatment group and the single-PVP group showed overall clinical benefit rates without significant difference (100% and 95.0%, respectively), their visual analogue pain scales (VAS; 2.26+-1.05 and 5.41+-0.94, respectively) and Karnofsky performance scores (KPS; 92.5+-7.1 and 87.7+-7.3, respectively) were significantly different after treatment (P = 0.028 and P = 0.009, respectively). Patients in both groups had 1-year follow-up, and the mean time to tumor progression (TTP) was 9.0 and 8.9 months, respectively (not significant). Conclusion: PVP is a minimally invasive procedure with small wounds and minor complications. It is effective in the alleviation of pain in metastatic spinal

  1. A dosimetric research on radioactive 125I seed plane implantation%125I 放射性粒子单平面布源剂量学研究

    Institute of Scientific and Technical Information of China (English)

    唐富龙; 任菊娜; 吴娟; 张宏涛; 高贞; 于慧敏; 王娟

    2014-01-01

    Objective To explore the dosimetric effects of the same number and activity of radioactive 125I seeds in different plane arrangements. Methods Simulated 9 distribution modes using 9 125I seeds were designed by three- dimensional treatment planning system (3D- TPS), and the isodose curves of 60 Gy, 80Gy, 130 Gy, 145 Gy and 200 Gy were obtained. The areas enclosed by the isodose curves, the longer and shorter radius of these isodose curves and the medical cost per unit area were calculated with the professional image analysis software. Results Obvious differences in areas enclosed by the isodose curves, the longer and shorter radius of these isodose curves and the medical cost per unit area existed between each other among the nine different distribution modes of 9 125I seeds. The distribution modes that had the maximum areas enclosed by 60 Gy, 80 Gy, 130 Gy, 145 Gy and 200 Gy isodose curves were x1.5y1.5, x1y1.5, x1y1, x1y1 and x0.5y1, respectively, with the corresponding areas of 1 583.86 mm2, 1 146.03 mm2, 768.30 mm2, 621.85 mm2 and 480.97 mm2, respectively. Conclusion The peripheral dose and the therapeutic efficacy are significantly influenced by the arrangement of 125I seeds when the same number and activity of the seeds are used. The dose distributions are more homogeneous when the maximum areas enclosed by the isodose curves are obtained.%目的:探讨同数量、同活度125I 粒子单平面不同排列的剂量分布及其效应。方法利用计算机三维治疗计划系统(3D- TPS)模拟9颗2.59×107 Bq 125I 粒子的9种排列方式,得出60 Gy、80 Gy、130 Gy、145 Gy 和200 Gy 等剂量分布曲线并计算曲线包含的面积、长径、短径及单位面积的医疗费用。结果粒子排列方式不同时相同等剂量曲线包含的面积、长径、短径和单位面积的医疗费用存在差异。60 Gy、80 Gy、130 Gy、145 Gy 和200 Gy 等剂量曲线内面积最大的粒子排列方式分别为:x1.5y1.5、x1y1.5、x1y1

  2. CT-guided radioactive 125I-seed implantation for the treatment of pancreatic carcinoma: a clinical observation of 19 cases

    International Nuclear Information System (INIS)

    Objective: To explore the dynamic changes of serum tumor markers after CT-guided radioactive 125I-seed implantation treatment in patients with pancreatic carcinoma and to assess the therapeutic effectiveness of 125I-seed implantation. Methods: CT-guided radioactive 125I-seed implantation was performed in 19 patients with unresectable advanced pancreatic cancer. Treatment planning system was used to reconstruct 3-dimentional images of the tumor, and the quantity and distribution of 125I-seeds to be implanted were thus determined. Under CT guidance 125I-seeds were embedded into pancreatic cancer. Before and after the 125I-seed implantation the levels of serum tumor markers, including CEA, CA19-9 and CA50, were determined by using radioimmunoassay method. The clinical effects were observed and the therapeutic results were statistically analyzed. Results: The pain stared to be relieved 2 to 5 days after implantation. The total effective rate (CR + PR) at one and three months after treatment was 68.42% (13 /19) and 63.16% (12 /19) respectively. One month after 125I-seed implantation, the levels of serum CEA, CA19-9 and CA50 were significantly different to that determined before implantation in all cases (P 125I-seed implantation is a safe and effective interventional treatment for advanced pancreatic cancer with reliable short-term result and remarkable pain-relieving effect. Moreover, this therapy can significantly lower the levels of many serum tumor markers, which play some suggestive roles in evaluating the clinical curativeness. (authors)

  3. Percutaneous transcatheter implantation of 125I iodine seeds for the treatment of liver cancer associated with portal vein tumor thrombus: initial experience in 19 cases

    International Nuclear Information System (INIS)

    Objective: To evaluate the feasibility and therapeutic efficacy of percutaneous transcatheter implantation of 125I iodine seeds in treating liver cancer associated with portal vein tumor thrombus. Methods: Nineteen patients with primary hepatocellular carcinoma complicated by portal vein tumor thrombus received implantation of 125I iodine seeds via portal vein. The puncturing of portal vein was guided by ultrasound. Under fluoroscopic guidance the 125I iodine seeds were implanted within the portal vein tumor thrombus at 8 mm distance. The number of 125I iodine seeds used in one procedure was 8 to 30 in total. The technical success rate, the postoperative complications, the hepatic and renal functions as well as routine blood test, and the suppression of portal vein tumor thrombus were determined, and the results were analyzed. Results: The implantation of 125I seeds was successfully accomplished in all the patients. No serious procedure-related complications occurred. During the follow-up period lasting for 3-22 months, the portal vein tumor thrombus showed a significant shrinkage in all patients. Conclusion: For the treatment of portal vein tumor thrombus, percutaneous transcatheter implantation of 125I iodine seeds is clinically feasible and effective. (authors)

  4. The clinical application of 125I seeds implantation together with bronchial arterial infusion chemotherapy for the treatment of advanced lung cancer

    International Nuclear Information System (INIS)

    Objective: To assess the clinical value of 125I seeds implantation combined with the bronchial arterial infusion chemotherapy in treating advanced lung cancer. Methods: 125I seeds implantation combined with the bronchial arterial infusion chemotherapy was performed in 30 patients with advanced lung cancer. About 3 -70 seeds of 125I (6711 type, 0.7 mCi / seed) were delivered in each patient. In all patients bronchial arterial infusion chemotherapy was carried out at the time of 7 days before the implantation and 30 and 60 days after the implantation. The results and complications were observed. The clinical data were retrospectively analyzed. The therapeutic efficacy was evaluated according to RECIST standards. Results: A total of 40 lesions were detected in all 30 patients and 125I seeds were successfully embedded in all lesions. No procedure-related complications occurred. All patients were followed up for 2 -24 months. The two-year survival rate was 86.6% (26 / 30). Therapeutic evaluation made at four months after the treatment showed that CR, PR, NC and PD was seen in 26, 10, 2 and 2 lesions respectively,with a total effective rate of 90%. Conclusion: 125I seeds implantation combined with the bronchial arterial infusion chemotherapy is a safe and effective therapy for advanced lung cancer with excellent clinical results. (authors)

  5. CT-guide coaxial 125I seeds implantation for the treatment of retroperitoneal lymph node metastasis: analysis of 21 cases

    International Nuclear Information System (INIS)

    Objective: To investigate the method, safety and clinical value of CT-guided coaxial percutaneous 125I seed implantation in treating retroperitoneal metastatic lymph nodes. Methods: CT-guided coaxial percutaneous 125II seed implantation, as interstitial brachytherapy, was carried out in 21 patients with retroperitoneal lymph node metastasis. Before operation therapeutic plan system (TPS) was used in all patients to design the distribution of radioactive particles, and after the procedure CT scanning was performed to verify the distribution of radioactive particles. After the treatment, the abdominal pain, abdominal distension, serum tumor marker levels and local reaction of the target lymph nodes were evaluated. Results: The technical success rate was 100%, and after the operation no serious complications such as gastrointestinal perforation, radiation enteritis, vascular injury, bleeding, etc. occurred. Follow-up CT scanning was conducted once every 1-2 months. Six months after the treatment, complete remission (CR) was obtained in 13 cases, partial remission (PR) in 6 cases, stable disease (SD) in 2 cases, and progression disease (PD) in none. The overall response (CR + PR) rate was 90.5%. The abdominal pain and abdominal distension were relieved in different degrees in 16 patients, and the serum tumor marker levels were decreased in different degrees in 14 patients. Conclusion: For the treatment of retroperitoneal lymph node metastasis, CT-guided coaxial percutaneous l25I seed implantation is effective, safe and reliable. This technique provides a new minimally-invasive treatment for retroperitoneal lymph node metastasis. (authors)

  6. 术中125I粒子植入治疗肿瘤的临床应用%The clinical application of 125I radionuclide implantation in tumor therapy

    Institute of Scientific and Technical Information of China (English)

    孙启和; 孙彬; 杨永青

    2010-01-01

    Objective To investigate the safety and clinical efficacy of permanent implantation of125I radioactive particle in the urgery of malignancies such as brain tumors,liver cancer,cholangiocarcinoma,lung cancer,prostate cancer and malignant teratoma.Methods Thirty eight patients proved by puncture biopsy,his-tology or cytology were retrospectively analyzed.Three-D images of the tumor were reconstructed using treat-ment planning system (TPS),the number and the dose rate distribution of 125I seeds were calculated.The matched eripheral dose of 125I seeds implantation was 60~120Gy,the number of 125I seeds implanted ranged from 6~40 per lesion,and the median amount of implanted 125I seeds were 23.Results Twelve months followup after the therapy showed 9 cases of complete relief,24 cases of partial relief and 5 cases of no change.The overall effective rate(complete relief+partial relief) of 12 months was 86.8%.Conclusion Permanent implantation of 125I radioactive particle in the surgery of malignancies treatment is a safe,effective treatment for tumors.%目的 探讨在手术中永久性植入125I粒子治疗脑瘤、肝癌、胆管癌、肺癌、直肠癌、前列腺癌及恶性畸胎瘤临床应用的安全性及疗效.方法 回顾性分析38例经穿刺活检、组织学或细胞学检查确诊的肿瘤患者,采用治疗计划系统(TPS)重建肿瘤的三维图像,计算出粒子植入的数量和剂量分布曲线,125I粒子治疗肿瘤处方剂量为60~120 Gy,每例植入粒子6~40颗,中位粒子数为23颗.结果 随访12个月,肿瘤完全缓解9例,部分缓解24例,无变化5例.12个月总有效率为86.8%.结论 术中植入125I粒子治疗肿瘤是一种安全、有效的方法.

  7. Effects of 125I-Labeled Peptide Nuclear Acid Targeting Ki67 on the Growth of Implanted Human Renal Cell Carcinoma in Nude Mice

    Institute of Scientific and Technical Information of China (English)

    JiacunChen; JunnianZheng; SongWu; HaibiaoLai; XiaoqingSun; JunjieLiu

    2004-01-01

    OBJECTIVE To investigate the potential of 125I-labeled anti-sense peptide nucleic acids (125I-AS-PNAs) to inhibit the expression of the Ki-67 gene and growth of implanted human renal carcinoma cells in nude mice.METHODS Anti-sense peptide nucleic acids (AS-PNAs) targeting the Ki67 gene were synthesized and labeled with 125I by the Chloraseptine-T method. Drugs including PNAs and 125I-AS-PNAs capsulated by cationic lipid were directly injected into tumors in nude mice. The Ki67 expression in tumors was detected by an immunohistochemical technique and Western blot. The apoptosis of tumor cells was detected by a TUNEL assay. Tumor volumes were measured every 3 days and tumor suppression rates were calculated at 12 days after treatment. Control groups were treated with AS-PNA, MMPNAs (mismatch PNAs) and 125I-Na.RESULTS The Ki67 expression rate of tumors treated by 125I-AS-PNAs [(15.3±1.8)%] was lower than that treated by AS-PNAs [(23.0±2.4)%] (P<0.01). The Ki67 protein production rate of tumors treated by 125I-AS-PNAs [(43.6±3.5)%] was lower than that treated by AS-PNAs [(59.7±2.3)%] (P<0.01 ). The apoptosis rate of tumors treated by 125I-AS-PNAs [(40.3±2.4)%] was higher than that treated by AS-PNAs [(31.1 ±2.0)%] (P<0.01). The volume of tumors treated by 125I-AS-PNAs [(330.4±57.8) mm3 ]was smallerthan that treated by AS- PNAs [(513.2±64.2 ) mm3] (P<0.01 ).CONCLUSION 125I-AS-PNAs targeted against the Ki67 gene have a greater inhibitory effect on the expression of the Ki67 gene and a larger apoptotic action on human renal carcinoma cells and can more efficiently inhibit tumor growth than AS-PNAs. 125I-AS-PNAs targeting the Ki67 gene may be a promising anti-sense/anti-gene radiotherapy method for treating renal cell carcinoma.

  8. Intra-operative dosimetry of trans-rectal ultrasound guided 125I prostate implants using C-arm fluoroscopic images

    Directory of Open Access Journals (Sweden)

    Ravindran Paul

    2006-01-01

    Full Text Available Permanent implantation of radioactive seeds is a viable and effective therapeutic option widely used today for early-stage prostate cancer. The implant technique has improved considerably during the recent years due to the use of image guidance; however, real-time dose distributions would allow potential cold spots to be assessed and additional seeds added. In this study, we investigate the use of a conventional C-arm fluoroscopy unit for image acquisition and evaluation of dose distribution immediately after the implant. The phantom study indicates that it is possible to obtain seed positions within ±2 mm. A pilot study carried out with three patients indicated that it is possible to obtain seed positions and calculate the dose distribution with C-arm fluoroscopy and about 95% of the seeds were reconstructed within ±2 mm. The results could be further improved with better digital imaging.

  9. CT-guided percutaneous vertebroplasty combined with 125I-seed implantation for metastatic vertebral carcinoma involving the spinal canal: analysis of 23 cases

    International Nuclear Information System (INIS)

    Objective: To evaluate the safety and efficacy of CT-guided percutaneous vertebroplasty (PVP) combined with 125I-seed implantation for the treatment of metastatic vertebral carcinoma involving the spinal canal. Methods: A total of 28 involved vertebrae were detected in 23 patients with metastatic vertebral carcinoma. Each patient had 1-2 diseased vertebrae. The lesions included cervical vertebra (n=4), thoracic vertebra (n=13) and lumbar vertebra (n=11). Destroyed posterior vertebral wall was seen in all involved vertebrae. Thirteen vertebrae found in 12 patients showed involvement of the epidural space. According to treatment planning system (TPS) CT-guided implantation of 125I seeds was carried out first for cervical lesions, which was followed by PVP. For the thoracic and lumbar lesions, unilateral or bilateral puncturing with several particle needles was employed to implant the 125I seeds, then, PVP with bone cement injection was performed. The complications and the clinical efficacy were analyzed. Results: Successful operation was obtained in all patients. The number of implanted 125I seeds ranged from 4 to 30 per vertebra, and the volume of injected bone cement was 1-6 ml per vertebra. After the operation the pain relief rate was 86.9% (n=20). The incidence of bone cement leakage was 17.8% (5/28). One patient had radicular pain caused by neuropore leakage, which was relieved after medication. No serious complications, such as spinal cord injury or radiation myelitis, occurred. Conclusion: CT-guided PVP combined with 125I-seed implantation is effective and safe for the treatment of metastatic vertebral carcinoma involving the spinal canal. This therapy can effectively relieve the pain and control the deterioration of tumor, besides, the incidence of bone cement leakage is very low. (authors)

  10. Preparation and deployment of indigenous 125I- seeds for the treatment of prostate cancer: dawn of prostate brachytherapy in India

    International Nuclear Information System (INIS)

    'Permanent seed implantation' using 125I- seeds represents an effective treatment modality for prostate cancer. An innovative strategy to prepare and deploy 125I- seeds for treatment of prostate cancer has been evolved. Seeds prepared by chemisorptions of 125I on palladium coated silver wires were characterized and encased in titanium tubes by ND:YAG laser. Several batches of critically evaluated seeds exhibiting release of 125I were supplied to P.D. Hinduja Hospital, Mumbai for treatment of prostate cancer patients. Successful deployment of indigenous seeds in prostate brachytherapy has opened a new window for making prostate brachytherapy affordable to needy cancer patients. (author)

  11. Methodology of quality control for brachytherapy {sup 125}I seeds

    Energy Technology Data Exchange (ETDEWEB)

    Moura, Eduardo S.; Zeituni, Carlos A.; Manzoli, Jose E.; Rostelato, Maria Elisa C.M. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)]. E-mail: esmoura@ipen.br

    2007-07-01

    This paper presents the methodology of quality control of {sup 125}I seeds used for brachytherapy. The {sup 125}I seeds are millimeter titanium capsules widely used in permanent implants of prostate cancer, allowing a high dose within the tumour and a low dose on the surrounding tissues, with very low harm to the other tissues. Besides, with this procedure, the patients have a low impotence rate and a small incidence of urinary incontinence. To meet the medical standards, an efficient quality control is necessary, showing values with the minimum uncertainness possible, concerning the seeds dimensions and their respective activities. The medical needles are used to insert the seeds inside the prostate. The needles used in brachytherapy have an internal diameter of 1.0 mm, so it is necessary {sup 125}I seeds with an external maximum diameter of 0.85 mm. For the seeds and the spacer positioning on the planning sheet, the seeds must have a length between 4.5 and 5.0 mm. The activities must not vary more than 5% in each batch of {sup 125}I seeds. For this methodology, we used two ionization chamber detectors and one caliper. In this paper, the methodology using one control batch with 75 seeds manufactured by GE Health care Ltd is presented. (author)

  12. Preparation and deployment of indigenous 125I-seeds for the treatment of prostate cancer. Dawn of prostate brachytherapy in India

    International Nuclear Information System (INIS)

    'Permanent seed implantation' using 125I- seeds has emerged as an effective treatment modality for management of prostate cancer. An indigenous technology for the production of 125I brachytherapy sources ('BARC 125I Ocu-Prosta seed') has been developed. In this current work, we describe an overview of our experience on large scale production of 125I brachytherapy sources, their quality assessment, in vivo bio-evaluation and initial experience on their journey from bench to bed-side for the treatment of prostate cancer. (author)

  13. 125I粒子植入治疗非小细胞肺癌的护理及辐射防护%Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer

    Institute of Scientific and Technical Information of China (English)

    刘莉; 杨景魁

    2012-01-01

    Lung cancer is the most common primary malignant tumor.Because most sufferers have already been in later stage in their first diagnosis,the lump body infringing upon the important organs often influences the excision of tumor.125I seeds permanent implantation is a new method for tumor brachytherapy,which contributes to kill the tumor completely,ensures the normal physiological functions of organs,reduces tissue injuries and treatment of complications,and raises the survival rate of sufferers.The rapid promotion of this technique is also followed by radiation risks in the treatment.Currently,the researches of 125I seeds implantation is limited to the aspects of treatment means and effects,with no detailed study in intraoperative usage,disinfection and protection.Although a satisfactory curative effect is the key in the treatment,the studies in protection principles,means and technological upgradation are also too important to be ignored.%肺癌是最常见的肺部原发性恶性肿瘤,由于多数患者就诊时已处于中晚期,瘤体侵犯重要脏器后常影响肿瘤的切除.125I粒子永久性组织间植入治疗是肿瘤近距离放疗的一种新兴方法,有助于肿瘤的整体杀灭,同时保证了脏器的正常生理功能,减少了组织创伤及治疗并发症,提高了患者的生存率.随着放射性粒子植入治疗技术的迅速推广,治疗过程中的辐射威胁也随之而至.目前,对125I粒子的研究局限于治疗手段和效果方面,尚未在术中使用、消毒及防护等方面进行详细研究.虽然能达到疗效是治疗的关键,但是防护的基本原则、具体方式和更新防护技术的研究也不容忽视,其研究结果势必对肿瘤的放射性粒子植入治疗有着重要意义.

  14. Permanent transvenous pacemaker implantation in forty dogs

    International Nuclear Information System (INIS)

    Permanent transvenous cardiac pacemakers were implanted in 40 dogs. Electrocardiographic diagnoses included persistent atrial standstill (3 dogs), sick sinus syndrome (8 dogs), and high-grade second-degree or third-degree atrioventricular (AV) block (29 dogs). Thirteen dogs were alive and well 4 to 42 months after pacemaker implantation (mean, 16.9 months). The mean and median survival times of the 26 dogs that died or were euthanatized during the study were 17.9 months and 13 months, respectively. Most of these dogs succumbed to problems unrelated to the arrhythmia and pacemaker implant. One dog was lost to follow-up. Complications associated with permanent transvenous pacemaker implantation included lead dislodgement, infection, hematoma formation, skeletal muscle stimulation, ventricular arrhythmia, migration of the pulse generator, and skin erosion. Lead dislodgement was the most common complication, occurring in 7 of 9 dogs paced using untined electrode leads and in 6 of 30 dogs paced using tined leads. Lead dislodgement did not occur in the only dog paced using an actively fixed endocardial lead. It was concluded that permanent transvenous cardiac pacing is a feasible, less traumatic alternative to epimyocardial pacing in dogs, but that successful use of this technique requires careful implantation technique and anticipation of the potential complications

  15. Occupational exposure of professionals during interstitial permanent prostate brachytherapy implants

    International Nuclear Information System (INIS)

    Full text of publication follows: Introduction: In this study we present dose measurements for professionals exposed during interstitial 125 I permanent prostate brachytherapy implants. Methods and Materials: The implant technique used was intra operative real time using strand and loose seeds. The professionals inside the operating room are an oncologist, a radiologist, a physicist, a nurse and an anesthesiologist. The oncologist and the physicist contact directly the loaded needle with radioactive seeds and two types of measurements were taken: total body and extremities (finger) dose. The rest of the team operates at long distances, but measurements were made. To measure total body equivalent dose we use a Berthold Umo LB 123 coupled with a LB 1236-H10 detector, and we recorded dose, time and distance from implant location. Finger dosemeters are thermo -luminescent dosimeter (TLD) rings that were controlled over one month. Results: 50 cases (average number of applications per year) were analysed for extremities measurements and 9 cases for total body measurements (in this case, the results were extrapolated for 50 cases), with an average of 26.1 mCi total activity per implant (in a range of 17.4 - 40.3 mCi). The finger dose was 1.8 mSv for the oncologist and 1.9 mSv for the physicist. The interpolation of total body equivalent dose for the oncologist was 24 mSv, for the radiologist 6 mSv and 9 mSv for the physicist. The rest of the team did not receive anything but background radiation. The annual national limit dose for workers is 20 mSv for total body irradiation, and 500 mSv for extremities. Conclusion: In conclusion we may say that during interstitial permanent prostate brachytherapy implants, total doses received for all groups are not significant when compared to annual limits for Portuguese laws 1. Even so, our main goal is always to get the less possible dose (ALARA principle). References: 1. Decreto Lei n. 180/2002 de 8 de Agosto. (authors)

  16. 应用125I粒子植入术治疗眼部肿瘤的临床观察%Clinical observation of 125I seed implantation for the treatment of ocular tumor

    Institute of Scientific and Technical Information of China (English)

    刘白雪; 张珂; 朱豫

    2016-01-01

    目的 观察125I粒子植入治疗眼部肿瘤的可行性、安全性及效果.方法 眼部肿瘤行直视下125I粒子植入术19例,并对其中3例可疑肿瘤扩散者行MRI或CT导航定位下125I粒子补种.19例粒子植入术均按术前计划完成.其中14例1次植入,3例行2次植入,1例行3次植入,1例4次植入.结果 术后观察2周~8年,平均(26.55±5.46)个月.19例中局部病变控制无复发者14例(73.68%);发现新病灶或病变扩散而经补种粒子病变控制者5例(26.32%).未出现病变转移者.19例中除3例(15.79%)眼睑轻度肿胀和少许皮下出血外,其余均未发生与植入手术操作相关的并发症.其他并发症有以下几种:125I粒子放置于眶前中部者1~3个月出现流泪、痒感、分泌物增多、结膜充血及上皮化,6个月后均自动消失;睫毛于1~3个月内可见脱落,4~6个月缓慢生长,6个月后恢复正常;1例粒子植入位置表浅,出现皮肤破溃及瘘管形成,抗炎对症治疗1周后恢复正常.植入泪腺区者:植入后发生干眼1例,6个月后恢复.植入眶中后部者:9个月术后出现组织纤维化、硬化,皮肤色素沉着.并发症均为可恢复性,眼前部并发症一般于术后6个月(3个半衰期)消失.结论 125I粒子植入治疗眼部肿瘤创伤小,疗效确切,并发症少,能最大限度保留视功能及外观,其可行性、安全性及疗效是肯定的.%Objective To observe the feasibiliy,safety and efficacy of 125 I seed implantation for the treatment of ocular tumor.Methods Nineteen patients received 125I seed implantation through intraoperative direct vision.In which 3 patients who had tumor spread received secondary 125I seed implantation through CT or MRI guiding.Nineteen patients received the operation successfully according to the preoperative plan.Fourteen cases were implanted 125I seed once,three cases received twice implantation,one case received implantation for three times,and one case received

  17. Oblate band in 125I

    International Nuclear Information System (INIS)

    The iodine isotopes belonging to the transitional region with Z ≥ 50 and N ≤ 82, have been the subject of extensive theoretical and experimental research as they exhibit various coexisting structures. The levels of 125I were studied via 123Sb (α, 2nγ) 125I fusion-evaporation reaction at 30-MeV beam energy

  18. Study of photon angular distribution from a new Best 2300 series 125I source for interstitial brachytherapy

    International Nuclear Information System (INIS)

    125I seeds employed for permanent and temporary interstitial implants exhibit significant radiation fluence anisotropy due to self absorption in the marker and oblique filtration through the encapsulation jacket. A silver wire 125I seed (Model 6711), introduced in 1983 by 3M Company, failed to improve the photon distribution anisotropy. In addition to the known 125I photon spectrum, the new seed emitted two silver characteristic x-rays, lowering the mean photon energy from 28.4 to 27.4 keV. A double wall uniform thickness encapsulated 125I source, laser welded at one end, has been developed for clinical use. The source uses a carbon coated thin tungsten filament for enhanced radiographic visualization. Measurements made by NaI and intrinsic Ge detectors indicate that the 2300 series 125I source emits a pure 125I spectrum. The angular dependence of individual photon peaks and total photon spectrum as well as the corresponding anisotropy factors were measured. The 4π averaged anisotropy factor for the total radiation fluence is 0.92 compared to 0.87 for model 6711 seed. The dose distribution around the new 125I source in water is very isotropic. (author). 11 refs., 8 figs., 2 tabs

  19. Permanent Breast Seed Implant Dosimetry Quality Assurance

    Energy Technology Data Exchange (ETDEWEB)

    Keller, Brian M., E-mail: Brian.Keller@sunnybrook.ca [Department of Medical Physics, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Ravi, Ananth [Department of Medical Physics, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Sankreacha, Raxa [Carlo Fidani Regional Cancer Center, Mississauga, ON (Canada); Pignol, Jean-Philippe [Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Center, Toronto, ON (Canada)

    2012-05-01

    Purpose: A permanent breast seed implant is a novel method of accelerated partial breast irradiation for women with early-stage breast cancer. This article presents pre- and post-implant dosimetric data, relates these data to clinical outcomes, and makes recommendations for those interested in starting a program. Methods and Materials: A total of 95 consecutive patients were accrued into one of three clinical trials after breast-conserving surgery: a Phase I/II trial (67 patients with infiltrating ductal carcinoma); a Phase II registry trial (25 patients with infiltrating ductal carcinoma); or a multi-center Phase II trial for patients with ductal carcinoma in situ (3 patients). Contouring of the planning target volume (PTV) was done on a Pinnacle workstation and dosimetry calculations, including dose-volume histograms, were done using a Variseed planning computer. Results: The mean pre-implant PTV coverage for the V{sub 90}, V{sub 100}, V{sub 150}, and V{sub 200} were as follows: 98.8% {+-} 1.2% (range, 94.5-100%); 97.3% {+-} 2.1% (range, 90.3-99.9%), 68.8% {+-} 14.3% (range, 32.7-91.5%); and 27.8% {+-} 8.6% (range, 15.1-62.3%). The effect of seed motion was characterized by post-implant dosimetry performed immediately after the implantation (same day) and at 2 months after the implantation. The mean V{sub 100} changed from 85.6% to 88.4% (p = 0.004) and the mean V{sub 200} changed from 36.2% to 48.3% (p < 0.001). Skin toxicity was associated with maximum skin dose (p = 0.014). Conclusions: Preplanning dosimetry should aim for a V{sub 90} of approximately 100%, a V{sub 100} between 95% and 100%, and a V{sub 200} between 20% and 30%, as these numbers are associated with no local recurrences to date and good patient tolerance. In general, the target volume coverage improved over the duration of the seed therapy. The maximum skin dose, defined as the average dose over the hottest 1 Multiplication-Sign 1-cm{sup 2} surface area, should be limited to 90% of the

  20. Permanent Breast Seed Implant Dosimetry Quality Assurance

    International Nuclear Information System (INIS)

    Purpose: A permanent breast seed implant is a novel method of accelerated partial breast irradiation for women with early-stage breast cancer. This article presents pre- and post-implant dosimetric data, relates these data to clinical outcomes, and makes recommendations for those interested in starting a program. Methods and Materials: A total of 95 consecutive patients were accrued into one of three clinical trials after breast-conserving surgery: a Phase I/II trial (67 patients with infiltrating ductal carcinoma); a Phase II registry trial (25 patients with infiltrating ductal carcinoma); or a multi-center Phase II trial for patients with ductal carcinoma in situ (3 patients). Contouring of the planning target volume (PTV) was done on a Pinnacle workstation and dosimetry calculations, including dose–volume histograms, were done using a Variseed planning computer. Results: The mean pre-implant PTV coverage for the V90, V100, V150, and V200 were as follows: 98.8% ± 1.2% (range, 94.5–100%); 97.3% ± 2.1% (range, 90.3–99.9%), 68.8% ± 14.3% (range, 32.7–91.5%); and 27.8% ± 8.6% (range, 15.1–62.3%). The effect of seed motion was characterized by post-implant dosimetry performed immediately after the implantation (same day) and at 2 months after the implantation. The mean V100 changed from 85.6% to 88.4% (p = 0.004) and the mean V200 changed from 36.2% to 48.3% (p 90 of approximately 100%, a V100 between 95% and 100%, and a V200 between 20% and 30%, as these numbers are associated with no local recurrences to date and good patient tolerance. In general, the target volume coverage improved over the duration of the seed therapy. The maximum skin dose, defined as the average dose over the hottest 1 × 1-cm2 surface area, should be limited to 90% of the prescription dose to minimize delayed skin toxicity.

  1. MR and CT image fusion for postimplant analysis in permanent prostate seed implants

    International Nuclear Information System (INIS)

    Purpose: To compare the outcome of two different image-based postimplant dosimetry methods in permanent seed implantation. Methods and materials: Between October 1999 and October 2002, 150 patients with low-risk prostate carcinoma were treated with 125I and 103Pd in our institution. A CT-MRI image fusion protocol was used in 21 consecutive patients treated with exclusive brachytherapy. The accuracy and reproducibility of the method was calculated, and then the CT-based dosimetry was compared with the CT-MRI-based dosimetry using the dose-volume histogram (DVH) related parameters recommended by the American Brachytherapy Society and the American Association of Physicists in Medicine. Results: Our method for CT-MRI image fusion was accurate and reproducible (median shift 100 = 82% vs. 88%, p 90 = 96% vs. 115%, p < 0.05. Those results depend on the institutional implant technique and reflect the importance of lowering inter- and intraobserver discrepancies when outlining prostate and organs at risk for postimplant dosimetry. Conclusions: Computed tomography-MRI fused images allow accurate determination of prostate size, significantly improving the dosimetric evaluation based on DVH analysis. This provides a consistent method to judge a prostate seed implant's quality

  2. Permanent and temporary pacemaker implantation after orthotopic heart transplantation

    Directory of Open Access Journals (Sweden)

    Bacal Fernando

    2000-01-01

    Full Text Available PURPOSE:To determine the indication for and incidence and evolution of temporary and permanent pacemaker implantation in cardiac transplant recipients. METHODS: A retrospective review of 114 patients who underwent orthotopic heart transplantation InCor (Heart Institute USP BR between March 1985 and May 1993. We studied the incidence of and indication for temporary pacing, the relationship between pacing and rejection, the need for pemanent pacing and the clinical follow-up. RESULTS: Fourteen of 114 (12%heart transplant recipients required temporary pacing and 4 of 114 (3.5% patients required permanent pacing. The indication for temporary pacing was sinus node dysfunction in 11 patients (78.5% and atrioventricular (AV block in 3 patients (21.4%. The indication for permanent pacemaker implantation was sinus node dysfunction in 3 patients (75% and atrioventricular (AV block in 1 patient (25%. We observed rejection in 3 patients (21.4% who required temporary pacing and in 2 patients (50% who required permanent pacing. The previous use of amiodarone was observed in 10 patients (71.4% with temporary pacing. Seven of the 14 patients (50% died during follow-up. CONCLUSION: Sinus node dysfunction was the principal indication for temporary and permanent pacemaker implantation in cardiac transplant recipients. The need for pacing was related to worse prognosis after cardiac transplantation.

  3. Nuclear lesions produced by 125I decay

    International Nuclear Information System (INIS)

    125I decay induced DNA damage was investigated in Chinese hamster ovary (CHO) cells which had incorporated 125I-iododeoxyuridine (125IUdR) into their DNA. 125I decays were accumulated in frozen cells. DNA strand breaks produced by low numbers (0--1,200 decays per cell) of 125I decays were assayed using the alkaline unwinding technique and the alkaline filter elution technique. Approximately 300 125I decays reduced the relative damage to 50%. DNA protein cross links were not detected after accumulation of 125I decay. The production of DNA double strand breaks by 125I decay was assayed by the neutral filter elution technique at pH 9.6 and 7.2 after accumulating 100--5,000 decays per cell. No alkali labile lesions were detected. Approximately 3,000 125I decays were required to reduce the mean value of the fractions to 50%. In all the assays, DNA damage induction data were fit to a straight line by regression analysis except at very low numbers of accumulated 125I decays where an initial drop in the fraction of DNA retained on the filter was observed. This drop suggests multiple chromatin fragmentation is produced by 125I decay

  4. 125I粒子植入对面神经超微结构影响的动物实验%Ultrastructural study on the facial nerve of rabbit after 125I seed implantation

    Institute of Scientific and Technical Information of China (English)

    左健; 宋铁砾; 鞠向群; 郑磊; 蔡志刚; 张建国

    2011-01-01

    目的 探讨 125I放射性粒子不同处方剂量近距离照射对家兔面神经超微结构的影响,旨为临床提供参考.方法 将大耳白兔54只随机分为3个实验组:40 Gy组、80 Gy组、120 Gy组,每组18只动物;每只动物自身对照,将 125I粒子植入一侧腮腺区面神经周围,另一侧作为对照植入粒子空壳.每组分别于2、4、6个月时取面神经干做透射电镜观察.结果 对照组:术后2、4、6个月均可见面神经轴膜连续、轴膜下轻度水肿,髓鞘局部松散.实验组:术后2个月均可见面神经轴膜下水肿、髓鞘松散,其中80 Gy组可见巨噬细胞和新生神经纤维,120 Gy组可见板层分离及新生神经纤维;4个月均可见面神经板层分离、髓鞘松散,其中40、80 Gy组可见胶原增生及轴膜下水肿; 6个月均可见新生神经纤维、髓鞘松散,其中80、120 Gy组可见板层分离、轴膜下水肿.结论 家兔面神经在接受40、80及120 Gy 125I照射后,面神经超微结构存在一定的损伤,面神经受照射剂量越大损伤程度越重;但在120 Gy 125I照射6个月后,髓鞘与轴突的完整性和连续性仍基本保持.%Objective To investigate the ultrastructural variation of the facial nerve of rabbit with different dosage of 125I seed brachytherapy. Methods Fifty-four big ear rabbits were divided into 3 groups randomly and given 40 Gy, 80 Gy, 120 Gy respectively. Radioactive seeds were implanted in one side of parotid gland, the other side was implanted with vacant shell as a control group. The facial nerves were obtained 2, 4, 6 months respectively after operation and the histological ultrastructural changes observed by electromicroscope. Results In the control group,epineurium was continuous, there was slight pitting edema under the epineurium, and axonal myelin was loose. In the test groups, there was slight pitting edema under the epineurium, and axonal myelin sheath was loose at 4th month. Macrophage and regenerated fibers were

  5. Influence of source batch Sk dispersion on dosimetry for prostate cancer treatment with permanent implants

    DEFF Research Database (Denmark)

    Perez-Calatayud, J; Casares-Magaz, O

    2015-01-01

    source. Three different prostate volumes (20, 30, and 40 cm(3)) were considered and two typical commercial sources of different radionuclides were used. Using a conventional TPS, clinically accepted calculations were made for (125)I sources; for the palladium, typical implants were simulated. To assess...

  6. Reevaluation of the indications for permanent pacemaker implantation after transcatheter aortic valve implantation

    DEFF Research Database (Denmark)

    Bjerre Thygesen, Julie; Loh, Poay Huan; Cholteesupachai, Jiranut;

    2014-01-01

    AIMS: Conduction abnormalities (CA) requiring permanent pacemaker (PPM) are a well-known complication after transcatheter aortic valve implantation (TAVI). This study aimed to determine the incidence of TAVI-related PPM and reevaluate the indications for PPM after the periprocedural period. METHO...

  7. Routine chest radiography after permanent pacemaker implantation: Is it necessary?

    Directory of Open Access Journals (Sweden)

    Edwards N

    2005-01-01

    Full Text Available Background and Aims: Chest radiographs (CXRs are performed routinely after permanent pacemaker implantation to identify pacemaker lead position and exclude pneumothorax. We assessed the clinical value and need for this procedure. Design: Retrospective analysis of pacemaker data and CXRs following permanent pacemaker insertion between December 2002 and February 2004. Materials and Methods: Post-procedural CXRs were available in 125/126 consecutive patients after either first endocardial pacemaker implantation or insertion of at least one new lead. Subclavian vein puncture was used for venous access in all cases. CXRs were examined to establish the incidence of pneumothorax and assess pacing lead positions. The clinical records were examined in all patients who had subsequent CXRs or a further pacemaker procedure to identify the indication for these and to establish whether CXR had influenced patient management. Results: In total, 192 post-procedural CXRs were performed, either postero-anterior (PA and/or lateral views. Ventricular and/or atrial pacing lead contour and electrode position was considered radiographically appropriate in 86% CXRs. Fourteen per cent of post-procedural radiographs were considered to have radiologically sub-optimal pacemaker lead positioning. None of the patients with these "abnormal" radiographs experienced subsequent pacemaker complications or had further radiographs recorded at a later date. Later repeat CXRs were performed in 16 patients (13% but only 3 patients (2% had pacing abnormalities as the primary indication. All three had satisfactory pacing lead position on initial post-implantation and later radiographs, but required further procedures for lead re-positioning. Iatrogenic pneumothorax occurred in one patient (incidence 0.8% in our series. CXR confirmed the clinical diagnosis and allowed an assessment of size to guide treatment. Conclusion: Routine CXR after permanent pacemaker insertion is not necessary in

  8. CT guided 125I seed brachytherapy for recurrent rectum cancer

    International Nuclear Information System (INIS)

    Objective: To investigate the technological feasibility, efficacy and morbidity of CT guided 125I seed implantation for recurrent rectum cancer. Methods: Twenty-three patients with recurrent rectum cancer were treated with CT guided interstitial 125I seed brachytherapy. In 20 patients the procedure was performed under epidural anesthesia and 3 patients under local anesthesia. Treatment planning system was used to calculate the number of seeds, the space distribution and the introduction of the seeding needles. Matched peripheral dose (MPD) of 121I seed implantation ranged from 90-120 Gy for patients who had had external radiotherapy, and 140- 160 Gy for those who had not. The planning target volume(PTV) was clinical target volume(CTV) plus 1 cm margin. The range of radioactivity of the 125I seeds was 18.5-25.9 MBq. All these 23 patients had CT scan at 5 mm intervals after implantation for quality evaluation, together with routine chest, pelvic X-ray films within 24-48 hours after seed implantation. Three patients received three-dimensional conformal radiation therapy(3DCRT) to a total dose of 45-50 Gy, with 2-3 Gy/f. Follow-up time was from 3 to 28 months. Results: All patients was able to tolerate seed implantation well. Complete pain relief was observed in 12/15, and partial relief in 2/15 and no response in 1/15, with a response rate of 93%. The local control rate was 87%. The 1- and 2-year survival rate was 93% and 50% respectively. Two of four patients have died of dissemination to the lung after 8 and 12 months. One seed has migrated into the pelvis without causing any untoward morbidity. Conclusion: CT guided 125I seed implantation for recurrent rectum cancer is safe, minimally invasive, causing only mild morbidity. It possesses a high efficacy, yet it should be given in combination with extemal beam radiation and chemotherapy, should distant metastasis be observed. (authors)

  9. 125I decay in synthetic oligodeoxynucleotides

    International Nuclear Information System (INIS)

    The availability of synthetic oligodeoxynucleotides provides the opportunity to study the effects of 125I in DNA with added precision and detail, compared to an earlier study (Martin and Haseltine, Science 214, 296, 1981). The authors have designed a template/primer system which enables incorporation of 125IdC into a defined location in a 31mer. The main advantage of this approach is that relatively large amounts (a few μCi) of DNA with both 32P and 125I can be produced quite easily. Consequently, when 125I-induced DNA damage is analyzed on DNA sequencing gels, the distribution of 32P-labeled cleavage products can be determined more accurately, following accumulation of decay events under various conditions (e.g. temperature, buffer components, free radical scavengers). The results of preliminary experiments suggest that the yield of DNA strand breaks per decay approaches one, at least for the 125I labeled strand. Extension of this experimental approach will also enable investigation of the nature of the terminii (e.g. phophoryl-versus phophorylglycollate) at either side of 125I decay-induced DNA strand breaks. The question of energy migration is also being investigated in the oligodeoxynucleotide system, by studying the effects of inclusion of BrUdR nucleotides at various distances from the 125IdC

  10. Dual-chamber implantable cardioverter-defibrillator. Is it useful in patient with permanent atrial fibrillation?

    Science.gov (United States)

    Porres-Aracama, José M; Cerezuela, José Luis; García-Urra, Francisco; Luque-Lezcano, Oscar; Herrero, Vicente

    2016-08-01

    In patients with permanent atrial fibrillation (AF) and implantable cardioverter-defibrillator (ICD) implant indication, a single-chamber device is the choice because AF does not provide interesting information for the treatment. It is very unusual to find patients with permanent AF that coexist with atrial tachycardia with various degree of Atrioventricular block. PMID:27525075

  11. Current research and progress of radioactive 125I seed in the treatment of malignant tumor

    International Nuclear Information System (INIS)

    Radioactive 125I seed implantation has been paid more and more attention and studied by national and international scholars due to its minimal invasivity, high local tumor control rate and low complications. In the clinical treatment, to achieve the best treatment effect, the clinician should minimize the risk of possible 125I related complications. Making an accurate implantation plan by using the type -B ultrasonic and CT technique appropriately is essential. In this paper, we summarized that the application status of the 125I seed implantation technique in the treatment of malignant tumor. We also discussed the safety of its clinical applications. This review can provide a reliable basis for future standardized seed implantation treatment for malignant tumors. (authors)

  12. Quality indicators for permanent I-125 prostate seed implants : seven years post implant dosimetry evaluation

    International Nuclear Information System (INIS)

    Full text: The aim of the current work is to assess the progress of prostate implant quality via post implant dosimetry over a 7-year time period. The roles of post implant dosimetry (PID) after permanent 1-125 implant are to: identify suboptimal implants; assess the dosimetric quality indicators and evaluate dose to organs at risk. The 7-years PID learning-curve shows clear changes in dosimetric trend. Beside the expected improvement in technique the following factors were investigated: the replacement of the computed tomography (CT)-delineation based PID with ultrasound (US)-CT fusion based, and the evolution and influence of parameters such as 090 and V I 00. The correlation between dosimetric parameters and clinical outcome was also evaluated. Results A study on 30 patients showed manual target contouring on CT tends to overestimate the prostate volume when compared to ultrasound data (mean difference 38.3%), translating to CT based D90 values being lower than US-CT D90 by an average of 6%. There was 4.7% patient relapse and urinary retention was reported in 2.7% of the patients. CT-based PID was found less reliable than US-CT fusion due to target overestimation. This result shows the biased interpretation of low D90 based on CT targeting and may not relate to patient relapse data. The low urinary retention statistics are in accordance with the PID data for the organ, as only 5.2% of patients had their PID D I 0 >218 Gy, i.e. above recommended GEC-ESTRO guidelines. Besides the 'learning' component, the 7-years PID D90 curve is influenced by PID technique.

  13. 125I Measurements for Occupational Exposure Assessment

    Science.gov (United States)

    Silva, L.; Pinhão, N. R.

    2008-08-01

    Whenever there is a risk of occupational exposure to dispersible radioactive material, it is necessary to have a monitoring program to assess the effective dose arising from the intake of radionuclides by workers. In this paper we present our experience in bioassay measurements of 125I in urine samples of workers using high resolution gamma spectrometry. For a 24-hour excretion period, we found activity values of the order of one Bq and estimated the committed effective doses to be less than one μSv. Although very small, these values led to a re-evaluation and improvement of the laboratory safety conditions. We discuss the calibration procedure followed for the activity measurements, the estimation of the uncertainty in the excreted activity, the calculation of detection and quantification limits and estimation of performance indicators. Aspects regarding the spectral analysis, true coincidence summing and matrix effects are also considered.

  14. [Intraoperative and post-implant dosimetry in patients treated with permanent prostate implant brachytherapy].

    Science.gov (United States)

    Herein, András; Ágoston, Péter; Szabó, Zoltán; Jorgo, Kliton; Markgruber, Balázs; Pesznyák, Csilla; Polgár, Csaba; Major, Tibor

    2015-06-01

    The purpose of our work was to compare intraoperative and four-week post-implant dosimetry for loose and stranded seed implants for permanent prostate implant brachytherapy. In our institute low-dose-rate (LDR) prostate brachytherapy is performed with encapsulated I-125 isotopes (seeds) using transrectal ultrasound guidance and metal needles. The SPOT PRO 3.1 (Elekta, Sweden) system is used for treatment planning. In this study the first 79 patients were treated with loose seed (LS) technique, the consecutive patients were treated with stranded seed (SS) technique. During intraoperative planning the dose constraints were the same for both techniques. All LSs were placed inside the prostate capsule, while with SS a 2 mm margin around the prostate was allowed for seed positioning. The prescribed dose for the prostate was 145 Gy. This study investigated prostate dose coverage in 30-30 randomly selected patients with LS and SS. Four weeks after the implantation native CT and MRI were done and CT/MRI image fusion was performed. The target was contoured on MRI and the plan was prepared on CT data. To assess the treatment plan dose-volume histograms were used. For the target coverage V100, V90, D90, D100, for the dose inhomogeneity V150, V200, and the dose-homogeneity index (DHI), for dose conformality the conformal index (COIN) were calculated. Intraoperative and postimplant plans were compared. The mean V100 values decreased at four-week plan for SS (97% vs. 84%) and for LS (96% vs. 80%) technique, as well. Decrease was observed for all parameters except for the DHI value. The DHI increased for SS (0.38 vs. 0.41) and for LS (0.38 vs. 0.47) technique, as well. The COIN decreased for both techniques at four-week plan (SS: 0.63 vs. 0.57; LS: 0.67 vs. 0.50). All differences were significant except for the DHI value at SS technique. The percentage changes were not significant, except the COIN value. The dose coverage of the target decreased significantly at four-week plans

  15. Implant-supported prostheses versus conventional permanent and removable dentures

    Directory of Open Access Journals (Sweden)

    Koszuta Agnieszka

    2014-06-01

    Full Text Available Social, economic and technological progress results in an increasing range of treatment and rehabilitation methods for patients with partial or complete edentulism. The role of the dentist is to inform the patient about the full range of available missing teeth treatment options leading to complete rehabilitation of the masticatory organ in agreement with the patient’s aesthetic and functional expectations. The aim of the paper was to identify the type of prostheses used by patients before opting for implantsupported teeth replacements, according to the patients’ age, sex, marital status, place of residence and education. The study covered 464 patients, women and men, aged 20-74, treated with dental implants. The patients answered questions in an anonymous questionnaire. The influence of the prosthetic replacement type according to age and marital status was highly statistically significant, whereas it was statistically significant according to sex, place of residence and education. The female respondents who previously used tissue-borne complete or partial dentures opted for implant treatment more frequently. The respondents younger than 40 and between 40-60 years of age who did not previously used any prosthetic replacements opted for implant treatment more frequently. The respondents who did not use any prosthetic replacements decided to undergo implant treatment most frequently, regardless of their marital status, education and place of residence. The patients opted for implant treatment to improve their quality of life, despite the high cost of such therapy.

  16. Optimization of 125I ophthalmic plaque brachytherapy

    International Nuclear Information System (INIS)

    Episcleral plaques containing 125I sources are often used in the treatment of ocular melanoma. Within four years post-treatment, however, the majority of patients experience some visual loss due to radiation retinopathy. The high incidence of late complications suggests that careful treatment optimization may lead to improved outcome. The goal of optimization would be to reduce the magnitude of vision-limiting complications without compromising tumor control. We have developed a three-dimensional computer model for ophthalmic plaque therapy which permits us to explore the potential of various optimization strategies. One simple strategy which shows promise is to maximize the ratio of dose to the tumor apex (T) compared to dose to the macula (M). By modifying the parameters of source location, activity distribution, source orientation, and shielding we find that the calculated T:M ratio can be varied by a factor of 2 for a common plaque design and posterior tumor location. Margins and dose to the tumor volume remain essentially unchanged

  17. CT-guided percutaneous perineal permanent implants with I-125

    International Nuclear Information System (INIS)

    The authors have combined the principles of CT-guided percutaneous biopsy and biplane fluoroscopy in performing outpatient percutaneous pelvic implantations of I-125 seeds for the treatment of unresectable or recurrent tumors of the pelvis, utilizing a transperineal approach. The technique allows implantations up to a depth of 16 cm from the perineum. No complications have been encountered. Twelve procedures have been performed. The types of tumor treated include five cases of recurrent carcinoma of the rectum, five cases of unresectable carcinoma of the prostate, one case of recurrent sarcoma of the rectum, and one case of adenocarcinoma of unknown origin involving the pelvic wall

  18. 支气管动脉化疗栓塞联合125I放射性粒子植入术治疗老年非小细胞肺癌的效果分析%Effect analysis of bronchial arterial chemoembolization combined with 125I active particle implantation in the treatment of elderly non-small cell lung cancer

    Institute of Scientific and Technical Information of China (English)

    杨海

    2015-01-01

    目的:分析支气管动脉化疗栓塞联合125I放射性粒子植入术治疗老年非小细胞肺癌的效果。方法选取2011年1月~2013年1月本院收治的90例无法进行根治性切除术的老年非小细胞肺癌患者,将其随机分为观察组、对照组,每组45例。观察组进行支气管动脉栓塞化疗联合125I放射性粒子植入治疗3~6个疗程,对照组行吉西他滨联合顺铂化疗(GP方案)4~6个疗程,比较两组患者的疗效、不良反应发生率、生存时间。结果观察组的有效率为73.33%,对照组为44.44%,两组比较,差异有统计学意义(P<0.05)。随访17个月后,观察组死亡4例,对照组死亡1例,观察组、对照组的中位生存时间分别为(399.2±19.5)、(331.5±16.4)d,组间比较,差异有统计学意义(P<0.05)。结论支气管动脉化疗栓塞联合125I放射性粒子植入术治疗无法进行根治性切除术的老年非小细胞肺癌的短期效果优于GP方案化疗。%Objective To analyze the effect of bronchial arterial chemoembolization combined with 125I active particle implantation in the treatment of elderly non-small cell lung cancer. Methods From January 2011 to January 2013,90 elderly patients with non-small cell lung cancer which could not undergo radical resection operation admitted into our hospital were selected.They were evenly divided into observation group and control group in random.In observation group,bronchial arterial chemoembolization combined with 125I active particle implantation was applied for 3-6 courses of treatment.Control group was provided with gemcitabine combined with cis-platinum chemotherapy (GP scheme) for 4-6 courses of treatment.The therapeutic effect,incidence rate of adverse reaction,and survival time between two groups was compared respectively. Results The effective rate in observation group and control group was 73.33%,44.44% re-spectively and there was a statistical difference between two groups (P<0

  19. The contamination on farm products from 125I

    International Nuclear Information System (INIS)

    The 125I contamination on 15 farm products have been investigated. The effects of 12 farm crops (wheat, bean, eggplants and other vegetables) contaminated by 125I during the growing stage on their fruits and seeds have been studied. The results show that the 125I radioactive substance is mainly concentrated on the fruit surface, and the radioactivity rapidly decreased towards its kernel. The fruits and seeds would not be contaminated when plants were contaminated in the seedling stage

  20. Dosimetric results in implant and post-implant and low rate in brachytherapy prostate cancer with loose seeds and attached

    International Nuclear Information System (INIS)

    The objective is determine differences dosimetry statistics on the dosimetry of the implant and post-implant in brachytherapy of low rate with implants permanent in prostate using seed of 125-I loose and attached Both in lives and in the post-prostatic plans dosimetric coverage is good and restrictions in urethra and rectum for both groups of patients are met. Not migrating with joined is evident, as well as better dosimetric homogeneity. (Author)

  1. Computational Program of Isodose and TPS of 125I Seed for Brachytherapy

    International Nuclear Information System (INIS)

    Radioactive sources are widely used in several fields including for medical purposes. One use of radioactive sources in medical field is radiotherapy to cure the cancerous organs. Brachytherapy term is the radiotherapy where the radiation source is placed inside or as close as possible to the cancer needing treatment. In order to support the domestic application of 125I seeds in brachytherapy, a computational program for isodose and TPS (Treatment Planning System) calculation shall be available. The preparation of the such program has been successfully developed using Microsoft Visual Basic for Windows and its supporting tools. This program can display the two-dimensions-isodose contour of 1-20 125I seeds presented in direction of lateral, anterior (AP) and caodal. The dose rate at the distances of 1, 2, 3 and 4 cm from the center point assumed as (0,0) can also be calculated from 1 to 360 days after implantation of the 125I seeds. The entered data as well as the resulting calculation and the contour presentation can be saved and be quickly traced and redisplayed at any time necessarily. This computer program is hopefully able to assist physicians in the implementation of 125I seeds implantation for brachytherapy. (author)

  2. 组织间125I放射粒子植入治疗头颈部恶性肿瘤颈部淋巴结转移的临床应用%Clinical application of interstitial implantation of 125I radion in the treatment of cervical lymph node metastasis of head and neck malignancy

    Institute of Scientific and Technical Information of China (English)

    李福生; 黄海; 徐绍年; 杜振广; 王亮

    2014-01-01

    目的:探讨组织间125I放射粒子植入治疗头颈部恶性肿瘤颈部淋巴结转移的价值。方法对21例头颈部恶性肿瘤颈部淋巴结转移患者进行125I放射粒子植入治疗,术前行TPS(computer-based treatment planning system)计划、根据计划在CT引导局部麻醉下行颈部淋巴结转移瘤125I放射粒子植入、术后复查CT进行质量验证。根据NRS评分对术前术后患者局部疼痛进行评估,按WHO标准对局部肿瘤控制疗效进行评价。结果随访7~29个月,21例患者均成功行手术治疗,术后3个月复查,完全缓解3例(14%)、部分缓解15例(71%)、病变稳定2例(10%)、病变进展1例(5%);6个月、1、2年的局部控制率(局部肿瘤无进展)分别为:84%、65%、39%;NRS疼痛评分术前、术后3个月、6个月分别为:(7.62±0.92)分,(2.81±0.68)分,(2.14±0.39)分(P<0.05)。3例患者术后出现发热,未超过38.5℃,3~5 d内恢复正常;3例皮肤黏膜1级急性放射性损伤,2例皮肤黏膜2级急性放射性损伤,无3~5级皮肤黏膜急性放射性损伤。所有患者未发生大出血、急性肺栓塞、窦道等严重并发症。结论组织间125I放射粒子植入治疗头颈部恶性肿瘤颈部淋巴结转移创伤小,并发症少,局部控制率较高,疼痛缓解明显,为不能手术的晚期头颈部恶性肿瘤颈部淋巴结转移的患者提供了一种新型治疗手段。%Objective To explore the value of interstitial implantation of 125I radion in the treatment of cervical lymph node metastasis of head and neck malignancy. Methods There were 21 patients with cervical lymph node metastasis of head and neck malignancy received 125I radion implantation. Computer-based treatment planning system (TPS) was operated before the surgery, and implantation of 125I radion was conducted under CT guidance and local anesthesia. Postoperative CT review was used for quality verification. Numerical rating scale (NRS) was used to assess patients

  3. Safety handling of 125I in animal experiments

    International Nuclear Information System (INIS)

    Isotope 125I in animal experiments is used for several purposes. One major problem with using 125I is to handle it extremely carefully. The careful handling is required when using 125I in animal experiments because of its higher evaporation and difficulty for sealing. When conducting animal experiments white using 125I, we have encountered several serious problems but have devised new techniques and methods for a long time. In this paper, we will describe the safety handling for requirements based on our experiments. The newly devised safety handling procedures are the following: a device for protecting isotope contamination during the preparation of the injectable solution, collection method of airborne radioactivity from the animals that were injected, enhancing the method for autoradiography of the whole body, finding of elusion of 125I from the tissues during fixative process, estimation of the exposed time for light microscopic autoradiography. (author)

  4. Online gamma-camera imaging of 103Pd seeds (OGIPS) for permanent breast seed implantation

    Science.gov (United States)

    Ravi, Ananth; Caldwell, Curtis B.; Keller, Brian M.; Reznik, Alla; Pignol, Jean-Philippe

    2007-09-01

    Permanent brachytherapy seed implantation is being investigated as a mode of accelerated partial breast irradiation for early stage breast cancer patients. Currently, the seeds are poorly visualized during the procedure making it difficult to perform a real-time correction of the implantation if required. The objective was to determine if a customized gamma-camera can accurately localize the seeds during implantation. Monte Carlo simulations of a CZT based gamma-camera were used to assess whether images of suitable quality could be derived by detecting the 21 keV photons emitted from 74 MBq 103Pd brachytherapy seeds. A hexagonal parallel hole collimator with a hole length of 38 mm, hole diameter of 1.2 mm and 0.2 mm septa, was modeled. The design of the gamma-camera was evaluated on a realistic model of the breast and three layers of the seed distribution (55 seeds) based on a pre-implantation CT treatment plan. The Monte Carlo simulations showed that the gamma-camera was able to localize the seeds with a maximum error of 2.0 mm, using only two views and 20 s of imaging. A gamma-camera can potentially be used as an intra-procedural image guidance system for quality assurance for permanent breast seed implantation.

  5. Online gamma-camera imaging of {sup 103}Pd seeds (OGIPS) for permanent breast seed implantation

    Energy Technology Data Exchange (ETDEWEB)

    Ravi, Ananth [Department of Medical Biophysics, University of Toronto (Canada); Caldwell, Curtis B [Department of Medical Biophysics, University of Toronto (Canada); Keller, Brian M [Medical Physics, Sunnybrook Health Sciences Centre (Canada); Reznik, Alla [Department of Medical Biophysics, University of Toronto (Canada); Pignol, Jean-Philippe [Department of Medical Biophysics, University of Toronto (Canada)

    2007-09-21

    Permanent brachytherapy seed implantation is being investigated as a mode of accelerated partial breast irradiation for early stage breast cancer patients. Currently, the seeds are poorly visualized during the procedure making it difficult to perform a real-time correction of the implantation if required. The objective was to determine if a customized gamma-camera can accurately localize the seeds during implantation. Monte Carlo simulations of a CZT based gamma-camera were used to assess whether images of suitable quality could be derived by detecting the 21 keV photons emitted from 74 MBq {sup 103}Pd brachytherapy seeds. A hexagonal parallel hole collimator with a hole length of 38 mm, hole diameter of 1.2 mm and 0.2 mm septa, was modeled. The design of the gamma-camera was evaluated on a realistic model of the breast and three layers of the seed distribution (55 seeds) based on a pre-implantation CT treatment plan. The Monte Carlo simulations showed that the gamma-camera was able to localize the seeds with a maximum error of 2.0 mm, using only two views and 20 s of imaging. A gamma-camera can potentially be used as an intra-procedural image guidance system for quality assurance for permanent breast seed implantation.

  6. Synthesis and application of PLGA labeled with 125I

    Institute of Scientific and Technical Information of China (English)

    2006-01-01

    The weight loss in vivo degradation of poly (lactide-co-glycolide) (PLGA) radiolabeled with 125I was investigated. PLGA with molecular weight (Mw) of 84000(LA/GA=85/15) were labeled with 125I in the chloroform media by circularly heating and round films of about 15 mm in diameter were formed. The composition and Mw of the 125I-PLGA were characterized by 1H-NMR and viscosimeter. The weight loss of this copolymer in vitro and in vivo degradation was quantified by determining radioactivity of materials. The results indicated that PLGA exhibited significantly faster degradation in vivo than that of in vitro conditions.

  7. Systemic administration of kainic acid induces selective time dependent decrease in [125I]insulin-like growth factor I, [125I]insulin-like growth factor II and [125I]insulin receptor binding sites in adult rat hippocampal formation

    International Nuclear Information System (INIS)

    Administration of kainic acid evokes acute seizure in hippocampal pathways that results in a complex sequence of functional and structural alterations resembling human temporal lobe epilepsy. The structural alterations induced by kainic acid include selective loss of neurones in CA1-CA3 subfields and the hilar region of the dentate gyrus followed by sprouting and permanent reorganization of the synaptic connections of the mossy fibre pathways. Although the neuronal degeneration and process of reactive synaptogenesis have been extensively studied, at present little is known about means to prevent pathological conditions leading to kainate-induced cell death. In the present study, to address the role of insulin-like growth factors I and II, and insulin in neuronal survival as well as synaptic reorganization following kainate-induced seizure, the time course alterations of the corresponding receptors were evaluated. Additionally, using histological preparations, the temporal profile of neuronal degeneration and hypertrophy of resident astroglial cells were also studied. [125I]Insulin-like growth factor I binding was found to be decreased transiently in almost all regions of the hippocampal formation at 12 h following treatment with kainic acid. The dentate hilar region however, exhibited protracted decreases in [125I]insulin-like growth factor I receptor sites throughout (i.e. 30 days) the study. [125I]Insulin-like growth factor II receptor binding sites in the hippocampal formation were found to be differentially altered following systemic administration of kainic acid. A significant decrease in [125I]insulin-like growth factor II receptor sites was observed in CA1 subfield and the pyramidal cell layer of the Ammon's horn at all time points studied whereas the hilar region and the stratum radiatum did not exhibit alteration at any time. A kainate-induced decrease in [125I]insulin receptor binding was noted at all time points in the molecular layer of the dentate

  8. Defect in Lung Perfusion and Ventilation Scanning of Patients with Permanent Transvenous Implantable Pacemaker

    OpenAIRE

    Matsuura, Yuichiro; Tamura, Mutsuo; Yamashina, Hideki; Higo, Masanori; Fujii, Takanori; Shimamoto, Hiroyuki; Kinoshita, Hirofumi

    1984-01-01

    Lung perfusion and ventilation scanning with 99mTc-MAA and 81mKr-Gass were studied in 138 patients with permanent transvenous implantable pacemaker. There were observed segmental or subsegmental defects in lung perfusion and ventilation scanning which were considered to be probably lung embolism of 47 cases. The incidence of lung embolism was high during the first postoperative 6 months, and it also increased progressively with aging. The patient with ischemic heart disease or va...

  9. A study on recombinant human interleukin 2 radioiodinated with 125I (125I-rIL-2) for RIA

    International Nuclear Information System (INIS)

    RIL-2 was labelled with 125I by Iodogen method. The products were purified by HPLC. Analysis of each radiolabelled preparation showed that greater than 95% of the radioiodine was associated with a single protein peak. The specific activity of radioiodinated rIL-2 was approximately 2.2 x 1016-2.8 x 1016 Bq/mol. The 125I-rIL-2 was designed for quantitating human IL-2 with sensitive radioimmunoassay (RIA). The bioactivity of 125I-rIL-2 is good

  10. Radioactive 125I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathway

    International Nuclear Information System (INIS)

    Glioblastoma multiforme (GBM) is the most common primary central nervous system neoplasm in adults. Radioactive 125I seed implantation has been widely applied in the treatment of cancers. Moreover, previous clinical trials have confirmed that 125I seeds treatment was an effective therapy in GBM. We sought to investigate the effect of 125I seed on GBM cell growth and Epithelial-mesenchymal transition (EMT). Cells were exposed to irradiation at different doses. Colony-formation assay, EdU assay, cell cycle analysis, and TUNEL assay were preformed to investigate the radiation sensitivity. The effects of 125I seeds irradiation on EMT were measured by transwell, Boyden and wound-healing assays. The levels of reactive oxygen species (ROS) were measured by DCF-DA assay. Moreover, the radiation sensitivity and EMT were investigated with or without pretreatment with glutathione. Additionally, nude mice with tumors were measured after treated with radiation. Radioactive 125I seeds are more effective than X-ray irradiation in inhibiting GBM cell growth. Moreover, EMT was effectively inhibited by 125I seed irradiation. A mechanism study indicated that GBM cell growth and EMT inhibition were induced by 125I seeds with the involvement of a ROS-mediated signaling pathway. Radioactive 125I seeds exhibit novel anticancer activity via a ROS-mediated signaling pathway. These findings have clinical implications for the treatment of patients with GBM by 125I seeds

  11. 术中125I粒子植入联合术后化学治疗中晚期食管鳞癌%125I radioactive seeds implantation combined with postoperative chemotherapy in treatment of advanced esophageal squamous cell carcinoma

    Institute of Scientific and Technical Information of China (English)

    吕进; 曹秀峰; 朱斌; 王冬冬; 纪律; 王山; 安红银

    2011-01-01

    目的 探讨术中125I粒子植入联合术后化学治疗治疗胸段中晚期食管鳞癌(ESCC)的安全性及疗效.方法 前瞻性队列研究,入组时间为2000年1月至2005年12月.根据ESCC术前CT分期标准,南京医科大学附属南京第一医院肿瘤外科和盐城市肿瘤医院胸外科298例Ⅱ~Ⅲ期胸段ESCC患者通过计算机随机数字法分为术中125I粒子植入联合术后化学治疗组(A组,98例)、术后放射化学治疗组(B组,100例)及单纯根治术组(C组,100例).三组均行食管癌根治术.再根据术后pTNM分期标准,最终实际入组Ⅱb~Ⅲ期胸段ESCC患者233例,三组分别为78例、75例、80例.依据治疗计划系统(TPS)所确定的剂量,A组于术中直视下植入125I粒子.选用0.5 mCi的125I粒子10~22粒,总活度在5~11 mCi,肿瘤匹配周边剂量60~70 Gy,术后通过影像学手段(CT、X线片)行粒子验证和质量评估.观察患者术后并发症,通过CT监测肿瘤影像学、局部复发情况,随访术后1、3、5、10年生存率.结果 A组术后粒子验证无移位、脱落,质量评估满意.A、B、C组局部复发率分别为11.5%、13.3%、38.8%,比较差异有统计学意义(P<0.05).3组并发症比较差异无统计学意义(P>0.05).3组1年生存率对比差异无统计学意义(P>0.05),A、B、C组3、5、10年总体及无进展生存率分别为64.8%,37.7%,25.1%;63.3%,36.9%,24.9%;43.6%,25.0%,12.6%)及63.5%,37.4%,15.1%;62.5%,36.6%,14.4%;42.5%,25.6%,6.2%;3组比较差异均有统计学意义(P<0.05).结论 术中125I粒子植入联合术后化疗与术后放化疗治疗中晚期食管鳞癌疗效相当,是简单、安全、有效的方法,可降低局部复发率、延长患者生存期.%Objective To evaluate the safety and efficacy of 125I radioactive seeds implantation combined with postoperative chemotherapy as a treatment option for thoracic advanced esophageal squamous cell carcinoma(ESCC). Methods A prospective cohort study was carried out

  12. A comparative study of 19-iodocholesterol-''125I 3-acetate and Na''125I in liquid scintillation measurements

    International Nuclear Information System (INIS)

    A comparative study of performance of 19-iodocholesterol-''125I 3-acetate and sodium iodine samples labelled with ''125 I is presented for liquid scintillation counting measurements. Quench effect, count rate stability and spectral evolution of samples have been followed for several weeks in Toluene, Hisafe II, Instagel, Dioxane-naphthalene and Toluene-alcohol scintillators. Organic samples have negligible quench effect in the interval of I''-concentration of 0-90 ug and inorganic samples only show a very small variation, lower than 12%, for Dioxane-naphthalene, in the same range of concentration. Satisfactory stability is obtained in general for both, organic and inorganic samples, but small counting losses, 0.03% for 19-iodocholesterol-''125I 3-acetate samples in Toluene-alcohol and 0.04% for Na''125I samples in Dioxane-naphthalene and Toluene-alcohol, have been reported. (Author) 8 refs

  13. The factor analysis of the incidence of pneumothorax after CT-guided 125I radioactive seed implantation for lung cancer%CT引导下125I粒子植入治疗肺癌术后气胸发生率的相关因素分析

    Institute of Scientific and Technical Information of China (English)

    霍小东; 杨景魁; 闫卫亮; 郑广钧; 柴树德; 孟娜; 杨瑞杰; 王俊杰

    2014-01-01

    Objective To analyze the impact factors of incidence of pneumothorax after CT guided puncture with radioactive 125I seed implantation in lung cancer patients.Methods 821 cases with lung cancer were treated with CT-guided percutaneous with radioactive particles implantation.198 cases of pneumothorax patients were collected.The impact factors of incidence of pneumothorax were analyzed by parallel unconditioned logistic regression.Results 24.1% (198/821) of cases had pneumothorax after CT guided puncture.Single variate analysis showed that the incidence of pneumothorax was ralated with seven factors,such as patients with the average depth of implanted needle,whether patients with COPD(chronic obstructive pulmonary diseases),atelectasis,implantation pin number and operation time,puncture angle,and the diameter of the tumor(x2 =10.293,11.463,5.310,8.868,13.348,9.326,16.504,P <0.05).176 patients of intercurrent COPD with postoperative pneumothorax suffered from 65 cases.The cases of distance between the chest wall and needle less than 6 cm(205 cases),8-12 cm(378 cases)and greater than 12 cm (238 cases),the postoperative pneumothorax occurred in 29 (14.1%),98 (25.9%),71 (29.8%)cases,respectively.The number of needles were less than 5(183 cases),5-10 (408 cases),more than 10 (230 cases),the postoperative pneumothorax occurred in 31 (16.9%),92 (22.5 %),75 (32.6%),respectively.The surgery time was less than 10 min(198 cases),10-20 min(412 cases)and more than 30 min(211 cases),the postoperative pneumothorax occurred in 27(13.6%),101 (24.5%),70(33.2%) respectively.19 cases(14.4%) with COPD (132 case) suffered from pneumothorax.The multivariate logistic regression analysis showed that the prior four factor were risk factors of pneumothorax (OR =1.676,2.147,1.827,2.368,P <0.05),and the last one is protective factor(OR =0.367,P < 0.05).Conclusions COPD disease history,long distance between lesion and chest wall,plenty of needles surgery time can affect

  14. An automated, fast and accurate registration method to link stranded seeds in permanent prostate implants

    International Nuclear Information System (INIS)

    The geometry of a permanent prostate implant varies over time. Seeds can migrate and edema of the prostate affects the position of seeds. Seed movements directly influence dosimetry which relates to treatment quality.We present a method that tracks all individual seeds over time allowing quantification of seed movements. This linking procedure was tested on transrectal ultrasound (TRUS) and cone-beam CT (CBCT) datasets of 699 patients. These datasets were acquired intraoperatively during a dynamic implantation procedure, that combines both imaging modalities.The procedure was subdivided in four automatic linking steps. (I) The Hungarian Algorithm was applied to initially link seeds in CBCT and the corresponding TRUS datasets. (II) Strands were identified and optimized based on curvature and linefits: non optimal links were removed. (III) The positions of unlinked seeds were reviewed and were linked to incomplete strands if within curvature- and distance-thresholds. (IV) Finally, seeds close to strands were linked, also if the curvature-threshold was violated. After linking the seeds an affine transformation was applied. The procedure was repeated until the results were stable or the 6th iteration ended.All results were visually reviewed for mismatches and uncertainties. Eleven implants showed a mismatch and in 12 cases an uncertainty was identified. On average the linking procedure took 42 ms per case.This accurate and fast method has the potential to be used for other time spans, like Day 30, and other imaging modalities. It can potentially be used during a dynamic implantation procedure to faster and better evaluate the quality of the permanent prostate implant. (note)

  15. An automated, fast and accurate registration method to link stranded seeds in permanent prostate implants

    Science.gov (United States)

    Westendorp, Hendrik; Nuver, Tonnis T.; Moerland, Marinus A.; Minken, André W.

    2015-10-01

    The geometry of a permanent prostate implant varies over time. Seeds can migrate and edema of the prostate affects the position of seeds. Seed movements directly influence dosimetry which relates to treatment quality. We present a method that tracks all individual seeds over time allowing quantification of seed movements. This linking procedure was tested on transrectal ultrasound (TRUS) and cone-beam CT (CBCT) datasets of 699 patients. These datasets were acquired intraoperatively during a dynamic implantation procedure, that combines both imaging modalities. The procedure was subdivided in four automatic linking steps. (I) The Hungarian Algorithm was applied to initially link seeds in CBCT and the corresponding TRUS datasets. (II) Strands were identified and optimized based on curvature and linefits: non optimal links were removed. (III) The positions of unlinked seeds were reviewed and were linked to incomplete strands if within curvature- and distance-thresholds. (IV) Finally, seeds close to strands were linked, also if the curvature-threshold was violated. After linking the seeds an affine transformation was applied. The procedure was repeated until the results were stable or the 6th iteration ended. All results were visually reviewed for mismatches and uncertainties. Eleven implants showed a mismatch and in 12 cases an uncertainty was identified. On average the linking procedure took 42 ms per case. This accurate and fast method has the potential to be used for other time spans, like Day 30, and other imaging modalities. It can potentially be used during a dynamic implantation procedure to faster and better evaluate the quality of the permanent prostate implant.

  16. Nursing care of patients with prostate cancer accepting permanent 125I radion implantation treatment%125I放射性粒子永久植入治疗前列腺癌的护理

    Institute of Scientific and Technical Information of China (English)

    郭红霞; 郝海龙

    2010-01-01

    @@ 前列腺癌是中老年男性生殖泌尿系统常见的恶性肿瘤.我国前列腺癌的发病率与欧美比较相对较低,但呈逐渐上升趋势[1].1983年美国Charyulu发明经会阴超声引导治疗前列腺癌技术,奠定了近代放射性粒子治疗前列腺癌的基础[2].与传统的前列腺癌的治疗方法相比,它具有创伤小、出血少、疗效好等优点[3].我院2004年1月-2009年1月采用经直肠超声(TRUS)引导下125I粒子植入术治疗前列腺癌病人31例,疗效较好.现将护理总结如下.

  17. Dosimetry of ophthalmic applications using 125I seed sources

    International Nuclear Information System (INIS)

    Intraocular melanoma is the most common primary malignancy of the eye and radiation therapy using ophthalmic plaque has proved successful for its management. The dose prescription point recommended for 125I eye plaque therapy is usually 5 mm from tumour base centre for tumours with 5 mm or less height and tumour apex, otherwise. A computational programme was written to generate data for the dosimetry of eye plaque therapy using 125I seeds. Variation of central axis depth dose and isodose distributions at reference depth have been studied for different diameter plaques. The reference dose rate chosen for a clinical application, based on treatment planning software, was compared with that derived from the data generated in the present study. The dosimetry data generated and presented in this paper will help pre-planning of ophthalmic applications, using 125I seeds. (author)

  18. Dosimetric results in implant and post-implant and low rate in brachytherapy prostate cancer with loose seeds and attached; Resultados dosimetricos en el implante y post-impante en braquiterapia de baja tasa en cancer de prostata con semillas sueltas y unidas

    Energy Technology Data Exchange (ETDEWEB)

    Juan-Senabre, X. J.; Albert Antequera, M.; Lopez-Tarjuelo, J.; Santos Serra, A.; Perez-Mestre, M.; Sanchez Iglesias, A. L.; Conde Moreno, A. J.; Gonzalez Vidal, V.; Beltran Persiva, J.; Muelas Soria, R.; Ferrer Albiach, C.

    2015-07-01

    The objective is determine differences dosimetry statistics on the dosimetry of the implant and post-implant in brachytherapy of low rate with implants permanent in prostate using seed of 125-I loose and attached Both in lives and in the post-prostatic plans dosimetric coverage is good and restrictions in urethra and rectum for both groups of patients are met. Not migrating with joined is evident, as well as better dosimetric homogeneity. (Author)

  19. Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation

    Directory of Open Access Journals (Sweden)

    Ruge Maximilian I

    2012-06-01

    Full Text Available Abstract Stereotactic brachytherapy (SBT has been described in several publications as an effective, minimal invasive and safe highly focal treatment option in selected patients with well circumscribed brain tumors 40 cGy/h in combination with adjuvant external beam radiation and/or chemotherapy for the treatment of malignant gliomas and metastases resulted in increased rates of radiation induced adverse tissue changes requiring surgical intervention. Vice versa, such effects have been only minimally observed in numerous studies applying low dose rate (LDR regiments (3–8 cGy/h for low grade gliomas, metastases and other rare indications. Besides these observations, there are, however, no data available directly comparing the long term incidences of tissue changes after HDR and LDR and there is, furthermore, no evidence regarding a difference between temporary or permanent LDR implantation schemes. Thus, recommendations for effective and safe implantation schemes have to be investigated and compared in future studies.

  20. Preparation and characterization of 125 I labeled bovine serum albumin

    Directory of Open Access Journals (Sweden)

    K S Ashwitha Rai

    2015-01-01

    Full Text Available Bovine serum albumin is a model protein, which has been conventionally used as protein standard and in many areas of biochemistry, pharmacology and medicine. Radioiodination procedure for bovine serum albumin employing chloramine-T as an oxidant with slight modification was evaluated critically to establish the optimal conditions for the preparation of radiolabeled tracer ( 125 I-BSA with required specific activity without impairing the immune reactivity and biological activity. Optimized radioiodination procedure involving 10 µg of chloramine-T along with 20 µg of sodium metabisulphite with 60 seconds incubation at 2° yielded 125 I-BSA with high integrity.

  1. Computer assisted treatment planning for 125I ophthalmic plaque radiotherapy

    International Nuclear Information System (INIS)

    This paper describes a computer program for planning the treatment of ocular tumors with 125I plaques. The program permits the input of the tumor configuration into a model eye and facilitates the viewing of the relative geometry of the tumor and various eye structures in different perspectives. Custom-designed 125I plaques can be localized onto the globe, and dose distributions can be calculated and superimposed on the eye structures in any plane or on the inner eye surface. The program allows efficient evaluation of the plaque design in terms of radiation dose distribution relative to the tumor and critical structures

  2. Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump.

    Science.gov (United States)

    Marymont, J V; Dakhil, S R; Travers, H; Housholder, D F

    1985-10-01

    The introduction of chemotherapeutic agents directly into the proper hepatic artery via an indwelling catheter results in perfusion of the gallbladder, because the cystic artery is usually a branch of the right hepatic artery. Five gallbladders, removed two to 16 months after insertion of permanently implanted Infusaid model 400 pumps, were examined. All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls. Fibrosis of the gallbladder wall was also a constant finding. Nuclear atypia of mucosal epithelium and connective tissue was common. Varying degrees of acute and chronic inflammation were present. These abnormalities may have a radiomimetic and direct irritant pathogenesis.

  3. Apical Ballooning Syndrome (Takotsubo Cardiomyopathy after Permanent Dual-Chamber Pacemaker Implantation

    Directory of Open Access Journals (Sweden)

    Armando Gardini

    2012-01-01

    Full Text Available Apical ballooning syndrome, also called takotsubo cardiomyopathy, has been recently reported. It may mimic acute myocardial infarction and is typically observed in postmenopausal women after stressful events. A 75-year-old female after permanent dual chamber pacemaker implant complained of chest pain with repolarization alterations suggesting acute myocardial ischemia. Echocardiography showed a left ventricle with akinesia of the apical portions and reduced global systolic function. The patient was treated with antithrombotic agents and intravenous nitrates. No coronary lesions were found at angiography. At ventriculography, a typical takotsubo-like shape of the left ventricle was observed. The clinical and echocardiographic picture normalized at discharge.

  4. Carbon cartridge standards for 125I and suggested applications.

    Science.gov (United States)

    Tries, M A; Ring, J P; Chabot, G E

    1997-09-01

    Carbon cartridge standards were prepared to assess the activity of 125I incident on, and adsorbed in, cartridge samples during air sampling. Each cartridge standard consisted of an 125I-spiked filter paper at a known depth, ranging from 0 to 19 mm, embedded in approximately 34 g of 20-30 mesh activated carbon contained within a 6.35 cm diameter by 2.22 cm deep metal cartridge with screened openings. The total counting efficiency values range from 17.8 to 20.8% for cartridges counted at 3.2 mm from a thin-crystal NaI(Tl) detector. The standards were analyzed using a front/back counting technique, and fitting functions were developed relating the front/back net counts ratio and counting efficiency to the 125I depth of burial. A method for determining sample activity that accounts for exponential radioiodine loading in cartridge samples is compared to a less complicated technique that assumes all the radioiodine is located at an equivalent depth of burial that is based on the sample front/back net counts ratio. In addition, methods are presented for determining airborne 125I activity for constant and variable concentrations. Variable concentrations are assumed to occur in a fume hood duct by one or more bulk releases as a result of iodinations that are performed during a given sampling interval. The two methods are shown to have maximum relative deviations ranging from -16 to +16%. PMID:9287093

  5. Preclinical pharmacological study on 125I-IPPA

    Institute of Scientific and Technical Information of China (English)

    1999-01-01

    Myocardial uptake of 125I-IPPA in rats showed a peak of 4.4% of injected dose per gram.The half elimination time of myocardium was 3.8min and the maximaluptake of thyroid is only 0.005%ID/organ at 120min.The initial halftime of 2.7min in rabbits was obtained from the elimination curve ofradioactivity in blood.In vitro binding test for 125I-IPPA to HSAshowed rather constant level of activation during two hours.The second peak of extraction was observed in major organs ofrats, in rabbits' elimination of radioactivity and in bindingtest for 125I-IPPA to albumin in vivo.Toxicity trial was up tostandard.The tolerance of a mouse to IPPA was 560 times as highas that of a person to IPPA.It demonstrated that 125I-IPPA couldbe quickly extracted by myocardium, and its catabolites were excretedin the urine with almost no iodine loss.All the results were found toagree with the expectations based on the principal metabolic path ofphenyl fatty acid.

  6. Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation

    International Nuclear Information System (INIS)

    Stereotactic brachytherapy (SBT) has been described in several publications as an effective, minimal invasive and safe highly focal treatment option in selected patients with well circumscribed brain tumors <4 cm. However, a still ongoing discussion about indications and technique is hindering the definition of a clear legitimation of SBT in modern brain tumor treatment. These controversies encompass the question of how intense the irradiation should be delivered into the target volume (dose rate). For instance, reports about the use of high does rate (HDR) implantation schemes (>40 cGy/h) in combination with adjuvant external beam radiation and/or chemotherapy for the treatment of malignant gliomas and metastases resulted in increased rates of radiation induced adverse tissue changes requiring surgical intervention. Vice versa, such effects have been only minimally observed in numerous studies applying low dose rate (LDR) regiments (3–8 cGy/h) for low grade gliomas, metastases and other rare indications. Besides these observations, there are, however, no data available directly comparing the long term incidences of tissue changes after HDR and LDR and there is, furthermore, no evidence regarding a difference between temporary or permanent LDR implantation schemes. Thus, recommendations for effective and safe implantation schemes have to be investigated and compared in future studies

  7. Bypassing the learning curve in permanent seed implants using state-of-the-art technology

    International Nuclear Information System (INIS)

    Purpose: The aim of this study was to demonstrate, based on clinical postplan dose distributions, that technology can be used efficiently to eliminate the learning curve associated with permanent seed implant planning and delivery. Methods and Materials: Dose distributions evaluated 30 days after the implant of the initial 22 consecutive patients treated with permanent seed implants at two institutions were studied. Institution 1 (I1) consisted of a new team, whereas institution 2 (I2) had performed more than 740 preplanned implantations over a 9-year period before the study. Both teams had adopted similar integrated systems based on three-dimensional (3D) transrectal ultrasonography, intraoperative dosimetry, and an automated seed delivery and needle retraction system (FIRST, Nucletron). Procedure time and dose volume histogram parameters such as D90, V100, V150, V200, and others were collected in the operating room and at 30 days postplan. Results: The average target coverage from the intraoperative plan (V100) was 99.4% for I1 and 99.9% for I2. D90, V150, and V200 were 191.4 Gy (196.3 Gy), 75.3% (73.0%), and 37.5% (34.1%) for I1 (I2) respectively. None of these parameters shows a significant difference between institutions. The postplan D90 was 151.2 Gy for I1 and 167.3 Gy for I2, well above the 140 Gy from the Stock et al. analysis, taking into account differences at planning, results in a p value of 0.0676. The procedure time required on average 174.4 min for I1 and 89 min for I2. The time was found to decrease with the increasing number of patients. Conclusion: State-of-the-art technology enables a new brachytherapy team to obtain excellent postplan dose distributions, similar to those achieved by an experienced team with proven long-term clinical results. The cost for bypassing the usual dosimetry learning curve is time, with increasing team experience resulting in shorter treatment times

  8. Production of 125I seed sources for brachytherapy uses

    International Nuclear Information System (INIS)

    The production of radioactive sources of 125I, used mainly for the brachytherapy of prostate and ocular cancer, is a work that is being carried out in the plant of production of radioisotopes (PPR) of the Nuclear Center Racso of the IPEN. The employed methodology is based on the 125I physical-chemistry adsorption at silver wires coated with palladium. In the realization of the tests, it has been considered the procedure used by India and Iran participants of this CRP. In the execution of this work, the 131I radioisotope is been used simulating the 125I, because in the PPR-IPEN we produce the 131I. In total 50 samples were used, they were divided in ten groups. In first place with nine working groups, the optimum conditions for work for the coating of the silver wires with palladium were obtained, these being the following: simple method, employing PdCl2 0.1 m, pH of 5.5 to 6.5 and a temperature of 100 deg. C. Later on, a series of tests were carried out to determine the appropriate parameters for the adsorption of 131I in the previously treated wires, these being the following: carrier concentration of Ki 0.03 m, time of adsorption of 6 hours, and temperature of 70 deg. C. Finally, the percentage of 131I adsorption was obtained in the silver wires tried previously with palladium chloride solution of 98.24%. The control of leachability was made, having very good results. To confirm these previously mentioned parameters, a test was made with ten pieces of silver wires, corresponding to the group 10, giving the confirmation as a result of these. Also, samples of the titanium tube have been sent for test with microplasma welding to a French company: air welding liquidates export. With these results obtained, subsequently the production of these radioactive sources will be carried out employing 125I as a radioisotope. (author)

  9. Preparation of 19 iodocholesterol labelled with 125I

    International Nuclear Information System (INIS)

    A new method of synthesis of 19-iodocholesterol labelled with 125I from commercial cholesterol is described. Its high chemical (96%) and radiochemical (99,9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriate for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (author). 2 figs., 9 refs

  10. Preparation of 19-iodocholesterol labelled with 125 I

    International Nuclear Information System (INIS)

    In this paper a new method of synthesis of 19-iodo cholesterol labelled with ''125 I, from commercial cholesterol, is described. Its high chemical (96%) and radiochemical (99.9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriates for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (Author) 9 refs

  11. 125I Labelling of Protein Using Immobilized Enzyme

    International Nuclear Information System (INIS)

    For an effective solid-phase labelling of protein with 125I, studies on the immobilization of lactoperoxidase (LPO) on the inner wall of polystyrene tubes were carried out. Labelling of bovine serum albumin (BSA) and insulin was also practiced using the LPO immobilized tubes. The immobilized enzyme of about 2.5 μ g/tube was sufficient for small scale labelling since the results of radio-paper chromatography of the labelling mixture of insulin indicated that the yields were sufficiently high (80%) even in the reactions conducted at room temperature for 60 sec. The results of the Sephadex column chromatography indicated that the labelled products were not contaminated with LPO-125I, and the radiochemical purity of the products was more than 90%. In considering the general trend that the 125I labelled protein obtained by using LPO maintains its intactness better than those obtained by using chloramine-T, together with the tendency of yield enhancing with increase of reactants-concentration, the LPO immobilized tube method is estimated to be one of the simple methods of labelling. The product might be applicable without further purification.

  12. Labeling Lanreotide with 125I and 188Re

    International Nuclear Information System (INIS)

    Lanreotide is a new somatostatin analogue. It can bind to human somatostatin receptor (hSSTR) subtype 2 through 5 with high affinity and to hSSTR subtype I with low affinity. We investigate labeling condition, quality control and stability in vitro of 125I-Lanreotide and 188Re-lanreotide respectively. (A) Lanreotide is labeled with 125I using Chloramine T. The effect of reaction condition (such as reaction time, pH value, Lanreotide amount, quantity of Chloramine T and reaction volume) on labeling yield is investigated in detail. (B) The labeling yield and radiochemical purity (RP) is measured with paper chromatography (PC) and Sep-Pak C18 Cartridge. (C) The stability of 125I-Lanreotide in vitro is investigated by labeling compound incubating for 48 hours at 37 deg C in the 0.9% sodium chloride solution and RP is tested by PC at specific time intervals. (D) Lanreotide is labeled directly with 188Re via the mixture of citrate and tartate using stannous chloride as reduced agent. The influence of reaction conditions such as pH, temperature, amount of stannous chloride, amount of Lanreotide and reaction time on labeling yield is investigated in detail. At the time, the stability in vitro quality control and animal test are evaluated

  13. Labeling Lanreotide with 125I and 188Re. China

    International Nuclear Information System (INIS)

    Lanreotide (D-β-Nal-Cys-Try-D-Trp-Lys-Val-Cys-Thr-NH2) is a new somatostatin analogue. It can bind to human somatostatin receptor (hSSTR) subtype 2 through 5 with high affinity and to hSSTR subtype 1 with low affinity. We investigate labeling condition, quality control and stability in vitro of 125I-Lanreotide and 188Re-lanreotide respectively. (A) Lanreotide is labeled with 125I using Chloramine T. The effect of reaction condition (such as reaction time, pH value, Lanreotide amount, quantity of Chloramine T and reaction volume) on labeling yield is investigated in detail. (B) The labeling yield and radiochemical purity (RP) is measured with paper chromatography (PC) and Sep-Pak C18 Cartridge. For PC method, 125I-Lanreotide is spotted on the Whatman No.1 paper and developed in the mixture of CH3CH2CH2CH2OH and CH3CH2OH and NH4OH (v/v/v=5:2:1), the Rf value of every component in the mobile phase is given in table 1. For Sep-Pak C18 Cartridge methods each cartridge is washed with 10 ml of ethanol followed by 10 ml of iso-CH3CH2CH2OH solution. Aliquots of 0.1 mI sample is loaded onto the cartridge, unbound peptide (sodium iodine-125) is eluted with 5 ml of 0.5mol/L sodium acetate solution, 125I-Lanreotide is eluted with 5 mI of 95% aqueous ethanol solution. (C) The stability of 125I-Lanreotide in vitro is investigated by labeling compound incubating for 48 hours at 37 deg. C in the 0.9% sodium chloride solution and RP is tested by PC at specific time intervals. (D) Lanreotide is labeled directly with 188Re via the mixture of citrate and tartate using stannous chloride as reduced agent. The influence of reaction conditions such as pH, temperature, amount of stannous chloride, amount of Lanreotide and reaction time on labeling yield is investigated in detail. At the time, the stability in vitro quality control and animal test are evaluated

  14. Autoradiographic comparison of [125I]epidepride and [125I]NCQ 298 binding to human brain extrastriated dopamine receptors

    International Nuclear Information System (INIS)

    Extrastriatal D2-dopamine receptors can be visualized in the monkey and human brain using the benzamides [11C]- and [76Br]FLB 457 in PET and [123I]epidepride in SPECT but not with the salicylamide analogues [76Br]FLB 463 and [123I]NCQ 298. To clarify the background for the differences in binding seen in vivo, we have compared the in vitro binding of [125I]epidepride and [125I]NCQ 298, using human whole hemisphere autoradiography. The images obtained with any radioligand showed detailed distribution with very dense binding in the putamen and the caudate nucleus and with the same detailed extrastriatal distribution. Thus, the divergent results obtained in vivo cannot be explained by different binding properties of the extrastriatal receptors

  15. Preparation of 19-iodo cholesterol labelled with 125 I; Preparacion del 19-yodocolesterol marcado con 125 I

    Energy Technology Data Exchange (ETDEWEB)

    Rodriguez, L.; Rebollo, D. V.; Ruiz, J. M.

    1986-07-01

    In this paper a new method of synthesis of 19-iodo cholesterol labelled with ''125 I, from commercial cholesterol, is described. Its high chemical (96%) and radiochemical (99.9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriates for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (Author) 9 refs.

  16. [Permanent endocardiac electrostimulation. Considerations on 511 implantations and reimplantations in 7 years of practice].

    Science.gov (United States)

    Mangiameli, S; Circo, A; Vanaria, D; Lombardo, D; Scalisi, A; Genovese, G; Galassi, A

    1977-06-30

    Permanent pacemakers were implanted and reimplanted in a total of 511 patients (mostly men) during a period of about 7 yr. Mean age was 67.9 yr. The cephalic route was used in nearly every case, with subclavicular implantation of the generator. Mean hospital stay was 7.6 days. Ventricular inhibition pacemakers were used in over 84% and fixed-frequency models in 7%. Mean pacemaker life was 24.1 months, with longer periods in the last months of the period of observation. The evaluation of battery run-down and recent and long-term complications is discussed, together with a particular type of decubitus of electrolytic origin. Hospital mortality was 2%. Survival was 91% at 1 yr and 54% at 6 yr. Emphasis is placed on the fact that subjects continue to be heart patients. Their well-being depends on psychological and general medical care, together with help from their, families and society, quite apart from cardiological attention. PMID:876509

  17. Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.

    Science.gov (United States)

    Tietz, Ole; Dzandzi, James; Bhardwaj, Atul; Valliant, John F; Wuest, Frank

    2016-03-15

    Cyclooxygenase-2 (COX-2) is the key enzyme in the prostaglandin synthesis pathway which is involved in various pathophysiological conditions. The enzyme is membrane bound and located inside of the endoplasmic reticulum and nuclear membrane. Effective perfusion of inhibitors to the active site requires lipophilic drugs, which consequently display high unspecific background accumulation, for example, in fatty tissues. The objective of this work was the development of a small molecule radiolabeled with a long-lived iodine radioisotope to enable longer imaging times and better target-to-background ratios. A group of iodinated compounds (8-10) was synthesized and identified as selective COX-2 inhibitors (COX-2 IC50=0.85-13 μM). Molecular docking results provided the theoretical support for the experimental COX-2 inhibition data. Furthermore, a novel (125)I-containing trifluoro-pyrimidine compound ([(125)I]Pyricoxib) was prepared via radioiododestannylation reaction as potent and selective COX-2 inhibitor. Radiosynthesis of [(125)I]Pyricoxib was accomplished with innovative fluorous chemistry using fluorous chloroamine-T (F-CAT) as novel oxidizing agent in high radiochemical yields of 91 ± 4%. PMID:26898334

  18. Development of procedure using plasma welding process to produce 125I seeds

    International Nuclear Information System (INIS)

    The prostate cancer, which is the second cause of death by cancer in men, overcome only by lung cancer, is a problem of public health in Brazil. Brachytherapy is among the possible available treatments for prostate cancer, in which small seeds containing 125I radioisotope are implanted in the prostate. The seed consists of a titanium sealed capsule with 0.8 mm external diameter and 4.5 mm length, containing a central silver wire with adsorbed 125I. The plasma arc welding is one of the viable techniques for the sealing process. The equipment used in this technique is less costly than in other processes. The main objective of this work was the development and the validation of the welding procedure using plasma welding process and the elaboration of a sealing routine according to Good Manufacturing Practices. The development of this work has presented the following phases: cut and cleaning of the titanium material, determination of the welding parameters, development of a device for holding the titanium tube during the welding process, validation of sealed sources according to ISO 2919 Sealed Radioactive Sources - General Requirements and Classification, leakage test according to ISO 9978 Sealed Radioactive Sources - Leakage Test Methods and metallographic assays. The developed procedure, to seal 125I seeds using plasma welding process, has shown to be efficient, satisfying all the established requirements of ISO 2919. The results obtained in this work have given the possibility to establish a routine production process according to the orientations presented in resolution RDC number 59 - Good Manufacturing Practices do Medical Products of the ANVISA - Brazilian Nacional Agency of Sanitary Surveillance. (author)

  19. Particle-rotor-model calculations in 125I

    Indian Academy of Sciences (India)

    Hariprakash Sharma; B Sethi; P Banerjee; Ranjana Goswami; R K Bhandari; Jahan Singh

    2001-07-01

    Recent experimental data on 125I has revealed several interesting structural features. These include the observation of a three quasiparticle band, prolate and oblate deformed bands, signature inversion in the yrast positive-parity band and identification of the unfavoured ℎ11/2 band showing very large signature splitting. In the present work, particle-rotor-model calculations have been performed for the ℎ11/2 band, using an axially symmetric deformed Nilsson potential. The calculations reproduce the experimental results well and predict a moderate prolate quadrupole deformation of about 0.2 for the band.

  20. The Anderson nomograms for permanent interstitial prostate implants: a briefing for practitioners

    International Nuclear Information System (INIS)

    Purpose: The objective of this report is to re-evaluate the role of the Anderson nomograms in treatment planning for permanent prostate implants. The incentive for revisiting this topic concerns three issues: (1) Although nomograms continue to be used in many centers for ordering seeds, few centers use them during treatment planning; (2) Whereas nomograms were designed to deliver a minimum peripheral dose for a uniform distribution of seeds in the gland, many practitioners use peripheral seed loading patterns to reduce urethral toxicity; and (3) As preoperative and intraoperative treatment planning is becoming standard, the apparent role of nomograms is diminished. The nomogram method is reviewed in terms of: (1) total activity predicted, (2) target coverage (as planned in the operating room and as calculated from postimplant computed tomography studies), and (3) reproducibility (i.e., patient-to-patient and planner-to-planner variability). In each case, the computer-optimization system for intraoperative planning currently in use at our institution was taken as the 'gold standard'. Methods and Materials: We compared for the same patient the results of nomogram planning to those yielded by genetic algorithm (GA) optimization in terms of total activity predicted (n=20 cases) and percent target coverage (n=5 cases). Furthermore, we examined retrospectively the dosimetry of 61 prostate implants planned with the GA (n=27) and the current implementation of Anderson nomograms (n=34). Results: Nomogram predictions of the total activity required are in good agreement (within 10%) with the GA-planned activity. However, computer-optimized plans consistently yield superior plans, as reflected in both pre- and postimplant analyses. We find also that user (specifically, treatment planner) implementation of the nomograms may be a major source of variability in nomogram planning - a difficulty to which robust computer optimization is less prone. Conclusions: Nomograms continue to

  1. 125I iothalamate an ideal marker for glomerular filtration

    International Nuclear Information System (INIS)

    The triiodinated angiographic contrast medium, iothalamate (usually labelled 125I), has been used extensively as a marker for glomerular filtration. The authors have studied the renal handling of 125I iothalamate (IOT) in vivo and in vitro in several species. In renal cortical slices from chicken, rabbit, rat, and monkey, the tissue-to-medium ratio of IOT was twice that of 51Cr-EDTA (EDTA) at 37 degrees C; a difference that was abolished at 0 degree C and markedly reduced by added o-iodohippurate or iodipamide. In five chickens the steady-state renal clearance of IOT (CIOT) was twice that of EDTA (CEDTA) or 3H inulin (C1); a difference that was abolished by administration of 100 mg/kg/hr of novobiocin, an organic anion transport inhibitor. CEDTA was similar to C1 before as well as after transport inhibition. Utilizing the Sperber technique the mean apparent tubular excretion fraction (ATEF) of IOT was 8%, while that of EDTA was 1%. After novobiocin coinfusion (new steady-state) ATEFIOT was significantly reduced and not different from that of EDTA (-1%). In the same animals the total urinary recovery of IOT was 84 and 57% before and after novobiocin, respectively, while corresponding values for EDTA was unchanged by the inhibitor. In seven rats the renal extraction of IOT was reduced from 29 to 17% by coinfusion of probenecid (5 mg/kg/hr). Corresponding extractions were 82 to 34% and 22% (unchanged) for PAH and EDTA, respectively

  2. Studies on characteristics of dosimetry for 125I ophthalmic applicator

    International Nuclear Information System (INIS)

    Isodose curves for 125I ophthalmic application in different geometry and activity can be obtained using the empirical formula based on suitable geometric model. The results of surface dose rate determined with lithium fluoride (LiF) thermoluminescent dosimeter (TLD's) chips in water-organic glass phantom and air had no obvious difference and the surface dose rate and its uniformity, (3.46 +- 0.011) and (0.178 +- 0.15) nGy/h·107Bq were obtained. Count measurements and dose determinations for the front and back etc. of the ophthalmic applicator with BaF2 scintillation detector and LiF TLD's had revealed the space distribution of dose for 125I ophthalmic applicator in which dose on the back was less than 0.1% of that on the front. The distribution of the absorbed dose rate along the eye axis had been measured using LiF TLD's in water-organic glass phantom. The measured and calculated dose data indicated that when measuring distances were larger than about 5 mm the experimental results agreed with those from calculation within the range of error, otherwise the measured values were lower, still it could be explained by experimental conditions

  3. Symptomatic sick sinus syndrome requiring permanent pacemaker implantation in a patient uwith mirror image dextrocardia with situs inversus and infertility.

    Science.gov (United States)

    Kahali, Dhiman; Mandal, Saroj; Mandal, Debasmita; Ghose, Arijit; Kanjilal, Souvik

    2013-01-01

    Situs inversus with dextrocardia is a congenital condition in which the heart is a mirror image of the anatomically normal heart on the right side. A patient presented with the sick sinus syndrome accompanying mirror image dextrocardia which was associated with double superior vena cava and a left sided inferior vena cava A permanent transvenous demand pacemaker was inserted because of repeated episodes of dizziness and a single episode of syncope with ECG showing bradycardia with junctional escape rhythm. Precise knowledge of the venous system and the location of the apex of the right ventricle were necessary prior to permanent pacemaker implantation. Without such knowledge pacing may be technically challenging.

  4. Pharmacokinetics and organ distribution of 125I-aprindine

    International Nuclear Information System (INIS)

    An attempt was made to label aprindine hydrochloride with I-125 by means of an exchange reaction. Organ distribution was determined in 10 rats where radioactivity was measured in the lung, heart, liver, kidney, spleen, brain, transverse muscle tissue and bone sections 5, 10, 30 and 60 min following i.v. injection. The high organ concentration was found in the lung, and also the maximum ratio organ: blood radioactivity was found for this organ. Whole body activity measurements revealed a half-life of nearly 6 hr. Excretion occurred primarily via the faeces. The pharmacokinetic properties of 14C- and 125I-aprindine hydrochloride do not therefore differ significantly. A whole body scintiscanning was carried out on an additional 12 rats and 6 rabbits. This revealed a marked enrichment in the lung compared to other organs in the time period 5 to 10 min. An image of relatively good quality was obtained compared to that of conventional perfusion scintiscanning with 131I-HSA. It is assumed that 125I-aprindine hydrochloride is concentrated in the lung parenchyma and is therefore largely unaffected by the immediate perfusion conditions. This is also confirmed in preliminary studies with 131I-aprindine in the scintiscanning of rabbits where voids of pneumonia activity are shown in the aprindine scintigram whereas with the perfusion method these are not. As expected, the reverse was shown to be true following experimental pulmonary embolism where voids were seen in the perfusion scintigram whilst the 131I-aprindine scintigram revealed hardly any areas of drops in activity. These properties possibly offer an improved diagnostic procedure for differentiating between pneumonia and lung infarct by combination with perfusion scintiscanning. (orig./MG)

  5. Autoradiographic comparison of [125I]epidepride and [125I]NCQ 298 binding to human brain extrastriated dopamine receptors.

    Science.gov (United States)

    Hall, H; Halldin, C; Jerning, E; Osterlund, M; Farde, L; Sedvall, G

    1997-07-01

    Extrastriatal D2-dopamine receptors can be visualised in the monkey and human brain using the benzamides [11C]- and [76Br]FLB 457 in PET and [123I]epidepride in SPECT but not with the salicylamide analogues [76Br]FLB 463 and [123I]NCQ 298. To clarify the background for the differences in binding seen in vivo, we have compared the in vitro binding of [125I]epidepride and [123I]NCQ 298, using human whole hemisphere autoradiography. The images obtained with any radioligand showed detailed distribution with very dense binding in the putamen and the caudate nucleus and with the same detailed extrastriatal distribution. Thus, the divergent results obtained in vivo cannot be explained by different binding properties of the extrastriatal receptors. PMID:9290072

  6. Metabolism and placental transfer of /sup 125/I-proinsulin and /sup 125/I-tyrosylated C-peptide in the pregnant rhesus monkey

    Energy Technology Data Exchange (ETDEWEB)

    Gruppuso, P.A.; Susa, J.B.; Sehgal, P.; Frank, B.; Schwartz, R.

    1987-10-01

    /sup 125/I-Proinsulin or /sup 125/I-tyrosylated-C-peptide (/sup 125/I-tyr-CP) was administered to pregnant Rhesus monkeys by bolus followed by constant infusion to examine placental transfer of these peptides. At the end of each infusion, fetuses were exsanguinated in situ via the umbilical vein. The bolus-constant infusion technique produced a steady state in maternal plasma of immunoprecipitable label, measured using excess insulin or C-peptide antiserum. In animals infused with /sup 125/I-proinsulin, analysis of umbilical venous plasma revealed no apparent transfer to the fetus of immunoprecipitable label. In animals infused with /sup 125/I-tyr-CP, 3-13% of the umbilical venous plasma radioactivity was immunoprecipitable, representing 1.4-5.8% of the immunoprecipitable radioactivity in maternal plasma at delivery. Gel filtration chromatography of umbilical venous plasma revealed that the immunoprecipitated moiety was a fragment of /sup 125/I-tyr-CP. Analysis of maternal plasma showed that the predominant peak of radioactivity represented intact C-peptide. A peak corresponding to the fetal immunoprecipitable peak was also present. Analysis of simultaneous maternal arterial and uterine vein plasma samples showed that degradation of /sup 125/I-tyr-CP occurred across the uterus. Studies in one nonpregnant and three postpartum animals indicated that pregnancy increased the rate of metabolism of /sup 125/I-tyr-CP. When /sup 125/I-tyr-CP was incubated with trophoblastic cells in culture, degradation to a species corresponding on gel filtration to the immunoprecipitable fetal metabolite was found. We conclude that proinsulin, like insulin, does not traverse the placenta. Immunoreactive fragments of C-peptide do cross, however, and pregnancy alters the metabolism of /sup 125/I-tyr-CP, probably owing to placental degradation.

  7. Metabolism and placental transfer of 125I-proinsulin and 125I-tyrosylated C-peptide in the pregnant rhesus monkey

    International Nuclear Information System (INIS)

    125I-Proinsulin or 125I-tyrosylated-C-peptide (125I-tyr-CP) was administered to pregnant Rhesus monkeys by bolus followed by constant infusion to examine placental transfer of these peptides. At the end of each infusion, fetuses were exsanguinated in situ via the umbilical vein. The bolus-constant infusion technique produced a steady state in maternal plasma of immunoprecipitable label, measured using excess insulin or C-peptide antiserum. In animals infused with 125I-proinsulin, analysis of umbilical venous plasma revealed no apparent transfer to the fetus of immunoprecipitable label. In animals infused with 125I-tyr-CP, 3-13% of the umbilical venous plasma radioactivity was immunoprecipitable, representing 1.4-5.8% of the immunoprecipitable radioactivity in maternal plasma at delivery. Gel filtration chromatography of umbilical venous plasma revealed that the immunoprecipitated moiety was a fragment of 125I-tyr-CP. Analysis of maternal plasma showed that the predominant peak of radioactivity represented intact C-peptide. A peak corresponding to the fetal immunoprecipitable peak was also present. Analysis of simultaneous maternal arterial and uterine vein plasma samples showed that degradation of 125I-tyr-CP occurred across the uterus. Studies in one nonpregnant and three postpartum animals indicated that pregnancy increased the rate of metabolism of 125I-tyr-CP. When 125I-tyr-CP was incubated with trophoblastic cells in culture, degradation to a species corresponding on gel filtration to the immunoprecipitable fetal metabolite was found. We conclude that proinsulin, like insulin, does not traverse the placenta. Immunoreactive fragments of C-peptide do cross, however, and pregnancy alters the metabolism of 125I-tyr-CP, probably owing to placental degradation

  8. Brain necrosis after permanent low-activity iodine-125 implants: case report and review of toxicity from focal radiation.

    Science.gov (United States)

    Bampoe, J; Nag, S; Leung, P; Laperriere, N; Bernstein, M

    2000-01-01

    Focal irradiation has emerged as a useful modality in the management of malignant brain tumors. Its main limitation is radiation necrosis. We report on the radiation dose distribution in the cerebellum of a patient who developed imaging and autopsy diagnosis of radiation necrosis after permanent iodine-125 implants for a solitary osseous plasmacytoma of her left occipital condyle. A 55-year-old woman initially presented with neck and occipital pain and a lytic lesion of her left occipital condyle. A cytological diagnosis of solitary osseous plasmacytoma was made by transpharyngeal needle biopsy. After an initial course of external beam radiation, the patient required further treatment with systemic chemotherapy 21 months later for clinical and radiographic progression of her disease. She ultimately required subtotal surgical resection of an anaplastic plasmacytoma with intracranial extension. Permanent low-activity iodine-125 seeds were implanted in the tumor cavity. Satisfactory local control was achieved. However, clinical and imaging signs of radiation damage appeared 28 months after iodine-125 seed implantation. Progressive systemic myeloma led to her death 11 years after presentation and 9 years after seed implantation. Radiation dose distribution is described, with a discussion of toxicity from focal radiation dose escalation.

  9. An algorithm for efficient metal artifact reductions in permanent seed implants

    Energy Technology Data Exchange (ETDEWEB)

    Xu Chen; Verhaegen, Frank; Laurendeau, Denis; Enger, Shirin A.; Beaulieu, Luc [Departement de Radio-Oncologie et Centre de Recherche en Cancerologie, Universite Laval, Centre Hospitalier Universitaire de Quebec, 11 Cote du Palais, Quebec, Quebec G1R 2J6 (Canada) and Departement de Genie Electrique et Genie Informatique, Laboratoire de Vision et Systemes Numeriques, Universite Laval, Quebec, Quebec G1K 7P4 (Canada); Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht 6201 BN (Netherlands) and Oncology Department, Montreal General Hospital, McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4 (Canada); Departement de Genie Electrique et Genie Informatique, Laboratoire de Vision et Systemes Numeriques, Universite Laval, Quebec, Quebec G1K 7P4 (Canada); Departement de Radio-Oncologie et Centre de Recherche en Cancerologie, Universite Laval, Centre Hospitalier Universitaire de Quebec, 11 Co circumflex te du Palais, Quebec, Quebec G1R 2J6 (Canada); Departement de Radio-Oncologie et Centre de Recherche en Cancerologie, Universite Laval, Centre Hospitalier Universitaire de Quebec, 11 Cote du Palais, Quebec, Quebec G1R 2J6 (Canada) and Departement de Physique, de Genie Physique et d' Optique, Universite Laval, Quebec, Quebec G1K 7P4 (Canada)

    2011-01-15

    Purpose: In permanent seed implants, 60 to more than 100 small metal capsules are inserted in the prostate, creating artifacts in x-ray computed tomography (CT) imaging. The goal of this work is to develop an automatic method for metal artifact reduction (MAR) from small objects such as brachytherapy seeds for clinical applications. Methods: The approach for MAR is based on the interpolation of missing projections by directly using raw helical CT data (sinogram). First, an initial image is reconstructed from the raw CT data. Then, the metal objects segmented from the reconstructed image are reprojected back into the sinogram space to produce a metal-only sinogram. The Steger method is used to determine precisely the position and edges of the seed traces in the raw CT data. By combining the use of Steger detection and reprojections, the missing projections are detected and replaced by interpolation of non-missing neighboring projections. Results: In both phantom experiments and patient studies, the missing projections have been detected successfully and the artifacts caused by metallic objects have been substantially reduced. The performance of the algorithm has been quantified by comparing the uniformity between the uncorrected and the corrected phantom images. The results of the artifact reduction algorithm are indistinguishable from the true background value. Conclusions: An efficient algorithm for MAR in seed brachytherapy was developed. The test results obtained using raw helical CT data for both phantom and clinical cases have demonstrated that the proposed MAR method is capable of accurately detecting and correcting artifacts caused by a large number of very small metal objects (seeds) in sinogram space. This should enable a more accurate use of advanced brachytherapy dose calculations, such as Monte Carlo simulations.

  10. 125I-TOC和125I-F-PGA放射化学纯度的测定%Determination of Radiochemical Purity of 125 I-TOC and 125 I-F-PGA

    Institute of Scientific and Technical Information of China (English)

    杨科亚; 范我; 张友九; 许玉杰; 朱然; 胡明江

    2006-01-01

    为比较3种测定125I标记的奥曲肽(TOC)和叶酸-青霉素酰化酶复合物(F-PGA)的放射化学纯度(RCP)的方法是否具有一致性,采用Iodogen法对TOC和F-PGA进行放射性碘标记,并用高效液相色谱法(HPLC)、三氯醋酸(TCA)沉淀法和纸层析法测定标记物的放射化学纯度(RCP),其中TCA沉淀法设4种蛋白浓度以观察其对RCP测定的影响.结果表明,HPLC和纸层析法均能有效分离标记物和游离碘,且HPLC测定这种标记物的RCP最为精确可信.在TCA沉淀法中,用0.2%的小牛血清白蛋白(BSA)测得的RCP最低,而用其它3个BSA浓度测得的RCP则无明显差异(P>0.05);当RCP<10%时,TCA沉淀法与纸层析法测得的RCP间无明显差异(P>0.05),而要高于HPLC(P<0.01);当RCP>10%时,对125I-TOC而言,TCA沉淀法要略低于HPLC和纸层析(P<0.05),但后2种方法无明显差异(P>0.05),且对125I-F-PGA而言,3种方法无明显差异(P>0.05).3种方法两两之间显著相关(r=0.996~0.999,P<0.001).

  11. Optimization of sup 125 I ophthalmic plaque brachytherapy

    Energy Technology Data Exchange (ETDEWEB)

    Astrahan, M.A.; Luxton, G.; Jozsef, G.; Liggett, P.E.; Petrovich, Z. (Univ. of Southern California School of Medicine, Los Angeles (USA))

    1990-11-01

    Episcleral plaques containing {sup 125}I sources are often used in the treatment of ocular melanoma. Within four years post-treatment, however, the majority of patients experience some visual loss due to radiation retinopathy. The high incidence of late complications suggests that careful treatment optimization may lead to improved outcome. The goal of optimization would be to reduce the magnitude of vision-limiting complications without compromising tumor control. We have developed a three-dimensional computer model for ophthalmic plaque therapy which permits us to explore the potential of various optimization strategies. One simple strategy which shows promise is to maximize the ratio of dose to the tumor apex (T) compared to dose to the macula (M). By modifying the parameters of source location, activity distribution, source orientation, and shielding we find that the calculated T:M ratio can be varied by a factor of 2 for a common plaque design and posterior tumor location. Margins and dose to the tumor volume remain essentially unchanged.

  12. Simulation of strand break induction by DNA incorporated 125I

    International Nuclear Information System (INIS)

    Monte Carlo calculation of 125I Auger cascades has provided electron spectra for individual decays with kinetic energies determined by Dirac-Fock methods. For these Auger electrons, track structures in liquid water have been generated and superimposed on a straight DNA plasmid model with atomic coordinates taken from X ray diffraction studies. Due to its high geometrical resolution, this DNA model makes it possible to localize the energy deposition or/and radical production events relative to the submolecular units of the DNA strands (base, sugar, phosphate). Furthermore, it is possible to distinguish between events inside (direct) and outside (indirect, radical production) of the atomic volumes of the DNA. On the basis of different assumptions for the effectiveness of strand break induction by direct hits and by OH· and H· radicals, the yields for single- and double strand breaks, as well as the strand break distribution as a function of the distance from the decay site, has been evaluated and compared with experimental and theoretical results from the literature

  13. Prostate dose calculations for permanent implants using the MCNPX code and the Voxels phantom MAX

    Energy Technology Data Exchange (ETDEWEB)

    Reis Junior, Juraci Passos dos; Silva, Ademir Xavier da, E-mail: jjunior@con.ufrj.b, E-mail: Ademir@con.ufrj.b [Coordenacao dos Programas de Pos-Graduacao de Engenharia (COPPE/UFRJ), RJ (Brazil). Programa de Engenharia Nuclear; Facure, Alessandro N.S., E-mail: facure@cnen.gov.b [Comissao Nacional de Energia Nuclear (CNEN), Rio de Janeiro, RJ (Brazil)

    2010-07-01

    This paper presents the modeling of 80, 88 and 100 of {sup 125}I seeds, punctual and volumetric inserted into the phantom spherical volume representing the prostate and prostate phantom voxels MAX. Starting values of minimum and maximum activity, 0.27 mCi and 0.38 mCi, respectively, were simulated in the Monte Carlo code MCNPX in order to determine whether the final dose, according to the integration of the equation of decay at time t = 0 to t = {infinity} corresponds to the default value set by the AAPM 64 which is 144 Gy. The results showed that consider sources results in doses exceeding the percentage discrepancy of the default value of 200%, while volumetric consider sources result in doses close to 144 Gy. (author)

  14. Binding and degradation of [125I]human growth hormone in rat adipocytes

    International Nuclear Information System (INIS)

    Iodinated human growth hormone [( 125I]hGH) binds to both specific and nonspecific sites on the surface of adipocytes isolated from the epididymal fat of normal rats. When adipocytes were incubated at 37 C with 1 nM [125I]hGH, specific binding increased for 30-60 min and thereafter remained approximately constant as long as the hormone was present in the medium. About 90% of the 125I released was soluble in 5% trichloroacetic acid and was in the form of iodotyrosine. The rate of 125I release from specific binding sites decreased by a factor of 4 when the temperature was lowered from 37 to 17 C. Replacement of some of the sodium chloride in the buffer with 25 mM ammonium chloride had little or no effect on the amount on 125I that bound to cells when [125I]hGH was present in the medium, but completely blocked the release of 125I from cells transferred to hormone-free medium. Ammonium chloride also significantly reduced both the release of 125I from nonspecific binding sites and the amount of 125I recovered in trichloroacetic acid-soluble form. Cloroquine, leupeptin, or colchicine nearly doubled the specific binding of [125I]hGH after 180 min and markedly slowed the release of 125I when cells were transferred to hormone-free medium. All of these agents also significantly reduced the rate of release of 125I from nonspecific binding sites. Incubation of adipose tissue from hypophysectomized rats with ammonium chloride, leupeptin, or colchicine failed to alter the ability of GH to increase glucose oxidation, induce refractoriness, or promote lipolysis in the presence of theophylline

  15. An (125)I-labeled octavalent peptide fluorescent nanoprobe for tumor-homing imaging in vivo.

    Science.gov (United States)

    Luo, Haiming; Shi, Jiyun; Jin, Honglin; Fan, Di; Lu, Lisen; Wang, Fan; Zhang, Zhihong

    2012-06-01

    Targeting radiopeptides are promising agents for radio-theranostics. However, in vivo evaluation of their targeting specificity is often obscured by their short biologic half-lives and low binding affinities. Here, we report an approach to efficiently examine targeting radiopeptides with a new class of octavalent peptide fluorescent nanoprobe (Octa-FNP) platform, which is composed of candidate targeting peptides and a tetrameric far-red fluorescent protein (tfRFP) scaffold. To shed light on this process, (125)I-Octa-FNP, (125)I-tfRFP and (125)I-peptide were synthesized, and their targeting functionalities were compared. Both fluorescence imaging and radioactive quantification results confirmed that (125)I-Octa-FNP had a significantly higher cellular binding capability than (125)I-tfRFP. In vivo biodistribution studies show that at 6 h post-injection, (125)I-Octa-FNP had 2-fold and 30-fold higher tumor uptake than that of (125)I-tfRFP and (125)I-peptide, respectively. Moreover, γ-imaging at 24 h post-injection revealed a remarkable accumulation of (125)I-Octa-FNP in the tumor while maintaining an extremely low background contrast, which was further confirmed by immunofluorescence analysis. These data suggested that, as an engineered and multivalent platform, Octa-FNP could enhance the tumor targeting of a designed peptide and provide excellent contrast radioimaging, making it a valuable tool for the evaluation of the targeting ability of specifically designed radiopeptides for cancer theranostics.

  16. Biodistribution of 125I labeled recombinant macrophage migration inhibitory factors in inflammatory model of mice

    International Nuclear Information System (INIS)

    To evaluate 125I labeled recombinant macrophage migration inhibitory factors (rMIF) for the scintigraphic imaging of inflammation, rMIF was labeled with 125I by Iodo- gen method. 125I-rMIF was isolated by Sephadex G25 column. The stability, immune specificity of 125I-rMIF and its biodistribution in inflammatory model of mice were studied. The labeling yield of 125I-rMIF was 96.5%. It was stable within 48 h at room temperature. The biodistribution results showed that the 125I-rMIF was metabolized by the liver, the radioactivity clearance mainly happened in the kidney and the speed of the blood clearance was rapid. After caudal vein iniection with 125I-rMIF, the ratio of radioactivity uptake between inflammatory limb (target) and contra lateral healthy limb (non target)(T/NT) were 1.42, 1.35, 2.18 and 2.05 at 0.5, 1, 6, 24 h respectively. 125I-rMIF had the capability of locating the inflammatory foci. The advance of it is more obviously at the late stage than that at the early stage. 125I-rMIF may be a potential agent for the diagnosis of concealed and subacute inflammatory disease. (authors)

  17. A comparative study of 19-iodo cholesterol-125I 3-acetate and Na 125I in liquid scintillation measurements; Estudio comparativo del acetato de 19-iodocolesterol- -125I con Nal25I en medidas por centelleo liquido

    Energy Technology Data Exchange (ETDEWEB)

    Rodriguez Barquero, L.; Grau Malonda, A.; Los Arcos Merino, J. M.; Grau Carles, A.

    1994-07-01

    A comparative study of performance of 19-iodo cholesterol {sup 1}25I 3-acetate and sodium iodide samples labeled with 125I is presented for liquid scintillation counting measurements. Quench effect, count rate stability and spectral evolution of samples have been followed for several weeks in Toluene, Hisafe II, Instagel, Dioxane-naphthalene and Toluene-alcohol scintillators. Organic samples have negligible quench effect in the interval of I concentration of 0-90 {mu}g and inorganic samples only show a very small variation, lower than 12%, for Dioxane-naphthalene, in the same range of concentration. Satisfactory stability is obtained in general for both, organic and inorganic samples, but small counting losses, 0.03% for 19-iodocholesterol 1 I 3-acetate samples in Tolue ne-alcohol and 0 .04% for Na 125I samples in Dioxane-naphthalene and Toluene-alcohol, have been reported. (Author) 8 refs.

  18. Novel Injectable Interpenetrating Polymer Network as a Semi-Permanent Injectable Implant for Soft Tissue Augmentation

    OpenAIRE

    Leung, Joanne C.

    2015-01-01

    Injectable fillers have been widely used for soft tissue augmentation in cosmetic procedures, as well as minimally invasive treatment for medical conditions such as urinary and fecal incontinence, vesicoureteral reflux and vocal cord repair. The market for injectable fillers is a multibillion dollar industry worldwide, and each FDA-approved injectable filler has its own drawbacks, namely, lack of durability for temporary fillers, and difficulty in injection for semi-permanent to permanent...

  19. 125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments

    Science.gov (United States)

    Gilani, Saba; Zhong, Zhihui; Zhang, Tao; Zhang, Fujun; Gao, Fei

    2016-01-01

    Purpose This study sought to assess the safety and effect of 125I seed implantation for palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments. Materials and Methods 89 patients with painful bone metastases secondary to lung cancer were consented and enrolled in this study from June 2013 to May 2015. All patients had failed or refused conventional treatments underwent percutaneous CT-guided 125I seed implantation. The Brief Pain Inventory (BPI) was used to measure pain intensity prior to treatment (T0), 2, 4, 6, 8 and 12 weeks (T2, T4, T6, T8 and T12) after treatment in a 24-hour period. Analgesic, quality of life (QOL) scores and complications were also recorded. Four patients were excluded as they were lost to follow-up or had incomplete data. Results 85 patients with 126 bone metastases from lung cancer were treated. There were significantly lower scores after treatment in the visual analog scale (VAS) and analgesic. The VAS scores for worst pain was 6.3±1.8 at T0. At T2, T4, T6, T8 and T12, the score in a 24-hour period decreased to 4.9±1.2 (Pmetastases from lung cancer after failure or rejection of conventional treatments. PMID:26919235

  20. First report of a permanent breast 103Pd seed implant as adjuvant radiation treatment for early-stage breast cancer

    International Nuclear Information System (INIS)

    Purpose: A new technique of adjuvant partial breast irradiation using 103Pd permanent breast seed implants (PBSI) is presented. The procedure is performed in a single 1-hour session under local anesthesia. Methods and Materials: Patients referred to a single institution for adjuvant radiotherapy after lumpectomy for an infiltrating ductal carcinoma ≤3 cm in diameter, surgical margin ≥2 mm, no extensive in situ carcinoma, no lymphovascular invasion, and minimal or negative lymph node involvement were offered a PBSI. Results: Between May and December 2004, 31 eligible patients underwent CT scan and ultrasound simulations assessing PBSI feasibility. Fifteen were excluded because of feasibility issues, and 16 received PBSI. A minimal peripheral dose of 90 Gy was prescribed to the planning target volume corresponding to the clinical target volume identified on the CT scan plus a margin of 1 cm. The procedure was well tolerated; 56% of the patients reported no pain during the procedure, and 46% of the patients developed National Cancer Institute Common Toxicity Criteria Grade 1 acute reaction. None experienced toxicity Grade 2 or 3. Conclusions: Permanent breast seed implantation seems feasible and well tolerated on these preliminary clinical data and represents an ultimate step in the reduction of treatment fraction for partial breast irradiation

  1. Influence of breast composition and interseed attenuation in dose calculations for post-implant assessment of permanent breast 103Pd seed implant

    Science.gov (United States)

    Afsharpour, Hossein; Pignol, Jean-Philippe; Keller, Brian; Carrier, Jean-François; Reniers, Brigitte; Verhaegen, Frank; Beaulieu, Luc

    2010-08-01

    The impact of tissue heterogeneity and interseed attenuation is studied in post-implant evaluation of five clinical permanent breast 103Pd seed implants using the Monte Carlo (MC) dose calculation method. Dose metrics for the target (PTV) as well as an organ at risk (skin) are used to visualize the differences between a TG43-like MC method and more accurate MC methods capable of considering the breast tissue heterogeneity as well as the interseed attenuation. PTV dose is reduced when using a breast tissue model instead of water in MC calculations while the dose to the skin is increased. Furthermore, we investigate the effect of varying the glandular/adipose proportion of the breast tissue on dose distributions. The dose to the PTV (skin) decreases (increases) with the increasing adipose proportion inside the breast. In a complete geometry and compared to a TG43-like situation, the average PTV D90 reduction varies from 3.9% in a glandular breast to 35.5% when the breast consists entirely of adipose. The skin D10 increases by 28.2% in an entirely adipose breast. The results of this work show the importance of an accurate and patient-dependent breast tissue model to be used in the dosimetry for this kind of low energy implant.

  2. Influence of breast composition and interseed attenuation in dose calculations for post-implant assessment of permanent breast {sup 103}Pd seed implant

    Energy Technology Data Exchange (ETDEWEB)

    Afsharpour, Hossein; Beaulieu, Luc [Departement de Radio-Oncologie et Centre de recherche en cancerologie de l' Universite Laval, Centre Hospitalier Universitaire de Quebec, 11 Cote du Palais, Quebec, QC G1R 2J6 (Canada); Pignol, Jean-Philippe; Keller, Brian [Department of Radiation Oncology, Sunnybrook and Women' s Health Sciences Centre, University of Toronto, Toronto, Ontario (Canada); Carrier, Jean-Francois [Departement de Radiologie, Radio-Oncologie et Medecine Nucleaire, Hopital Notre-Dame de CHUM, 1560 Sherbrooke E, Montreal, QC H2L 4M1 (Canada); Reniers, Brigitte; Verhaegen, Frank, E-mail: beaulieu@phy.ulaval.c [Department of Radiation Oncology (MAASTRO), GROW, University Hospital Maastricht, Maastricht (Netherlands)

    2010-08-21

    The impact of tissue heterogeneity and interseed attenuation is studied in post-implant evaluation of five clinical permanent breast {sup 103}Pd seed implants using the Monte Carlo (MC) dose calculation method. Dose metrics for the target (PTV) as well as an organ at risk (skin) are used to visualize the differences between a TG43-like MC method and more accurate MC methods capable of considering the breast tissue heterogeneity as well as the interseed attenuation. PTV dose is reduced when using a breast tissue model instead of water in MC calculations while the dose to the skin is increased. Furthermore, we investigate the effect of varying the glandular/adipose proportion of the breast tissue on dose distributions. The dose to the PTV (skin) decreases (increases) with the increasing adipose proportion inside the breast. In a complete geometry and compared to a TG43-like situation, the average PTV D{sub 90} reduction varies from 3.9% in a glandular breast to 35.5% when the breast consists entirely of adipose. The skin D{sub 10} increases by 28.2% in an entirely adipose breast. The results of this work show the importance of an accurate and patient-dependent breast tissue model to be used in the dosimetry for this kind of low energy implant.

  3. Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds

    International Nuclear Information System (INIS)

    The aim was to identify preimplant factors affecting postimplant prostate volume and the increase in prostate volume after transperineal interstitial prostate brachytherapy with 125I free seeds. We reviewed the records of 180 patients who underwent prostate brachytherapy with 125I free seeds for clinical T1/T2 prostate cancer. Eighty-one (45%) of the 180 patients underwent neoadjuvant hormonal therapy. No patient received supplemental external beam radiotherapy. Postimplant computed tomography was undertaken, and postimplant dosimetric analysis was performed. Univariate and multivariate analyses were performed to identify preimplant factors affecting postimplant prostate volume by computed tomography and the increase in prostate volume after implantation. Preimplant prostate volume by transrectal ultrasound, serum prostate-specific antigen, number of needles, and number of seeds implanted were significantly correlated with postimplant prostate volume by computed tomography. The increase in prostate volume after implantation was significantly higher in patients with neoadjuvant hormonal therapy than in those without. Preimplant prostate volume by transrectal ultrasound, number of needles, and number of seeds implanted were significantly correlated with the increase in prostate volume after implantation. Stepwise multiple linear regression analysis showed that preimplant prostate volume by transrectal ultrasound and neoadjuvant hormonal therapy were significant independent factors affecting both postimplant prostate volume by computed tomography and the increase in prostate volume after implantation. The results of the present study show that preimplant prostate volume by transrectal ultrasound and neoadjuvant hormonal therapy are significant preimplant factors affecting both postimplant prostate volume by computed tomography and the increase in prostate volume after implantation

  4. Development of procedure using plasma welding process to produce {sup 125}I seeds; Desenvolvimento de procedimento utilizando processo de soldagem plasma para confeccao de sementes de {sup 125}I

    Energy Technology Data Exchange (ETDEWEB)

    Feher, Anselmo

    2006-07-01

    The prostate cancer, which is the second cause of death by cancer in men, overcome only by lung cancer, is a problem of public health in Brazil. Brachytherapy is among the possible available treatments for prostate cancer, in which small seeds containing {sup 125}I radioisotope are implanted in the prostate. The seed consists of a titanium sealed capsule with 0.8 mm external diameter and 4.5 mm length, containing a central silver wire with adsorbed {sup 125}I. The plasma arc welding is one of the viable techniques for the sealing process. The equipment used in this technique is less costly than in other processes. The main objective of this work was the development and the validation of the welding procedure using plasma welding process and the elaboration of a sealing routine according to Good Manufacturing Practices. The development of this work has presented the following phases: cut and cleaning of the titanium material, determination of the welding parameters, development of a device for holding the titanium tube during the welding process, validation of sealed sources according to ISO 2919 Sealed Radioactive Sources - General Requirements and Classification, leakage test according to ISO 9978 Sealed Radioactive Sources - Leakage Test Methods and metallographic assays. The developed procedure, to seal {sup 125}I seeds using plasma welding process, has shown to be efficient, satisfying all the established requirements of ISO 2919. The results obtained in this work have given the possibility to establish a routine production process according to the orientations presented in resolution RDC number 59 - Good Manufacturing Practices do Medical Products of the ANVISA - Brazilian Nacional Agency of Sanitary Surveillance. (author)

  5. Exploration of dopamine transporter and D2 receptors in morphine dependent rats through 125I-β-CTT, 125I-IBZM cerebral autoradiography and the biodistribution study

    International Nuclear Information System (INIS)

    Objective: To explore the variation of cerebral dopamine (DA) transmitting system in morphine dependent (MD) rats using dopamine transporter (DAT) and D2 receptors imaging agent. Methods: MD model rats were established by using a two-compartment (C1 and C2-morphine conditioned compartment) apparatus for assessing morphine conditioned place preferences in rats. 125I-2β-carbomethoxy-3β-(4-iodophenyl) tropane (125I-β-CIT) and 125I-3-iodo-2-hydroxy-6-methoxy-N[(1-ethyl-2-pyrrolidinyl) methyl] benzamide (125I-IBZM) cerebral DAT and D2 receptor autoradiography and biodistribution study were used to evaluate the variation of DAT and D2 receptors in morphine dependent rats. Results: The mean time of MD rats entering from C1 to C2 was (0.84 +- 0.50) min after 6 days' conditioned place preference training, shorter than that of the control group [(2.40 +- 1.10) min, P 125I-β-CIT uptake ratio of striatum (ST)/cerebellum (CB) and nucleus acumens (NAC)/CB in MD group were 4.76 +- 0.92 and 2.72 +- 0.96, significantly lower than that of control group (5.92 +- 0.67 and 4.16 +- 0.56, P 125I-IBZM uptake ratio in MD group were 4.11 +- 0.56 and 2.64 +- 0.25, lower than that in control group (5.43 +- 0.74 and 3.49 +- 0.65, P 125I-β-CIT, 125I-IBZM biodistribution study also showed that the DAT and D2 binding sites were reduced in ST of MD group by (21.68 +- 11.11)% and (18.69 +- 9.97)% comparing to the controls, respectively. Conclusions: The DAT and D2 receptors in both ST and NAC were all involved and reduced to some extent in morphine dependent model rats, the DAT and D2 receptor imaging agent could reflect the variation of DAT and D2receptors, this would afford the theoretical basis for D2 receptors and DAT imaging in study on preventing drug addiction and on its abstinence

  6. Some quantitative aspects of the labelling of proteins with 125 I by the iodine monochloride method.

    Science.gov (United States)

    Ceska, M; Sjödin, A V; Grossmüller, F

    1971-01-01

    The labelling of proteins by the iodine monochloride method was studied by using a mathematical model. The equations used were primarily derived from the mass law equation of the isotopic exchange reaction between [(125)I]iodide and iodine monochloride. For convenient application, all equations were programmed into a computing desk-top calculator. To support the validity of the theoretical model, a series of iodinations of insulin were performed under various labelling conditions. The results of these experiments compare well with the theoretically derived values. Deviations from the theoretical values occurring at molar ratios of [(125)I]iodide to iodine monochloride 4.0 are explained and suggestions made about how to prevent them. The mathematical model was used to simulate the isotopic exchange, and the iodination reaction under various conditions, to study (a) the influence of the amount of [(125)I]iodide on the amount of [(125)I]iodine monochloride formed, (b) the influence of the specific radioactivity of [(125)I]iodide on the amount of [(125)I]iodine monochloride formed, and (c) the influence of the specific radioactivity of [(125)I]iodide on the number of millicuries needed for labelling to a desired extent.

  7. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique

    International Nuclear Information System (INIS)

    Purpose: To compare the target coverage and dose to normal tissues after I-125 transperineal permanent implantation (TPI) of the prostate in 90 patients treated with one of three different transperineal techniques. Methods and Materials: Detailed postimplant dosimetric evaluations of permanent I-125 implantation procedures were performed on 30 consecutive patients treated between 1995-1996 who underwent TPI using a preplanning CT-based technique, on 30 consecutive patients treated in 1997-1998 who underwent an ultrasound-guided approach with intraoperative determination of seed distribution based on an I-125 nomogram, and on 30 consecutive patients in 1998-1999 who underwent TPI with intraoperative computer-based 3-dimensional conformal optimization. For all three techniques, postimplant CT scans were obtained 4-6 hours after TPI. Dosimetric parameters included V100, V90, V150, D100, D90, D80, as well as maximal and average doses to the urethra and rectal wall. These parameter outcomes are reported as a percentage of the prescription dose. Results: The intraoperative 3D-optimized technique (I-3D) provided superior target coverage with the prescription dose for all dosimetric variables evaluated compared to the other treatment techniques. The median V100, V90, and D90 values for the I-3D technique were 96%, 98%, and 116%, respectively. In contrast, the V100, V90, and D90 values for the CT preplan and ultrasound manual optimization approaches were 86%, 89%, and 88%, respectively and 88%, 92%, and 94%, respectively (I-3D versus other techniques: p < 0.001). The superior target coverage with the I-3D technique was also associated with a higher cumulative implant activity required by the optimization program. A multivariate analysis determined that the treatment technique (I-3D versus other approaches) was an independent predictor of improved target coverage for each parameter analyzed (p < 0.001). In addition, higher cumulative implant activities and smaller prostate

  8. Efficient radiolabeling of rutin with 125I and biodistribution study of radiolabeled rutin

    International Nuclear Information System (INIS)

    The purpose of the current research is to synthesize radiolabeled rutin for biodistribution study and SPECT/CT image of rutin. The optimized radiolabeling condition provided 125I-labeled rutin with 53.5 % of radiochemical yield. Most of orally administered 125I-labeled rutin was initially found in the stomach and small intestine and a portion of the product was then distributed in internal organs. While intravenously injected 125I-labeled rutin was accumulated in liver and then a large part of it was transferred to small intestine. The present results provided an efficient radiolabeling method of flavonoid glycoside as well as quantitative organ distribution of rutin. (author)

  9. Labelling of ochratoxins with sup 3 H or sup 125 I

    Energy Technology Data Exchange (ETDEWEB)

    Schmiedova, D.; Veres, K.; Cerny, B. (Ceskoslovenska Akademie Ved, Prague (Czechoslovakia). Ustav Nuklearni Biologie a Radiochemie); Ruprich, J. (Institut Hygieny a Epidemiologie, Prague (Czechoslovakia)); Nemecek, J. (Slovak Academy of Sciences, Prague (Czechoslovakia). Inst. of Microbiology)

    1989-01-01

    Catalytic hydrogenation of ochratoxin A by carrier-free tritium was used to prepare {sup 3}H-ochratoxin B with a high specific activity. Iodination of ochratoxin B by carrier-free Na {sup 125}I using the chloramine method yielded {sup 125}I-ochratoxin with a high specific activity. Another {sup 125}I-derivative of ochratoxin A was prepared by iodination of an ochratoxin A - L-tyrosine-methylester conjugate. All three radioactive preparations were found to be useful for radioimmunoassay. (author).

  10. OER and RBE for 125I and 192Ir at low dose rate on mammalian cells

    International Nuclear Information System (INIS)

    The oxygen enhancement ratio (OER) for 125I and 192Ir as well as the relative biological effectiveness (RBE) at low dose rates (40-80 cGy h-1) were determined for B16 melanoma cells in culture. The OER was found to be 2.1±0.03 for 125I and 2.7±0.04 for 192Ir. The RBE for 125I relative to 192Ir was determined as 1.8±0.03 under aerated conditions and as 2.4±0.03 under hypoxia. 18 refs.; 5 figs.; 1 table

  11. In vivo study about specific captation of 125 I-insulin by rat brain structures

    International Nuclear Information System (INIS)

    The specific captation of 125 I-insulin was evaluated by brain structures, as olfactory bulbous, hypothalamus and cerebellum in rats, from in vivo experiences that including two different aspects: captation measure of 125 I-insulin after the intravenous injection of the labelled hormone, in fed rats and in rats with 48 h of fast or convulsion, procedure by the pentylene tetrazole; captation measure of 125 I-insulin after intra-cerebral-ventricular injection of the labelled hormone in fed rats. (C.G.C.)

  12. Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds

    International Nuclear Information System (INIS)

    The aim was to determine the incidence of seed migration not only to the chest, but also to the abdomen and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds. We reviewed the records of 267 patients who underwent prostate brachytherapy with loose 125I seeds. After seed implantation, orthogonal chest radiographs, an abdominal radiograph, and a pelvic radiograph were undertaken routinely to document the occurrence and sites of seed migration. The incidence of seed migration to the chest, abdomen, and pelvis was calculated. All patients who had seed migration to the abdomen and pelvis subsequently underwent a computed tomography scan to identify the exact location of the migrated seeds. Postimplant dosimetric analysis was undertaken, and dosimetric results were compared between patients with and without seed migration. A total of 19,236 seeds were implanted in 267 patients. Overall, 91 of 19,236 (0.47%) seeds migrated in 66 of 267 (24.7%) patients. Sixty-nine (0.36%) seeds migrated to the chest in 54 (20.2%) patients. Seven (0.036%) seeds migrated to the abdomen in six (2.2%) patients. Fifteen (0.078%) seeds migrated to the pelvis in 15 (5.6%) patients. Seed migration occurred predominantly within two weeks after seed implantation. None of the 66 patients had symptoms related to the migrated seeds. Postimplant prostate D90 was not significantly different between patients with and without seed migration. We showed the incidence of seed migration to the chest, abdomen and pelvis. Seed migration did not have a significant effect on postimplant prostate D90

  13. Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats

    International Nuclear Information System (INIS)

    The insulin-like growth factors (IGF-I and IGF-II) and insulin are localized within distinct brain regions and their respective functions are mediated by specific membrane receptors. High densities of binding sites for these growth factors are discretely and differentially distributed throughout the brain, with prominent levels localized to the hippocampal formation. IGFs and insulin, in addition to their growth promoting actions, are considered to play important roles in the development and maintenance of normal cell functions throughout life. We compared the anatomical distribution and levels of IGF and insulin receptors in young (five month) and aged (25 month) memory-impaired and memory-unimpaired male Long-Evans rats as determined in the Morris water maze task in order to determine if alterations in IGF and insulin activity may be related to the emergence of cognitive deficits in the aged memory-impaired rat. In the hippocampus, [125I]IGF-I receptors are concentrated primarily in the dentate gyrus (DG) and the CA3 sub-field while high amounts of [125I]IGF-II binding sites are localized to the pyramidal cell layer, and the granular cell layer of the DG. [125I]insulin binding sites are mostly found in the molecular layer of the DG and the CA1 sub-field. No significant differences were found in [125I]IGF-I, [125I]IGF-II or [125I]insulin binding levels in any regions or laminae of the hippocampus of young vs aged rats, and deficits in cognitive performance did not relate to altered levels of these receptors in aged memory-impaired vs aged memory-unimpaired rats. Other regions, including various cortical areas, were also examined and failed to reveal any significant differences between the three groups studied.It thus appears that IGF-I, IGF-II and insulin receptor sites are not markedly altered during the normal ageing process in the Long-Evans rat, in spite of significant learning deficits in a sub-group (memory-impaired) of aged animals. Hence, recently reported

  14. The Effect of Radiation on Complication Rates and Patient Satisfaction in Breast Reconstruction using Temporary Tissue Expanders and Permanent Implants.

    Science.gov (United States)

    Anker, Christopher J; Hymas, Richard V; Ahluwalia, Ravinder; Kokeny, Kristine E; Avizonis, Vilija; Boucher, Kenneth M; Neumayer, Leigh A; Agarwal, Jayant P

    2015-01-01

    The optimal method of reconstruction following mastectomy for breast cancer patients receiving radiation therapy (RT) is controversial. This study evaluated patient satisfaction and complication rates among patients who received implant-based breast reconstruction. The specific treatment algorithm analyzed included patients receiving mastectomy and immediate temporary tissue expander (TE), followed by placement of a permanent breast implant (PI). If indicated, RT was delivered to the fully expanded TE. Records of 218 consecutive patients with 222 invasive (85%) or in situ (15%) breast lesions from the Salt Lake City region treated between 1998 and 2009 were retrospectively reviewed, 28% of whom received RT. Median RT dose was 50.4 Gy, and 41% received a scar boost at a median dose of 10 Gy. Kaplan-Meier analyses were performed to evaluate the cumulative incidence of surgical complications, including permanent PI removal. Risk factors associated with surgical events were analyzed. To evaluate cosmetic results and patient satisfaction, an anonymous survey was administered. Mean follow-up was 44 months (range 6-144). Actuarial 5-year PI removal rates for non-RT and RT patients were 4% and 22%, respectively. On multivariate analysis (MVA), the only factor associated with PI removal was RT (p = 0.009). Surveys were returned describing the outcomes of 149 breasts. For the non-RT and RT groups, those who rated their breast appearance as good or better were 63% versus 62%, respectively. Under 1/3 of each group was dissatisfied with their reconstruction. RT did not significantly affect patient satisfaction scores, but on MVA RT was the only factor associated with increased PI removal. This reconstruction technique may be considered an acceptable option even if RT is needed, but the increased complication risk with RT must be recognized.

  15. Radioiodination of ibuprofen with 125I and its biological behavior in mice

    International Nuclear Information System (INIS)

    A procedure for radioiodination of Ibuprofen with iodine-125 is carried out via an electrophilic substitution reaction. The reaction parameters were studied Ibuprofen concentration, pH of the reaction mixture, reaction time temperature, and different oxidizing agents to optimize the conditions for the labeling of Ibuprofen to abstain a high radiochemical yield of 125I-Ibuprofen (125I-Ib up). Using 3.7 MBq of of Na 125I, 100μg of ibuprofen as substrate and 100μg of iodogen as oxidizing agent in ethanol at 60 OC for 10 min, a maximum radiochemical yield of 125I-Ib up (78%) was obtained. The labeled compound was separated and purified from inactive Ibuprofen by means of high-pressure liquid chromatography (HPLC). The biological distribution in normal and inflamed mice indicates the suitability of radioiodinated Ibuprofen for imaging of inflammation only induced with turpentine oil. (Author)

  16. Preparation and characterization of 125I-labelled proinsulin for radioimmunoassay (Preprint No. CT-62)

    International Nuclear Information System (INIS)

    Bovine proinsulin is iodinated with 125I. The labelled proinsulin was purified over sephadex. The preparation was characterized for stability and immunoreactivity. A radioimmunoassay was standardized using this labelled preparation. (author)

  17. (E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter

    International Nuclear Information System (INIS)

    The premise that, over the course of Alzheimer's disease (AD), changes in the levels of the vesicular acetylcholine transporter (VAChT) occur in parallel with changes to other cholinergic marker proteins provides the basis for the applicability of benzovesamicol derivatives as radioligands for AD studies by single photon emission computed tomography or positron emission tomography. We report the synthesis of enantiopure benzovesamicol derivatives: (R,R) or (S,S)-(E)-2-hydroxy-5-(3-iodoprop-2-en-1-oxy)-3- (4-phenylpiperidino)tetralin [(R,R)-AOIBV: Kd=0.45 nM or (S,S)-5-AOIBV: Kd=4.3 nM] and their corresponding tributyltin precursors for radioiodination. (R,R or S,S)-5-AOIBV was labeled with iodine-125 from their corresponding n-tributyltin precursors. Both compounds were obtained with radiochemical and optical purity greater than 97% and in radiochemical yields ranging 34-36%. To determine if these compounds could provide an advantage when compared to [125I]-iodo benzovesamicol (IBVM), IBVM was also labeled and used as the reference compound in all ex vivo experiments. Ex vivo biodistribution experiments in rats revealed that [125I]-(R,R)-5-AOIBV displayed the most suitable pharmacological profile as the radioactivity distribution corresponded well with the known VAChT brain density. Moreover, pre-injection of vesamicol prevented the uptake of [125I]-(R,R)-5-AOIBV in striatum, cortex and hippocampus, demonstrating selectivity for the VAChT. However, even if time activity curves of [125I]-(R,R)-5-AOIBV confirmed that this compound could be used to visualize the VAChT in vivo, at each point of the kinetic study, [125I]-(R,R)-5-AOIBV showed a lower specific binding compared to [125I]-IBVM. These results made [125I]-( R,R)-5-AOIBV inferior to [125I]-IBVM for the VAChT exploration in vivo

  18. Inhibition effects of 125I-triplex forming oligonucleotide to hepatoma cells

    International Nuclear Information System (INIS)

    Objective: Triplex forming oligonucleotide (TFO) has been reported as a new antigene strategy. The purpose of this study was to observe the inhibition effects of 125I-TFO on hepatoma cells and to investigate the possibility of using 125I-TFO as an antigene radiotherapy technique for hepatocellular carcinoma (HCC) related to HBV. Methods: TFO complementary to the initiator of S gene of HBV was synthesized and labeled with 125I. HepG2.2.15 cells, in which HBV genome was integrated, were incubated with 125I-TFO, TFO and 125I respectively. After incubation, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) of each group were assayed with ELISA and the survival rate of cells in each group was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT) reduction assay. Results: 125I-TFO showed a high stability with a radiolabeling rate of >93%. The radiochemical purity of labeled compound was 90.8%, 81.1% and 73.2% respectively after 12, 48 and 72 h at 37 degree C. The peak inhibition effect of 125I-TFO on synthesizing HBsAg and HBeAg by HepG2.2.15 cells were found at 48 h after transfection, with significantly the highest inhibition rate of 45.2% for HBsAg and 74.5% for HBeAg expression among the three groups(P125I-TFO may inhibit the antigen expression of HBV and the growth of hepatocarcinoma cells, thus it may provide a new approach to develop gene-based radiotherapeutic pharmaceuticals for anti-HBV and HCC. (authors)

  19. Surface redistribution of 125I-insulin in cultured human lymphocytes

    OpenAIRE

    1981-01-01

    The cultured human lymphocyte (IM-9) binds 125I-insulin by a receptor- mediated process; the receptor, in turn, is regulated by the ligand. In the present study we have examined quantitatively the morphologic events involved in 125I-insulin interaction with the surface of the lymphocyte. At 2 min of incubation of 15 degrees or 37 degrees C, the ligand localizes preferentially at the villous surface of the cell, whereas with longer periods of incubation, the ligand distributes indistinguishabl...

  20. Intracellular modification of 125I-labeled epidermal growth factor by normal human foreskin fibroblasts

    International Nuclear Information System (INIS)

    Intracellular processing of 125I-labeled epidermal growth factor (EGF) in normal human foreskin fibroblasts was examined after incubation with saturating concentrations of [125I]EGF. This report describes the column chromatographic separation of multiple processed forms of EGF generated by human foreskin fibroblasts and their structural characterization. More than 95% of the cell-bound [125I]EGF was converted into multiple forms, which were separated into four distinct peaks of radioactivity using columns of Bio-Gel P-150 equilibrated with 0.2% sodium dodecyl sulfate. These were designated peaks 1-4. Cellular generation of these four peaks was dependent on culture conditions. Differences in absolute and relative amounts of peaks 1-4 were observed as a function of time of incubation at 37 C. In addition, chromatographic profiles of cell-associated 125I varied in relation to cell density. The radioactivity in peak 1 comigrated with 125I-labeled native EGF on nondenaturing polyacrylamide gels (pH 9.5), whereas peaks 2 and 3 exhibited more rapid electrophoretic mobilities. Electrophoretic mobilities of the radioactivity in peaks 2 and 3 were indistinguishable from those of chemically prepared derivatives of [125I]EGF which were lacking either one or six amino acid residues from the carboxyterminus, respectively. The EGF receptor bound the radioactive material in peak 2 with an affinity equal to or greater than that of EGF; however, the radioactivity in peak 3 was bound to a much lesser extent. The radiolabel in both peaks 2 and 3 was greater than 95% precipitable by antiserum to native EGF. The labeled material in peak 4 was composed of [125I]monoiodotyrosine, 125I-, and an unidentified peptide. None of the radiolabeled compounds in peak 4 interacted with the EGF receptor or with antiserum to native EGF

  1. Tissue distribution and excretion of 125I-lidamycin in mice and rats

    Institute of Scientific and Technical Information of China (English)

    You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Chang-Xiao Liu

    2005-01-01

    AIM: To investigate the tissue distribution, urinary and fecal excretions of 125I-lidamycin (125I-C-1027) in mice and its biliary excretion in rats.METHODS: The total radioactivity assay (RA method) and the radioactivity assay after precipitation with 200 mL/L trichloroacetic acid (TCA-RA method) were used to dete-rmine the tissue distribution, and the urinary and fecal excretions of 125I-C-1027 in mice and its biliary excretion in rats.RESULTS: Tissue concentrations reached the peak at the fifth minute after administration of 125I-C-1027 to mice. The highest concentration was in kidney, and the lowest in brain at all test-time points. The organs of the concentrations of 125I-C-1027 from high to low were kidney, lung, liver, stomach, spleen, uterus, ovary, intestine, muscle, heart, testis, fat, and brain in mice. The accumulative excretionamounts of 0-24 h, and 0-96 h after administration of125I-C-1027 were 68.36 and 71.64% in urine, and 2.60 and 3.21% in feces of mice, respectively, and the accumulative excretion amount of 0-24 h was 3.57% in bile in rats.CONCLUSION: Our results reflect the characteristics of the tissue distribution, urinary and fecal excretions of 125IC-1027 in mice and the biliary excretion of 125I-C-1027and its metabolites in rats, and indicate that 125I-C-1027and its metabolites are mainly distributed in kidney, and excreted in urine.

  2. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience

    International Nuclear Information System (INIS)

    Purpose: To report outcomes and toxicity of the first Canadian permanent prostate implant program. Methods and Materials: 396 consecutive patients (Gleason ≤6, initial prostate specific antigen (PSA) ≤10 and stage T1-T2a disease) were implanted between June 1994 and December 2001. The median follow-up is of 60 months (maximum, 136 months). All patients were planned with fast-simulated annealing inverse planning algorithm with high activity seeds ([gt] 0.76 U). Acute and late toxicity is reported for the first 213 patients using a modified RTOG toxicity scale. The Kaplan-Meier biochemical failure-free survival (bFFS) is reported according to the ASTRO and Houston definitions. Results: The bFFS at 60 months was of 88.5% (90.5%) according to the ASTRO (Houston) definition and, of 91.4% (94.6%) in the low risk group (initial PSA ≤10 and Gleason ≤6 and Stage ≤T2a). Risk factors statistically associated with bFFS were: initial PSA >10, a Gleason score of 7-8, and stage T2b-T3. The mean D90 was of 151 ± 36.1 Gy. The mean V100 was of 85.4 ± 8.5% with a mean V150 of 60.1 ± 12.3%. Overall, the implants were well tolerated. In the first 6 months, 31.5% of the patients were free of genitourinary symptoms (GUs), 12.7% had Grade 3 GUs; 91.6% were free of gastrointestinal symptoms (GIs). After 6 months, 54.0% were GUs free, 1.4% had Grade 3 GUs; 95.8% were GIs free. Conclusion: The inverse planning with fast simulated annealing and high activity seeds gives a 5-year bFFS, which is comparable with the best published series with a low toxicity profile

  3. Heparin blocks /sup 125/I-calmodulin internalization by isolated rat renal brush border membrane vesicles

    Energy Technology Data Exchange (ETDEWEB)

    Meezan, E.; Elgavish, A.; Roden, L.; Wallace, R.W.

    1986-03-05

    /sup 125/I-Calmodulin is internalized by isolated rat renal brush border membrane vesicles (BBV) in a time, temperature and calcium dependent manner. Internalization of /sup 125/I-calmodulin into the osmotically sensitive space of BBV was distinguished from binding of the ligand to the outer BBV surface by examining the interaction of ligand and BBV at different medium osmolarities (300-1100 mosm), uptake was inversely proportional to medium osmolarity. Internalized /sup 125/I-calmodulin was intact and Western blots of solubilized BBV with /sup 125/I-calmodulin demonstrated the presence of several calmodulin-binding proteins of 143, 118, 50, 47.5, 46.5 and 35 kilodaltons which could represent potential intravesicular binding sites for the ligand. Heparin and the related glycosaminoglycan heparin sulfate both showed a dose-dependent inhibition (0.5-50 ..mu..g/ml) of /sup 125/I-calmodulin uptake by BBV, but other sulfated and nonsulfated glycosaminoglycans including chondroitin sulfates, keratan sulfate and hyaluronic acid showed little or no inhibitory effect. Desulfation of heparin virtually abolished the inhibition of uptake while depolymerization reduced it. Heparin did not block the binding of /sup 125/I-calmodulin to BBV proteins as assessed by Western blotting technique suggesting its effect was on internalization of the ligand rather than on its association with internal membrane proteins.

  4. Combination of bilateral pelvic lymphadenectomy, permanent iodine-125 implantation, and percutaneous irradiation of the locally confined prostatic cancer. Pt. 1

    International Nuclear Information System (INIS)

    Since the beginning of 1981, 32 patients at an age of 52 to 72 years who suffered from a locally confined adenocarcinoma of the prostate were treated by permanent implantation of I-125 seeds. 25 patients were evaluated after a median observation period of 30 months. The first group consisting of 19 patients was submitted to a combined percutaneous and interstitial treatment, the other 6 patients were initially treated only by interstitial therapy because of severe complications observed in the meantime. After bilateral pelvic staging lymphadenectomy, permanent I-125 seeds were implanted into the patients of stage T1, T2, early T3 and pN0-1, in case of microscopic lymph node manifestation without capsular perforation also into patients of stage pN2 and pN4. 8 weeks later the patients received a moving beam irradiation with 10 MV photons at the linear accelerator. The centre of the prostate was faded out by a specially constructed H absorber in such a way that the prescribed target dose of 36 Gy in 4 weeks to the 90%-isodose was only applied to a spherical surface around the implant. 1 patient died perioperatively from an embolism due to phlebothrombosis of the thigh. 22 out of the other 24 patients are in complete remission, 1 patient had a local recurrence in the right seminal vesicle which appeared 28 months after primary therapy, and 1 patient developed skeletal metastases. The objective side effects and late complications of our combined treatment are considerable with respect to their incidence as well as their severity: a slight or medium radioproctitis was found after a latent period of 1 to 2 years in 28% (5/18) of cases, after a latent time of about 1 1/2 to 2 years another 28% (5/18) developed subsequently to a proctitis an urethral stricture and an ulcer situated on the anterior rectum wall facing the prostate, and 4 patients presented finally a prostato-rectal fistula. (orig.)

  5. Permanent transvenous pacemaker implantation in a patient with Cor triatriatum dextrum

    Institute of Scientific and Technical Information of China (English)

    Kun; Xiang; George; V; Moukarbel; Blair; Grubb

    2015-01-01

    Cor triatriatum dextrum is an extremely rare congenital heart abnormality in which the right atrium is separatedinto two chambers by a persistent fibrous membrane. A transvenous approach to place a dual-chamber pacemaker in such patients is technically challenging. We report the first case of a transvenous permanent pacemaker placement in a patient with cor triatriatum dextrum. An 87-year-old woman was diagnosed with paroxysmal atrial fibrillation. She was accidentally found to have cor triatriatum dextrum during the transesophageal echocardiography(TEE) prior to cardioversion. Later during her hospital stay, it was indicated to place a permanant pacemaker due to high grade atrioventricular block. After thorough reviewing TEE imagings, a transvenous catheter-based approach was decided feasible. Patient successfully received a dual chamber pacemaker through left subclavian venous approach. Furthermore in our case, using specially designed pacemaker leads and cautious intra-procedural maneuvering under fluoroscopic guidance ensured procedural success. In summary, a thorough pre-operative evaluation with transesophageal echocardiography is critical for the planning and eventual success of the transvenous placement of rightsided leads.

  6. DNA strand breakage by 125I-decay in oligoDNA

    International Nuclear Information System (INIS)

    Full text: A double-stranded oligodeoxynucleotide containing 125I-dC in a defined location, with 5'- or 3'-32P-end-labelling of either strand, was used to investigate DNA strand breakage resulting from 125I decay. Samples of the 32P-end-labelled and 125I-dC containing oligoDNA were incubated in 20 mM phosphate buffer (PB), or PB + 2 M dimethylsulphoxide (DMSO) at 4 deg during 18-20 days. The 32P-end-labelled DNA fragments produced by 125I decays were separated on denaturing polyacrylamide gels, and the 3P activity in each fragment was determined by scintillation counting after elution from the gel. The fragment size distribution was then converted to a distribution of single stranded break probabilities at each nucleotide position. The results indicate that each 125I decay event produces at least one break in the 125I-dC containing strand, and causes breakage of the opposite strand in 75-80% of events. Thus, the double stranded break is produced by 125I decay with probability ∼0.8. Most of single stranded breaks (around 90%) occurred within 5-6 nucleotides of the 125I-dC, however DNA breaks were detected up to 18-20 nucleotides from the decay site. The average numbers of single stranded breaks per decay are 3.7 (PB) and 3.3 (PB+DMSO) in 125I-dC containing strand, and 1.5 (PB) and 1.3 (PB+DMSO) in the opposite strand. Deconvolution of strand break probabilities as a function of separation from the 125I, in terms of both distance (to target deoxyribosyl carbon atoms, in B-DNA) and nucleotide number, show that the latter is an important parameter for the shorter-range damage. This could indicate a role for attenuation/dissipation of damage through the stacked bases. In summary, the results represent a much more extensive set of data than available from earlier experiments on DNA breakage from l25I-decay, and may provide new mechanistic insights

  7. SU-E-J-166: Sensitivity of Clinically Relevant Dosimetric Parameters to Contouring Uncertainty During Post Implant Dosimetry of Prostate Permanent Seed Implants

    Energy Technology Data Exchange (ETDEWEB)

    Mashouf, S [Sunnybrook Odette Cancer Centre, Toronto, ON (Canada); University of Toronto, Dept. of Radiation Oncology, Toronto, ON (Canada); Ravi, A; Morton, G; Song, W [Sunnybrook Odette Cancer Centre, Toronto, ON (Canada); University of Toronto, Dept. of Radiation Oncology, Toronto, ON (Canada); Sunnybrook Research Institute, Toronto, ON (Canada)

    2015-06-15

    Purpose: There is a strong evidence relating post-implant dosimetry for permanent seed prostate brachytherpy to local control rates. The delineation of the prostate on CT images, however, represents a challenge as it is difficult to confidently identify the prostate borders from soft tissue surrounding it. This study aims at quantifying the sensitivity of clinically relevant dosimetric parameters to prostate contouring uncertainty. Methods: The post-implant CT images and plans for a cohort of 43 patients, who have received I–125 permanent prostate seed implant in our centre, were exported to MIM Symphony LDR brachytherapy treatment planning system (MIM Software Inc., Cleveland, OH). The prostate contours in post-implant CT images were expanded/contracted uniformly for margins of ±1.00mm, ±2.00mm, ±3.00mm, ±4.00mm and ±5.00mm (±0.01mm). The values for V100 and D90 were extracted from Dose Volume Histograms for each contour and compared. Results: The mean value of V100 and D90 was obtained as 92.3±8.4% and 108.4±12.3% respectively (Rx=145Gy). V100 was reduced by −3.2±1.5%, −7.2±3.0%, −12.8±4.0%, −19.0±4.8%, − 25.5±5.4% for expanded contours of prostate with margins of +1mm, +2mm, +3mm, +4mm, and +5mm, respectively, while it was increased by 1.6±1.2%, 2.4±2.4%, 2.7±3.2%, 2.9±4.2%, 2.9±5.1% for the contracted contours. D90 was reduced by −6.9±3.5%, −14.5±6.1%, −23.8±7.1%, − 33.6±8.5%, −40.6±8.7% and increased by 4.1±2.6%, 6.1±5.0%, 7.2±5.7%, 8.1±7.3% and 8.1±7.3% for the same set of contours. Conclusion: Systematic expansion errors of more than 1mm may likely render a plan sub-optimal. Conversely contraction errors may Result in labeling a plan likely as optimal. The use of MRI images to contour the prostate should results in better delineation of prostate organ which increases the predictive value of post-op plans. Since observers tend to overestimate the prostate volume on CT, compared with MRI, the impact of the

  8. SU-E-J-166: Sensitivity of Clinically Relevant Dosimetric Parameters to Contouring Uncertainty During Post Implant Dosimetry of Prostate Permanent Seed Implants

    International Nuclear Information System (INIS)

    Purpose: There is a strong evidence relating post-implant dosimetry for permanent seed prostate brachytherpy to local control rates. The delineation of the prostate on CT images, however, represents a challenge as it is difficult to confidently identify the prostate borders from soft tissue surrounding it. This study aims at quantifying the sensitivity of clinically relevant dosimetric parameters to prostate contouring uncertainty. Methods: The post-implant CT images and plans for a cohort of 43 patients, who have received I–125 permanent prostate seed implant in our centre, were exported to MIM Symphony LDR brachytherapy treatment planning system (MIM Software Inc., Cleveland, OH). The prostate contours in post-implant CT images were expanded/contracted uniformly for margins of ±1.00mm, ±2.00mm, ±3.00mm, ±4.00mm and ±5.00mm (±0.01mm). The values for V100 and D90 were extracted from Dose Volume Histograms for each contour and compared. Results: The mean value of V100 and D90 was obtained as 92.3±8.4% and 108.4±12.3% respectively (Rx=145Gy). V100 was reduced by −3.2±1.5%, −7.2±3.0%, −12.8±4.0%, −19.0±4.8%, − 25.5±5.4% for expanded contours of prostate with margins of +1mm, +2mm, +3mm, +4mm, and +5mm, respectively, while it was increased by 1.6±1.2%, 2.4±2.4%, 2.7±3.2%, 2.9±4.2%, 2.9±5.1% for the contracted contours. D90 was reduced by −6.9±3.5%, −14.5±6.1%, −23.8±7.1%, − 33.6±8.5%, −40.6±8.7% and increased by 4.1±2.6%, 6.1±5.0%, 7.2±5.7%, 8.1±7.3% and 8.1±7.3% for the same set of contours. Conclusion: Systematic expansion errors of more than 1mm may likely render a plan sub-optimal. Conversely contraction errors may Result in labeling a plan likely as optimal. The use of MRI images to contour the prostate should results in better delineation of prostate organ which increases the predictive value of post-op plans. Since observers tend to overestimate the prostate volume on CT, compared with MRI, the impact of the

  9. Cetuximab affects the capacity of DNA repair in colorectal cancer cells after 125I seeds irradiation

    International Nuclear Information System (INIS)

    Objective: To investigate the effect of C225 on DNA repair and molecular pathways in CL187 colorectal cancer cells after irradiated by 125I radioactive seeds. Methods: In the experiment involved were four groups:control group, 100 nmol/L C225 treatment group,125I radioactive seeds continuous low-dose rate irradiation group and C225 combined with 125I radioactive seeds continuous low dose rate irradiation group. Cells were collected at 48 h after 4 Gy irradiation, and γH2AX foci/cell and γH2AX foci positive cells were counted with immunofluorescence. At the same time, DNA repair proteins were detected by Western blot. Cells were analyzed immediately after 4 Gy irradiation,and changes in EGFR downstream signaling molecules were detected by Western blot. Results: Compared with 125I seeds irradiated cells,cells treated with C225 and 125I seeds irradiation showed more γH2AX foci per cell (t=8.0, P=0.05), and more γH2AX foci positive cells (t=6.8, P<0.05) and less expression of Ku70 (t=6.6, P<0.05) and DNA-PKcs (t=5.6, P<0.05). Combined with 125I-CLDR irradiation, C225 reduced cellular EGFR level (t=4.9, P<0.05) and inhibited the activation of Akt (t=5.5, P<0.05). Conclusions: In the condition of 125I seeds irradiation, C225 reduced the expression of Ku70 and DNA-PKcs, inhibited the activation of Akt and attenuated the DNA damage repair capacity in CL187 colorectal cancer cells. (authors)

  10. Autoradiographic comparison of [{sup 125}I]epidepride and [{sup 125}I]NCQ 298 binding to human brain extrastriated dopamine receptors

    Energy Technology Data Exchange (ETDEWEB)

    Hall, Haakan; Halldin, Christer; Jerning, Eva; Oesterlund, Marie; Farde, Lars; Sedvall, Goeran

    1997-07-01

    Extrastriatal D{sub 2}-dopamine receptors can be visualized in the monkey and human brain using the benzamides [{sup 11}C]- and [{sup 76}Br]FLB 457 in PET and [{sup 123}I]epidepride in SPECT but not with the salicylamide analogues [{sup 76}Br]FLB 463 and [{sup 123}I]NCQ 298. To clarify the background for the differences in binding seen in vivo, we have compared the in vitro binding of [{sup 125}I]epidepride and [{sup 125}I]NCQ 298, using human whole hemisphere autoradiography. The images obtained with any radioligand showed detailed distribution with very dense binding in the putamen and the caudate nucleus and with the same detailed extrastriatal distribution. Thus, the divergent results obtained in vivo cannot be explained by different binding properties of the extrastriatal receptors.

  11. Assaying multiple 125I seeds with the well-ionization chamber SourceCheck4π 33005 and a new insert

    Science.gov (United States)

    Ballester, Facundo; Perez-Calatayud, Jose; Vijande, Javier

    2015-01-01

    Purpose To provide a practical solution that can be adopted in clinical routine to fulfill the AAPM-ESTRO recommendations regarding quality assurance of seeds used in prostate permanent brachytherapy. The aim is to design a new insert for the well-ionization chamber SourceCheck4π 33005 (PTW, Germany) that allows evaluating the mean air-kerma strength of up to ten 125I seeds with one single measurement instead of measuring each seed individually. Material and methods The material required is: a) the SourceCheck4π 33005 well-ionization chamber provided with a PTW insert to measure the air-kerma strength S K of one single seed at a time; b) a newly designed insert that accommodates ten seeds in one column, which allows measuring the mean S K of the ten seeds in one single measurement; and c) a container with ten seeds from the same batch and class of the seeds used for the patient implant, and a set of nine non-radioactive seeds. The new insert is characterized by determining its calibration coefficient, used to convert the reading of the well-chamber when ten seeds are measured to their mean S K. The proposed method is validated by comparing the mean S K of the ten seeds obtained from the new insert with the individual measurement of S K of each seed, evaluated with the PTW insert. Results The ratio between the calibration coefficient of the new insert and the calibration coefficient of the PTW insert for the SourceCheck4π 33005 is 1.135 ± 0.007 (k = 1). The mean S K of a set of ten seeds evaluated with this new system is in agreement with the mean value obtained from measuring independently the S K of each seed. Conclusions The new insert and procedure allow evaluating the mean S K of ten seeds prior to the implant in a single measurement. The method is faster and more efficient from radiation protection point of view than measuring the individual S K of each seed. PMID:26816507

  12. Use of brachytherapy with permanent implants of iodine-125 in localized prostate cancer; La curietherapie par implants permanents d'I-125 dans le cancer localise de la prostate

    Energy Technology Data Exchange (ETDEWEB)

    Bladou, F.; Serment, G. [Hopital Salvador, Service d' Urologie, 13 - Marseille (France); Salem, N.; Simonian, M. [Hopital Salvador, Dept. de Radiotherapie, 13 - Marseille (France); Rosello, R.; Ternier, F. [Institut Paoli-Calmettes, Dept. de Radiologie, 13 - Marseille (France)

    2002-07-01

    Approximately 15,000 cases of early stage prostate cancer T1 and T2 are diagnosed every year in France by testing for PSA and performing prostatic biopsies. The treatment of these localized forms is based in most cases on radical prostatectomy or nn external beam radiotherapy. Although the ontological results obtained by these two therapeutic methods are satisfactory and equivalent in the long term, the side effects can be important. For a number of years, trans-perineal brachytherapy using permanent implants of iodine -125 or palladium-103 has proved itself as an alternative therapy with equivalent medium to long-term results. The low urinary, digestive and sexual side effects of prostate brachytherapy are important reasons for the enthusiasm among patients and the medical community for this therapy and the growing number of applications and centres which practice it. In September 1998 we started the prostate brachytherapy programmes- in Marseilles with close collaboration between the department of urology of the Hopital Salvator, and the departments of radiotherapy, medical imaging and medical physics of the Institut Paoli-Calmettes. To date, around 250 patients with localized adenocarcinoma of the prostate have benefited from this alternative therapy in our centre. Preliminary results, with a 3 year-follow-up, are comparable to results published in the literature by pioneer teams. (authors)

  13. Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine

    International Nuclear Information System (INIS)

    Purpose: Iodine-125 induces cell death by a mechanism similar to that of high linear energy transfer (high-LET) radiation. This study investigates the cytotoxicity of high-specific-activity [125I]meta-iodobenzylguanidine (125I-mIBG) in human SK-N-MC neuroblastoma cells grown as three-dimensional multicellular spheroids. Materials and Methods: Spheroids were incubated with high-specific-activity 125I-mIBG (6 mCi/μg, 1000 times that of the conventional specific activity used for autoradiography). Cytotoxicity was assessed by fluorescence viability markers and confocal microscopy for intact spheroids, fluorescence-activated cell sorting and clonogenic assay, and clonogenic assays for dispersed whole spheroids. Distribution of radioactive mIBG was determined by quantitative light-microscope autoradiography of spheroid cryostat sections. Dose estimation was based on temporal knowledge of the retained radioactivity inside spheroids, and of the radiolabel's emission characteristics. Findings were compared with those of spheroids treated under the same conditions with 131I-mIBG, cold mIBG, and free iodine-125. Results: 125I-mIBG exerted significant cell killing. Complete spheroids were eradicated when they were treated with 500 μCi of 125I-mIBG, while those treated with 500 μCi or 1000 μCi of 131I-mIBG were not. The observed difference in cytotoxicity between treatments with 125I- and 131I-mIBG could not be accounted for by the absorbed dose of spheroid alone. The peripheral, proliferating cell layer of the spheroids remained viable at the moderate radioactivity of 100 μCi for both isotopes. Cytotoxicity induced by 125I-mIBG was quantitatively comparable by the peripheral rim thickness to that of 131I-mIBG at the dose of 100 μCi. The peripheral rim thickness decreased most significantly in the first 17 hours after initial treatment. There was no statistical decrease in the rim thickness identified afterwards for the second, third, and fourth days of incubation

  14. Long-term outcome in patients receiving permanent pacemaker implantation for atrioventricular block: Comparison of VDD and DDD pacing.

    Science.gov (United States)

    Liao, Jo-Nan; Chao, Tze-Fan; Tuan, Ta-Chuan; Kong, Chi-Woon; Chen, Shih-Ann

    2016-08-01

    A permanent pacemaker (PPM) with dual chamber pacing (DDD) offers atrioventricular synchronization for patients with atrioventricular block (AVB). Single lead atrial synchronous ventricular pacing mode (VDD) is an alternative, but there are concerns about its efficacy and risk of atrial undersensing. Whether VDD can be a good alternative in patients with AVB remains unknown. The aim of the present study was to compare the long-term risk of mortality of VDD with DDD pacing.A total of 207 patients undergoing PPM implantations for AVB with VDD mode were enrolled from 2000 to 2013. Another 828 age- and sex-matched patients undergoing DDD implantations during the same period of time were selected as the control group in a 1 to 4 ratio. The study endpoint was mortality.A total of 1035 patients (64.3% male) were followed up for 46.5 ± 43.2 months. The mean ages were 75.0 years for VDD, and 74.9 years for DDD. The Kaplan-Meier survival analysis showed no significant difference in long-term survival between the VDD and DDD groups (log-rank P = 0.313). After adjustment for baseline characteristics, the VDD and DDD groups had a similar long-term prognosis with an adjusted hazard ratio of 0.875 (P = 0.445). Further analyses for the risk of cardiovascular and noncardiovascular deaths also showed no significant differences between the 2 groups.The long-term prognosis of VDD mode is comparable to that of DDD mode. Single lead VDD can be considered as an alternative choice in patients with AVB without sinus nodal dysfunction.

  15. Monte Carlo dosimetry for 125I and 60Co in eye plaque therapy

    International Nuclear Information System (INIS)

    Monte Carlo calculations of radiation dosimetry using morse code are performed for 125I and 60Co point sources in a cylindrical head phantom that simulates the geometry of eye plaque therapy for choroidal melanoma. We obtain the dose variation in the eye at submillimeter intervals over distances as close as 1 mm and up to 2.5 cm from the source. The calculations for 125I are performed for the phantom media of water, protein, and a homogenized protein--water mixture simulating the composition of the eye. Relative dose functions for 125I for these phantom media are fitted to second-degree polynomials. Agreement is found with published results. The relative dose function for 60Co at eye position in the water head phantom is fitted to a third-degree polynomial and compared with that for 60Co at the center of a large water sphere. A boundary effect due to the head phantom--air interface on the dose distribution for 60Co is demonstrated. The dose falloff with distance is faster for the eye geometry compared with the bulk geometry. We also show that the relative dose distributions within the tumor are comparable for 125I and 60Co by comparing their relative dose functions. This result is consistent with the success of clinical trials of large melanoma treatments with 125I plaques

  16. /sup 125/I-spiperone: a novel ligand for D/sub 2/ dopamine receptors

    Energy Technology Data Exchange (ETDEWEB)

    Gundlach, A.L.; Largent, B.L.; Synder, S.H.

    1984-11-05

    /sup 125/I-Spiperone binds with high affinity K/sub D/ 0.3 nM) to a single specific site (B/sub max/ 34 pmole/g wet weight) in homogenates of rat corpus striatum. Specific binding is about 40-60 percent of total binding and is displaced stereo-specifically by butaclamol and clopenthixol. Neuroleptic drugs of various classes are potent inhibitors of /sup 125/I-spiperone binding (/sub i/'s 1-10 nM). Selective dopamine antagonists such as sulpiride (K/sub i/ 50 nM) and dopamine agonists such as apomorphine (K/sub i/ 200 nM) are also potent inhibitors. The drugs specificity of /sup 125/I-spiperone binding correlates well with that of /sup 3/H-spiperone binding, providing good evidence that /sup 125/I-spiperone labels D/sub 2/ dopamine receptors in striatal membranes. /sup 125/I-Spiperone, with its high specific activity (2200 Ci/mmol) may prove to be a useful ligand in studies examining D/sub 2/ dopamine receptors in soluble preparations and by autoradiography. Furthermore iodinated spiperone may be useful in radioreceptor assays of neuroleptic drug levels and, in a /sup 123/I-labeled form for imaging of dopamine receptors, in vivo, using single photon tomography. 18 references, 4 figures, 1 table.

  17. Labeling and biodistribution of therapeutic radiopharmaceutical for brain cancer 125I-Nimotuzumab in normal mice

    International Nuclear Information System (INIS)

    Nimotuzumab is a monoclonal antibody which known giving contribution in anti proliferation, pro apoptosis and antiangionik effect on the therapy of brain cancer (glioma). The labeling of monoclonal antibody nimotuzumab with 125I which radiate auger electrons has been done with idogen method. The best result of radiochemical purity (97%) was shown in fraction 6 with the mol ratio of nimotuzumab towards potassium iodide and iodogen was 1 : 2 : 1200. Radiochemical purity was examined by paper chromatography with whatman paper no. 1 as the stationary phase and ethano!-butanol-ammonium hydroxide with a ratio of 3 : 2 : 1 as the mobile phase. Rf Values for 125I-nimotuzumab is 0.0, while Rf value of 125I .is 0.9. The biodistribution result on normal mice for 72 hours showed that 125I-nimotuzumab not only has a long half-life time but also has high accumulation in liver (1.97 + 1.18%), kidney (0.82 + 0.28%) and muscle (0.61+ 0.98%). The highest accumulation in brain on normal mice (0.128 + 0.06 %) occurred 24 hours after injection. Based on the therapeutic effects and organ accumulation on normal mice, 125I-nimotuzumab could be potentially used for brain cancer therapy. (author)

  18. Synthesis of 125 I - Salicyl Hydroxamic Acid for Urinary Bladder Imaging

    International Nuclear Information System (INIS)

    Salicylhydroxamic acid is a salicylate derivative. Radiolabeling of Salicyl hydroxamic acid ( SHA ) with iodine-125 may have considerable interest for imaging of urinary bladder. This study is aimed to optimize the radiolabeling yield of Salicyl hydroxamic with radio iodine (125-123) using chloramine - T (CAT) as an oxidizing agent with respect to factors that affect the reaction conditions such as SHA amount, CAT amount, reaction time and ph of the reaction mixture. In - vitro stability of the radiolabeled complex was checked and it was found to be stable for up to 24 h. 125 I-SHA was injected via intravenous administration routes into normal male Sprague – Dawley rats. Bio - distribution studies have revealed that 125I-SHA was excreted in urine with extent that it could give a clear image for urinary bladder especially if the bladder it tightly closed. The amount of 125 I - Salicyl hydroxamic excreted was increased in case of giving potassium bicarbonate to rat before injection of 125 I-SHA. The result of biodistribution study of 125 I - SHA in experimental animal suggest ed the possibility of using 123 I-SHA to image the urinary bladder

  19. Study on apoptosis of prostate cancer cell induced by 125I seed irradiation

    International Nuclear Information System (INIS)

    Objective: To explore the mechanism of apoptosis induced by 125I seed irradiation on PC3 cells. Methods: Human prostate cancer cell line PC3 was treated by irradiation of 125I (2.77 cGy/h) with various dose. Agarose gel electrophoresis of DNA and flows cytometry were used to detect the apoptosis of PC3 cells and indirect immunofluorescence assay was used to detect the expression of Bcl-2. The activity of Caspase-3 was measured by Caspase Colorimetric Assay Kits. Results: Apoptosis of PC3 cells could be efficiently induced by 125I seed irradiation. The apoptotic peaks were found by flow cytometry and DNA ladder appeared on 1.8% agarose gel. The activity of Caspase-3 on PC3 cells treated by 125I seed irradiation was not changed significantly. Bcl-2 gene expression was down-regulated with the sample concentration increased. Conclusion: 125I irradiation can induce the apoptosis of PC3 cells and the mechanism of apoptosis is related with down regulation of Bcl-2 gene expression and is not related with Caspase-3 activity. (authors)

  20. 99mTc-albumin can replace 125I-albumin to determine plasma volume repeatedly

    DEFF Research Database (Denmark)

    Bonfils, Peter K; Damgaard, Morten; Stokholm, Knud H;

    2012-01-01

    OBJECTIVE: Plasma volume assessment may be of importance in several disorders. The purpose of the present study was to compare the reliability of plasma volume measurements by technetium-labeled human serum albumin ((99m)Tc-HSA) with a simultaneously performed plasma volume determination with...... iodine-labeled human serum albumin ((125)I-HSA). MATERIALS AND METHODS: In 15 healthy volunteers, simultaneous plasma volume measurements with (99m)Tc-HSA and (125)I-HSA were performed after ½ hour in the supine position. Blood samples were obtained 10, 15, 20, and 30 minutes after the injection for...... accurate retropolation from the plasma counts to time zero to correct for leakage of the isotopes from the circulation. RESULTS: The mean difference (bias) between plasma volume measured with (125)I-albumin and (99m)Tc-albumin was 8 ml (0.1 ml/kg) with limits of agreement (bias ±1.96 SD) ranging from -181...

  1. Radiolabelling and assay of Chinese agkistrodon acutus venom with carrier-free Na 125I

    International Nuclear Information System (INIS)

    Chinese agkistrodon acutus venom (CAAV) was radiolabelled with carrier-free Na125I by the method of Iodogen. The specific activity and radiochemical purity for radiolabelled products were 4236.5 x 1010 Bq/mmol and 98%, respectively. Each CAAV molecule carried 0.52 125I atom. Physical and chemical characterization of radiolabelled CAAV was similar to unradiolabelled CAAV. Binding analysis showed that 125I-CAAV was bound to platelet in a saturable manner. Binding sites per platelet were 13255 +-6292/platelet. The dissociation constant (Kd) was 3.2 +- 0.69 x 10-10 mol/L. These results are similar to binding sites of other snake venom on platelet. The investigation showed that radiolabelled CAAV made by our laboratory was useful for radioligand binding assay

  2. Preparation and Evaluation of (125I) Daunorubicin as a Potential Agent for Tumor Detection and radiotherapy

    International Nuclear Information System (INIS)

    In this study, the optimization of daunorubicin labeling with iodine-125 and its biological evaluation were described. Daunorubicin was labeled via direct electrophilic substitution using chloramine-T as oxidizing agent. The optimum amounts of reactants were: 40μg daunorubicin, 30μg Chloramine-T and ∼ 19 KBq carrier free Na125I. The labeled daunorubicin was stable for more than 24 hours. Results of the in-vivo evaluation revealed that the tracer, [125I] daunorubicin, tends to localize in tissues with high proliferation rate with preferential accumulation in cancerous tissues. Imaging should be carried at 3 hours post injection. The in-vitro cell growth inhibition assay showed that the effect of [125I] Daunorubicin was stronger than the effect of cold daunorubicin which strongly suggested that its cytotoxicity was mainly due to radiotoxicity rather than chemotherapeutic activity.

  3. Simulation of 125I induced DNA strand breaks in a CAP-DNA complex

    International Nuclear Information System (INIS)

    The E. coli catabolite gene activator protein (CAP)-DNA complex with 125I located at the position of the H5 atom of the cytosine near the centre was incorporated into the PARTRAC track structure code. DNA strand breaks due to irradiation were calculated by track structure and radical attack simulations: strand breaks due to neutralisation of the highly charged 125Te ion were derived from a semi-empirical distribution. According to the calculations, the neutralisation effect dominates the strand breakage frequency at 2 bases away from the 125I decay site on both strands. The first breakage distribution counted from a 32P labelled end on the strand with 125I agreed well with experimental data, but on the opposite strand, the calculated distribution is more concentrated around the decay site and its yield is about 20% larger than the measured data. (author)

  4. Development of thyroid monitoring system for the measurement of 125I

    International Nuclear Information System (INIS)

    Iodine-125 has gained wide acceptance in medical science for diagnosis and therapeutic applications. A considerable number of radiation workers of BARC and BRIT are involved in the production of 125I and preparation of radio immunoassay (RIA) kits to meet medical requirement of the country. A state of the art Thyroid Monitoring System incorporated with 51 mm diameter x 3 mm thick NaI(Tl) detector is developed for in-vivo monitoring of 125I in radiation workers handling this radioisotope. The developed system also has provision to accommodate variable body sizes (child to adult). This paper presents the different aspects of the system and its calibration using IAEA neck phantom for estimation of thyroidal content of 125I. (author)

  5. Binding and degradation of 125I-insulin by renal glomeruli and tubules isolated from rats

    International Nuclear Information System (INIS)

    Isolated rat renal glomeruli and tubules were shown to exhibit specific binding of 125I-insulin and enzymatic degradation of the hormone. Binding to both renal fractions reached a plateau by 1 h at 220C and increased linearly with increasing protein concentrations. Binding was inhibited in both preparations by insulin and its analogues in the order of relative potency: insulin > despentapeptide insulin > proinsulin, but insulin was ten times more potent in inhibiting 125I-insulin binding to glomeruli than that to tubules, indicating a different affinity of receptors for the hormone in the two renal fractions (about 17 versus 210 μg unlabelled insulin/1 inhibiting 50% of the 125I-insulin binding to glomeruli and tubules, respectively). Bound 125I-insulin dissociated at a faster rate from tubules than from glomeruli; this release was accelreated by unlabelled insulin in both renal fractions, but to a greater extent in glomeruli than in tubules. Two-thirds of the total bound material released from glomeruli was found to be intact insulin as measured by trichloroacetic acid precipitation, whereas only one-third of the material released from tubules was intact. No direct relationship beteen binding and degradation of 125I-insulin in these renal fractions could be demonstrated, however, because of the release of proteolytic enzymes into the incubation medium resulting in almost all degradation being extracellular. Although differing in their affinity for 125I-insulin the high affinity glomerular insulin receptor and the lower affinity tubular insulin receptor have characteristics similar to those of insulin receptors in insulin responsive tissues. (orig.)

  6. Optimization of the synthesis of a high specific activity 125 I-labelled hapten for radioimmunoassays

    International Nuclear Information System (INIS)

    In this first report it is described the synthesis, separation and purification of the 2-radioiodinated histamine ''125 I-labelled histamine by a mixed anhydride reaction. About 75% incorporation of I''1125, from Na''125, I, was achieved with a molecular ratio of 1:1 mixed anhydride:histamine. The radiochemical purity of the conjugate by TLC was >99% and its theoretical specific activity, 3850 mu Ci/mug. Dissolved in ethanol and held at -20 degree centigree under darkness decomposition on storage did not exceed 1% per month

  7. Sequence-specific DNA double-strand breaks induced by triplex forming 125I labeled oligonucleotides.

    OpenAIRE

    Panyutin, I G; Neumann, R D

    1994-01-01

    A triplex-forming oligonucleotide (TFO) complementary to the polypurine-polypyrimidine region of the nef gene of the Human Immunodeficiency Virus (HIV) was labeled with 125I at the C5 position of a single deoxycytosine residue. Labeled TFO was incubated with a plasmid containing a fragment of the nef gene. Decay of 125I was found to cause double-strand breaks (DSB) within the nef gene upon triplex formation in a sequence specific manner. No DSB were detected after incubation at ionic conditio...

  8. Effects of temperature and gamma radiation on the stability of 125I-19-iodocholesterol

    International Nuclear Information System (INIS)

    The effect of the temperature and the gamma radiations on the 125I-19-iodocholesterol synthesized in our laboratory, has been studied; the time of caducity (t90) have been fixed from the rate constants of decomposition (k-bar) (20,9; 32,1 y 144.10-3h-1) for different temperatures (35, 50 and 75oC), and the value of Go(-M) (1,52) by radiation of samples of 19-iodocholesterol-125I (0,94 mg/ml) with 60Co (0,177 Mrad/h). (author). 4 figs., 8 refs

  9. Selective binding of 2-[{sup 125}I]iodo-nisoxetine to norepinephrine transporters in the brain

    Energy Technology Data Exchange (ETDEWEB)

    Kung, M.-P.; Choi, Seok-Rye; Hou, Catherine; Zhuang, Z.-P.; Foulon, Catherine; Kung, Hank F. E-mail: kunghf@sunmac.spect.upenn.edu

    2004-07-01

    A radioiodinated ligand, (R)-N-methyl-(2-[{sup 125}I]iodo-phenoxy)-3-phenylpropylamine, [{sup 125}I]2-INXT, targeting norepinephrine transporters (NET), was successfully prepared. A no-carrier-added product, [{sup 125}I]2-INXT, displayed a saturable binding with a high affinity (K{sub d}=0.06 nM) in the homogenates prepared from rat cortical tissues as well as from LLC-PK{sub 1} cells expressing NET. A relatively low number of binding sties (B{sub max}=55 fmol/mg protein) measured with [{sup 125}I]2-INXT in rat cortical homogenates is consistent with the value reported for a known NET ligand, [{sup 3}H]nisoxetine. Competition studies with various compounds on [{sup 125}I]2-INXT binding clearly confirmed the pharmacological specificity and selectivity for NET binding sites. Following a tail-vein injection of [{sup 125}I]2-INXT in rats, a good initial brain uptake was observed (0.56% dose at 2 min) followed by a slow washout from the brain (0.2% remained at 3 hours post-injection). The hypothalamus (a NET-rich region) to striatum (a region devoid of NET) ratio was 1.5 at 3 hours post-i.v. injection. Pretreatment of rats with nisoxetine significantly inhibited the uptake of [{sup 125}I]2-INXT (70-100% inhibition) in locus coeruleus, hypothalamus and raphe nuclei, regions known to have a high density of NET; whereas escitalopram, a serotonin transporter ligand, did not show a similar effect. Ex vivo autoradiography of rat brain sections of [{sup 125}I]2-INXT (at 3 hours after an i.v. injection) displayed an excellent regional brain localization pattern corroborated to the specific NET distribution in the brain. The specific brain localization was significantly reduced by a dose of nisoxetine pretreatment. Taken together, the data suggest that [{sup 123}I]2-INXT may be useful for mapping NET binding sites in the brain.

  10. Prospective study of tricuspid valve regurgitation associated with permanent leads in patients undergoing cardiac rhythm device implantation: Background, rationale, and design

    Science.gov (United States)

    Dokainish, Hisham; Elbarasi, Esam; Masiero, Simona; Van de Heyning, Caroline; Brambatti, Michela; Ghazal, Sami; AL-Maashani, Said; Capucci, Alessandro; Buikema, Lisanne; Leong, Darryl; Shivalkar, Bharati; Saenen, Johan; Miljoen, Hielko; Morillo, Carlos; Divarakarmenon, Syam; Amit, Guy; Ribas, Sebastian; Brautigam, Aaron; Baiocco, Erika; Maolo, Alessandro; Romandini, Andrea; Maffei, Simone; Connolly, Stuart; Healey, Jeff

    2015-01-01

    Given the increasing numbers of cardiac device implantations worldwide, it is important to determine whether permanent endocardial leads across the tricuspid valve can promote tricuspid regurgitation (TR). Virtually all current data is retrospective, and indicates a signal of TR being increased after permanent lead implantation. However, the precise incidence of moderate or greater TR post-procedure, the exact mechanisms (mechanical, traumatic, functional), and the hemodynamic burden and clinical effects of this putative increase in TR, remain uncertain. We have therefore designed a multicenter, international, prospective study of 300 consecutive patients (recruitment completed, baseline data presented) who will undergo echocardiography and clinical assessment prior to, and at 1-year post device insertion. This prospective study will help determine whether cardiac device-associated TR is real, what are its potential mechanisms, and whether it has an important clinical impact on cardiac device patients. PMID:26779517

  11. 直视下永久性人工鼻泪管植入术的临床应用%Clinical application of permanent artificial nasolacrimal duct implantation

    Institute of Scientific and Technical Information of China (English)

    张弘

    2015-01-01

    目的 评价泪道手术失败后永久性人工鼻泪管植入术的临床效果.方法 对经过手术治疗后复发的慢性泪囊炎108例(110眼),进行泪囊鼻腔吻合术并直视下植入永久性人工鼻泪管.结果 直视下植入人工鼻泪管的手术效果良好,术后1月和1年复查,有效率均为100%.结论 采用泪囊鼻腔吻合术的同时植入永久性人工鼻泪管,该方法将人工鼻泪管准确植入泪囊窝位置,准确,可靠,有效率高.%Objective To evaluate the clinical effect of permanent artificial nasolacrimal duct implantation for lacrimal surgical failed cases.Methods The permanent artificial nasolacrimal duct was implanted in 110 eyes of 108 recurrent chronic dacryocystitis cases after failed lacrimal surgery.Results One year after operation,the irrigation of lacrimal passage was patent in all cases.The surgical effective rate was 100%.Conclusion The implantation of permanent artificial nasolacrimal duct is a safe and reliable with high effective rate method for lacrimal surgical failed cases.

  12. CT-guided {sup 125}I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: Effectiveness and safety in 16 patients

    Energy Technology Data Exchange (ETDEWEB)

    Gao, Fei, E-mail: gaof@sysucc.org.cn [State Key Laboratory of Oncology in South China, Guangzhou 510060 (China); Department of Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060 (China); Li, Chuanxing, E-mail: licx@sysucc.org.cn [State Key Laboratory of Oncology in South China, Guangzhou 510060 (China); Department of Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060 (China); Gu, Yangkui, E-mail: guyk@sysucc.org.cn [State Key Laboratory of Oncology in South China, Guangzhou 510060 (China); Department of Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060 (China); Huang, Jinhua, E-mail: huangjh@sysucc.org.cn [State Key Laboratory of Oncology in South China, Guangzhou 510060 (China); Department of Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060 (China); Wu, Peihong, E-mail: vivian-link@163.com [State Key Laboratory of Oncology in South China, Guangzhou 510060 (China); Department of Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060 (China)

    2013-02-15

    Objectives: To retrospectively evaluate effectiveness and safety of CT-guided {sup 125}I brachytherapy in 16 patients with mediastinal metastatic lymph nodes recurrence from esophageal carcinoma. Materials and methods: Sixteen metastatic lymph nodes in 16 patients were percutaneously treated in 19 {sup 125}I brachytherapy sessions. Each metastatic lymph node was treated with computed tomographic (CT) guidance. Follow-up contrast material-enhanced CT or positron emission tomographic (PET) scans were reviewed and the treatment's effectiveness was evaluated. Results: Months are counted from the first time of {sup 125}I brachytherapy and the median duration of follow-up was 11 months (range, 5–16 months). The local control rates after 3, 6, 10 and 15 months were 75.0, 50.0, 42.9 and 33.3% respectively. At the time of writing, four patients are alive without evidence of recurrence at 16, 9, 16 and 9 months. The 4 patients presented good control of local tumor and no systemic recurrence, and survived throughout the follow-up period. The other 12 patients died of multiple hematogenous metastases 5–15 months after brachytherapy. A small amount of local hematoma occurred in 2 patients that involved applicator insertion through the lung. Two patients presented pneumothorax with pulmonary compression of 30 and 40% after the procedure and recovered after drainage. One patient had minor displacement of radioactive seeds. Severe complications such as massive bleeding and radiation pneumonitis did not occur. Conclusion: {sup 125}I radioactive seed implantation is effective and may be safely applied to mediastinal metastatic lymph nodes recurrence from esophageal carcinoma.

  13. The effectiveness of 125I seed interstitial brachytherapy for transplantation tumor of human pancreatic carcinoma in nude mice: an experiment in vivo

    International Nuclear Information System (INIS)

    Objective: To discuss the effectiveness and therapeutic mechanism of 125I interstitial brachytherapy for transplantation tumor of human pancreatic carcinoma in nude mice. Methods: The human pancreatic cell line Sw1990 was subcutaneously injected into the right lower limb partially dorsal area next to the groin of the immunodeficient BABL /c nude mice. The tumor was removed and cut into small pieces after it was formed,then the tumor pieces were inoculated in nude mice. The tumor developed to 8-10 mm in size after six weeks. A total of 16 nude mice with the suitable tumor size were used in this study. The 16 experimental mice were randomly and equally divided into two groups. The mice in study group (n = 8) were implanted with 125I seeds, while the mice in control group (n = 8) were implanted with ghost seeds. After the implantation both the long and short diameter of the tumors as well as the mouse body weight were measured every 4 days. The tumor weight was measured when the mouse was sacrificed. The paraffin-embedded samples were sent for histopathological examination. Apoptotic cells were checked with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method. Expression of proliferating cell nuclear antigen (PCNA) was detected with immuno-histochemical staining. Results: The tumor grew slowly in the study group, but rapidly in the control group. The tumor weight in the study group and the control group was (2.68 ± 0.70)g and (4.68 ± 1.45)g, respectively, the difference between two groups was statistically significant (P = 0.021). The tumor inhibition rate was about 42.66%. No significant difference in body weight of nude mice existed between two groups both before and after the treatment (P > 0.05). Marked tumor necrosis was seen in study group, but no obvious, or only a little, tumor necrosis could be observed in the control group. The apoptotic index checked with the TUENL method in the study group and control group was (23.2 ± 1.9)% and

  14. Studies on the influence on the excretory kinetics of 125I-Adipiodon

    International Nuclear Information System (INIS)

    The possibility of influencing distribution and elimination of 125I-Adipiodon (125I-iodipamide meglumine) by a preceding administration of Falignost (iomeglamic acid) as well as by dose-time variants of the mechanic intravenous application of contrast medium was tested in 55 anicteric and 2 icteric patients within clinically indicated cholegraphic examination with the aim of methodical optimization. For the detection of principal regularities comparative studies with 125I-Adipiodon and Falignost in rats as well as examinations of protein binding of 125I-Adipiodon in the plasm of rats and in the plasm and in mixed serum (application in vitro) of patients by gel filtration with Epidex B 2 coarse and batch operation on more than 1,200 samples were additionally carried out. For combined cholecystography with intravenous infusion of Adipiodon in immediate temporal connection with the administration of Falignost a reduced visibility of the biliary tract in the X-ray picture is not to be expected as the consequence of the mutual influence of the contrast media. For intact excretory function of liver and kidneys the combined cholecystography can be recommended. The effects of a dose increase, of protracted infusion of Adipiodon and of the intravenous administration of 0.01 g metroclopramide on the demonstration of the biliary tract in the intravenous cholegram are outlined. (author)

  15. Studies on the influence on the excretory kinetics of /sup 125/I-Adipiodon

    Energy Technology Data Exchange (ETDEWEB)

    Koenig, H. (Martin-Luther-Universitaet Halle-Wittenberg, Halle (German Democratic Republic). Radiologische Klinik)

    1982-07-01

    The possibility of influencing distribution and elimination of /sup 125/I-Adipiodon (/sup 125/I-iodipamide meglumine) by a preceding administration of Falignost (iomeglamic acid) as well as by dose-time variants of the mechanic intravenous application of contrast medium was tested in 55 anicteric and 2 icteric patients within clinically indicated cholegraphic examination with the aim of methodical optimization. For the detection of principal regularities comparative studies with /sup 125/I-Adipiodon and Falignost in rats as well as examinations of protein binding of /sup 125/I-Adipiodon in the plasma of rats and in the plasma and in mixed serum (application in vitro) of patients by gel filtration with Epidex B 2 coarse and batch operation on more than 1,200 samples were additionally carried out. For combined cholecystography with intravenous infusion of Adipiodon in immediate temporal connection with the administration of Falignost a reduced visibility of the biliary tract in the X-ray picture is not to be expected as the consequence of the mutual influence of the contrast media. For intact excretory function of liver and kidneys the combined cholecystography can be recommended. The effects of a dose increase, of protracted infusion of Adipiodon and of the intravenous administration of 0.01 g metroclopramide on the demonstration of the biliary tract in the intravenous cholegram are outlined.

  16. A dot assay for the erythropoietin receptor using human recombinant sup 125 I-erythropoietin

    Energy Technology Data Exchange (ETDEWEB)

    Vannucchi, A.M.; Grossi, A.; Rafanelli, D.; Vannucchi, L.; Ferrini, P.R. (Univ. and USL 10/D, Florence (Italy))

    1989-10-01

    A dot assay was developed for the detection of membrane receptor(s) for erythropoietin (Ep). A relatively homogeneous population of cells bearing the receptor for Ep was generated in the spleen of mice made anemic with phenylhydrazine and crude membrane extracts were prepared from spleen cell suspensions. Aliquots of the membrane extracts were applied to microdishes of nitrocellulose in a volume of 4 microliters. After free reactive sites were blocked, the microdishes were incubated for 2 h at 37 degrees C with {sup 125}I-labeled human recombinant Ep ({sup 125}I-rEp), and nitrocellulose bound radioactivity was determined thereafter. Reproducible curves were obtained, and a significant correlation between bound radioactivity and the amount of membrane proteins applied to the nitrocellulose dishes was found. Specific binding was saturable, reaching a plateau at 2.5 nM. Binding parameters of nitrocellulose-immobilized receptor were not significantly different from the values calculated using intact cells. No appreciable binding of {sup 125}I-rEp to control membranes at low Ep-receptor content was observed. Among a panel of growth factors, only unlabeled rEp was able to compete for the binding of {sup 125}I-rEp to nitrocellulose-immobilized membrane proteins in a dose-dependent fashion. The technique described herein may be of use in the study of the Ep receptor and as an assay for its purification. Moreover, it may also be of general application in the study of receptor-ligand interactions.

  17. Binding of 125I-human growth hormone to specific receptors in human cultured lymphocytes

    International Nuclear Information System (INIS)

    The interaction of human growth hormone with human lymphocytes from an established culture (IM-9) was studied using 125I- human growth hormone. The binding of 125I-human growth hormone was rapid; with human growth hormone at 0.1 nM a steady state was observed in 90 min at 300. Bound labeled human growth hormone was dissociated rapidly by addition of excess unlabeled human growth hormone. Binding of 125I-human growth hormone to cultured lymphocytes was relatively insensitive to alterations in the pH and in the concentrations of Ca2+, Mg2+, EDTA. At 800 there was very little degradation of labeled human growth hormone or of the specific receptor sites. Tryptic digestion destroyed the capacity of cells to bind human growth hormone. The IM-9 cells bound all human growth hormone preparations but not unrelated hormones or nonprimate growth hormones. The binding of 125I-human growth hormone was inhibited 10 to 14 percent with 1 to 2 ng per ml of unlabeled human growth hormone and 50 percent with 30 to 40 ng per ml, well within the range of hormone concentrations in vivo. Analysis of steady state data revealed a single order of binding sites with an affinity constant of 1.3 x 109 M-1 and about 4000 binding sites per cell. Numerous human growth hormone preparations were assayed by use of this receptor system as well as by immunoassay and by bioassay in vivo. The po

  18. Absolute intensity of internal bremsstrahlung from the electron capture decay of 125I

    International Nuclear Information System (INIS)

    The absolute intensity of the internal bremsstrahlung spectrum accompanying the electron capture decay of 125I has been measured and compared to the recent calculation of Suric et al. The measured intensity above the 1s end point is found to be (86±10)% of the calculated intensity

  19. Cortisol decreases 2[[sup 125]I] iodomelatonin binding sites in the duck thymus

    Energy Technology Data Exchange (ETDEWEB)

    Poon, A.M.S.; Liu, Z.M.; Tang, F.; Pang, S.F. (Univ. of Hong Kong (China))

    1994-03-01

    The immunosuppressive effect of chronic glucocorticoid treatment on 2[[sup 125]I] iodomelatonin binding in the duck thymus was studied. Two-week-old ducks were injected intraperitoneally with either 1 mg of cortisol per day (experimental group) or an equivalent volume of vehicle (control group) in the middle of the light period for seven days. 2[[sup 125]I] iodomelatonin binding assays were performed on thymic membranes. Cortisol injection reduced the body weight gain, size of the bursa of Fabricius and absolute weights of the primary lymphoid organs but had no effect on the spleen weights. The relative weights of the spleen were increased while those of the primary lymphoid organs were unchanged. The density of the thymus 2[[sup 125]I] iodomelatonin binding sites was decreased while the affinity was not affected. The modulation of the thymic 2[[sup 125]I] iodomelatonin binding sites by changes in the immune status of the duck suggests that these binding sites represent physiologically relevant melatonin receptors and that melatonin exerts its action on the lymphoid tissues directly. The authors findings support the hypothesis that the thymus is the target site for the immunomodulatory interactions between the pineal melatonin and the adrenal steroids. A possible inhibitory influence of adrenal steroids on the immuno-enhancing effect of melatonin is also suggested. 34 refs., 3 tabs.

  20. Preparation and animal testing of 125-I-IMP as a scintigraphic agent for brain

    International Nuclear Information System (INIS)

    RS-N-isopropyl-p-iodoamphetamine (IMP) is radio-iodinated by isotopic exchange using Cu (I) as catalyst in presence of an excess of Sn (II) as reductor. The metod is simple and fast. A quantitative (99%) labelling yield of 125I-IMP can be obtained within 30 minutes. Free ionic 125I is less than 3%. After ether extraction, radiochemical purity is greater than 98%, free ionic 125I 125I-IMP in Spragne-Dawlay rat, the brain uptake is prompt, with 1.32%/g of the injected dose reaching the brain by 5 min and peak uptake (1.49%/g) at 1h. There is a slight fall in brain activity after 3h. At all times the brain-to-blood ratio is more than 12. After the administration the highest radioactivity ratios of brain/blood, brain/skeletal muscle and brain/bone are 17.5, 5 and 9 at 30-60 min respectively

  1. Staff dose of hospitalization in the treatment of patients in ophthalmic brachytherapy with 125 I

    International Nuclear Information System (INIS)

    The objective of this work, therefore, has been the evaluation of the dose levels which nursing staff can receive in care for ophthalmic brachytherapy patients treated with 125 I from measurements made on the same, evaluating, in an experimental way, job security following the PR rules laid down for these treatments. (Author)

  2. Effects of age and sex on 125I-β-CIT binding to DAT

    International Nuclear Information System (INIS)

    Objective: To investigate effects of age and sex on 125I-β-CIT binding to dopamine transporter (DAT). Methods: Detection of the differences in 125I-β-CIT binding kinetics in vivo between 6 week and 6 month old KM mice, and the differences of in vivo binding between female and male, and between 3 month and 12 month old SD rats.The animals were sacrificed 2 h after injection. Results: Uptake of 125I-β-CIT in the striatum, frontal cortex, parietal cortex, temporal cortex, occipital cortex, hippocampus, brain stem and whole brain in 6 week old mice was higher than that in 6 month old mice, and similar uptake pattern happened in between 3 month old and in 12 month old SD rats. In 12 months old SD rats, female rats had higher uptake in the striatum than male rats did. Conclusions: Young mice and rats have a higher uptake of 125I-β-CIT in the striatum than aged ones and female rats have a higher uptake than male ones do. This result indicates that the density of DAT in rat or mouse striatum may be reduced with aging

  3. Preparation of 125I labelled nerve growth factor and study of its pharmacokinetics

    International Nuclear Information System (INIS)

    125I-Nerve growth factor (125I-NGF) with more than 95% of radiochemical purity is prepared by chloramine-T method. After I.V. and I.M. injection of 125I-NGF, pharmacokinetics of NGF in mice is determined by SDS-PAGE method. The results show that concentration-time curves after I.V. injection are fitted to a 2-compartment model are those after I.M. injection are fitted to a 1-compartment model. After I.V. injection of 25 μg/kg, the elimination half life (t1/2(β)) is 3.65 h. After I.M. injection of 75, 25, 10, 3.3 μg/kg, t1/2(β) is 1.79, 2.25, 2.30, 3.24 h, respectively. The mean plasma clearance (CLs) is 0.37 L/(h·kg), the appearance volume of distribution (Vd) is 1.18 L/kg and the mean residence time (tr-bar) in mice is 2.78 h. The pharmacokinetics of 125I-NGF in mice is useful for clinical trial

  4. Retention and degradation of 125I-insulin by perfused livers from diabetic rats.

    Science.gov (United States)

    Terris, S; Steiner, D F

    1976-04-01

    The retention of degradation of insulin by isolated perfused liver have been examined. Noncyclically perfused livers from streptozotocin-diabetic rats retained 25% and degraded 10% of 125I-insulin administered as a 1-min pulse. On gel filtration (Sephadex G50F), the degradation products released into the vascular effluent eluted in the salt peak. During the 45-min interval after the end of the 125I-insulin infusion, 0.19% of the total dose was excreted in the bile. 60-90% of this material consisted of iodinated, low-molecular-weight degradation products. Inclusion of native insulin with the 125I-insulin in the pulse depressed both the retention and degradation of iodinated material; however, this reflected increased retention and degradation of the total insulin dose (125I-insulin plus native hormone). The log of the total amounts of insulin retained and degraded were linearly related to the log of the total amount of insulin infused at concentrations between 12.7 nM and 2.84 muM. Increasing the amount of native insulin in the infused pulse also depressed the total amount of iodinated material found in the bile and led to the appearance in the bile of intermediate-sized degradation products that did not simultaneously appear in the vascular effluent. Addition of high concentrations of glucagon to the infused 125I-insulin had no effect on the retention or degradation of the labeled hormone, or on the apparent size and amount of iodinated degradation products found in the vascular effluent or in the bile. Preinfusion of concanavalin A inhibited both 125I-insulin retention and degradation. A greater depression by concanavalin A of degradation than binding was also observed with isolated hepatocytes. In contrast to 125I-insulin, the retention and degradation of two iodinated insulin analogues of relative low biological potency, proinsulin and desalanyl-desasparaginyl insulin, were small. The amount of radioactivity appearing in the bile after infusion of these

  5. Comparison of (/sup 125/I)HIPDm and (/sup 125/I)iodoantipyrine in quantifying regional cerebral blood flow in rats

    Energy Technology Data Exchange (ETDEWEB)

    Albright, R.E. Jr.; Friedman, A.H.; Fram, E.K.; Harbury, O.L.; Molter, B.A.; Skatoff, J.H.; Harris, C.C.; Coleman, R.E.; Drayer, B.P.

    1988-11-01

    We determined regional cerebral blood flow (rCBF) using (/sup 125/I)HIPDm (N,N,N'-trimethyl-N'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamin e) and (/sup 125/I)iodoantipyrine autoradiography under control and pathologic conditions (hypercapnia (acidosis), hypocapnia (alkalosis), and disrupted blood-brain barrier) conditions in 35 rats. In control rats, HIPDm rCBF (indicator fractionation method, n = 5) was lower than the corresponding IAP rCBF (diffusible indicator method, n = 4), most notably in the infratentorial regions and subcortical nuclei. In hypercapnia, rCBF increased by 100% and 37% in the HIPDm (n = 5) and IAP (n = 5) groups, respectively. In hypocapnia, IAP rCBF (n = 4) decreased 34% but HIPDm rCBF (n = 4) did not change. Following disruption of the blood-brain barrier by intracarotid infusion of mannitol in eight rats, both radiotracers (HIPDm n = 4, IAP n = 4) showed decreased rCBF to regions of disruption as defined by trypan blue extravasation. Our work indicates that modeling HIPDm uptake to quantify rCBF using the indicator fractionation method will underestimate blood flow and that HIPDm kinetics are influenced by compartmental pH dynamics that will limit the accuracy of this method in quantifying rCBF in pathologic conditions.

  6. Cytotoxic effects of 125I-labeled PBZr ligand PK 11195 in prostatic tumor cells: therapeutic implications

    International Nuclear Information System (INIS)

    The effect of [125I]PK 11195 was examined in human prostatic tumor cells (DU 145) in culture and compared with Na[125I] and non-radioactive PK 11195. [125I]PK 11195 was clearly cytocidal. The data for dose-related cell survival with [125I]PK 11195 showed a linear relationship. Na[125I] or non-labeled PK 11195 at similar concentrations did not lead to any cell killing. The uptake of [125I]PK 11195 and [3H]PK 11195 in cells was very similar. Fragmentation of DNA measured by agarose gel electrophoresis showed that exposure of DU 145 cells to [125I]PK 11195 for 1, 4 or 24 h caused no fragmentation. These results indicate that nuclear DNA is not the prime binding site for [125I]PK 11195, which is consistent with the presence of specific peripheral benzodiazepine receptors (PBZr) in the mitochondria. The cell killing effect of [125I]PK 11195 suggests the use of PBZr ligand for radiotherapy

  7. Long-Term Efficacy and Toxicity of Low-Dose-Rate {sup 125}I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer

    Energy Technology Data Exchange (ETDEWEB)

    Kittel, Jeffrey A.; Reddy, Chandana A.; Smith, Kristin L.; Stephans, Kevin L.; Tendulkar, Rahul D. [Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio (United States); Ulchaker, James; Angermeier, Kenneth; Campbell, Steven; Stephenson, Andrew; Klein, Eric A. [Department of Urology, Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, Ohio (United States); Wilkinson, D. Allan [Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio (United States); Ciezki, Jay P., E-mail: ciezkij@ccf.org [Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio (United States)

    2015-07-15

    Purpose/Objectives: To report long-term efficacy and toxicity for a single-institution cohort of patients treated with low-dose-rate prostate brachytherapy permanent implant (PI) monotherapy. Methods and Materials: From 1996 to 2007, 1989 patients with low-risk (61.3%), intermediate-risk (29.8%), high-intermediate-risk (4.5%), and high-risk prostate cancer (4.4%) were treated with PI and followed up prospectively in a registry. All patients were treated with {sup 125}I monotherapy to 144 Gy. Late toxicity was coded retrospectively according to a modified Common Terminology Criteria for Adverse Events 4.0 scale. The rates of biochemical relapse-free survival (bRFS), distant metastasis-free survival (DMFS), overall survival (OS), and prostate cancer–specific mortality (PCSM) were calculated. We identified factors associated with late grade ≥3 genitourinary (GU) and gastrointestinal (GI) toxicity, bRFS, DMFS, OS, PCSM, and incontinence. Results: The median age of the patients was 67 years, and the median overall and prostate-specific antigen follow-up times were 6.8 years and 5.8 years, respectively. The overall 5-year rates for bRFS, DMFS, OS, and PCSM were 91.9%, 97.8%, 93.7%, and 0.71%, respectively. The 10-year rates were 81.5%, 91.5%, 76.1%, and 2.5%, respectively. The overall rates of late grade ≥3 GU and GI toxicity were 7.6% and 0.8%, respectively. On multivariable analysis, age and prostate length were significantly associated with increased risk of late grade ≥3 GU toxicity. The risk of incontinence was highly correlated with both pre-PI and post-PI transurethral resection of the prostate. Conclusions: Prostate brachytherapy as monotherapy is an effective treatment for low-risk and low-intermediate-risk prostate cancer and appears promising as a treatment for high-intermediate-risk and high-risk prostate cancer. Significant long-term toxicities are rare when brachytherapy is performed as monotherapy.

  8. Synthesis and binding characteristics of N-(1-naphthyl)-N'-(3-[{sup 125}I]-iodophenyl)-N'-methylguanidine ([{sup 125}I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation

    Energy Technology Data Exchange (ETDEWEB)

    Owens, Jonathan E-mail: j.owens@clinmed.gla.ac.uk; Tebbutt, Andrew A.; McGregor, Ailsa L.; Kodama, K.; Magar, Sharad S.; Perlman, Michael E.; Robins, David J.; Durant, Graham J.; McCulloch, James

    2000-06-01

    N-(1-Naphthyl)-N'-(3-[{sup 125}I]-iodophenyl)-N'-methylguanidine ([{sup 125}I]-CNS 1261) was synthesized as a potential radioligand to image N-methyl-D-aspartate (NMDA) receptor activation. [{sup 125}I]-CNS 1261 was prepared by radioiodination of N-(1-naphthyl)-N'-(3-tributylstannylphenyl)-N'-methylguanidine using Na{sup 125}I and peracetic acid. [{sup 125}I]-CNS 1261 uptake in vivo reflected NMDA receptor distribution in normal rat brain, whereas in ischemic rat brain, uptake was markedly increased in areas of NMDA receptor activation. Radiolabeled CNS 1261 appears to be a good candidate for further development as a single photon emission computed tomography tracer in the investigation of NMDA receptor activation in cerebral ischemia.

  9. Human growth hormone radioiodination using different batches of 125I of various ages

    International Nuclear Information System (INIS)

    The reproducibility and the influence of the batch and decay level of Na125I on the radioiodination of human growth hormone (hGH) were examined by a polyacrylamide gel electrophoresis (PAGE) technique. The between-day coefficient of variation (CV) exhibited a value of 11.9% for labelling yields and 14.3% for antibody specific binding. The within-day variation for different shipments and isotope decay-levels was similar to that for the control experiment, carried out under the same conditions, using Na125I from a single lot. The results indicate that the decay-level and batch do not significantly influence either the yields or the immunological properties of the labelled product. The suitability of this PAGE technique as a control test for radioiodinated proteins is established by comparison with gel chromatography on Sephadex G-100. (Auth.)

  10. A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1

    DEFF Research Database (Denmark)

    Angelo, Kamilla; Korolkova, Yuliya V; Grunnet, Morten;

    2003-01-01

    constant, k(on)=3.6 x 10(7) M(-1)s(-1); dissociation rate constant, k(off)=0.005 s(-1)). Wild-type BeKm-1 displaced binding of [125I]-BeKm-1 with half-maximal inhibitory concentrations of 44 pM. In contrast, competition experiments with a BeKm-1 mutant BeKm-1-K18A, in which the toxin interaction site...... is disrupted, resulted in a drop in affinity by more than 300-fold as compared to the wild-type toxin. Iberiotoxin and apamin, peptide inhibitors of Ca2+-activated K+-channels, had no effect on [125I]-BeKm-1 binding. Adding the classical rapid delayed rectifier current (IKr) blocker E-4031 reduced binding...

  11. Preparation of [123I]- and [125I]epidepride: a dopamine D-2 receptor antagonist radioligand

    International Nuclear Information System (INIS)

    (S)-(-)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[123I] iodo-2,3-dimethoxybenzamide (TDP 517) (proposed generic name, [123I]epidepride) is the iodine-123 substituted analogue of isoremoxipride (FLB 457), both of which are very potent dopamine D-2 antagonists (epidepride KD 0.024 nM). [123I] Epidepride was radioiodinated in 60-70% radiochemical yields in 35 min from the corresponding 5-(tributyltin) derivative using Na123I with a specific radioactivity of 3000 Ci/mmol, and oxidized in situ with chloramine-T. The aryltin precursor was prepared from non-labelled epidepride by palladium-catalyzed stannylation using bis(tri-n-butyltin) in triethylamine. Alternatively, using no carrier-added Na125I as the radioisotope, [125I] epidepride at 2000 Ci/mmol specific radioactivity was prepared in 86% radiochemical yield and 99% radiochemical purity after purification by reverse phase HPLC in ethanolic phosphate buffer. (author)

  12. PSA bounce after {sup 125}I-brachytherapy for prostate cancer as a favorable prognosticator

    Energy Technology Data Exchange (ETDEWEB)

    Engeler, Daniel S.; Schwab, Christoph; Schmid, Hans-Peter [Cantonal Hospital St. Gallen, Department of Urology, St. Gallen (Switzerland); Thoeni, Armin F. [Lindenhofspital Berne, Department of Radiation Oncology, Berne (Switzerland); Hochreiter, Werner [Hirslanden Klinik Aarau, Department of Urology, Aarau (Switzerland); Prikler, Ladislav [Klinik Uroviva Buelach, Department of Urology, Buelach (Switzerland); Suter, Stefan [Cantonal Hospital Zug, Department of Urology, Zug (Switzerland); Stucki, Patrick [Cantonal Hospital Lucerne, Department of Urology, Lucerne (Switzerland); Schiefer, Johann; Plasswilm, Ludwig; Putora, Paul Martin [Cantonal Hospital St. Gallen, Department of Radiation Oncology, St. Gallen (Switzerland)

    2015-10-15

    Permanent low-dose-rate brachytherapy (BT) with iodine 125 is an established curative treatment for localized prostate cancer. After treatment, prostate-specific antigen (PSA) kinetics may show a transient rise (PSA bounce). Our aim was to investigate the association of PSA bounce with biochemical control. Patients treated with BT in Switzerland were registered in a prospective database. Only patients with a follow-up of at least 2 years were included in our analysis. Clinical follow-up and PSA measurements were assessed after 1.5, 3, 6, and 12 months, and annually thereafter. If PSA increased, additional follow-up visits were scheduled. Cases of PSA bounce were defined as a rise of at least 0.2 ng/ml above the initial PSA nadir with a subsequent decline to or below the initial nadir without treatment. Biochemical failure was defined as a rise to nadir + 2 ng/ml. Between March 2001 and November 2010, 713 patients with prostate cancer undergoing BT with at least 2 years of follow-up were registered. Median follow-up time was 41 months. Biochemical failure occurred in 28 patients (3.9 %). PSA bounce occurred in 173 (24.3 %) patients; only three (1.7 %) patients with PSA bounce developed biochemical failure, in contrast to 25 (4.6 %) patients without previous bounce (p < 0.05). The median time to bounce was 12 months, the median time to biochemical failure was 30 months. The median bounce increase was 0.78 ng/ml. Twenty-eight patients with bounce (16.5 %) had a transient PSA rise of + 2 ng/ml above the nadir. In most cases, an early increase in PSA after BT indicates PSA bounce and is associated with a lower risk of biochemical failure. (orig.) [German] Die permanente Low-dose-rate-Brachytherapie (BT) mit {sup 125}I ist ein etabliertes kuratives Verfahren bei lokalisiertem Prostatakarzinom. Posttherapeutisch koennen die PSA-Konzentrationen einen voruebergehenden Anstieg zeigen (Bounce-Phaenomen). Untersucht werden sollte ein moeglicher Zusammenhang mit der

  13. Detection of IgG antibodies against Bordetella pertussis with /sup 125/I-protein A

    Energy Technology Data Exchange (ETDEWEB)

    Wirsing von Koenig, C.H.; Finger, H.

    1981-01-01

    A method for the detection of IgG antibodies against Bordetella pertussis is described, based on the principle of 'sandwich' radioimmunoassay. /sup 125/I protein A is used as radioactive tracer. The influence of amounts of antigen, antibody, radioactive tracer, incubation time and temperature were tested and the optimal conditions for the assay are described. The procedure offers a simple, quick, and sensitive method for detecting antibodies against B. pertussis. Application and limitation of the test are discussed.

  14. Effects of hypothyroidism on vascular 125I-albumin permeation and blood flow in rats

    International Nuclear Information System (INIS)

    Effects of hypothyroidism on vascular 125I-albumin permeation and on blood flow were assessed in multiple tissues of male Sprague-Dawley rats rendered hypothyroid by dietary supplementation with 0.5% (wt/wt) 2-thiouracil or by thyroidectomy. In both thiouracil-treated and thyroidectomized rats, body weights, kidney weight, arterial blood pressure, and pulse rate were decreased significantly v age-matched controls. After 10 to 12 weeks of thiouracil treatment, 125I-albumin permeation was increased significantly in the kidney, aorta, eye (anterior uvea, choroid, retina), skin, and new granulation tissue, remained unchanged in brain, sciatic nerve, and heart, and was decreased in forelimb skeletal muscle. A similar pattern was observed in thyroidectomized rats, except that increases in 125I-albumin permeation for all tissues were smaller than those observed in thiouracil-treated rats, and 125I-albumin permeation in retina did not differ from controls. In both thiouracil-treated and thyroidectomized rats, changes in blood flow (assessed with 15-microns, 85Sr-labeled microspheres) relative to the decrease in arterial blood pressure were indicative of a decrease in regional vascular resistance except in the choroid and in the kidney, in which vascular resistance was increased significantly. Glomerular filtration rate was decreased, but filtration fraction and urinary excretion of albumin remained unchanged by thiouracil treatment and thyroidectomy. These results indicate that vascular hemodynamics and endothelial cell barrier functional integrity are modulated in many different tissues by the thyroid. In view of the correspondence of hypothyroid- and diabetes-induced vascular permeability changes, these results raise the possibility that altered thyroid function in diabetes may play a role in the pathogenesis of diabetic vascular disease

  15. Localization of 125I-insulin binding sites in the rat hypothalamus by quantitative autoradiography

    International Nuclear Information System (INIS)

    In vitro autoradiography and computer video densitometry were used to localize and quantify binding of 125I-insulin in the hypothalamus of the rat brain. Highest specific binding was found in the arculate, dorsomedial, suprachiasmatic, paraventricular and periventricular regions. Significantly lower binding was present in the ventromedial nucleus and median eminence. The results are consistent with the hypothesis that insulin modulates the neural regulation of feeding by acting at sites in the hypothalamus. (author)

  16. A one-pot radiosynthesis of [125I]iodoazido photoaffinity labels

    International Nuclear Information System (INIS)

    A useful method for preparing radioiodinated photoaffinity labels from alkyl anilines which offer significant advantages over present methods is described. The one-pot synthesis gives good radiochemical yields (40-64%) of pure, high specific activity (350-1500 mCi/μmol) 124I labelled iodaryl azides while minimising manipulation of radioactive materials. Purification of the [125I]iodoazido photoaffinity labels is achieved by high performance liquid chromatography. (author)

  17. A new 125I-anti-DNA-radioimmunoassay for the diagnosis of systematic Lupus erythematosus

    International Nuclear Information System (INIS)

    For a differential diagnosis distinguishing between systematic lupus erythematosus and progressive and chronic polyarthritis, a special RIA method has been developed and tested. The anti-DNA activity was determined as follows: the antigen was a high-molecular double strand DNA from a human tumour cell strain biologically labelled with 125I-desoxyuridine. Free and bound antigen was separated by precipitation using saturated ammonium sulfate solution. Recovery and interassay variance of this RIA are comparable with that of other RIAs. (GSE)

  18. Brachytherapy of ocular melanoma : physical and dosimetric aspects of 125I ophthalmic plaques

    International Nuclear Information System (INIS)

    Off-axis absorbed dose distribution of ophthalmic plaques is a useful parameter for the explanation of some observed biological effects. From a specific dosimetric software, developed in our brachytherapy department, and from our measurements around 125I eye plaque, we studied the dose distribution effects on the spread of activities inside the plaques. After analysis of experimental data, we observed also that the dose distribution in the penumbra area may be described easily with decrement lines. (author). 17 refs., 9 figs

  19. Protein radioiodination in a radioassay laboratory: evaluation of commercial Na125I reagents and related biohazards

    International Nuclear Information System (INIS)

    Three commercial Na125I solutions (Amersham, New England Nuclear, and Union Carbide) have been examined with respect to multiple parameters affecting their use in the radioiodination of three representative peptides (insulin, growth hormone, and gastrin): % of radioiodine incorporation in protein; immunoreactivity and non-specific binding properties of the radiolabeled proteins; pH, volatility, and radionuclidic purity of radioiodine solutions; and vial construction with respect to multidose use. All three commercial Na125I produced radioiodinated proteins of good quality for use in radioligand assays. The radioiodines differed with respect to the amount of iodine released during initial vial opening as a consequence of different pH levels. Two of the three products were shipped in vials with poor construction with respect to multidose use. Selection of a radioiodine was therefore reduced to the secondary considerations of iodine volatility and vial construction. The volatilized radioiodine observed during the spill of millicuries quantities of unbuffered pH 7.5 Na125I was 14 microcuries per millicurie within the first 30 minutes. One thickness of rubber gloves reduced potential skin contamination from an accidental spill to insignificant levels: 20-30 picocuries per microcurie. Common good housekeeping procedures: i.e. rubber gloves, laboratory coat and a fume hood were found to be sufficient protection to eliminate most radioiodine volatility and contamination hazards associated with protein radiolabeling procedures

  20. Plasma clearance of human 125I-low density lipoproteins (LDL) in copper-deficient rats

    International Nuclear Information System (INIS)

    The rate of plasma removal of human LDL was measured in copper-deficient (CuD), as compared with copper-adequate (CuA) rats. Purified human LDL (d 1.02-1.063) were labeled with 125I. Faster recipient rats were injected via the jugular vein with a dose of 20.6 μg LDL protein. The 125I radioactivity in 0.2 ml plasma was determined at 1, 2, 4 and 6 hr after dose injection. Percent clearance was calculated based on the plasma volume determined by radioisotope dilution. Mean plasma volumes of CuD and CuA rats were 4.2 and 3.5 ml/100 g bw, respectively. Data showed that LDL were removed at a faster rate in CuD rats. The half-times (t1/2) of LDL in CuD and CuA groups were 4.90 ± 0.20 and 5.80 ± 0.3 hr, respectively. The plasma TCA-soluble 125I radioactivity was significantly and steadily increased in CuD rats at each interval, reflecting the faster removal and degradation of LDL. The findings suggest that the LDL receptor may be up-regulated in CuD rats and that a defective uptake via the receptor is not a cause of the hypercholesterolemia observed in copper deficiency

  1. 125I brachytherapy combined with chemotherapy of advanced non-small cell lung cancer

    Institute of Scientific and Technical Information of China (English)

    林元强; 孙昱; 王任婕; 高识; 陈滨; 孙步彤; 马庆杰; 纪铁凤; 张海山

    2015-01-01

    This study was to evaluate effect of 125I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer (NSCLC). Patients with NSCLC in stages III to IV were divided into two groups: Group A (n = 27) received 125I brachytherapy combined with gemcitabine and cisplatin (GP) chemotherapy, and Group B (n = 27) received GP chemotherapy only. The results showed that the overall response rate and median progression-free survival time were 78%and 11.5 months in Group A, 41%and 8 months in Group B, respectively (P 0.05). The interventional complications in Group A included 5 patients with postoperative pneumothorax and 4 patients with hemoptysis. No patients had radiation pneumonia, radiation esophagitis or esophagotracheal fistula. Chemotherapy treatment-related toxicities were not significantly different between the two groups. The relief of tumor-associated symptoms including cough, hemoptysis, chest pain, and short breath was found in both groups, without statistical difference in remission rates between Groups A and B (P >0.05). In conclusion, 125I brachytherapy combined with chemotherapy proved to be safe and effective for treating advanced NSCLC with few complications. It improves local control rate and prolongs the progression-free survival time.

  2. Synthesis and 125I labelling of a precursor for imaging nicotinic acetylcholine receptors

    International Nuclear Information System (INIS)

    Nicotinic Acetylcholine Receptors (nAChRs) are involved in various pharmacological effects or diseases, such as Alzheimer's Disease, Parkinson's Disease and tobacco addiction. It will be very appealing to image nAChRs in vivo, diagnose and treat the above diseases, and probe the mechanism of nAChRs in tobacco addiction if the suitable radioactive labeled compound can be synthesized. In this study, (s)-5-(tri-butylstannyl)-3{[1-(tert-butoxycarbonyl)-2-azetidinyl]methoxy} pyridine, a precursor for imaging nAChRs, was synthesized with commercial 2-furfurylamine and (s)-2-azetidinecarboxylic acid as starting materials, and was further labeled with 125/123I. The whole procedure for radiosynthesis needs 50-55 min and more than 30% of the 125I are found in the purified 5-[125I]-A-85380. Even staying for 3 days at room temperature in vitro, the purified 5-[125I]-I-85380 can maintain its stability, with a radiochemical purity of more than 95%. (authors)

  3. Pharmacokinetics of 125-I-labelled meta-iodo-benzyl-guanidine : Preliminary results

    International Nuclear Information System (INIS)

    The study of some pharmacokinetics providing the mechanism of uptake amd metabolism parameters for the 125-I-mIBG is described. NMRI mice are used for plasma binding study, the animals are killed by decapitation after intravenously (IV) injection of 125-I-mIBG. Wistar rats are used in urinary excretion study. After IV injection, animals are placed in metabolic cages to collect urine. For biodistribution, the rats are killed at different time intervals. The considered organs are removed. The radioactivity of all parameters was performed by gamma counter. The results show that the blood clearance is very high after several hours post injection and very high after 72 hours. Furthermore, we note a rapid excretion of radioactivity 24 hours post injection. However, we observe that 72 hours after injection, the radioactivity per gram of different organs was normalized according to the adrenal glands. Also, we note, that the adrenal glands may be the only target organs 48 hours post injection. These results confirm that 125-I-mIBG a high affinity for the adrenergic innervation organs (Adrenal glands, salivary glands, heart and spleen)

  4. Backscatter measurements from a single seed of 125I for ophthalmic plaque dosimetry

    International Nuclear Information System (INIS)

    To determine the dosimetric effect of a gold plaque applicator used in 125I ophthalmic irradiation, relative dose rates at points 2--18 mm transverse to the axis of a single seed of 125I were measured in an acrylic phantom under three different measurement conditions. The detectors were 1-mm diameter x 3-mm length LiF thermoluminescent dosimeters (TLD's). Conditions corresponded to the following: (i) full scatter, (ii) the presence of an ophthalmic gold plaque, and (iii) no scatter material on the side of the seed opposite to the TLD's. The dose rate with the gold plaque is less than that with full scatter phantom. There is no significant decrease in dose rate at 2.2 mm from the seed. Dose rate is significantly reduced at greater distances. The does rate decrease ranges from 4% at 5 mm to 10% at 18 mm. The 125I seed in the gold plaque gives 3%--5% higher dose rate than in the absence of backscatter material

  5. Characterization of pancreatic somatostatin binding sites with a 125I-somatostatin 28 analog

    International Nuclear Information System (INIS)

    Somatostatin binding to guinea pig pancreatic acinar cell plasma membranes was characterized with an iodinated stable analog of somatostatin 28 (S28): 125I-[Leu8,DTrp22,Tyr25]S28. The binding was highly dependent on calcium ions. In 0.2 mM free Ca2+ medium, binding at 37 degrees C was saturable, slowly reversible and exhibited a single class of high affinity binding sites (KD = 0.05 +/- 0.01 nM, Bmax = 157 +/- 33 fmol/mg protein). Dissociation of bound radioactivity occurred with biphasic kinetics. Rate of dissociation increased when dissociation was measured at a time before equilibrium binding was reached. In 30 nM free Ca2+ medium, binding affinity and maximal binding capacity were decreased by about 4-fold. Decreasing calcium concentrations increased the amount of rapidly dissociating form of the receptor. Somatostatin 14 antagonist, Des AA1,2[AzaAla4-5,DTrp8, Phe12-13]-somatostatin was active at the membrane level in inhibiting the binding. We conclude that using 125I-[Leu8,DTrp22,Tyr25]S28 as radioligand allows us to characterize a population of specific somatostatin receptors which are not different from those we previously described with the radioligand 125I-[Tyr11]-somatostatin. Somatostatin receptors could exist in two interconvertible forms. Calcium ions are an essential component in the regulation of the conformational change of somatostatin receptors

  6. Photon counting readout pixel array in 0.18-μm CMOS technology for on-line gamma-ray imaging of 103palladium seeds for permanent breast seed implant (PBSI) brachytherapy

    Science.gov (United States)

    Goldan, A. H.; Karim, K. S.; Reznik, A.; Caldwell, C. B.; Rowlands, J. A.

    2008-03-01

    Permanent breast seed implant (PBSI) brachytherapy technique was recently introduced as an alternative to high dose rate (HDR) brachytherapy and involves the permanent implantation of radioactive 103Palladium seeds into the surgical cavity of the breast for cancer treatment. To enable accurate seed implantation, this research introduces a gamma camera based on a hybrid amorphous selenium detector and CMOS readout pixel architecture for real-time imaging of 103Palladium seeds during the PBSI procedure. A prototype chip was designed and fabricated in 0.18-μm n-well CMOS process. We present the experimental results obtained from this integrated photon counting readout pixel.

  7. Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.

    Science.gov (United States)

    Gardette, Maryline; Viallard, Claire; Paillas, Salomé; Guerquin-Kern, Jean-Luc; Papon, Janine; Moins, Nicole; Labarre, Pierre; Desbois, Nicolas; Wong-Wah-Chung, Pascal; Palle, Sabine; Wu, Ting-Di; Pouget, Jean-Pierre; Miot-Noirault, Elisabeth; Chezal, Jean-Michel; Degoul, Francoise

    2014-08-01

    We previously selected two melanin-targeting radioligands [(125)I]ICF01035 and [(125)I]ICF01040 for melanoma-targeted (125)I radionuclide therapy according to their pharmacological profile in mice bearing B16F0 tumors. Here we demonstrate in vitro that these compounds present different radiotoxicities in relation to melanin and acidic vesicle contents in B16F0, B16F0 PTU and A375 cell lines. ICF01035 is effectively observed in nuclei of achromic (A375) melanoma or in melanosomes of melanized melanoma (B16F0), while ICF01040 stays in cytoplasmic vesicles in both cells. [(125)I]ICF01035 induced a similar survival fraction (A50) in all cell lines and led to a significant decrease in S-phase cells in amelanotic cell lines. [(125)I]ICF01040 induced a higher A50 in B16 cell lines compared to [(125)I]ICF01035 ones. [(125)I]ICF01040 induced a G2/M blockade in both A375 and B16F0 PTU, associated with its presence in cytoplasmic acidic vesicles. These results suggest that the radiotoxicity of [(125)I]ICF01035 and [(125)I]ICF01040 are not exclusively reliant on DNA alterations compatible with γ rays but likely result from local dose deposition (Auger electrons) leading to toxic compound leaks from acidic vesicles. In vivo, [(125)I]ICF01035 significantly reduced the number of B16F0 lung colonies, enabling a significant increase in survival of the treated mice. Targeting melanosomes or acidic vesicles is thus an option for future melanoma therapy. PMID:24691673

  8. The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells

    Directory of Open Access Journals (Sweden)

    Zhuang Hong-Qing

    2009-01-01

    Full Text Available Abstract Background To investigate the effectiveness and mechanism of 125I seed continuous low-dose-rate irradiation on colonic cell line CL187 in vitro. Methods The CL187 cell line was exposed to radiation of 60Coγ ray at high dose rate of 2 Gy/min and 125I seed at low dose rate of 2.77 cGy/h. Radiation responses to different doses and dose rates were evaluated by colony-forming assay. Under 125I seed low dose rate irradiation, a total of 12 culture dishes were randomly divided into 4 groups: Control group, and 2, 5, and 10 Gy irradiation groups. At 48 h after irradiation, apoptosis was detected by Annexin and Propidium iodide (PI staining. Cell cycle arrests were detected by PI staining. In order to investigate the influence of low dose rate irradiation on the MAPK signal transduction, the expression changes of epidermal growth factor receptor (EGFR and Raf under continuous low dose rate irradiation (CLDR and/or EGFR monoclonal antibodies were determined by indirect immunofluorescence. Results The relative biological effect (RBE for 125I seeds compared with 60Co γ ray was 1.41. Apoptosis rates of CL187 cancer cells were 13.74% ± 1.63%, 32.58% ± 3.61%, and 46.27% ± 3.82% after 2 Gy, 5 Gy, and 10 Gy irradiation, respectively; however, the control group apoptosis rate was 1.67% ± 0.19%. G2/M cell cycle arrests of CL187 cancer cells were 42.59% ± 3.21%, 59.84% ± 4.96%, and 34.61% ± 2.79% after 2 Gy, 5 Gy, and 10 Gy irradiation, respectively; however, the control group apoptosis rate was 26.44% ± 2.53%. P 2/M cell cycle arrest. After low dose rate irradiation, EGFR and Raf expression increased, but when EGFR was blocked by a monoclonal antibody, EGFR and Raf expression did not change. Conclusion 125I seeds resulted in more effective inhibition than 60Co γ ray high dose rate irradiation in CL187 cells. Apoptosis following G2/M cell cycle arrest was the main mechanism of cell-killing effects under low dose rate irradiation. CLDR could

  9. [Radiological trap and oncological precautions in a patient who has undergone a permanent withdrawal of PIP breast implants].

    Science.gov (United States)

    Koutsomanis, A; Bruant-Rodier, C; Roedlich, M-N; Bretz-Grenier, M-F; Perrot, P; Bodin, F

    2015-12-01

    We report the case of a 57-year-old patient who presented radiological images similar to ruptured breast implants one year after the supposed withdrawal of the latter. This woman had benefited for the first time from cosmetic PIP breast implants in 2000. Early in 2014, she requested the removal of the implants without renewal because she was feeling pain and functional discomfort. A few months after the operation, she consulted for breast swelling in the upper pole of the breast. Radiological assessment showed liquid formations compatible with the presence of implants. At our request, the rereading of the MRI by the radiologist definitively concluded on a bilateral seroma within the persistent fibrous capsule. In the absence of symptoms, clinical monitoring had been decided. But at the recrudescence of anaplastic large cell lymphoma cases associated with breast implants, a cytological sampling was intended. In case of cytological abnormality or recurrence of the seroma, a surgical procedure should be performed. In conclusion, the removal of a breast implant without capsulectomy may result in the formation of a seroma whose images resemble those of an implant. It is always worthwhile to provide precise clinical data to the radiologist in order to help him to make informed interpretations. Every serous effusion in a breast lodge having contained a silicone implant must evoke the diagnosis of anaplastic large cell lymphoma.

  10. Characterization of the PTW SourceCheck ionization chamber with the Valencia lodgment for (125)I seed verification.

    Science.gov (United States)

    Tornero-López, Ana M; Torres Del Río, Julia; Ruiz, Carmen; Perez-Calatayud, Jose; Guirado, Damián; Lallena, Antonio M

    2015-12-01

    In brachytherapy using (125)I seed implants, a verification of the air kerma strength of the sources used is required. Typically, between 40 and 100 seeds are implanted. Checking all of them is unaffordable, especially when seeds are disposed in sterile cartridges. Recently, a new procedure allowing the accomplishment of the international recommendations has been proposed for the seedSelectron system of Elekta Brachytherapy. In this procedure, the SourceCheck ionization chamber is used with a special lodgment (Valencia lodgment) that allows to measure up to 10 seeds simultaneously. In this work we analyze this procedure, showing the feasibility of the approximations required for its application, as well as the effect of the additional dependence with the air density that shows the chamber model used. Uncertainty calculations and the verification of the approximation needed to obtain a calibration factor for the Valencia lodgment are carried out. The results of the present work show that the chamber dependence with the air density is the same whether the Valencia lodgment is used or not. On the contrary, the chamber response profile is influenced by the presence of the lodgment. The determination of this profile requires various measurements due to the nonnegligible variability found between different experiments. If it is considered, the uncertainty in the determination of the air-kerma strength increases from 0.5% to 1%. Otherwise, a systematic additional uncertainty of 1% would occur. This could be relevant for the comparison between user and manufacturer measurements that is mandatory in the case studied here.

  11. The incidence of radioepidermitis and the dose-response relationship in parotid gland cancer patients treated with 125I seed brachytherapy. Incidence of radioepidermitis and the dose-response relationship

    Energy Technology Data Exchange (ETDEWEB)

    Mao, Ming-Hui; Zheng, Lei; Gao, Hong; Zhang, Jie; Liu, Shu-ming; Huang, Ming-wei; Shi, Yan [Peking University School and Hospital of Stomatology, Department of Oral and Maxillofacial Surgery, Beijing (China); Zhang, Jian-Guo [Peking University School and Hospital of Stomatology, Department of Oral and Maxillofacial Surgery, Beijing (China); Fujian Provincial Hospital, Fujian (China)

    2014-09-09

    We studied the incidence and dose-response relationship of radioepidermitis in parotid gland carcinoma patients treated with [{sup 125}I] seed brachytherapy in the hopes of designing an optimized pre-implant treatment plan that would reduce the incidence and severity of radioepidermitis in patients receiving this therapy. Between January 2007 and May 2010, 100 parotid gland cancer patients were treated postoperatively with [{sup 125}I] seed brachytherapy. The matched peripheral dose (MPD) was 80-140 Gy, and [{sup 125}I] seed activity was 0.7-0.8 mCi. The mean dose delivered to the skin was calculated in the post-implant CT on day 0 following implantation. Grades of acute and late dermatitis were evaluated at 2, 6, 12, and 18 months post-implantation. Most patients experienced grade 0-2 acute and late skin side effects (86 and 97 %, respectively), though a small subset developed severe complications. Most grade 1-3 effects resolved within 6 months of implantation, though some grade 1-3 effects and all grade 4 effects remained unchanged throughout the 18-month follow-up period. Grade 3 and 4 effects were most prominent (75 and 25 %, respectively) with doses of 110-140 Gy; doses higher than 140 Gy produced only grade 4 effects. [{sup 125}I] seed brachytherapy produced acceptable levels of acute and late radioepidermitis with a good clinical outcome. A mean dose under 100 Gy delivered to the skin was safe, though doses of 110-140 Gy should be given with caution and extra monitoring; doses greater than 140 Gy are dangerous and likely to produce grade 4-5 effects. (orig.) [German] Wir untersuchten die Inzidenz und die Dosis-Wirkung-Beziehung bei Patienten mit Ohrspeicheldruesenkrebs, die mit [{sup 125}I]-Seed-Brachytherapie behandelt wurden, in der Hoffnung, eine optimierte praeimplantologische Behandlung zu entwickeln, welche die Inzidenz und Schwere der Radioepidermitis bei Patienten, die diese Therapie erhalten haben, reduziert. Zwischen Januar 2007 und Mai 2010

  12. Metabolic and kinetic considerations in the use of [125I]HIPDM for quantitative measurement of regional cerebral blood flow

    International Nuclear Information System (INIS)

    The metabolic degradation and the kinetics of the cerebral uptake of N,N,N'-trimethyl-N'-(2-hydroxy-3-methyl-5-[125I]iodobenzyl)-1, 3-propanediamine ([125I]HIPDM) have been studied in conscious, adult male Sprague-Dawley rats to determine its suitability as a tracer for the quantitative measurement of regional CBF (rCBF). rCBF was calculated by the indicator fractionation and the tissue equilibration methods in experiments of different durations up to 1 h. The values of rCBF obtained with [125I]HIPDM were compared with those obtained in concurrent measurements with [14C]iodoantipyrine in the same animals. Results of the experiments demonstrate that [125I]HIPDM is an inadequate tracer for use with the indicator fractionation method and that any method that employs [125I]HIPDM for the determination of rCBF must take into account its metabolic degradation, diffusion limitations, and bidirectional flux across the blood-brain barrier. With the tissue equilibration method, consistent determinations of rCBF may be possible with [125I]HIPDM by measurement of the time course of its concentration in arterial blood, corrected for the presence of 125I-labeled metabolic products, and its concentration in the brain at any time up to 1 h after its administration. The method may be adapted to measure rCBF in humans by means of single-photon emission tomography with [123I]HIPDM

  13. Bioactivity assays and application of 125I labeled human mouse chimeric anti-CD22 monoclonal antibody SM03

    International Nuclear Information System (INIS)

    To investigate the bioactivity and application of 125I labeled human mouse chimeric monoclonal SM03, SM03 was labeled with 125I using Indogen method. The labeled mixture was purified by Sephacryl S-300 HR separation chromospectry. The purity and concentration of separated fractions were determined by HPLC and Protein Assay Kit, respectively. Competitive binding method and ELISA method were used for bioactivity assays. 125I-SM03 was applied to screen cell lines which express the most abundant CD22 antigen. The purity and recovery of 125I-SM03 were >99% and >47%, respectively. The bioactivity of 125I- SM03 and SM03 hasn't significant difference in statistics. Ramos cell line had the strongest special radioactivity when 125I-SM03 bound with in Raji, Daudi and Ramos cell lines. Indogen method is a good way to label Human mouse chimeric anti-CD22 monoclonal antibody SM03 and the label will not affect the activity of SM03. The 125I-SM03 not only can be used for detect agent, but also may be put into market for NHL therapy. (authors)

  14. 125I-labeled protein A as a general tracer in immunoassay: suitability of goat and sheep antibodies

    International Nuclear Information System (INIS)

    The immunoassay method in which 125I-labeled staphylococcal Protein A ([125I]PA) serves as a general tracer has been extended to include goat and sheep IgG antibodies. Goat and sheep IgG normally do not react significantly with PA. However, once IgG antibody is bound to immobilized antigen or hapten, binding of [125I]PA is enhanced markedly. Binding efficiencies of [125I]PA to immune complexed goat anti-human IgM, human IgE, methotrexate and sheep anti-IgE were determined and compared quantitatively to rabbit IgG with the corresponding specificity. Immunoassays were developed based on the inhibition of [125I]PA binding as a measure of antibody inhibition by fluid-phase homologous ligand. Goat antibody to the monovalent hapten methotrexate behaved anomalously: for each concentration of IgG tested, there was an optimal amount of methotrexate beads that gave maximum binding of [125I]PA. In the other immune systems, for each antibody concentration maximum binding of tracer was a function only of the amount of immobilized anitgen added. In contrast to the results obtained with solid-phase antigen, solutions containing antibody and amounts of antigen ranging from large antigen excess to antibody excess failed to react significantly with PA or [125I]PA. (Auth.)

  15. A study of thyroid contaminations with 125I and of their blocking

    International Nuclear Information System (INIS)

    A sensitive method for the detection of 125I contaminations of the thyroid was set up, the uptakes being determined by comparison with a standard curve, obtained by placing various calibrated sources of in a neck phantom. The detector efficiency was of the order of 0.25% with a stability of +- 0.011% (CV=4.4%) over a six month period. Accuracy was also confirmed, while precision studies showed an inter measurement coefficient of variation of 2 - 6 % when the measured activities were above 1 kBq. Sensitivity determined according to two different definitions ranged between 30 and 80 Bq. Thirty workers, performing routine 125I labeling in several laboratories of the city of Sao Paulo (Brazil), were monitored, 25 of which (83%) presented significant thyroid contaminations, the maximum being 24 kBq (650 nCi) at the moment of first detection. In five individuals the effective half-life of life of 125I could also be calculated, with enough precision, resulting in a value of 39.4 +- 6.1 d. With basis on these findings and methodology a study was carried out in an animal model (dog) in order to find an useful correlation between maximum thyroid uptake and radioiodine urinalysis at a certain time after contamination, that still could allow the intervention with an adequate blocking agent. The best correlation was found considering 125I thyroid uptake 48 hours (T-48) and urine radioactivity 4 to 6 hours (U-4, U-5, U-6) after contamination (r = 0.974 with a level of significance pT-48 = 0.790 XU-4 + 2.973. could also be calculated, with enough precision, resulting in a value of 39.4 +- 6.1 d. With basis on these findings and methodology a study was carried out in an animal model (dog) in order to find an useful correlation between maximum thyroid uptake and radioiodine urinalysis at a certain time after contamination, that still could allow the intervention with an adequate blocking agent. The best correlation was found considering 125I thyroid uptake 48 hours (T-48) and urine

  16. Molecular suicide studies of 125I and 3H disintegration in the DNA of Chinese hamster cells

    International Nuclear Information System (INIS)

    Several recent experiments are discussed which yield some new data to help further understand the dramatic sensitivity of mammalian cells to 125I induced reproductive death. The authors discuss the effects of halogenated pyrimidines on removing the shoulder of the survival curve after tritium thymidine suicide; the effect of oxygen on 125I decay effects as a functions of the localization of the decays within the nucleus; and recent data on the induction of chromosome aberrations by 125I DNA decays in CHO cells stored in the G1-stage of the cell cycle. (B.R.H.)

  17. Stability of 125I and 14C labelled boom clay organic matter

    International Nuclear Information System (INIS)

    The candidate host formation for the disposal of radioactive waste in Belgium is boom clay which may contain up to 4% organic matter (OM). A limited fraction (less than 0.05%) of this OM is mobile. OM can complex radionuclides and so influence their migration. The migration behaviour of the OM itself has been extensively studied but to date such studies have used absorbancy measurements to quantify the OM. Unfortunately various problems accompany the use of absorbancy measurements. The particular problems may be overcome by using radiolabelled OM. Accordingly as a precursor to planned in situ migration experiments in boom clay (BC) using radiolabelled OM, stability studies on 125I and 14C labelled materials have been conducted. The 125I containing solutions were analysed using gel permeation chromatography (GPC) and the 14C solutions using high performance size exclusion chromatography (HPSEC). Dissappointingly at the relevant pH of 8.5, even in the absence of the clay, the 125I label was found to be unstable. However the 14C labelled OM (14C-BC-OM) was stable under the mild conditions employed in the test, so its stability was investigated in the presence of boom clay. The results were compared with that of 14C labelled humic acids (14C-HA), treated similarly. Unexpectedly the 14C labelled material was found to be partially unstable in the presence of boom clay. However the instability has not hampered the laboratory column experiments and should not hamper the proposed in situ experiments with this material. (orig.)

  18. A Dose–Response Analysis of Biochemical Control Outcomes After 125I Monotherapy for Patients With Favorable-Risk Prostate Cancer

    International Nuclear Information System (INIS)

    Purpose: To define the optimal dose for 125I prostate implants by correlating postimplantation dosimetry findings with biochemical failure and toxicity. Methods and Materials: Between 2003 and 2009, 683 patients with prostate cancer were treated with 125I prostate brachytherapy without supplemental external beam radiation therapy and were followed up for a median time of 80 months. Implant dose was defined as the D90 (the minimal dose received by 90% of the prostate) on postoperative day 1 and 1 month after implantation. Therefore, 2 dosimetric variables (day 1 D90 and day 30 D90) were analyzed for each patient. We investigated the dose effects on biochemical control and toxicity. Results: The 7-year biochemical failure-free survival (BFFS) rate for the group overall was 96.4% according to the Phoenix definition. A multivariate analysis found day 1 D90 and day 30 D90 to be the most significant factors affecting BFFS. The cutoff points for day 1 D90 and day 30 D90, calculated from ROC curves, were 163 Gy and 175 Gy, respectively. By use of univariate analysis, various dosimetric cutoff points for day 30 D90 were tested. We found that day 30 D90 cutoff points from 130 to 180 Gy appeared to be good for the entire cohort. Greater D90s were associated with an increase in late genitourinary or gastrointestinal toxicity ≥ grade 2, but the increase was not statistically significant. Conclusions: Improvements in BFFS rates were seen with increasing D90 levels. Day 30 D90 doses of 130 to 180 Gy were found to serve as cutoff levels. For low-risk and low-tier intermediate-risk prostate cancer patients, high prostate D90s, even with doses exceeding 180 Gy, achieve better treatment results and are feasible

  19. A Dose–Response Analysis of Biochemical Control Outcomes After {sup 125}I Monotherapy for Patients With Favorable-Risk Prostate Cancer

    Energy Technology Data Exchange (ETDEWEB)

    Shiraishi, Yutaka, E-mail: shiraishi@rad.med.keio.ac.jp [Department of Radiology, Keio University School of Medicine, Tokyo (Japan); Department of Radiology, National Hospital Organization Tokyo Medical Center, Tokyo (Japan); Yorozu, Atsunori [Department of Radiology, National Hospital Organization Tokyo Medical Center, Tokyo (Japan); Ohashi, Toshio [Department of Radiology, Keio University School of Medicine, Tokyo (Japan); Toya, Kazuhito [Department of Radiology, National Hospital Organization Tokyo Medical Center, Tokyo (Japan); Saito, Shiro; Nishiyama, Toru; Yagi, Yasuto [Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo (Japan); Shigematsu, Naoyuki [Department of Radiology, Keio University School of Medicine, Tokyo (Japan)

    2014-12-01

    Purpose: To define the optimal dose for {sup 125}I prostate implants by correlating postimplantation dosimetry findings with biochemical failure and toxicity. Methods and Materials: Between 2003 and 2009, 683 patients with prostate cancer were treated with {sup 125}I prostate brachytherapy without supplemental external beam radiation therapy and were followed up for a median time of 80 months. Implant dose was defined as the D90 (the minimal dose received by 90% of the prostate) on postoperative day 1 and 1 month after implantation. Therefore, 2 dosimetric variables (day 1 D90 and day 30 D90) were analyzed for each patient. We investigated the dose effects on biochemical control and toxicity. Results: The 7-year biochemical failure-free survival (BFFS) rate for the group overall was 96.4% according to the Phoenix definition. A multivariate analysis found day 1 D90 and day 30 D90 to be the most significant factors affecting BFFS. The cutoff points for day 1 D90 and day 30 D90, calculated from ROC curves, were 163 Gy and 175 Gy, respectively. By use of univariate analysis, various dosimetric cutoff points for day 30 D90 were tested. We found that day 30 D90 cutoff points from 130 to 180 Gy appeared to be good for the entire cohort. Greater D90s were associated with an increase in late genitourinary or gastrointestinal toxicity ≥ grade 2, but the increase was not statistically significant. Conclusions: Improvements in BFFS rates were seen with increasing D90 levels. Day 30 D90 doses of 130 to 180 Gy were found to serve as cutoff levels. For low-risk and low-tier intermediate-risk prostate cancer patients, high prostate D90s, even with doses exceeding 180 Gy, achieve better treatment results and are feasible.

  20. 125I-labeling and purification of peptide hormones and bovine serum albumin

    International Nuclear Information System (INIS)

    The iodination and separation of various diagnostically and/or experimentally important peptides including (Tyr1)-somatostatin-14, rat Tyr-α-calcitonin gene-related peptide (23-37), motilin and vasoactive intestinal peptide, furthermore bovine serum albumin are described. All species were iodinated by the iodogen method. The 125I-labeled peptide products were separated by reversed-phase HPLC, the specific activities of mono-iodinated forms are near identical with the theoretical value. The labeled bovine serum albumin was separated by Sephadex G-100 gel filtration. (author)

  1. Ocular penetration of (/sup 125/I)IVDU, a radiolabeled analogue of bromovinyldeoxyuridine

    Energy Technology Data Exchange (ETDEWEB)

    Maudgal, P.C.; Verbruggen, A.M.; De Clercq, E.; Busson, R.; Bernaerts, R.; de Roo, M.; Ameye, C.; Missotten, L.

    1985-01-01

    Following topical application of (/sup 125/)IVDU, the radiolabeled analogue of bromovinyldeoxyuridine ((E)-5-(2-bromovinyl)-2'-deoxyuridine), as 0.5% or 0.3% eyedrops, to rabbits, (/sup 125/I)IVDU appeared in the anterior chamber fluid at drug levels well above the minimum concentration (0.01 microgram/mL) required for inhibition of herpes simplex virus type 1 replication. These findings are consistent with the efficacy of 0.5% bromovinyldeoxyuridine eyedrops in the topical treatment of herpes simplex uveitis.

  2. A defense in depth approach to radiation protection for 125I production activities.

    Science.gov (United States)

    Culp, T; Potter, C A

    2001-08-01

    Not all operational radiation protection situations lend themselves to simple solutions. Often a Radiation Protection Program must be developed and implemented for difficult situations. A defense in depth approach to radiation protection was developed for 125I production activities. Defense in depth relies on key radiation protection elements that tend to be mutually supportive and in combination provide reasonable assurance that the overall desired level of protection has been provided. For difficult situations, defense in depth can provide both a reasonable and appropriate approach to radiation protection.

  3. Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours

    Directory of Open Access Journals (Sweden)

    Gonçalo dos Santos Clemente

    2011-03-01

    Full Text Available Erythropoietin (EPO is a glycoprotein hormone responsible for regulating erythropoiesis. Expression of EPO and EPO receptors (EPOr has recently been demonstrated in some neoplastic cell lines and tumours, suggesting a potential new target for therapy. In this work, EPO was labeled with iodine-125 using the lactoperoxidase method, known to prevent damage to protein during radioiodination, and labeling conditions were optimized. In vitro stability studies have shown that 125I-EPO is radiochemically stable for 20 days after radiolabeling. In vitro cell binding studies have demonstrated very low binding (A eritropoetina (EPO é um hormônio glicoprotéico responsável pela regulação da eritropoese. Recentemente foi demonstrado que os receptores de EPO (EPOr estão expressos em algumas linhas celulares neoplásicas, o que sugere a sua potencialidade como um novo alvo terapêutico. Neste trabalho a EPO foi radiomarcada com iodo-125 através do método da lactoperoxidase, menos agressivo para a viabilidade biológica das proteínas. A 125I-EPO revelou ser radioquimicamente estável durante 20 dias após a síntese. Um estudo biológico in vitro em linhas celulares tumorais demonstrou que a 125I-EPO apresenta uma ligação muito fraca (<2%, tanto em células normais como nas linhagens tumorais testadas. A biodistribuição em camundongos saudáveis apresentou taxas de fixação relativamente maiores nos órgãos excretores e a tireóide revelou ser o órgão crítico, o que pode indicar a dissociação in vivo da 125I-EPO. No estudo em camundongos com melanoma induzido a fixação no tumor foi residual. Serão, no entanto, necessários novos estudos em outras linhagens tumorais para entender o seu processo de internalização e ligação nas células. Estudos da EPO radiomarcada com carbono-11 poderão também revelar-se interessantes, já que neste método há maior probabilidade da atividade biológica ser preservada.

  4. Development of virtual patient models for permanent implant brachytherapy Monte Carlo dose calculations: interdependence of CT image artifact mitigation and tissue assignment

    International Nuclear Information System (INIS)

    This work investigates and compares CT image metallic artifact reduction (MAR) methods and tissue assignment schemes (TAS) for the development of virtual patient models for permanent implant brachytherapy Monte Carlo (MC) dose calculations. Four MAR techniques are investigated to mitigate seed artifacts from post-implant CT images of a homogeneous phantom and eight prostate patients: a raw sinogram approach using the original CT scanner data and three methods (simple threshold replacement (STR), 3D median filter, and virtual sinogram) requiring only the reconstructed CT image. Virtual patient models are developed using six TAS ranging from the AAPM-ESTRO-ABG TG-186 basic approach of assigning uniform density tissues (resulting in a model not dependent on MAR) to more complex models assigning prostate, calcification, and mixtures of prostate and calcification using CT-derived densities. The EGSnrc user-code BrachyDose is employed to calculate dose distributions. All four MAR methods eliminate bright seed spot artifacts, and the image-based methods provide comparable mitigation of artifacts compared with the raw sinogram approach. However, each MAR technique has limitations: STR is unable to mitigate low CT number artifacts, the median filter blurs the image which challenges the preservation of tissue heterogeneities, and both sinogram approaches introduce new streaks. Large local dose differences are generally due to differences in voxel tissue-type rather than mass density. The largest differences in target dose metrics (D90, V100, V150), over 50% lower compared to the other models, are when uncorrected CT images are used with TAS that consider calcifications. Metrics found using models which include calcifications are generally a few percent lower than prostate-only models. Generally, metrics from any MAR method and any TAS which considers calcifications agree within 6%. Overall, the studied MAR methods and TAS show promise for further retrospective MC dose

  5. Development of virtual patient models for permanent implant brachytherapy Monte Carlo dose calculations: interdependence of CT image artifact mitigation and tissue assignment

    Science.gov (United States)

    Miksys, N.; Xu, C.; Beaulieu, L.; Thomson, R. M.

    2015-08-01

    This work investigates and compares CT image metallic artifact reduction (MAR) methods and tissue assignment schemes (TAS) for the development of virtual patient models for permanent implant brachytherapy Monte Carlo (MC) dose calculations. Four MAR techniques are investigated to mitigate seed artifacts from post-implant CT images of a homogeneous phantom and eight prostate patients: a raw sinogram approach using the original CT scanner data and three methods (simple threshold replacement (STR), 3D median filter, and virtual sinogram) requiring only the reconstructed CT image. Virtual patient models are developed using six TAS ranging from the AAPM-ESTRO-ABG TG-186 basic approach of assigning uniform density tissues (resulting in a model not dependent on MAR) to more complex models assigning prostate, calcification, and mixtures of prostate and calcification using CT-derived densities. The EGSnrc user-code BrachyDose is employed to calculate dose distributions. All four MAR methods eliminate bright seed spot artifacts, and the image-based methods provide comparable mitigation of artifacts compared with the raw sinogram approach. However, each MAR technique has limitations: STR is unable to mitigate low CT number artifacts, the median filter blurs the image which challenges the preservation of tissue heterogeneities, and both sinogram approaches introduce new streaks. Large local dose differences are generally due to differences in voxel tissue-type rather than mass density. The largest differences in target dose metrics (D90, V100, V150), over 50% lower compared to the other models, are when uncorrected CT images are used with TAS that consider calcifications. Metrics found using models which include calcifications are generally a few percent lower than prostate-only models. Generally, metrics from any MAR method and any TAS which considers calcifications agree within 6%. Overall, the studied MAR methods and TAS show promise for further retrospective MC dose

  6. Relationship between alveolar bone measured by /sup 125/I absorptiometry with analysis of standardized radiographs: 1. Magiscan

    Energy Technology Data Exchange (ETDEWEB)

    Hausmann, E.; Ortman, L.F.; McHenry, K.; Fallon, J.

    1982-05-01

    Previous studies have shown that /sup 125/I absorptiometry gives an accurate and sensitive measure of alveolar bone mass. The purpose of this study was to determine the relationship between alveolar bone mass determined by /sup 125/I absorptiometry and bone density obtained by analysis of standardized intraoral radiographs by the Magiscan System. A defect of increasing size was made at one site of the alveolar bone in a human skull. The amount of bone remaining at each step was calculated using /sup 125/I absorptiometry. Standardized radiographs were also taken at each step and the relative density in the area of the defect was determined by the Magiscan System. The Magiscan's System Computer Memory permits analysis of identical areas on a longitudinal series of films of the same alveolar bone location. The results indicate that in estimating amounts of alveolar bone the Magiscan analysis of standardized intraoral radiography is similar in sensitivity and accuracy to /sup 125/I absorptiometry.

  7. Pharmacokinetics of 125I-labelled recombinant epidermal growth factor after intravenous injection of the drug in rabbits

    International Nuclear Information System (INIS)

    125I-rhEGF was prepared by Iodogen method. Purity was (97.1 +- 0.45)% as determined by SDS-PAGE. The results revealed that plasma radioactivities remained at high level within 8 hours, while fraction of 125I-rhEGF determined by RHPLC decreased rapidly and 125I labelled hydrophilic fraction increased simultaneously. Concentration-time curve of 125I-rhEGF was best fitted with two-compartment model. Disintegration half-lives were 9 min and 11.6 h, respectively. Levels in tissues were urine>thyroid gland>contents in jejunum>kidneys>plasma>bile>submaxillary glands>lungs. A total of (20.3 +- 5.1)% of injected radioactivity was excreted through urine within 8 h

  8. Application of different /sup 125/I tracers in radioimmunoassays of estradiol-17. beta

    Energy Technology Data Exchange (ETDEWEB)

    Bienert, R.; Flentje, H.; Herzmann, H. (Akademie der Wissenschaften der DDR, Berlin-Buch. Zentralinstitut fuer Isotopen- und Strahlenforschung; Akademie der Wissenschaften der DDR, Leipzig. Zentralinstitut fuer Isotopen- und Strahlenforschung)

    1984-01-01

    Some different /sup 125/I-labelled estradiol tracers were produced by direct radioiodizing of estradiol and also of the histamine and tyramine conjugates of estradiol-3-carboxymethylether (E/sub 2/-3-CM) by means of the chloramine-T method. The linkage properties of these tracers were investigated in relation to the /sup 3/H-labelled estradiol opposite to the antisera, which were produced against the cow serum albumin (RSA) conjugates of E/sub 2/-3-CM and estradiol-6-carboxymethyloxime (E/sub 2/-6-CMO). As suitable system for the radioimmunological estradiol determination could be revealed 4-/sup 125/I-iodine estradiol in connection with one antiserum in each case of the radioligand antiserum combinations against E/sub 2/-3-CM-RSA- and E/sub 2/-6-CMO-RSA-conjugate. The double antibody method is used for separation in optimized RIA systems. The first and the second antibody reaction take place simultaneously.

  9. Search for 17-keV neutrinos in the internal bremsstrahlung spectrum of 125I

    International Nuclear Information System (INIS)

    We have conducted an experiment to search for the signature of a 17-keV neutrino in the internal bremsstrahlung (IB) spectrum of 125I. Gamma rays from a ∼ 100 mCi 125I point source were counted in a planar HPGe detector which is 16 mm in diameter and 10 mm in depth and which has a resolution of 560 eV at 122 keV. The source was counted for 61 d and the background for 17 d. At the start of the counting period the count rate was 650 s-1; the number of counts 17 keV below the 2p endpoint is 106 per keV. Data in the energy interval 120-150.5 keV were fitted with a theoretical spectrum calculated using nonrelativistic Hartree-Fock atomic wavefunctions. The preliminary fits reject the hypothesis of a 0.8% 17-keV neutrino at a confidence level of ≥ 98%. We are in the process of reanalyzing the data using recent relativistic theoretical shapes

  10. Plasma kinetics of 125I beta endorphin turnover in lean and obese Zucker rats

    International Nuclear Information System (INIS)

    Plasma clearance kinetics for Beta Endorphin (BEP) are not well-defined and no definitive data exist for lean versus obese animals. To determine such kinetic parameters, a bolus of 125I BEP (1μCi/kg) was infused into awake lean(L) and obese(O) Zucker rats. Arterial blood samples were withdrawn initially at 20 seconds intervals and less frequently as a 3-hour experimental period progressed. Donor rat blood was infused (venous catheter) to replace withdrawn blood. At 180 minutes approximately 10% of the initial dose remained in the plasma. Clearance kinetics for 125I BEP were analyzed by compartmental analysis. A 3-component equation (i.e., 3 compartment model) provided the best fit for both L and O groups. Plasma transit times were very rapid; however, plasma fractional catabolic rate was low. Plasma mean residence time was similar for both groups (50 minutes) as was recycle time. These data suggest that BEP kinetics are similar in L and O rats, and that this peptide may undergo extensive recycling into and out of the plasma compartment. The identity of the other two compartments requires further investigation

  11. Composition of cross-linked 125I-follitropin-receptor complexes

    International Nuclear Information System (INIS)

    Both of the alpha and beta subunits of intact human follitropin (FSH) were radioiodinated with 125I-sodium iodide and chloramine-T and could be resolved on sodium dodecyl sulfate-polyacrylamide gels. Radioiodinated FSH was affinity-cross-linked with a cleavable (nondisulfide) homobifunctional reagent to its membrane receptor on the porcine granulosa cell surface as well as to a Triton X-100-solubilized form of the receptor. Cross-linked samples revealed three additional bands of slower electrophoretic mobility, corresponding to 65, 83, and 117 kDa, in addition to the hormone bands. The hormone alpha beta dimer band corresponded to 43 kDa. Formation of the three bands requires the 125I-hormone to bind specifically to the receptor with subsequent cross-linking. Binding was prevented by an excess of the native hormone but not by other hormones. A monofunctional analog of the cross-linking reagent failed to produce the three bands. Reagent concentration-dependent cross-linking revealed that their formation was sequential; smaller complexes formed first and then larger ones. When gels of cross-linked complexes were treated to cleave covalent cross-links and then electrophoresed in a second dimension, 18-, 22-, and 34-kDa components were released, in addition to the alpha and beta subunits of the hormone

  12. DNA strand breakage by 125I decay: Plasmid DNA in dilute aqueous solution

    International Nuclear Information System (INIS)

    The question of the extent of damage to DNA, in particular double strand breaks, that can be caused by the decay of the Auger emitter 125I when it is covalently incorporated into the DNA requires resolution. In particular, experiments with plasmid DNA reported by Linz and Stoecklin would seem to indicate that the range of effect extends over the whole length of the molecule (a few 1,000's base pairs (bp)) in contrast to the generally accepted view that the decay is very localized (i.e. effect over a few 10's bp). This raises the question of whether a long range energy migration process is operative in DNA or whether the fragmentation can be accounted for by free radical diffusion. The authors report here experiments to help resolve this issue by investigating and trying to eliminate the possible effects of free radicals. The results which are broadly consistent with the findings of Linz and Stoecklin indicate that long-range damage in labeled DNA in aqueous solution is due to effects of free radicals. The authors confirm the high-LET nature of the 125I decay

  13. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helin forming oligonucleotide directed against androgen receptor

    Institute of Scientific and Technical Information of China (English)

    ZHANG Yong; MA Yi; LU Han-ping; GAO Jin-hui; LIANG Chang-sheng; LIU Chang-zheng; ZOU Jun-tao; WANG Hua-qiao

    2008-01-01

    Background The failure of hormone treatment for advanced prostate cancer might be related to aberrant activation of the androgen receptor.We have shown that 125I labeled triple-helix forming oligonucleotide (TFO) against the androgen receptor gene inhibits androgen receptor expression and cell proliferation of LNCaP prostate cancer cells in vitro.This study aimed at exploring the effects of the 125I-TFO on prostate tumor growth in vivo using a nude mouse xenograft model.Methods TFO was labeled with 125I by the iodogen method.Thirty-two nude mice bearing LNCaP xenograft tumors were randomized into 4 groups and were intratumorally injected with 125I-TFO,unlabeled TFO,Na125I and normal saline.Tumor size was measured weekly.The tumor growth inhibition rate (RI) was calculated by measurement of tumor weight.The expression of the androgen receptor gene was performed by RT-PCR and immunohistochemical study.The prostate specific antigen (PSA) serum levels were measured by enzyme linked immunosorbent assay.The tumor cell apoptosis index (Al) was detected by TUNEL assay.Results Tumor measurements showed that tumor development was significantly inhibited by either 125I-TFO or TFO,with tumor RIs of 50.79% and 32.80% respectively.125I-TFO caused greater inhibition of androgen receptor expression and higher Als in tumor tissue than TFO.Both the tumor weight and the PSA serum levels in 125I-TFO treated mice ((0.93±0.15) g and (17.43±1.85) ng/ml,respectively) were significantly lower than those ((1.27±0.21) g and (28.25±3.41)ng/ml,respectively) in TFO treated mice (all P<0.05).Na125I did not significantly affect tumor growth and androgen receptor expression in tumor tissue.Conclusions The 125I-TFO can effectively inhibit androgen receptor expression and tumor growth of human prostate cancer xenografts in vivo.The inhibitory efficacy of 125I-TFO is more potent than that of TFO,providing a reference for future studies of antigen radiotherapy.

  14. DNA strand breakage by 125I-decay in a synthetic oligodeoxynucleotide. Fragment distribution and evaluation of DMSO protection effect

    International Nuclear Information System (INIS)

    A double stranded oligodeoxynucleotide containing a single 125I-dC in a defined location was used to investigate DNA strand breakage resulting from 125I decay. Samples of a 41 bp oligodeoxynucleotide were incubated in 20 mM phosphate buffer (PB), or PB plus 2 M dimethylsulphoxide (DMSO), at 4 C during 18-20 days. The 32P-5'-end labelled DNA fragments produced by 125I decays were separated on denaturing polyacrylamide gels, and the 32P activity in each fragment was determined by scintillation counting after elution of fragments from gel. Most of the breaks, around 90%, occurred within 4-5 nucleotides of the 125I-dC, but DNA breaks were detected up to 16 nucleotides from the decay site. The 125I-dC was located at the 21st nucleotide from the 32P-5'-end label, and since 32P was not detected in fragments longer than 20 nucleotides, it was assumed that all 125I decay events produce at least one break in the 125I-labelled DNA strand. The results show a considerable protection effect of DMSO on DNA breaks at sites >5-6 nucleotides from the 125I location. The probability of breaks in this region was decreased with DMSO by a factor of 2 to 8-fold, suggesting significant role for radical-mediated DNA breaks at the more distant sites. However, the total protection effect of DMSO is rather small: 1.1, because of the small contribution of breakage at distant sites to the total yield. (orig.)

  15. Heterogeneity in mouse seminal vesicle epithelial cells responding to androgen as evaluated by incorporation of [125I]iododeoxyuridine

    International Nuclear Information System (INIS)

    When the uptake of 5-[125I]iodo-2'-deoxyuridine ([125I]IdUrd) into the seminal vesicle of castrated mice was measured 3 days after starting injections of various doses of testosterone propionate (TP), logarithmic values of [125I]IdUrd uptake were proportional to the logarithmic doses of TP in the range of 0.04-2 micrograms/g BW. The [125I]IdUrd uptake values correlated well with the labeling and mitotic indices of epithelial cells. Since daily injections of 0.4 microgram TP/g BW did not increase significantly the weight or DNA content or protein content of the seminal vesicle, the [125I]IdUrd uptake is a sensitive index of androgen action. Moreover, this suggests that low doses of androgen induce division of epithelial cells without resulting in the increase in cell number. The [125I]IdUrd radioactivity in the seminal vesicle was measured 2-15 days after the injection of [125I]IdUrd, since the value represented the fraction of surviving cells synthesizing DNA at the time of [125I]IdUrd injection. When injections of 4 micrograms TP/g BW were continued, the incorporated radioactivity was retained. In contrast, continuous injections of 0.2 microgram TP/g BW did not maintain the radioactivity, of which incorporation was induced by the same dose of TP. Thus, the present result suggests the presence of heterogeneity in androgen-responsive epithelial cells of the seminal vesicle

  16. The effect of 125I labeled anti-androgen receptor agent on the proliferation of prostate cancer cells

    International Nuclear Information System (INIS)

    Objective: Based on the previous experience of using anti-androgen receptor triple helix forming oligonucleotide (TFO) to inhibit proliferation of prostate cancer cells, a 125I labeled TFO was prepared and tested in this experiment as an androgen receptor targeted antigene radiotherapy. Methods: 125I-TFO was labeled through Iodogen and then transfected LNCaP prostate cancer cells via liposome. The unlabeled TFO, 125I, and naturally cultured cells served as controls. The cellular proliferation was detected by methyl thiazolium tetrazolium (MTT) method, the expression of androgen receptor gene was carried out by RT-PCR and immunohistochemical study. Results: The radiolabeling efficiency, radiochemical purity and specific activity of 125I-TFO were 63.7%, 95.6% and 80.1 kBq/μg, respectively. At the same TFO concentration, the androgen receptor expression level in 125I-TFO treated cells was markedly lower than that of TFO group (P125I-TFO on cellular proliferation was significantly higher (P< 0.01). Conclusion: The inhibitory effect on androgen receptor expression and cell proliferation of prostate cancer cells of antigene therapy with radio-labeled TFO were significantly more obvious than that of classical antigene therapy. (authors)

  17. Identification of 2-[125I]iodomelatonin binding sites in the thymus of mice and its significance

    Institute of Scientific and Technical Information of China (English)

    刘志民; 赵瑛; 彭树勋

    1995-01-01

    The melatonin binding sites in membrane preparations of the mouse thymus were demonstratedusing 2-[125I] iodomelatonin as a radioligand.The binding sites were stable,saturable,reversible and of highaffinity.Studies on specificity of 2-[125I] iodomelatonin binding suggested that the 2-[125I] iodomelatonin bindingsites are highly specific for melatonin.These binding sites fulfilled the standard criteria for receptors.Ourwork suggested that melatonin should have direct regulatory action on immune system mediated through themelatonin binding sites.Studies on the circadian rhythm showed that there existed the circadian rhythm in the bind-ing capacity for 2-[125I] iodomelatonin in the mouse thymus with the peak values at 12:00-16:00 andthe trough values between 00:00 and 4:00.The subceUular distribution of 2-[125I] iodomelatonin binding sitesin the mouse thymus was in the following descending order:nuclear>mitochondrial>microsomal>cytosolic frac-tion.There was also an age-related decrease in 2-[125I] iodomelatonin binding in the mouse thymus.This iscorrelated with the involution of the thymus.

  18. Breast reconstruction - implants

    Science.gov (United States)

    Breast implants surgery ... wait 1 to 3 months before the permanent breast implant is placed during the second stage. In the ... from your chest and replaces it with a breast implant. This surgery takes 1 to 2 hours. Before ...

  19. 125I-UdR瘤内注射治疗Lewis肺癌荷瘤小鼠效果观察%Therapeutic effect of intratumoral injection using 125I-UdR on Lewis lung cancer

    Institute of Scientific and Technical Information of China (English)

    李智勇; 刘增礼; 吴锦昌; 周俊东; 申咏梅; 劳勤华

    2013-01-01

    目的 研究125I标记脱氧尿嘧啶核苷(125I-UdR)在Lewis肺癌荷瘤小鼠模型治疗中的药物分布、用药安全性和治疗效果.方法 在Lewis肺癌荷瘤小鼠模型瘤内注射125I-UdR(3.7 MBq/10 μL),通过γ-计数器测量各脏器放射性活度和SPECT显像来观察125I-UdR的药物分布;分析用药后外周血象、肝肾功能等指标及骨髓象来评价125I-UdR的安全性;观察用药后瘤体的组织细胞学变化并作生存分析.结果 125I-UdR局部注射后可在瘤内持续浓聚并致肿瘤细胞坏死;其外周血象、肝肾功能和骨髓象无明显变化,接受治疗的荷瘤鼠生存期明显延长.结论 荷瘤鼠瘤内注射125I-UdR治疗Lewis肺癌安全有效.%Objective To investigate the distribution,safety and therapeutic effect of 125I-UdR (5-[125I] Iodo-2-deoxyuridine) (3.7 MBq/10 ul) in C57 BL/6 mice bearing Lewis lung cancer.Methods After 125I-UdR intratumoral injection,the radioactivity of various organs was determined by γ-well counter and the distribution of 125 I-UdR was observed by SPECT scintigraphy; the safety of 125 I-UdR was analyzed by observing peripheral hemogram,marrow cell and blood biochemistry indexes; the changes of histology and cytology of the tumor were observed and the survival rate was analyzed.Results 125I-UdR was persistently stayed in the tumor,and led to tumor necrosis after partly intratumoral injection.Mice hemogram,marrow cell,hepatic and renal function had no obvious changes,and the survival time of tumor-bearing mice treated by 125 I-UdR distinctly was extended.Conclusion It is safe and effective to inject 125I-UdR (3.7 MBq/10 ul) into the transplanting tumor of tumor-bearing mice with Lewis lung cancer.

  20. Optimal implantation depth and adherence to guidelines on permanent pacing to improve the results of transcatheter aortic valve replacement with the medtronic corevalve system: The CoreValve prospective, international, post-market ADVANCE-II study

    OpenAIRE

    Petronio, Anna S; Sinning, Jan-Malte; Van Mieghem, Nicolas; Zucchelli, Giulio; Nickenig, Georg; Bekeredjian, Raffi; Bosmans, B.; Bedogni, Francesco; Branny, Marian; Stangl, Karl; Kovac, Jan; Schiltgen, Molly; Kraus, Stacia; De Jaegere, Peter

    2015-01-01

    textabstractObjectives The aim of the CoreValve prospective, international, post-market ADVANCE-II study was to define the rates of conduction disturbances and permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement with the Medtronic CoreValve System (Minneapolis, Minnesota) using optimized implantation techniques and application of international guidelines on cardiac pacing. Background Conduction disturbances are a frequent complication of transcatheter aortic va...

  1. Radiosynthesis, in vitro cellular uptake and in vivo biodistribution of 3'-O-(3-benzenesulfonylfuroxan-4-yl)-5-[{sup 125}I]iodo-2'-deoxyuridine, a nucleoside-based nitric oxide donor

    Energy Technology Data Exchange (ETDEWEB)

    Moharram, Sameh [Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); Zhou, Aihua [Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); Kumar, Piyush [Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); Knaus, Edward E. [Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); Wiebe, Leonard I. [Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada)]. E-mail: leonard.wiebe@ualberta.ca

    2005-08-01

    Introduction: 3'-O-(3-Benzenesulfonylfuroxan-4-yl)-5-iodo-2'-deoxyuridine (1) is a cytotoxic nitric oxide (NO) donor-nucleoside dual action prodrug designed to exploit both NO and an antimetabolite nucleoside for cancer therapy. Methods: 1 was radiolabeled by radioiodide exchange and purified by HPLC in 16% overall radiochemical yield. The specific activity of [{sup 125}I]1 was 31.8 {mu}Ci/{mu}g (680 MBq/{mu}M). Protein binding, deiodination, cellular uptake and incorporation of 1 into cellular nucleic acids were measured by standard methods, and its in vivo biodistribution was determined in Balb/c mice bearing implanted EMT-6 tumors following intravenous injection. Results: [{sup 125}I]1 degraded rapidly during the in vitro tests, thus impeding unequivocal assessment but indicating that it was only weakly protein bound and that it was resistant to deiodination under test conditions. Uptake of [{sup 125}I]1 by murine tumor cells (KBALB and KBALB-STK) in vitro was low ({approx}17 fmol/{mu}g protein over 2 h) with only {approx}0.3% (0.04-0.06 fmol/{mu}g protein) of total uptake present in the DNA fraction. In the murine tumor model, liver, kidney, intestine and tumor showed the greatest uptake, with liver, intestine and blood all containing >5 injected dose per gram of tissue (%ID/g) during the 15-min to 2-h postinjection period. Maximum tissue/blood level ratios were 3.6 (2 h) for tumor and 6.4 (24 h) for liver. Low uptake in thyroid and stomach was indicative of minimal in vivo deiodination. Conclusions: [{sup 125}I]1 undergoes only minimal deoiodination under both in vitro and in vivo conditions. Under conditions of the in vitro NO release assay, 1 reacts to produce a single, major, unstable adduct that decomposes upon workup. Protein binding of [{sup 125}I]1 could not be assessed because of similar chemical reaction with albumin. Incorporation of radioactivity into the cellular nucleic acid fraction was low, and in vivo distribution of [{sup 125}I]1 was

  2. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain

    International Nuclear Information System (INIS)

    The 5-HT2 (serotonin) receptor has traditionally been labeled with antagonist radioligands such as [3H]ketanserin and [3H]spiperone, which label both agonist high-affinity (guanyl nucleotide-sensitive) and agonist low-affinity (guanyl nucleotide-insensitive) states of this receptor. The hallucinogen 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) is an agonist which labels the high-affinity guanyl nucleotide-sensitive state of brain 5-HT2 receptors selectively. In the present study, conditions for autoradiographic visualization of (+/-)-[125I]DOI-labeled 5-HT2 receptors were optimized and binding to slide-mounted sections was characterized with respect to pharmacology, guanyl nucleotide sensitivity and anatomical distribution. In slide-mounted rat brain sections (+/-)-[125I]DOI binding was saturable, of high affinity (KD approximately 4 nM) and displayed a pharmacologic profile typical of 5-HT2 receptors. Consistent with coupling of 5-HT2 receptors in the high-affinity state to a guanyl nucleotide regulatory protein, [125I]DOI binding was inhibited by guanyl nucleotides but not by adenosine triphosphate. Patterns of autoradiographic distribution of [125I]DOI binding to 5-HT2 receptors were similar to those seen with [3H]ketanserin- and [125I]-lysergic acid diethylamide-labeled 5-HT2 receptors. However, the density of 5-HT2 receptors labeled by the agonist [125I]DOI was markedly lower (30-50%) than that labeled by the antagonist [3H]ketanserin. High densities of [125I]DOI labeling were present in olfactory bulb, anterior regions of cerebral cortex (layer IV), claustrum, caudate putamen, globus pallidus, ventral pallidum, islands of Calleja, mammillary nuclei and inferior olive. Binding in hippocampus, thalamus and hypothalamus was generally sparse

  3. Preliminary radiochemical and biological studies on the liposome encapsulated platinum-[125I]iodohistamine complex

    International Nuclear Information System (INIS)

    The platinum-iodohistamine complex with in vitro cytostatic activity toward colon and mammary cancer cells has been synthesised recently in our laboratory. The pharmacokinetics of radioactive complex analogues, labelled with I-131 and I-125, has been examined in murine model of spontaneous mammary adenocarcinoma. The present work is devoted to the examination of the potential use of liposomes as a carrier system for the radioactive platinum-[*I]iodohistamine complex in vivo. Encapsulations of the Pt-125I]iodohistamine were studied using a different molar ratio of the complex and liposomes with positive surface charge, as well as various incubation procedures. Biodistribution of the initial and the liposomal form of the complex were studied in C3H tumour-bearing mice with spontaneously developed and transplantable (16C) mammary adenocarcinoma. Comparative biodistribution studies in C3H/16C mice and in mice with spontaneously developed mammary tumour have shown that in the former model pharmacokinetics of the Pt-[125 I]iodohistamine complex is more predictable and more similar to that observed for cisplatin. Therefore, the transplantable tumour model is more advantageous for the complex and its liposomal form evaluation. In C3H/16C mice, significant differences in the biodistribution between the radioactive platinum complex and its liposomal form were observed. The concentration of the activity in blood after 2 h p.i.v. was two times lower for the encapsulated complex, and the uptake of the radioactivity by liver, spleen, and lungs was twice as high as that obtained for the free Pt-[125I]iodohistamine preparation. The radioactivity in tumour was almost constant for liposomal platinum complex (ca. 2% ID/g), although it was two times lower compared to the initial platinum complex. The results of the present study indicate that platinum-[*I]iodohistamine can be efficiently incorporated into cationic liposomes (c. 40%). However, the uptake of the encapsulated complex by

  4. Comparison of /sup 125/I-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias

    Energy Technology Data Exchange (ETDEWEB)

    Mombelli, G.; Roux, A.; Haeberli, A.; Straub, P.W.

    1982-08-01

    To provide more information on the pathways of fibrinogen catabolism in generalized cancer, the effect of heparin on fibrinopeptide A (fpA) and on /sup 125/I-fibrinogen kinetics was studied in 15 patients with disseminated neoplasia. Three patients had evidence of venous thrombosis and in 2 additional patients a low fibrinogen level together with increased amounts of FDP/fdp and a positive ethanol test indicated disseminated intravascular coagulation (DIC). The plasma levels of fpA were grossly elevated (4.6--20, mean 11.4 ng/ml, normal values 1.01 +/- 0.45 ng/ml) in patients with thrombosis or DIC, and normal to grossly elevated (0.4--10.4, mean 6.1 ng/ml) in the other patients. Intravenous heparin bolus lowered the fpA level in 11/11 patients, and continuous heparin treatment led to an impressive suppression or complete normalization of the plasma fpA in 5/6 patients. This finding is thought to reflect heparin suppression of thrombin activity on fibrinogen. In some cases, the fpA fall after heparin bolus was slow and/or incomplete, suggesting fpA generation at sites not easily accessible to heparin or insufficient heparin dosage. The /sup 125/I-fibrinogen kinetics were characterized by a significantly shorter half-life (t1/2: 2.5 days), increased catabolic rate constant (j: 0.44 days-1), and increased absolute turnover (68.9 mg fibrinogen/kg/day) as compared to 4 normal subjects (t1/2: 4.2 days; j: 0.26 days-1; turnover 21.7 mg fibrinogen/kg/day). As estimated from the fpA generation rates, intravascular thrombin action on fibrinogen contributed only in minor part to increase the turnover of /sup 125/I-fibrinogen. In particular, the turnover was greatly accelerated in heparin-treated patients despite impressive suppression or normalization of the fpA levels in 5/6 cases.

  5. Preparation of {sup 125}I-iodotyraminehemisuccinyltaxol ({sup 125}ITHT) for competitive taxol radioimmunoassay

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Tae Sup; Awh, Ok Doo; Choi, Tae Hyun; Kim, Hyun Suk; Hong, Jun Pyo; Lee, Eun Sook [College of Medicine, Yonsei Univ., Wonju (Korea, Republic of); Choi, Chang Woon; Lim, Sang Moo [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    2002-04-01

    Taxol(Paclitaxel), an antineoplastic agent, has been used in the treatment of ovarian and breast cancers. The determination of optimal Taxol concentrations in human serum was required for enhancing therapeutic effect and maintaining the appropriate Taxol level in blood. This study was aimed to synthesize radiolabeled Taxol derivatives as radiotracer in competitive radioimmuoassay for monitoring Taxol concentrations in blood and to determine the usefulness of its derivatives. Hemisuccinyltaxol(HT) was synthesized by esterification of Taxol with succinic anhydride. Tyraminehemisuccinyltaxol (THT) was synthesized by coupling of HT with tyramine using isobutylchloroformate as coupling agent and purified by HPLC. By using chloramine-T(5.25 mg/ml, 10 {mu}l) as oxidant agent, THT (4 mg/ml, 30 {mu}l) was labeled with {sup 125}I (37 MBq, 1 mCi). To estimate the stability of purified THT, {sup 125}I-iodotyraminehemisuccinyltaxol ({sup 125}ITHT) was dissolved in 80% acetonitrile aqueous solution, and the solution was incubated at 4 .deg. C and 37 .deg. C for 7 days. At various time intervals, the stability of THT and {sup 125}ITHT was monitored. The titer of Taxol monoclonal antibody, 3G5A7, was determined by competitive radioimmunoassay using {sup 125}ITHT as a labeled antigen. A standard dose-response curve was demonstrated by Taxol competitive radioimmunoassay. HT and THT were synthesized with 79.9% and 19.5% yield, respectively. The labeling yield of {sup 125}ITHT was 93%. After 7 days, the chemical purity of THT was 96.5% at 4 .deg. C, and 97.5% at 37 .deg. C. After 3 days, {sup 125}ITHT was stable with 94.7% at 4 .deg. C and 93.4% at 37 .deg. C. After 7 days radiochemical purity was diminished to 88.1% at 4 .deg. C and 86.1% at 37 .deg. C. The titer of Taxol monoclonal antibody, 3G5A7, was determined to 1:256. A standard dose-response cure demonstrated good collinearity (R{sup 2}=0.971) as Taxol concentration-dependent manner. Competitive radioimmunoassay using {sup 125

  6. Dexamethasone effects on [125I]albumin distribution in experimental RG-2 gliomas and adjacent brain

    International Nuclear Information System (INIS)

    A total of 72 RG-2 transplanted gliomas were studied in 58 rats at three time points (1, 30, 240 min) after intravenous injection of [125I]radioiodinated serum albumin ([125I]RISA). The animals were divided into two groups: a control group that received no treatment and a second group that was treated with five doses of 1.5 mg/kg of dexamethasone over 2.5 days. Local tissue concentrations of [125I]RISA were measured with quantitative autoradiography based on morphological features of the tumors and used to calculate the tissue distribution space. Two models were used to analyze the data. A two compartment model yielded estimates of local blood-to-tissue influx constants (K1), lower limit extracellular volumes (Ve), and plasma vascular volumes (Vp) in different tumor regions. Treatment with dexamethasone consistently reduced the RISA distribution space in the RG-2 tumors; the reduction in Ve was statistically significant in almost all tumor regions: whole tumor Ve (mean +/- SE) was reduced from 0.14 +/- 0.02 ml g-1 in control animals to 0.08 +/- 0.01 ml g-1 in dexamethasone treated animals. K1 and Vp were also decreased in all tumor regions after treatment with dexamethasone (whole tumor K1 decreased from 2.36 +/- 0.89 to 0.83 +/- 0.29 microliter g-1 min-1 and Vp decreased slightly from 0.016 +/- 0.013 to 0.010 +/- 0.005 ml g-1 after dexamethasone treatment), but these changes were not statistically significant. A comparison of the tumor influx constants in control animals and the aqueous diffusion constants of two different size molecules (RISA and aminoisobutyric acid) suggests that the ''pores'' across RG-2 capillaries are large and may not restrict the free diffusion of RISA (estimated minimum pore diameter greater than 36 nm) and that the total pore area is approximately 6.2 X 10(-5) cm2 g-1 in RG-2 tumor tissue

  7. Search for a 17 keV neutrino in the internal bremsstrahlung spectrum of 125I

    International Nuclear Information System (INIS)

    We have searched for evidence of the emission of a 17 keV neutrino in the internal bremsstrahlung (IB) spectrum accompanying the electron capture decay of 125I. The IB spectrum, recorded in a planar Ge detector, has 1.2x106 counts per keV at 17 keV below the 2p end point. We set an upper limit of 0.4% for the admixture of a 17 keV neutrino, at the 90% confidence level, and exclude a 0.8% admixture at the 99.6% confidence level. The QEC value is found to be 185.77±0.06 keV. We also find that the recent calculations of Suric et al., which employ relativistic self-consistent-field atomic wave functions, reproduce the shape and relative intensity of IB partial spectra within a few percent

  8. /sup 125/I-peptide mapping of protein III isolated from four strains of Neisseria gonorrhoeae

    Energy Technology Data Exchange (ETDEWEB)

    Judd, R.C.

    1982-08-01

    Gonococcal outer-membrane protein I (PI) and PIII were isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis from reduced and unreduced whole-cell and outer-membrane lysates of four strains of nonpiliated (P-), transparent (O-) Neisseria gonorrhoeae. These proteins were radioiodinated and digested with alpha-chymotrypsin. The resultant /sup 125/I-peptides were then resolved by high-voltage thin-layer electrophoresis, followed by ascending thin-layer chromatography, and visualized by autoradiography. Results corroborated previous observations regarding the structural relationships of PIs having different apparent subunit molecular weights. All PIIIs had very similar apparent primary structures, regardless of the strain from which they were isolated, the source (i.e., whole cells or outer membranes), or the reduction state of the sodium dodecyl sulfate lysates. By the techniques used, it appeared that PIII is structurally similar in all of the gonococcal strains studied, even though each strain had structurally unique PIs.

  9. Binding studies of the antitumoral radiopharmaceutical 125I-Crotoxin to Ehrlich ascites tumor cells

    International Nuclear Information System (INIS)

    The development of tools for functional diagnostic imaging is mainly based on radiopharmaceuticals that specifically target membrane receptors. Crotoxin (Crtx), a polypeptide isolated from Crotalus durissus terrificus venom, has been shown to have an antitumoral activity and is a promising bioactive tracer for tumor detection. More specific radiopharmaceuticals are being studied to complement the techniques applied in the conventional medicine against breast cancer, the most frequent cause of death from malignant disease in women. Crtx's effect has been shown to be related with the overexpression of epidermal growth factor receptor (EGFR), present in high levels in 30 to 60% of breast tumor cells. Our objective was to evaluate Crtx as a tracer for cancer diagnosis, investigating its properties as an EGFR-targeting agent. Ehrlich ascites tumor cells (EAT cells) were used due to its origin and similar characteristics to breast tumor cells, specially the presence of EGFR. Crtx was labeled with 125I and binding experiments were performed. To evaluate the specific binding in vitro of Crtx, competition binding assay was carried out in the presence of increasing concentrations of non-labelled crotoxin and epidermal growth factor (EGF). Specific binding of 125I-Crtx to EAT cells was determined and the binding was considered saturable, with approximately 70% of specificity, high affinity (Kd = 19.7 nM) and IC50 = 1.6 x 10-11 M. Our results indicate that Crtx's interaction with EAT cells is partially related with EGFR and increases the biotechnological potential of Crtx as a template for radiopharmaceutical design for cancer diagnosis. (author)

  10. /sup 125/I-human epidermal growth factor specific binding to placentas and fetal membranes from varoius pregnancy states

    Energy Technology Data Exchange (ETDEWEB)

    Hofmann, G.E.; Siddiqi, T.A.; Rao, Ch. V.; Carman, F.R.

    1988-01-01

    Specific binding of /sup 125/I-human epidermal growth factor (hEGF) to homogenates of term human placentas and fetal membranes from normal and appropriate for gestational age (N = 20), intrauterine growth retarded (N = 9), twin (N = 11), White class AB diabetic (N = 12), and large for gestational age (N = 13) pregnancies was measured. In all pregnancy states, placentas bound approximately four times more /sup 125/I-hEGF than did fetal membranes (P<0.0001). There was no significant differnce in /sup 125/I-hEGF binding to fetal membranes from the various pregnancy states (P<0.05). /sup 125/I-hEGF specific binding to placentas from intrauterine growth retarded or twin pregnancies was significantly greater compared with placentas from normal and appropriate for gestational age pregnancies (P<0.05). The binding to placentas from pregnancies complicated by White class AB diabetes or large for gestational age infants, on the other hand, was not significantly different from that to placentas from normal and appropriate for gestational age pregnancies. /sup 125/I-hEGF specific binding did not differ between placentas from intrauterine growth retarded or twin pregnancies (P<0.05). Placental and fetal membrane /sup 125/I-hEGF binding did not vary with fetal sex, maternal race, placental weight, or gestational age between 37 to 42 weeks (P<0.05). Placental but not fetal membrane /sup 125/I-hEGF binding increased with increasing infant weight when appropriate for gestational age and large for gestational age infants were included (P<0.05, r = 0.38, N = 32) but not for intrauterine growth retarded, appropriate for gestational age, or large for gestational age infants alone.

  11. Changes in 125I-insulin binding antibodies in diabetic pregnant women on insulin therapy and hypoglycemia in newborns

    International Nuclear Information System (INIS)

    To elucidate whether insulin antibodies in pregnant diabetics are related to changes in insulin requirement during pregnancy, and whether hypoglycemia in newborns of diabetic mothers is influenced by insulin antibodies transferred through the placenta, changes in 125I-insulin percent binding to insulin antibodies were measured at the first, second and third trimesters of pregnancy and at delivery, in 20 deliveries by 17 diabetics treated with insulin. The free insulin levels in the same serum were also measured for each patient in whom the 125I-insulin binding was decreased more than 5% in the third trimester. The mean percent of 125I-insulin binding in the 20 diabetic pregnancies was unchanged in the first (21.2%) and second trimester (21.1%), but tended to decrease to 17.6% in the third trimester and to increase to 24.6% after delivery. The 125I-insulin percent binding of 5 patients with neonatal hypoglycemia was significantly higher than that of the other patients without hypoglycemia (p125I-insulin percent binding was decreased in the third trimester in contrast with an increased insulin dosage. The finding that hypoglycemia tended to occur in the newborns of diabetic mothers with high insulin percent binding to insulin antibody during the third trimester, suggests that maternal insulin antibodies may affect the fetal pancreas. (author)

  12. Separation of {sup 134}Cs and {sup 137}Cs from {sup 125}I solution for medical applications

    Energy Technology Data Exchange (ETDEWEB)

    Ram, Ramu; Dash, Ashutosh [Bhabha Atomic Research Centre, Trombay, Mumbai (India). Isotope Production and Applications Div.; Banerjee, Dayamoy [Bhabha Atomic Research Centre, Trombay, Mumbai (India). Process Development Div.

    2015-06-01

    While neutron irradiation of natural Xe gas followed by wet chemical dissolution of activation products constitutes a successful paradigm for the small scale production {sup 125}I, the concomitant production of {sup 134}Cs and {sup 137}Cs emerged as the primary impediment which necessitates purification of {sup 125}I solution. This paper describes an ion-exchange chromatographic technique using Resorcinol Formaldehyde (RF) resin to purify {sup 125}I solution from {sup 134}Cs and {sup 137}Cs impurities. A thorough investigation of the adsorption parameters of RF resin was carried out to arrive at the experimental conditions resulting optimum retention of {sup 134}Cs and {sup 137}Cs impurities. Based on the experimental findings, an optimized separation procedure was developed in which the neutron irradiated dissolved products at pH ∝ 13 was passed through a chromatography column containing RF resin where in {sup 134}Cs and {sup 137}Cs impurities gets adsorbed leaving behind {sup 125}I to appear in the effluent. The overall recovery of {sup 125}I was >90% with acceptable purity amenable for clinical applications.

  13. Benzodiazepine effect of {sup 125}I-iomazenil-benzodiazepine receptor binding and serum corticosterone level in a rat model

    Energy Technology Data Exchange (ETDEWEB)

    Fukumitsu, Nobuyoshi [Proton Medical Research Center, University of Tsukuba, Ibaragi, 305-8575 (Japan)]. E-mail: gzl13162@nifty.ne.jp; Ogi, Shigeyuki [Department of Radiology, Jikei University School of Medicine, Tokyo, 105-8461 (Japan); Uchiyama, Mayuki [Department of Radiology, Jikei University School of Medicine, Tokyo, 105-8461 (Japan); Mori, Yutaka [Department of Radiology, Jikei University School of Medicine, Tokyo, 105-8461 (Japan)

    2005-01-01

    To test the change in free or unoccupied benzodiazepine receptor (BZR) density in response to diazepam, we investigated {sup 125}I-iomazenil ({sup 125}I-IMZ) binding and serum corticosterone levels in a rat model. Wistar male rats, which received psychological stress using a communication box for 5 days, were divided into two groups according to the amount of administered diazepam: no diazepam [D (0)] group and 10 mg/kg per day [D (10)] group of 12 rats each. The standardized uptake value (SUV) of {sup 125}I-IMZ of the D (10) group were significantly lower (P<.05) than those of the D (0) group in the frontal, parietal and temporal cortices, globus pallidus, hippocampus, amygdala and hypothalamus. The serum corticosterone level ratio in the D (10) group was significantly lower than that in the D (0) group (P<.05). From the change in serum corticosterone levels, diazepam attenuated the psychological stress produced by the physical stress to animals in adjacent compartments. From the reduced binding of {sup 125}I-IMZ, it is clear that diazepam competed with endogenous ligand for the free BZR sites, and the frontal, parietal and temporal cortices, globus pallidus, hippocampus, amygdala and hypothalamus are important areas in which {sup 125}I-IMZ binding is strongly affected by administration of diazepam.

  14. {sup 125}I-iomazenil - benzodiazepine receptor binding and serum corticosterone level during psychological stress in a rat model

    Energy Technology Data Exchange (ETDEWEB)

    Fukumitsu, Nobuyoshi E-mail: GZL13162@nifty.ne.jp; Ogi, Shigeyuki; Uchiyama, Mayuki; Mori, Yutaka

    2004-02-01

    To test the hypothesis that benzodiazepine receptor density decreases in response to stress, we correlated {sup 125}I-iomazenil ({sup 125}I-IMZ) binding with serum corticosterone levels in a rat model. Wistar male rats were divided into four groups; control group (CON, 10 rats), no physical or psychological stress; and one-, three-, and five-day stress groups of 12 rats each (1-DAY, 3-DAY, and 5-DAY, respectively), receiving psychological stress for the given number of days. Psychological stress were given to rats with a communication box. The standardized uptake value (SUV) of {sup 125}I-iomazenil of the 3-DAY and 5-DAY showed that {sup 125}I-iomazenil - benzodiazepine receptor binding was significantly reduced in the cortices, accumbens nuclei, amygdala and caudate putamen (p<0.05). Serum corticosterone level ratio appeared to be slightly elevated in 3-DAY and 5-DAY, although this elevation was not significant. These data suggest that {sup 125}I-IMZ is a useful radioligand to reflect received stress and its binding in the cortices, accumbens nuclei, amygdala and caudate putamen is strongly affected by psychological stress.

  15. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride.

    Science.gov (United States)

    Hall, H; Farde, L; Halldin, C; Hurd, Y L; Pauli, S; Sedvall, G

    1996-06-01

    Epidepride is a benzamide with high affinity for central D2- and D3-dopamine receptors. The anatomical distribution of [125I]epidepride binding was examined by autoradiography, using postmortem human whole-hemisphere cryosections. The density of [125I]epidepride binding sites was high in caudate nucleus and putamen. [125I]epidepride also labeled receptors in extrastriatal region such as in the pallidum, some thalamic nuclei, the neocortex, and the substantia nigra. The neocortical binding was heterogeneously distributed. In most cortical regions, binding sites were located in superficial layers (I-II). However, in basal levels of the occipital cortex, [125I]epidepride binding was located in a deeper layer, probably corresponding to layer V. Competition studies indicated that most of the [125I]epidepride binding represented predominantly D2-dopamine receptors, in striatal as well as in extrastriatal regions. The presence of extrastriatal D2-dopamine receptor populations is of particular interest for research on schizophrenia and antipsychotic drug action. PMID:8723716

  16. Health-Related Quality of Life up to Six Years After 125I Brachytherapy for Early-Stage Prostate Cancer

    International Nuclear Information System (INIS)

    Purpose: Health-related quality of life (HRQOL) after prostate brachytherapy has been extensively described in published reports but hardly any long-term data are available. The aim of the present study was to prospectively assess long-term HRQOL 6 years after 125I prostate brachytherapy. Methods and Materials: A total of 127 patients treated with 125I brachytherapy for early-stage prostate cancer between December 2000 and June 2003 completed a HRQOL questionnaire at five time-points: before treatment and 1 month, 6 months, 1 year, and 6 years after treatment. The questionnaire included the RAND-36 generic health survey, the cancer-specific European Organization for Research and Treatment of Cancer core questionnaire (EORTCQLQ-C30), and the tumor-specific EORTC prostate cancer module (EORTC-PR25). A change in a score of ≥10 points was considered clinically relevant. Results: Overall, the HRQOL at 6 years after 125I prostate brachytherapy did not significantly differ from baseline. Although a statistically significant deterioration in HRQOL at 6 years was seen for urinary symptoms, bowel symptoms, pain, physical functioning, and sexual activity (p 125I prostate brachytherapy. HRQOL scores returned to approximately baseline values at 1 year and remained stable up to 6 years after treatment. 125I prostate brachytherapy did not adversely affect patients' long-term HRQOL.

  17. Effects of whole-body irradiation on the degradation of 125I insulin and Na131I insulin in rabbits

    International Nuclear Information System (INIS)

    The degradation of simultaneously (i.v.) injected Na131I- and 125I-bovine insuline by rabbit blood and the urinary excretion of Na131I- and 125I-containing insulin degradation products have been investigated before and 24 h after 700 R X-ray irradiation. Also, the distribution of the two substances in the livers, kidneys, spleens, and KI-blocked thyroids was observed after irradiation. Radiation effects on the distribution of Na131I- and 125I-insulin on the livers, kidneys, and spleens of rabbits were not observed. On irradiation, there was a significant reduction of diuresis and also of the urinary excretion of 131I and 125I radioactivity. Irradiation had no influence on the distribution of Na131I-and 125I-insulin between plasma and extravascular space. The renal excretion function for water, iodide, and insulin degradation products was clearly impaired after irradiation. The same applies to the insulincatabolism by the degrading organs. The leukocyte count was reduced to about 17% during the first 4 days after irradiation. (orig./MG)

  18. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of solid CNS tumors in rats

    International Nuclear Information System (INIS)

    We have been investigating the therapeutic efficacy of the thymidine analog 5-iodo-2'-deoxyuridine (IUdR) when radiolabeled with the Auger electron emitter 125I in rats bearing intrathecal (i.t.) or intracerebral (i.c.) 9L gliosarcoma solid tumors. [125I]IUdR was infused i.t. (via subarachnoid catheters) or intracerebrally over a 5- or 2-day period; equimolar concentrations of [127I]IUdR were infused into control animals. High-leg paralysis and/or survival were followed over time. The results indicate that compared with [127I]IUdR, rats bearing intrathecal tumors and infused i.t. with [125I]IUdR showed significant prolongation of the onset of medium paralysis (15.2 versus 9 days). Similarly, the median survival of rats bearing intracerebral tumors and infused i.c. with [125I]IUdR was significantly increased (24 versus 17 days). The data substantiate the antineoplastic potential of [125I]IUdR and indicate a promising role for this radiopharmaceutical in the treatment of CNS cancers. (orig.)

  19. Optimal implantation depth and adherence to guidelines on permanent pacing to improve the results of transcatheter aortic valve replacement with the medtronic corevalve system: The CoreValve prospective, international, post-market ADVANCE-II study

    NARCIS (Netherlands)

    A.S. Petronio (Anna S.); J.-M. Sinning (Jan-Malte); N.M. van Mieghem (Nicolas); G. Zucchelli (Giulio); G. Nickenig (Georg); R. Bekeredjian (Raffi); B. Bosmans; F. Bedogni (Francesco); M. Branny (Marian); K. Stangl (Karl); J. Kovac (Jan); M. Schiltgen (Molly); S. Kraus (Stacia); P.P.T. de Jaegere (Peter)

    2015-01-01

    textabstractObjectives The aim of the CoreValve prospective, international, post-market ADVANCE-II study was to define the rates of conduction disturbances and permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement with the Medtronic CoreValve System (Minneapolis, Minnes

  20. Radioautographic identification of lactogen binding sites in rat median eminence using 125I-human growth hormone

    International Nuclear Information System (INIS)

    The binding characteristics of human growth hormone were exploited to identify radioautographically lactogen binding sites in the rat median eminence following systemic injection 125I-human growth hormone bound preferentially to the lateral palisade zone, a region of median eminence rich in dopamine and LHRH. Coinjection of 125I-human growth hormone with an excess of unlabeled human growth hormone or ovine prolactin, but not bovine growth hormone, competitively blocked 125I-human growth hormone binding to the external median eminence. These observations provide direct evidence of recognition sites for lactogenic hormones in a discrete region of the median eminence associated with hypothalamic regulation of hypophyseal prolactin and luteinizing hormone secretion. Median eminence lactogen binding sites may mediate presumed direct effects of lactogenic hormones on the reproductive functions of the hypophysiotropic hypothalamus. (orig.)

  1. Binding and degradation of /sup 125/I-insulin by renal glomeruli and tubules isolated from rats

    Energy Technology Data Exchange (ETDEWEB)

    Meezan, E.; Freychet, P.

    1982-04-01

    Isolated rat renal glomeruli and tubules were shown to exhibit specific binding of /sup 125/I-insulin and enzymatic degradation of the hormone. Binding to both renal fractions reached a plateau by 1 h at 22/sup 0/C and increased linearly with increasing protein concentrations. Binding was inhibited in both preparations by insulin and its analogues in the order of relative potency: insulin > despentapeptide insulin > proinsulin, but insulin was ten times more potent in inhibiting /sup 125/I-insulin binding to glomeruli than that to tubules, indicating a different affinity of receptors for the hormone in the two renal fractions (about 17 versus 210 ..mu..g unlabelled insulin/1 inhibiting 50% of the /sup 125/I-insulin binding to glomeruli and tubules, respectively). Bound /sup 125/I-insulin dissociated at a faster rate from tubules than from glomeruli; this release was accelerated by unlabelled insulin in both renal fractions, but to a greater extent in glomeruli than in tubules. Two-thirds of the total bound material released from glomeruli was found to be intact insulin as measured by trichloroacetic acid precipitation, whereas only one-third of the material released from tubules was intact. No direct relationship between binding and degradation of /sup 125/I-insulin in these renal fractions could be demonstrated, however, because of the release of proteolytic enzymes into the incubation medium resulting in almost all degradation being extracellular. Although differing in their affinity for /sup 125/I-insulin the high affinity glomerular insulin receptor and the lower affinity tubular insulin receptor have characteristics similar to those of insulin receptors in insulin responsive tissues.

  2. Evaluation of [{sup 125}I]7{alpha}-O-iodoally diprenophine as a new potential SPECT opioid receptor imaging agent

    Energy Technology Data Exchange (ETDEWEB)

    Wang, R.F.; Tafani, J.A.M.; Frances, B.; Bergon, M.; Coulais, Y.; Zajac, J. M.; Guiraud, R

    1997-08-01

    A new iodinated diprenorphine analog, [{sup 125}I]7{alpha}-O-iodoallyl diprenorphine ([{sup 125}I]7{alpha}-O-IA-DPN), was prepared by iododestannylation and characterized. As an opioid antagonist, this agent showed very high affinity (K{sub i} = 0.4 {+-} 0.2 nM) and 63% of specific binding by in vitro and in vivo binding studies. Inhibition curves indicated that this tracer labeled with the same affinities to three opioid receptors ({mu} = {delta} = {kappa}). The findings demonstrate that this proposed compound appears to be a potential radioprobe for future study of opioid receptors by in vivo SPECT.

  3. Comparison of two procedures for labelling the surface of the hydatid disease organism, Echinococcus granulosus, with /sup 125/I

    Energy Technology Data Exchange (ETDEWEB)

    McManus, D.P.; McLaren, D.J.; Clark, N.W.T.; Parkhouse, R.M.E.

    1987-03-01

    Living, intact protoscoleces of the British horse and sheep strains of Echinococcus granulosus were subjected to surface radioiodination procedures using /sup 125/I and Iodogen and /sup 125/I-Bolton Hunter reagent. Subsequent combined electron microscopy and autoradiography revealed specific surface membrane labelling with the Iodogen procedure, but significant tegumental labelling with the Bolton-Hunter reagent. The two parasite strains yielded different profiles of electrophoretically separated labelled proteins; the Iodogen method, not surprisingly, resulted in a less complex pattern of labelled polypeptides than the Bolton and Hunter reagent.

  4. Monitoring intervals for measurement of the radionuclides 125 I and 129I in thyroid glands

    International Nuclear Information System (INIS)

    This work shows the monitoring interval, which can be implemented in the Laboratorio de Contaminacion Interna del Centro de Proteccion e Higiene de las Radiaciones, for direct measurement in the thyroid gland of radionuclides 125I and 129I . Were used two measuring systems, one employing a scintillating detector and the other detector Phoswich. Both detectors were placed inside a depth camera, 2.5 x 2.5 x 2.5m of dimension covered with 15 cm of steel, 3 mm lead, 1.8 mm tin and 1.5 mm of copper. Was calculated for each system, the minimum detectable activity, and based on this, the monitoring interval is determined. Was obtained, for 125, all tested intervals, 120, 90,60,30 , 14, and 7 days may be implemented with both systems. In the case of the radionuclide 129 I, with the installation of scintillating detector can only be implemented the intervals 120, 90, and 60 days , and for installation with Phoswich, all evaluated

  5. ( sup 125 I)(+)FISCH: A new CNS D-1 dopamine receptor imaging ligand

    Energy Technology Data Exchange (ETDEWEB)

    Billings, J.; Kung, M.P.; Chumpradit, S.; Pan, S.; Kung, H.F. (Univ. of Pennsylvania, Philadelphia (USA))

    1989-01-01

    Radiolabeling and in vitro and in vivo evaluation of an iodinated benzazepine: ({sup 125}I)FISCH 7-Chloro-8-hydroxy-1-(4{prime}-iodophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, as a potential imaging agent for CNS D-1 dopamine receptors in animals, were investigated. After an iv injection, this benzazepine derivative showed good brain uptake in rats. The striatum/cerebellum ratio was 2.50 at 60 min after the injection. The regional distribution in rat brain, as measured by ex vivo autoradiography, displayed highest uptake in the regions of the striatal complex and the substantia nigra, regions known to have a high concentration of D-1 dopamine receptors. Furthermore, this localized regional cerebral distribution was blocked by pretreatment with SCH-23390, a selective D-1 dopamine receptor antagonist. The in vitro binding affinity of this agent in rat striatum tissue preparation displayed a Kd of 1.43 {plus minus} 0.15 nM. Competition data (in vitro) showed the following rank order of potency: SCH-23390 > ({plus minus})IBZP >> apomorphine > WB 4101 > ketanserin {approximately} spiperone. The preliminary data suggest that this analog of SCH-23390 shows similar selectivity for the CNS D-1 receptor.

  6. A proteomics analysis for certain signature proteins of rabbit lacrimal passages after 125I seeds brachytherapy

    International Nuclear Information System (INIS)

    To search for certain signature proteins and the expression profiles in lacrimal passage stenosis, rabbit models of lacrimal passage stenosis were treated by 125I seed brachytherapy. All the signature proteins were separated by two-dimensional electrophoresis, and identified by mass spectrometry. The results show that the up-regulated proteins are peptidyl-prolyl cis-trans isomerase A (PPIase A), and epidermal fatty acid-binding protein (E-FABP), while the down-regulated proteins are myosin light chain 1 (isomer of skeletal muscle), myosin light polypeptide 6 (isomer 1 of smooth muscle and non-muscle), myosin light chain 1 (isomer of slow-twitch muscle A), isomer 2 of ERC protein 2, and α-crystalline family protein. The proteins may play a role in healing the wound and regulating synaptic active zone of neurons due to correlation to cell apoptosis, proliferation and migration of smooth muscle cell. These provide molecular mechanism for preventing stenosis and restenosis of lacrimal passage. (authors)

  7. Differential dose contributions on total dose distribution of (125)I brachytherapy source.

    Science.gov (United States)

    Camgöz, B; Yeğin, G; Kumru, M N

    2010-01-01

    This work provides an improvement of the approach using Monte Carlo simulation for the Amersham Model 6711 (125)I brachytherapy seed source, which is well known by many theoretical and experimental studies. The source which has simple geometry was researched with respect to criteria of AAPM Tg-43 Report. The approach offered by this study involves determination of differential dose contributions that come from virtual partitions of a massive radioactive element of the studied source to a total dose at analytical calculation point. Some brachytherapy seeds contain multi-radioactive elements so the dose at any point is a total of separate doses from each element. It is momentous to know well the angular and radial dose distributions around the source that is located in cancerous tissue for clinical treatments. Interior geometry of a source is effective on dose characteristics of a distribution. Dose information of inner geometrical structure of a brachytherapy source cannot be acquired by experimental methods because of limits of physical material and geometry in the healthy tissue, so Monte Carlo simulation is a required approach of the study. EGSnrc Monte Carlo simulation software was used. In the design of a simulation, the radioactive source was divided into 10 rings, partitioned but not separate from each other. All differential sources were simulated for dose calculation, and the shape of dose distribution was determined comparatively distribution of a single-complete source. In this work anisotropy function was examined also mathematically.

  8. Determination of dosimetric parameters for 125I seed source using MCNP5 and EGSnrc MC codes

    International Nuclear Information System (INIS)

    Background: Seed source has become a popular treatment option in the management of various tumors, particularly in the prostate. Purpose: The aim is to develop accurate and reliable dosimetric parameters that could be used to measure the dose delivered to organs at risk. Methods: Dosimetric parameters (dose rate constant, radial dose function and anisotropy function) of model 6711 125I seed source were calculated with MCNP5 and EGSnrc MC codes following AAPM TG43U1 recommendations. Results: The two results were compared with the relative data recommend by AAPM TG43U1, and the data were as follows: dose rate constant with MCNP5 was in agreement with 0.62%, while that with EGSnrc was 2.07%; radial dose function with MCNP5 was within 0.15%-5.12%, while that with EGSnrc was within 0%-2.48%. Conclusion: The results of two MC codes are in accordance with the recommendations. But that with EGSnrc MC code is better. (authors)

  9. Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3{beta}-(4-[{sup 125}I]iodophenyl) tropan-2{beta}-carboxylic acid isopropyl ester ([{sup 125}I]RTI-121)

    Energy Technology Data Exchange (ETDEWEB)

    Lever, John R.; Scheffel, Ursula; Stathis, Marigo; Seltzman, Herbert H.; Wyrick, Christopher D.; Abraham, Philip; Parham, Karol; Thomas, Brian F.; Boja, John W.; Kuhar, Michael J.; Carroll, F. Ivy

    1996-04-01

    A selective ligand for the dopamine transporter 3{beta}-(4-iodophenyl)tropan-2{beta}-carboxylic acid isopropyl ester (RTI-121) has been labeled with iodine-125 by electrophilic radioiododestannylation. The [{sup 125}I]RTI-121 was obtained in good yield (86 {+-} 7%, n = 3) with high radiochemical purity (>99%) and specific radioactivity (1210-1950 mCi/{mu}mol). After i.v. administration of [{sup 125}I]RTI-121 to mice, the rank order of regional brain tissue radioactivity (striatum > olfactory tubercles >> cortex, hippocampus, thalamus, hypothalamus, cerebellum) was consistent with dopamine transporter labeling. Specific in vivo binding in striatum and olfactory tubercles was saturable, and was blocked by the dopamine transporter ligands GBR 12,909 and ({+-})-nomifensine. By contrast, binding was not reduced by paroxetine, a serotonin transporter inhibitor, or desipramine, a norepinephrine transporter inhibitor. A variety of additional drugs having high affinities for recognition sites other than the neuronal dopamine transporter also had no effect. The [{sup 125}I]RTI-121 binding in striatum and olfactory tubercles was inhibited by d-amphetamine in dose-dependent fashion. Nonmetabolized radioligand represents 85% of the signal observed in extracts of whole mouse brain. Thus, [{sup 125}I]RTI-121 is readily prepared, and is a useful tracer for dopamine transporter studies in vivo.

  10. Complications after cardiac implantable electronic device implantations

    DEFF Research Database (Denmark)

    Kirkfeldt, Rikke Esberg; Johansen, Jens Brock; Nohr, Ellen Aagaard;

    2013-01-01

    Complications after cardiac implantable electronic device (CIED) treatment, including permanent pacemakers (PMs), cardiac resynchronization therapy devices with defibrillators (CRT-Ds) or without (CRT-Ps), and implantable cardioverter defibrillators (ICDs), are associated with increased patient...

  11. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1'-piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer.

    Science.gov (United States)

    John, C S; Bowen, W D; Fisher, S J; Lim, B B; Geyer, B C; Vilner, B J; Wahl, R L

    1999-05-01

    The goal of this study was to investigate the potential use of a radioiodinated benzamide, N-[2-(1'-piperidinyl)ethyl]-3-iodo[125I]-4-methoxybenzamide (P[125I]MBA), a sigma receptor binding radioligand for imaging breast cancer. The chemical and radiochemical syntheses of PIMBA are described. The pharmacological evaluation of PIMBA was carried out for sigma-1 and sigma-2 receptor sites. The in vivo pharmacokinetics of the radioiodinated benzamide were determined in rats and comparison of P[125I]MBA with Tc-99m sestamibi were made in a rat mammary tumor model. Sigma-1 affinity (Ki) for PIMBA in guinea pig brain membranes using [3H](+)pentazocine was found to be 11.82 +/- 0.68 nM, whereas sigma-2 affinity in rat liver using [3H]DTG (1,3-o-di-tolylguanidine) was 206 +/- 11 nM. Sites in guinea pig brain membranes labeled by P[125I]MBA showed high affinity for haloperidol, (+)-pentazocine, BD1008, and PIMBA (Ki = 4.87 +/- 1.49, 8.81 +/- 1.97, 0.057 +/- 0.005, 46.9 +/- 1.8 nM, respectively). Competition binding studies were carried out in human ductal breast carcinoma cells (T47D). A dose-dependent inhibition of specific binding was observed with several sigma ligands. Ki values for the inhibition of P[125I]MBA binding in T47D cells for haloperidol, N-[2-(1'-piperidinyl)]ethyl]4-iodobenzamide (IPAB), N-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP), and PIMBA were found to be 1.30 +/- 0.07, 13 +/- 1.5, 5.19 +/- 2.3, 1.06 +/- 0.5 nM, respectively. The in vitro binding data in guinea pig brain membranes and breast cancer cells confirmed binding to sigma sites. The saturation binding of P[125I]MBA in T47D cells as studied by Scatchard analysis showed saturable binding, with a Kd = 94 +/- 7 nM and a Bmax = 2035 +/- 305 fmol/mg of proteins. Biodistribution studies in Sprague-Dawley rats showed a rapid clearance of P[125I]MBA from the normal organs. The potential of PIMBA in imaging breast cancer was evaluated in Lewis rats bearing syngeneic RMT breast cancers, a cancer that

  12. Monte Carlo study of interseed attenuation and tissue composition effect for clinical cases of prostate permanent implants.

    Science.gov (United States)

    Carrier, Jean-Francois; Beaulieu, Luc

    2006-03-01

    Monte Carlo simulations were used to study the interseed attenuation and the effect of tissue composition on prostate implant dosimetry. Using computed tomography images of postimplant analysis, the precise anatomy of the patient was considered voxel by voxel. The physical density of each voxel was set according to the Hounsfield Unit and the specific elemental composition of each voxel was set depending on the radiation-oncologist organ contours and the local density. Mixes of different tissues were available: muscle, prostate tissue, rectum tissue, adipose tissue, bone and prostate calcification. Typically, more than 300 combinations of elemental composition and density were used for each patient. The Monte Carlo dosimetry results were compared to the clinically approved TG43-based calculations for 30 patients. The results show an interseed attenuation of about 4.5% for the D90 parameter (minimal dose received by 90% of the target volume). The effect of the tissue composition varies from one patient to the other. Globally, the difference between the TG43-based calculations and the Monte Carlo results can reach more than 10 Gy for the D90 values. From a clinical perspective, the difference level can be non-negligible for the target volume and for the surrounding organs at risk.

  13. Radiosynthesis and in vivo evaluation of the pseudopeptide {delta}-opioid antagonist [{sup 125}I]-ITIPP({psi})

    Energy Technology Data Exchange (ETDEWEB)

    Collier, T.L. E-mail: TC311@columbia.edu; Schiller, P.W.; Waterhouse, R.N

    2001-05-01

    The radioiodinated tetrapeptide {delta}-opioid antagonist [{sup 125}I]ITIPP({psi}) [H-Tyr(3'I)-Tic{psi}[CH{sub 2}NH]Phe-Phe-OH] (Ki({delta}) 2.08 nM; Ki({mu})/Ki({delta}) = 1280) has been synthesized and evaluated as a potential lung tumour imaging agent. [{sup 125}I]ITIPP({psi}) was obtained, via electrophilic iodination, in 46% yield (>44,000 MBq/{mu}mol) from the parent TIPP({psi}). The biodistribution of [{sup 125}I]ITIPP({psi}) in nu/nu mice bearing SCLC-SW210.5 xenographs revealed good uptake and prolonged retention of radioactivity in organs known to possess {delta}-opioid receptors. Metabolite analysis showed that [{sup 125}I]ITIPP({psi}) was largely unmetabolized at 25 min PI and blocking studies showed significant reduction of uptake of the tracer in the brain, liver, intestine and tumor indicating that the iodinated tetrapeptide binds to {delta} opioid receptors in vivo.

  14. Experimental study of triplex-forming oligonucleotide targeted to the initiator of S gene of HBV labeled with 125I

    International Nuclear Information System (INIS)

    This study is used to investigate the feasibility of employing the Iodogen method to label triplex-forming oligonucleofide (TFO) targeted to the initiator of the S gene of HBV with 125I. A 17-mer oligonucleotides sequence was synthesized and grafted at the 5' terminal with a tyramine group. Radioiodination of the tyramine-TFO with 125I was then performed using the Iodogen method. After TFO was labeled with 125I using the Iodogen method, the labeling rate, the radiochemical purity, stability and bioactivity were determined, respectively. The results show that the radiolabeling rate and the radiochemical purity were 93% and 99%, respectively; and the radiochemical purity is more than 90% in vitro at -20 degree C on the 5th day after labeling; and the rate of 125I-tyramine-TFO binding to HepG2.2.15 cells was (37.2 ± 1.4)% and statistically different from the rate of HepG2 (p<0.5). Hence, it is concluded that the labeling of oligonucleotides conjugated with tyramine using the Iodogen method is successful and is characterized with a high labeling rate, high stability, and a low loss of bioactivity of the labeled agent. (authors)

  15. Relationship between alveolar bone measured by /sup 125/I absorptiometry with analysis of standardized radiographs: 2. Bjorn technique

    Energy Technology Data Exchange (ETDEWEB)

    Ortman, L.F.; McHenry, K.; Hausmann, E.

    1982-05-01

    The Bjorn technique is widely used in periodontal studies as a standardized measure of alveolar bone. Recent studies have demonstrated the feasibility of using /sup 125/I absorptiometry to measure bone mass. The purpose of this study was to compare /sup 125/I absorptiometry with the Bjorn technique in detecting small sequential losses of alveolary bone. Four periodontal-like defects of incrementally increasing size were produced in alveolar bone in the posterior segment of the maxilla of a human skull. An attempt was made to sequentially reduce the amount of bone in 10% increments until no bone remained, a through and through defect. The bone remaining at each step was measured using /sup 125/I absorptiometry. At each site the /sup 125/I absorptiometry measurements were made at the same location by fixing the photon source to a prefabricated precision-made occlusal splint. This site was just beneath the crest and midway between the borders of two adjacent teeth. Bone loss was also determined by the Bjorn technique. Standardized intraoral films were taken using a custom-fitted acrylic clutch, and bone measurements were made from the root apex to coronal height of the lamina dura. A comparison of the data indicates that: (1) in early bone loss, less than 30%, the Bjorn technique underestimates the amount of loss, and (2) in advanced bone loss, more than 60% the Bjorn technique overestimates it.

  16. Characterization of [125I]omega-conotoxin binding to brain N calcium channels and (-)[3H] desmethoxyverapamil binding to novel calcium channels in osteoblast-like osteosarcoma cells

    International Nuclear Information System (INIS)

    This dissertation provides molecular evidence for a diversity of Ca2+ channels in neuronal and non-neuronal tissues. First, I demonstrated specific, reversible, saturable binding sites for omega [125I]conotoxin GVIA (omega[125I]CTX) in rat brain and rabbit sympathetic ganglion. Omega [125I]CTX binding has a unique pharmacology, ion selectivity, and anatomical distribution in rat brain. Omega [125I]CTX binding was solubilized, retaining an appropriate pharmacology and ion selectivity. Omega[125I]CTX binding may be associated with a Ca2+ channel because the K/sub D/ of omega [125I]CTX is similar to the IC50 of inhibition of depolarization-induced 45Ca2+ flux into rat brain synaptosomes. Specific (-)[3H]desmethoxyverapamil ((-)[3H]DMV) binding sites were demonstrated on osteoblast-like osteosarcoma cell membranes

  17. Radiosynthesis and in vivo evaluation of [125I]2-(4-iodophenethyl)-2-methylmalonic acid as a potential radiotracer for detection of apoptosis

    International Nuclear Information System (INIS)

    The aim of this study is to synthesize 125I-labeled 2-(4-iodophenethyl)-2-methylmalonic acid ([125I]IMA) for the development of new apoptosis imaging tracer. The optimized radiolabeling procedure provided [125I]IMA with high radiochemical yield (75.5 ± 5.2 %) and radiochemical purity ([99 %) within 100 min. Specific radioactivity of [125I]IMA was 31.0 MBq/lmol. Biodistribution study of [125I]IMA was carried out using ICR mouse and the result showed the uptake values in apoptotic cells of the testes of the male mice were 1.7-3.2 fold higher than those of leg muscle. Therefore, [125I]IMA will be a promising radiotracer for in vivo SPECT imaging of apoptotic cells. (author)

  18. Ocular brachytherapy dosimetry for 103Pd and 125I in the presence of gold nanoparticles: a Monte Carlo study.

    Science.gov (United States)

    Asadi, Somayeh; Vaez-Zadeh, Mehdi; Vahidian, Mohammad; Marghchouei, Mahdieh; Masoudi, S Farhad

    2016-01-01

    The aim of the present Monte Carlo study is to evaluate the variation of energy deposition in healthy tissues in the human eye which is irradiated by brachytherapy sources in comparison with the resultant dose increase in the gold nanoparticle (GNP)-loaded choroidal melanoma. The effects of these nanoparticles on normal tissues are compared between 103Pd and 125I as two ophthalmic brachytherapy sources. Dose distribution in the tumor and healthy tissues has been taken into account for both brachytherapy sources. Also, in certain points of the eye, the ratio of the absorbed dose by the normal tissue in the presence of GNPs to the absorbed dose by the same point in the absence of GNPs has been calculated. In addition, differences of the absorbed dose in the tumor observed in the comparison of simple water phantom and actual simulated human eye in presence of GNPs are also a matter of interest that have been considered in the present work. The difference between the eye globe and the water phantom is more obvious for 125I than that of the 103Pd when the ophthalmic dosimetry is done in the presence of GNPs. Whenever these nanoparticles are utilized in enhancing the absorbed dose by the tumor, the use of 125I brachytherapy source will greatly amplify the amount of dose enhancement factor (DEF) in the tumor site without inflicting much dam-age to healthy organs, when compared to the 103Pd source. For instance, in the concentration of 30 mg GNPs, the difference amongst the calculated DEF for 125I between these phantoms is 5.3%, while it is 2.45% for 103Pd. Furthermore, in Monte Carlo studies of eye brachytherapy, more precise definition of the eye phantom instead of a water phantom will become increasingly important when we use 125I as opposed to 103Pd. PMID:27167265

  19. 2-(/sup 125/I)iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution

    Energy Technology Data Exchange (ETDEWEB)

    Duncan, M.J.; Takahashi, J.S.; Dubocovich, M.L.

    1988-05-01

    Studies in a variety of seasonally breeding mammals have shown that melatonin mediates photoperiodic effects on reproduction. Relatively little is known, however, about the site(s) or mechanisms of action of this hormone for inducing reproductive effects. Although binding sites for (3H)melatonin have been reported previously in bovine, rat, and hamster brain, the pharmacological selectivity of these sites was never demonstrated. In the present study, we have characterized binding sites for a new radioligand, 2-(125I)iodomelatonin, in brains from a photoperiodic species, the Syrian hamster. 2-(125I)Iodomelatonin labels a high affinity binding site in hamster brain membranes. Specific binding of 2-(125I)iodomelatonin is rapid, stable, saturable, and reversible. Saturation studies demonstrated that 2-(125I)iodomelatonin binds to a single class of sites with an affinity constant (Kd) of 3.3 +/- 0.5 nM and a total binding capacity (Bmax) of 110.2 +/- 13.4 fmol/mg protein (n = 4). The Kd value determined from kinetic analysis (3.1 +/- 0.9 nM; n = 5) was very similar to that obtained from saturation experiments. Competition experiments showed that the relative order of potency of a variety of indoles for inhibition of 2-(125I)iodomelatonin binding site to hamster brain membranes was as follows: 6-chloromelatonin greater than or equal to 2-iodomelatonin greater than N-acetylserotonin greater than or equal to 6-methoxymelatonin greater than or equal to melatonin greater than 6-hydroxymelatonin greater than or equal to 6,7-dichloro-2-methylmelatonin greater than 5-methoxytryptophol greater than 5-methoxytryptamine greater than or equal to 5-methoxy-N,N-dimethyltryptamine greater than N-acetyltryptamine greater than serotonin greater than 5-methoxyindole (inactive).

  20. 2-[125I]iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution

    International Nuclear Information System (INIS)

    Studies in a variety of seasonally breeding mammals have shown that melatonin mediates photoperiodic effects on reproduction. Relatively little is known, however, about the site(s) or mechanisms of action of this hormone for inducing reproductive effects. Although binding sites for [3H]melatonin have been reported previously in bovine, rat, and hamster brain, the pharmacological selectivity of these sites was never demonstrated. In the present study, we have characterized binding sites for a new radioligand, 2-[125I]iodomelatonin, in brains from a photoperiodic species, the Syrian hamster. 2-[125I]Iodomelatonin labels a high affinity binding site in hamster brain membranes. Specific binding of 2-[125I]iodomelatonin is rapid, stable, saturable, and reversible. Saturation studies demonstrated that 2-[125I]iodomelatonin binds to a single class of sites with an affinity constant (Kd) of 3.3 +/- 0.5 nM and a total binding capacity (Bmax) of 110.2 +/- 13.4 fmol/mg protein (n = 4). The Kd value determined from kinetic analysis (3.1 +/- 0.9 nM; n = 5) was very similar to that obtained from saturation experiments. Competition experiments showed that the relative order of potency of a variety of indoles for inhibition of 2-[125I]iodomelatonin binding site to hamster brain membranes was as follows: 6-chloromelatonin greater than or equal to 2-iodomelatonin greater than N-acetylserotonin greater than or equal to 6-methoxymelatonin greater than or equal to melatonin greater than 6-hydroxymelatonin greater than or equal to 6,7-dichloro-2-methylmelatonin greater than 5-methoxytryptophol greater than 5-methoxytryptamine greater than or equal to 5-methoxy-N,N-dimethyltryptamine greater than N-acetyltryptamine greater than serotonin greater than 5-methoxyindole (inactive)

  1. Suppression of 125I-uptake in mouse thyroid by seaweed feeding

    International Nuclear Information System (INIS)

    We conducted an animal experiment to determine how dietary seaweeds rich in iodine and dietary fibers suppress radioactive iodine uptake by the thyroid, using mice and four kinds of experimental diets, three with 1% or 2% powdered fronds of the kelp Laminaria religiosa and 2% powdered laver Porphyra yezoensis, and one with cellulose. Iodine content of a hot-water extract of the kelp was 0.530±0.001%, and its dietary fiber (DF) values were 52.8±1.2%. Iodine in an extract of the laver was 0.008±0.001%, and its DF values were 41.4%±0.7%. A statistically significant reduction of 125I uptake by the thyroid, 3 hours after intragastric administration of the radionuclide at a dosage of 18.5 kBq or 185 kBq in 0.3 ml aqueous solution per mouse, was observed in mice previously fed the experimental diets containing 1% and 2% kelp during periods varying from 24 hours to 7 days. The degree of the suppression was observed to depend on the amount of iodine in the diet or in the injected sample, no matter whether organic or inorganic, judging from the results of an additional experiment. Thus, we conclude that previously fed iodine-rich material, especially dietary seaweeds rich in iodine and other minerals, vitamins, and β-carotene, such as kelps or laver supplemented with inorganic iodine, may be effective in prevention of internal radiation injury of the thyroid. (author)

  2. Exposure to environmental tobacco smoke measured by cotinine sup 125 I-radioimmunoassay

    Energy Technology Data Exchange (ETDEWEB)

    Knight, G.J.; Palomaki, G.E.; Lea, D.H.; Haddow, J.E. (Foundation for Blood Research, Scarborough, ME (USA))

    1989-06-01

    We describe a polyclonal-antiserum-based {sup 125}I-radioimmunoassay for cotinine that is suitable for measuring nonsmokers' passive exposure to tobacco smoke in the environment. The standard curve ranged from 0.25 to 12.0 micrograms/L, with an estimated lower limit of sensitivity of 0.2 microgram/L (95% B/Bo = 0.2 microgram/L; 50% B/Bo = 4.0 micrograms/L). The median within-assay CVs for patients' samples with cotinine values from 0.4 to 1.3, 1.4 to 2.4, 2.5 to 4.6, and 4.7 to 15.6 micrograms/L were 13.9%, 7.2%, 5.1%, and 5.7%, respectively. Between-assay CVs for two quality-control sera with average values of 1.53 and 3.68 micrograms/L were 14.3% and 7.8%, respectively. Analytical recoveries of cotinine from smokers' sera diluted in zero calibrant ranged from 91% to 116%. Cotinine values determined on 79 paired sera and urines from nonsmokers showed significant correlation with self-reported exposure to environmental tobacco smoke (r = 0.49, P less than 0.001 for sera; r = 0.57, P less than 0.001 for urine). The log of the values for serum and urine cotinine were also significantly correlated (r = 0.85, P less than 0.001). Evidently, polyclonal antiserum can be used to develop a cotinine assay for measuring exposure to environmental tobacco smoke that compares well with that described for monoclonal-based assays.

  3. Assessment of compensatory renal function and [125I]iothalamate clearance in sheep.

    Science.gov (United States)

    Filippich, L J; English, P B; Ainscow, J

    1985-11-01

    Compensatory renal function and sodium [125I]iothalamate clearance were studied in 4 adult Merino ewes. Renal clearances of inulin (CIN), iothalamate (CIOT), and p-aminohippurate (CPAH) were used to measure renal function before and 7 and 170 days after 50% and 75% reductions in renal mass. Renal mass reduction to 50% of normal was achieved by ligation of the right renal artery, and to 25% of normal by ligating the right renal artery and branches of the left renal artery. Renal function (CIN and CPAH) after 50% renal mass reduction was 78% of normal on postligation day (PLD) 7 and 64% of normal on PLD 170. This decrease in renal function between PLD 7 and 170 was significant (P less than 0.05). Renal function (CIN and CPAH) after 75% renal mass reduction was 55% of normal on PLD 7 and 48% on PLD 170; however, this decrease in renal function between PLD 7 and 170 was not significant. Results indicated that, shortly after 50% renal mass reduction by renal arterial ligation, renal function in ewes was greater than that previously reported after unilateral nephrectomy and that a further decrease in renal function developed within 6 months after ligation. The mean CIOT in healthy ewes was 2.46 ml/min/kg of body weight. In healthy ewes and in ewes after renal mass reduction, regression of the simultaneous CIOT and CIN was CIOT = 0.276 + 1.05 CIN. The CIOT was higher than the corresponding CIN, and remained significantly (P less than 0.01) and consistently higher. Therefore, iothalamate can be used to estimate glomerular filtration rate in sheep, although a correction factor is required.

  4. Iodine-125 thin seeds decrease prostate swelling during transperineal interstitial permanent prostate brachytherapy

    International Nuclear Information System (INIS)

    Prostate swelling following seed implantation is a well-recognised phenomenon. The purpose of this intervention was to assess whether using thinner seeds reduces post-implant swelling with permanent prostate brachytherapy. Eighteen consecutive patients eligible for prostate seed brachytherapy underwent seed implantation using iodine-125 (I-125) thin seeds. Operative time, dosimetry, prostate swelling and toxicity were assessed and compared with standard I-125 stranded seed controls, sourced from the department's brachytherapy database. A learning curve was noted with the thin seeds in terms of greater bending and deviation of needles from their intended path. This translated into significantly longer total operative time (88 vs 103 minutes; P=0.009, 95% confidence interval (CI) 4.1-24.3) and time per needle insertion (2.6 vs 3.7 minutes; P<0.001, 95% CI 0.5-1.3) for the thin seeds. Day 30 prostate volumes were significantly smaller in the thin seed group compared with standard seeds (40.9cc vs 46.8cc; P=0.001, 95% CI 1.5-5.6). The ratio of preoperative transrectal ultrasound to day 30 post-implant CT volume was also smaller in the thin seed group (1.2±0.1 for standard seeds vs 1.1±0.1 for thin seeds). Post-implant dosimetric parameters were comparable for both groups. No significant differences were seen in acute urinary morbidity or quality of life between the two groups. I-125 thin seeds are associated with an initial learning curve, with longer operative time, even for experienced brachytherapists. The significant reduction in day 30 prostate volumes with the thin seeds has useful implications in terms of optimising dose coverage to the prostate in the early period post-implantation, as well as improving the accuracy of post-implant dosimetric assessments.

  5. Low elastic modulus Ti–Ta alloys for load-bearing permanent implants: Enhancing the biodegradation resistance by electrochemical surface engineering

    Energy Technology Data Exchange (ETDEWEB)

    Kesteven, Jazmin [Biomaterials and Engineering Materials (BEM) Laboratory, School of Engineering and Physical Sciences, James Cook University, Townsville, Queensland 4811 (Australia); Kannan, M. Bobby, E-mail: bobby.mathan@jcu.edu.au [Biomaterials and Engineering Materials (BEM) Laboratory, School of Engineering and Physical Sciences, James Cook University, Townsville, Queensland 4811 (Australia); Walter, Rhys; Khakbaz, Hadis [Biomaterials and Engineering Materials (BEM) Laboratory, School of Engineering and Physical Sciences, James Cook University, Townsville, Queensland 4811 (Australia); Choe, Han-Choel [Department of Dental Materials, Chosun University, Gwangju 501-759 (Korea, Republic of)

    2015-01-01

    In this study, the in vitro degradation behaviour of titanium–tantalum (Ti–Ta) alloys (10–30 wt.% Ta) was investigated and compared with conventional implant materials, i.e., commercially pure titanium (Cp-Ti) and titanium–aluminium–vanadium (Ti6Al4V) alloy. Among the three Ti–Ta alloys studied, the Ti20Ta (6.3 × 10{sup −4} mm/y) exhibited the lowest degradation rate, followed by Ti30Ta (1.2 × 10{sup −3} mm/y) and Ti10Ta (1.4 × 10{sup −3} mm/y). All the Ti–Ta alloys exhibited lower degradation rate than that of Cp-Ti (1.8 × 10{sup −3} mm/y), which suggests that Ta addition to Ti is beneficial. As compared to Ti6Al4V alloy (8.1 × 10{sup −4} mm/y), the degradation rate of Ti20Ta alloy was lower by ∼ 22%. However, the Ti30Ta alloy, which has closer elastic modulus to that of natural bone, showed ∼ 48% higher degradation rate than that of Ti6Al4V alloy. Hence, to improve the degradation performance of Ti30Ta alloy, an intermediate thin porous layer was formed electrochemically on the alloy followed by calcium phosphate (CaP) electrodeposition. The coated Ti30Ta alloy (3.8 × 10{sup −3} mm/y) showed ∼ 53% lower degradation rate than that of Ti6Al4V alloy. Thus, the study suggests that CaP coated Ti30Ta alloy can be a viable material for load-bearing permanent implants. - Highlights: • In vitro degradation of titanium–tantalum (Ti–Ta) alloys was studied. • Ta addition to Ti is beneficial for better degradation resistance. • Ti–Ta alloys perform better than commercially pure Ti. • Calcium phosphate coated Ti–Ta alloy is superior to Ti6Al4V alloy.

  6. Low elastic modulus Ti–Ta alloys for load-bearing permanent implants: Enhancing the biodegradation resistance by electrochemical surface engineering

    International Nuclear Information System (INIS)

    In this study, the in vitro degradation behaviour of titanium–tantalum (Ti–Ta) alloys (10–30 wt.% Ta) was investigated and compared with conventional implant materials, i.e., commercially pure titanium (Cp-Ti) and titanium–aluminium–vanadium (Ti6Al4V) alloy. Among the three Ti–Ta alloys studied, the Ti20Ta (6.3 × 10−4 mm/y) exhibited the lowest degradation rate, followed by Ti30Ta (1.2 × 10−3 mm/y) and Ti10Ta (1.4 × 10−3 mm/y). All the Ti–Ta alloys exhibited lower degradation rate than that of Cp-Ti (1.8 × 10−3 mm/y), which suggests that Ta addition to Ti is beneficial. As compared to Ti6Al4V alloy (8.1 × 10−4 mm/y), the degradation rate of Ti20Ta alloy was lower by ∼ 22%. However, the Ti30Ta alloy, which has closer elastic modulus to that of natural bone, showed ∼ 48% higher degradation rate than that of Ti6Al4V alloy. Hence, to improve the degradation performance of Ti30Ta alloy, an intermediate thin porous layer was formed electrochemically on the alloy followed by calcium phosphate (CaP) electrodeposition. The coated Ti30Ta alloy (3.8 × 10−3 mm/y) showed ∼ 53% lower degradation rate than that of Ti6Al4V alloy. Thus, the study suggests that CaP coated Ti30Ta alloy can be a viable material for load-bearing permanent implants. - Highlights: • In vitro degradation of titanium–tantalum (Ti–Ta) alloys was studied. • Ta addition to Ti is beneficial for better degradation resistance. • Ti–Ta alloys perform better than commercially pure Ti. • Calcium phosphate coated Ti–Ta alloy is superior to Ti6Al4V alloy

  7. Solid-phase radioimmunoassay for IgG gliadin antibodies using /sup 125/I-labelled staphylococcal protein A

    Energy Technology Data Exchange (ETDEWEB)

    Troncone, R.; Pignata, C.; Farris, E.; Ciccimarra, F. (Naples Univ. (Italy). II Facolta di Medicina)

    1983-10-14

    A sensitive radioimmunoassay for IgG gliadin antibodies is described. Serum specimens were added to wells of plastic microtitre plates coated with gliadin. After removal of the unbound material, gliadin antibodies were detected by adding /sup 125/I-labelled staphylococcal protein A (/sup 125/I-SpA). Serum specimens from coeliac patients on a normal diet or on a gluten-free diet were tested, as well as sera from an age-matched control group. Measurements to obtain precise quantitative values were made with gliadin antibody-rich serum as reference standard. High titres of gliadin antibodies were found in 18 out of 19 coeliac patients on a normal diet (95%); in patients on a strict gluten-free diet serum values did not exceed 2 S.D. of the control mean. Due to the high sensitivity of the method a low but detectable amount of gliadin antibody was present in the sera of all controls.

  8. Synthesis and characterization of [{sup 125}I]N-(2-aminoethyl)-4-iodobenzamide as a selective monoamine oxidase B inhibitor

    Energy Technology Data Exchange (ETDEWEB)

    Rafii, Hamid; Chalon, Sylvie; Ombetta, Jean-Edouard; Frangin, Yves; Garreau, Lucette; Dognon, Anne-Marie; Lena, Isabelle; Bodard, Sylvie; Vilar, Marie-Paule; Besnard, Jean-Claude; Guilloteau, Denis

    1995-07-01

    We described the radiosynthesis of an analog of Ro 16-6491, [{sup 125}I]N-(2-aminoethyl)-4-iodobenzamide, for SPECT exploration of the monoamine oxidase B (MAO-B) in human brain. The radiolabelling was carried out by nucleophilic exchange of the brominated precursor at solid-state phase in presence of ammonium sulphate. The radiochemical purity of radioiodinated product was higher than 95%. In comparison with Ro 16-6491, the in vitro studies showed a good selectivity of stable N-(2-aminoethyl)-4-iodobenzamide for MAO-B but a slightly lower affinity. Biodistribution studies in the rat showed a high and selective uptake of this compound in the pineal gland 1 h after i.v. injection. The cerebral uptake was low, but the coupling of [{sup 125}I]N-(2-aminoethyl)-4-iodobenzamide with a lipophilic radical to enhance the passage through the blood-brain barrier can be envisaged.

  9. /sup 125/I)-(d(CH2)5, Sar7)AVP: a selective radioligand for V1 vasopressin receptors

    Energy Technology Data Exchange (ETDEWEB)

    Kelly, J.M.; Abrahams, J.M.; Phillips, P.A.; Mendelsohn, F.A.; Grzonka, Z.; Johnston, C.I.

    1989-01-01

    Arginine8-vasopressin (AVP) acts on vascular and hepatic V1 receptors to influence blood pressure and glycogenolysis respectively. We have radioiodinated the AVP V1 receptor antagonist, (1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic-acid), 7-sarcosine, 8-arginine) vasopressin ((d(CH2)5, Sar7)AVP) and determined its receptor-binding properties in rat liver and kidney plasma membranes. The binding was of high affinity to single classes of receptors (liver: Kd = 3.0 nM and Bmax = 530 +/- 10 fmol/mg protein, kidney: Kd = 0.5 +/- 0.9 nM and Bmax = 11 +/- 8 fmol/mg protein). Competition of (125I)-(d(CH2)5, Sar7)AVP binding by unlabelled AVP analogues gave the following order of potency in both tissues, consistent with that expected for binding to a V1 receptor: (d(CH2)5, Tyr(Me)2)AVP greater than AVP greater than (d(CH2)5, D-Ile2, Ile4) AVP greater than DDAVP. No degradation of (125I)-(d(CH2)5, Sar7)AVP during incubation or storage was detected by HPLC analysis. We have used (125I)-(d(CH2)5, Sar7)AVP and in vitro autoradiography to demonstrate its use in localizing brain AVP receptors. These studies suggest that (125I)-(d(CH2)5, Sar7)AVP is a suitable selective radioligand for labelling V1 receptors and will provide a valuable tool for the study of the localization and regulation of AVP V1 receptors in tissues and in receptor isolation.

  10. Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter

    International Nuclear Information System (INIS)

    The full text of the publication follows. The increasing incidence of melanoma and the lack of effective therapy on the disseminated form have led to an urgent need for new specific therapies. Several iodo-benzamides or analogs are known to possess specific affinity for melanoma tissue. New hetero-aromatic derivatives have been designed with a cytotoxic moiety and termed DNA intercalating agents. These compounds could be applied in targeted radionuclide therapy using 125I, Auger electrons emitter which gives high-energetic localized irradiation. Two iodinated acridine derivatives have been reported to present an in vivo kinetic profile conducive to application in targeted radionuclide therapy. The aim of the present study was to perform a preclinical evaluation of these compounds. The DNA intercalating property was confirmed for both compounds. After radiolabeling with 125I, the two compounds induced in vitro a significant radiotoxicity on B16F0 melanoma cells. The acridine compound, ICF01040, appeared more radio toxic than the acridone compound, ICF01035. While cellular uptake was similar for both compounds, SIMS analysis and in vitro protocol showed a stronger affinity for melanin with ICF01035, which was able to induce a predominant scavenging process in the melanosome and restrict access to the nucleus. Nevertheless, an important radiotoxicity was measured for the two compounds while the nuclear accumulation was low. Indeed, even if nuclear localization remains the main target sensitive to Auger electrons, the cell membrane remains sensitive to 125I decays. So, these compounds may induce secondary toxic effects of irradiation, such as membrane lipid damage. Conducted to current experiments are evaluate such hypothesis. Taken together, these results suggest that ICF01040 is a better candidate for application in targeted radionuclide therapy using 125I. The next step will be in vivo evaluation, where high tumoral vectorization gives promising perspectives

  11. Biodistribution and γ imaging of 125I-labeled goat anti-human IgG polyclonal antibody in nude mice bearing human colon cancer xenografts

    International Nuclear Information System (INIS)

    The possibility of IgG secreted from tumor cells as a target for radioimmunoimaging and targeted therapy of cancers were investigated. Goat anti-human IgG polyclonal anti- body (GAHG) was radioiodinated using Iodogen method, and the in vitro stability and pharmacokinetics were evaluated. The biodistribution and γ imaging of 125I-GAHG were performed in nude mice bearing HT-29 human colon cancer xenografts. 125I-GAHG showed good in vitro stability, and its blood clearance was defined as a two-compartment model, with T1/2α and T1/2β were 1.19 h and 43.99 h, respectively. The tumor uptake of 125I-GAHG was higher than that of 125I-labeled normal goat IgG control (125I-GIgG). 125I-GAHG showed good tumor retention when injecting via intra-tumor. In the biodistribution study, the highest tumor uptake of 125I-GAHG was 6.71±2.19%ID/g at 72 h postinjection and the T/NT increased along with the postinjection time. The results show that 125I-GAHG have good tumor-specific uptake which may provide a novel idea for radioimmunoimaging and targeted therapy of cancers. (authors)

  12. The adsorption kinetics of the testosterone-bovine serum albumin-125 I conjugate on the surface of a piezoelectric crystal

    International Nuclear Information System (INIS)

    This paper presents the adsorption kinetics of a radioactive protein conjugate on the surface of a piezoelectric crystal. This study is necessary to characterize the interaction of a protein with the surface of a piezoelectric immuno-sensor. The used immunogenic conjugate was obtained in our laboratory by coupling the bovine serum albumin with a carboxy derivative of testosterone (testosterone - 3 - carboxy methyloxime) followed by labeling with 125 I. The purified radioactive conjugate was used to determine kinetic parameters as: rate constants for adsorption and desorption, the rate of surface coverage change and the time for reaching the physico-chemical equilibrium. After incubation at different times, the crystals were washed twice with distilled water, dried and then the radioactivity was measured with a gamma counter (the efficiency of the counter for 125 I was 70%). The measurements of the kinetics parameters of the adsorption of the testosterone-bovine serum albumin-125 I on the surface of a piezoelectric crystal under the above exposed conditions lead to an equilibrium constant of 7.5x109 l x mol-1. The rate constants for adsorption and desorption are (1.29 to 1.36) x 105 l x mol-1 x min-1 and 1.71x10-4 min-1 respectively. These results indicate a good stability of the system.The adsorption method could be useful for developing piezoelectric crystal based immuno-sensors. (authors)

  13. Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter.

    Science.gov (United States)

    Gardette, Maryline; Papon, Janine; Bonnet, Mathilde; Desbois, Nicolas; Labarre, Pierre; Wu, Ting-Dee; Miot-Noirault, Elisabeth; Madelmont, Jean-Claude; Guerquin-Kern, Jean-Luc; Chezal, Jean-Michel; Moins, Nicole

    2011-12-01

    The increasing incidence of melanoma and the lack of effective therapy on the disseminated form have led to an urgent need for new specific therapies. Several iodobenzamides or analogs are known to possess specific affinity for melanoma tissue. New heteroaromatic derivatives have been designed with a cytotoxic moiety and termed DNA intercalating agents. These compounds could be applied in targeted radionuclide therapy using (125)I, which emits Auger electrons and gives high-energy, localized irradiation. Two iodinated acridine derivatives have been reported to present an in vivo kinetic profile conducive to application in targeted radionuclide therapy. The aim of the present study was to perform a preclinical evaluation of these compounds. The DNA intercalating property was confirmed for both compounds. After radiolabeling with (125)I, the two compounds induced in vitro a significant radiotoxicity to B16F0 melanoma cells. Nevertheless, the acridine compound appeared more radiotoxic than the acridone compound. While cellular uptake was similar for both compounds, SIMS analysis and in vitro protocol showed a stronger affinity for melanin with acridone derivative, which was able to induce a predominant scavenging process in the melanosome and restrict access to the nucleus. In conclusion, the acridine derivative with a higher nuclear localization appeared a better candidate for application in targeted radionuclide therapy using (125)I. PMID:20567996

  14. Binding of [125I]iodipine to parathyroid cell membranes: Evidence of a dihydropyridine-sensitive calcium channel

    International Nuclear Information System (INIS)

    The parathyroid cell is unusual, in that an increase in extracellular calcium concentrations inhibits PTH release. Calcium channels are glycoproteins that span cell membranes and allow entry of extracellular calcium into cells. We have demonstrated that the calcium channel agonist (+)202-791, which opens calcium channels, inhibits PTH release and that the antagonist (-)202-791, which closes calcium channels, stimulates PTH release. To identify the calcium channels responsible for these effects, we used a radioligand that specifically binds to calcium channels. Bovine parathyroid cell membranes were prepared and incubated under reduced lighting with [125I] iodipine (SA, 2000 Ci/mmol), which recognizes 1,4-dihydropyridine-sensitive calcium channels. Bound ligand was separated from free ligand by rapid filtration through Whatman GF/B filters. Nonspecific binding was measured by the inclusion of nifedipine at 10 microM. Specific binding represented approximately 40% of the total binding. The optimal temperature for [125I] iodipine binding was 4 C, and binding reached equilibrium by 30 min. The equilibrium dissociation constant (Kd) was approximately 550 pM, and the maximum number of binding sites was 780 fmol/mg protein. Both the calcium channel agonist (+)202-791 and antagonist (-)202-791 competitively inhibited [125I] iodipine binding, with 50% inhibition concentrations of 20 and 300 nM, respectively. These data indicate the presence of dihydropyridine-sensitive calcium channels on parathyroid cell membranes

  15. DNA breakage, repair and lethality after 125I decay in rec+ and recA strains of Escherichia coli

    International Nuclear Information System (INIS)

    Iodine-125 decays by electron capture and is known to cause extensive molecular fragmentation via the Auger effect. 125I was incorporated into the DNA of exponentially-growing E. coli K12 AB2487, a recA mutant, and E. coli K12 AB2497, the corresponding rec+ strain as 5-iododeoxyuridine (IUdR), an analogue of thymidine. Radioactive bacteria were stored at -1960C, and samples were periodically assayed for loss of viability and for the induction of double-strand breaks (DSBs) in DNA. Each 125I decay in the DNA of either strain induced one DSB, i.e. proportional to (DSB) = 1.0. For the recA strain, proportional to (lethal) = 0.9 and for the rec+ strain, 0.4. Assays for biological repair of DSBs, involving incubation of thawed samples in growth-medium at 370C before the extraction of DNA, demonstrated significant repair of 125I-induced DSBs by rec+ cells but none by recA cells. For small numbers of decays, there was approximately a 1 : 1 correlation, for either strain, between lethal decays and post-incubation residual DSBs. Comparison with data for larger numbers of decays indicated that a typical rec+ cell can repair no more than three to four DSBs per completed genome (2.5 x 109 daltons). (author)

  16. Cellular uptake of 125I-mIBG and of 111In-pentetreotide by human neuroblastoma cells in culture

    International Nuclear Information System (INIS)

    Aim. Neuroblastoma have various prognosis, leading or not to heavy therapeutics. MIBG scan is the reference for assessment of the disease extent, but somatostatin analogs are promising as somatostatin receptors expression might indicate neuroendocrine tumoral cell differentiation. The aim of our study was to establish an experimental model to assess cellular uptake of 125I-meta-iodo-benzyl-guanidine (125I-mIBG) and of 111In pentetreotide (111In-OCT), by neuroblastoma cells culture. Material and methods. We compared the uptake of these tracers by SK-N-SH human neuroblastoma cell line in monolayer culture. After cell characterization, toxicity of ligands and of their competitive inhibitors was studied. Experiments with separate incubation of each tracer, using different times and concentrations, determined optimal conditions, which were then applied to simultaneous incubation studies. Results. Total uptakes after simultaneous 3 h-incubation with 125I-mIBG (106 M) and 111In-OCT (108 M) (respectively 3.5 % and 0.03 % of administered activity per 105 cells) were not different from total uptake with separate incubation. Conclusions. Our results confirms the validity of the methodology which is now under use to study the influence of cell differentiation on cellular uptake. (authors)

  17. Dose Escalation to the Dominant Intraprostatic Lesion Defined by Sextant Biopsy in a Permanent Prostate I-125 Implant: A Prospective Comparative Toxicity Analysis

    International Nuclear Information System (INIS)

    Purpose: Using real-time intraoperative inverse-planned permanent seed prostate implant (RTIOP/PSI), multiple core biopsy maps, and three-dimensional ultrasound guidance, we planned a boost volume (BV) within the prostate to which hyperdosage was delivered selectively. The aim of this study was to investigate the potential negative effects of such a procedure. Methods and Materials: Patients treated with RTIOP/PSI for localized prostate cancer with topographic biopsy results received an intraprostatic boost (boost group [BG]). They were compared with patients treated with a standard plan (reference group [RG]). Plans were generated using a simulated annealing inverse planning algorithm. Prospectively recorded urinary, rectal, and sexual toxicities and dosimetric parameters were compared between groups. Results: The study included 120 patients treated with boost technique who were compared with 70 patients treated with a standard plan. Boost technique did not significantly change the number of seeds (55.1/RG vs. 53.6/BG). The intraoperative prostate V150 was slightly higher in BG (75.2/RG vs. 77.2/BG, p = 0.039). Urethra V100, urethra D90, and rectal D50 were significantly lower in the BG. No significant differences were seen in acute or late urinary, rectal, or sexual toxicities. Conclusions: Because there were no differences between the groups in acute and late toxicities, we believe that BV can be planned and delivered to the dominant intraprostatic lesion without increasing toxicity. It is too soon to say whether a boost technique will ultimately increase local control.

  18. Clinical outcome of intermediate risk prostate cancer treated with iodine 125 mono-therapy: The Hotel-Dieu of Quebec experience;Evolution clinique des patients atteints d'un cancer prostatique de risque intermediaire traites par implants permanents d'iode-125: l'experience de l'Hotel-Dieu de Quebec

    Energy Technology Data Exchange (ETDEWEB)

    Zebentout, O.; Apardian, R.; Beaulieu, L.; Harel, F.; Martin, A.G.; Vigneault, E. [Departement de radiotherapie, CHUQ Hotel-Dieu, QC (Canada); Beaulieu, L.; Harel, F. [Centre de recherche en cancerologie, CHUQ Hotel-Dieu, universite de Laval, QC (Canada); Beaulieu, L. [Departement de physique, de genie physique et d' optique, universite de Laval, QC (Canada)

    2010-06-15

    Purpose To describe the biochemical failure-free survival (B.F.F.S.), G.U. toxicity and erectile dysfunction in intermediate risk prostate cancer treated with iodine 125 mono-therapy ({sup 125}I). Patients and methods Between October 1994 and October 2007, 1282 patients were treated with {sup 125}I at the Hotel Dieu de Quebec. Two hundred patients were intermediate risk prostate cancer. One hundred and fifty-seven had enough follow-up to be evaluated in this study. Biochemical failure-free survival is reported using Phoenix definition. Acute and late G.U. toxicity was described using the International Prostate Symptoms Score (I.P.S.S.) as well as with the rate of bladder catheter. Erectile dysfunction was also reported. Results The mean age of the patients was 65.6 years (S.D. = 6 years) and the mean pretreatment P.S.A. was 8.7 ng/ml. About half of the patients (51%) were T2b/T2c. About 44.6% had a P.S.A. greater than 10 and 4.5% had Gleason score of 7/10. More than half of the patients received a short course of hormones of less than 6 months for cyto-reduction (57.4%). The median follow-up was 60 months. Biochemical failure-free survival at 60-month and 96-month were 87.1% and 81% according to Phoenix definition. The mean I.P.S.S. rose from 5 immediately after the implant to 15 1 month after and then slowly decreased to 8 at 24 months. Acute urinary retention with bladder catheter occurred in 10.9% of patients. Only 4.3% presented erectile dysfunction at 5 months post-implant. Conclusion {sup 125}I mono-therapy for intermediate risk prostate implant gives biochemical failure-free survivals at 5 years and 8 years comparable to those obtained with high dose external beam radiotherapy. G.U. toxicity and erectile dysfunction were low and acceptable. Therefore, the use of {sup 125}I alone in this group of patients could be presented and discussed with the patient in the waiting of phase III validation. (authors)

  19. Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrence After Initial PPI for Prostate Cancer

    Energy Technology Data Exchange (ETDEWEB)

    Hsu, Charles C., E-mail: hsucc@radonc.ucsf.edu [Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California (United States); Hsu, Howard [Department of Radiation Oncology, New York University, New York, New York (United States); Pickett, Barby [Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California (United States); Crehange, Gilles [Department of Radiation Oncology, Dijon University, Dijon (France); Hsu, I-Chow Joe; Dea, Ryan [Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California (United States); Weinberg, Vivian [Biostatistics and Computational Biology Core, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California (United States); Gottschalk, Alexander R. [Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California (United States); Kurhanewicz, John [Department of Radiology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California (United States); Shinohara, Katsuto [Department of Urology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California (United States); Roach, Mack [Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California (United States)

    2013-02-01

    Purpose: To assess the feasibility of magnetic resonance imaging (MRI)-planned partial salvage permanent prostate implant (psPPI) among patients with biopsy-proven local recurrence after initial PPI without evidence of distant disease. Methods and Materials: From 2003-2009, 15 patients underwent MRI/magnetic resonance spectroscopy (MRS) planning for salvage brachytherapy (psPPI, I-125 [n=14; 144 Gy]; Pd-103 [n=1; 125 Gy]) without hormone therapy. Full dose was prescribed to areas of recurrence and underdosage, without entire prostate implantation. Limiting urethral and rectal toxicity was prioritized. Follow-up was from salvage date to prostate-specific antigen (PSA) concentration failure (Phoenix criteria = nadir + 2.0; ASTRO = 3 consecutive rises), recurrence, distant metastases, or last follow-up PSA level. Progression-free survival (PFS) was defined as no PSA failure or biopsy-proven recurrence without all-cause mortality. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4.0. Results: At salvage, median age was 68 years, and PSA concentration was 3.5 ng/mL (range, 0.9-5.6 ng/mL). Abnormal MRI/MRS findings were evident in 40% of patients. Biopsy-proven recurrences consisted of a single focus (80%) or 2 foci (20%). At recurrence, Gleason score was 6 (67%) or {>=}7 (27%). Median interval between initial and salvage implantation was 69 months (range, 28-132 months). psPPI planning characteristics limited doses to the rectum (mean V100 = 0.5% [0.07 cc]) and urethra (V100 = 12% [0.3 cc]). At median follow-up (23.3 months; range, 8-88 months), treatment failure (n=2) resulted only in localized recurrence; both patients underwent second psPPI with follow-up PSA tests at 12 and 26 months, resulting in 0.6 and 0.7 ng/mL, respectively. American Society for Radiation Oncology PFS rates at 1, 2, and 3 years were 86.7%, 78.4%, and 62.7%, respectively, with 5 patients for whom treatment failed (n=3 with negative transrectal ultrasound

  20. Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrence After Initial PPI for Prostate Cancer

    International Nuclear Information System (INIS)

    Purpose: To assess the feasibility of magnetic resonance imaging (MRI)-planned partial salvage permanent prostate implant (psPPI) among patients with biopsy-proven local recurrence after initial PPI without evidence of distant disease. Methods and Materials: From 2003-2009, 15 patients underwent MRI/magnetic resonance spectroscopy (MRS) planning for salvage brachytherapy (psPPI, I-125 [n=14; 144 Gy]; Pd-103 [n=1; 125 Gy]) without hormone therapy. Full dose was prescribed to areas of recurrence and underdosage, without entire prostate implantation. Limiting urethral and rectal toxicity was prioritized. Follow-up was from salvage date to prostate-specific antigen (PSA) concentration failure (Phoenix criteria = nadir + 2.0; ASTRO = 3 consecutive rises), recurrence, distant metastases, or last follow-up PSA level. Progression-free survival (PFS) was defined as no PSA failure or biopsy-proven recurrence without all-cause mortality. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4.0. Results: At salvage, median age was 68 years, and PSA concentration was 3.5 ng/mL (range, 0.9-5.6 ng/mL). Abnormal MRI/MRS findings were evident in 40% of patients. Biopsy-proven recurrences consisted of a single focus (80%) or 2 foci (20%). At recurrence, Gleason score was 6 (67%) or ≥7 (27%). Median interval between initial and salvage implantation was 69 months (range, 28-132 months). psPPI planning characteristics limited doses to the rectum (mean V100 = 0.5% [0.07 cc]) and urethra (V100 = 12% [0.3 cc]). At median follow-up (23.3 months; range, 8-88 months), treatment failure (n=2) resulted only in localized recurrence; both patients underwent second psPPI with follow-up PSA tests at 12 and 26 months, resulting in 0.6 and 0.7 ng/mL, respectively. American Society for Radiation Oncology PFS rates at 1, 2, and 3 years were 86.7%, 78.4%, and 62.7%, respectively, with 5 patients for whom treatment failed (n=3 with negative transrectal ultrasound

  1. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function

    Energy Technology Data Exchange (ETDEWEB)

    Gagne, Nolan L.; Leonard, Kara L.; Rivard, Mark J. [Department of Radiation Oncology, Tufts University School of Medicine, Boston, Massachusetts 02111 (United States)

    2012-06-15

    Purpose: Clinical optimization of Collaborative Ocular Melanoma Study (COMS) eye plaque brachytherapy is currently limited to tumor coverage, consensus prescription dosage, and dose calculations to ocular structures. The biologically effective dose (BED) of temporary brachytherapy treatments is a function of both chosen radionuclide R and implant duration T. This study endeavored to evaluate BED delivered to the tumor volume and surrounding ocular structures as a function of plaque position P, prescription dose, R, and T. Methods: Plaque-heterogeneity-corrected dose distributions were generated with MCNP5 for the range of currently available COMS plaques loaded with sources using three available low-energy radionuclides. These physical dose distributions were imported into the PINNACLE{sup 3} treatment planning system using the TG-43 hybrid technique and used to generate dose volume histograms for a T = 7 day implant within a reference eye geometry including the ciliary body, cornea, eyelid, foveola, lacrimal gland, lens, optic disc, optic nerve, retina, and tumor at eight standard treatment positions. The equation of Dale and Jones was employed to create biologically effective dose volume histograms (BEDVHs), allowing for BED volumetric analysis of all ROIs. Isobiologically effective prescription doses were calculated for T = 5 days down to 0.01 days, with BEDVHs subsequently generated for all ROIs using correspondingly reduced prescription doses. Objective functions were created to evaluate the BEDVHs as a function of R and T. These objective functions are mathematically accessible and sufficiently general to be applied to temporary or permanent brachytherapy implants for a variety of disease sites. Results: Reducing T from 7 to 0.01 days for a 10 mm plaque produced an average BED benefit of 26%, 20%, and 17% for {sup 103}Pd, {sup 125}I, and {sup 131}Cs, respectively, for all P; 16 and 22 mm plaque results were more position-dependent. {sup 103}Pd produced a 16

  2. Effects of different batches of /sup 125/iodine on properties of /sup 125/I-hFSH and characteristics of radioligand-receptor assays

    Energy Technology Data Exchange (ETDEWEB)

    Melson, B.E.; Sluss, P.M.; Reichert, L.E. Jr.

    1987-02-01

    Radioiodination of highly purified human follicle-stimulating hormone (hFSH) (4000 IU/mg) was performed every other week for 23 weeks using 2 mCI carrier free Na/sup 125/I (Amersham Corp., 15 mCi/micrograms I2) in the presence of lactoperoxidase. Incorporation of /sup 125/I into hFSH was determined by the method of R. C. Greenwood, W. M. Hunter, and J. S. Grover (1963) Biochem. J. 89, 114). Hormone binding was studied in vitro under steady-state conditions (16 h, 20 degrees C) using different calf testis membrane preparations having similar receptor characteristics. Each /sup 125/I-hFSH preparation was characterized for maximum bindability, specific activity of bindable radioligand as determined by self-displacement analysis, and by determination of Ka and Rt. Incorporation of /sup 125/I into FSH was relatively constant over the large number of experiments (62.4 +/- 6.4 microCi/micrograms; n = 23). By comparison, however, specific radioactivity of the receptor bindable fraction of /sup 125/I-hFSH was related to the lot of /sup 125/I utilized, and was significantly (P less than or equal to 0.01) lower and more variable (28.7 +/- 10.5 microCi/micrograms). Maximum bindability of /sup 125/I-hFSH was not correlated to specific activity (r = 0.06) but was negatively correlated to hFSH /sup 125/I incorporation (r = -0.47; P less than or equal to 0.05). These observations demonstrate the need to assess the quality of each batch of radioligand before undertaking radioligand-receptor assays and suggest that differences in Na/sup 125/I lots affect specific radioactivity of the radioligand and its receptor binding characteristics.

  3. Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study

    International Nuclear Information System (INIS)

    The incidence and associated factors of loose seed migration were investigated in cohort 1 of the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS). The study subjects were 2160 patients, consisting of 1641 patients who underwent permanent iodine-125 seed implantation (PI) and 519 patients who underwent PI combined with external beam radiation therapy (PI + EBRT). The presence or absence of seed migration to the chest and abdominal/pelvic region was determined. Seed migration was observed in 22.7 % of PI group patients and 18.1 % of PI + EBRT group patients (p = 0.0276). Migration to the lungs and abdominal/pelvic region was observed in 14.6 % and 11.1 % of the patients in the PI group, and 11.2 % and 8.5 % of the patients in the PI + EBRT group, respectively. In the PI group, the number of implanted seeds was associated with the seed migration incidence. Neither the PI nor the PI + EBRT group showed any difference in the volume of the prostate receiving 100 % of the prescribed dose (V100 [%]) or the minimal dose received by 90 % of the prostate volume (D90 [Gy]) between the patients with and without seed migration. This prospective cohort study investigating the largest number of past cases showed no difference in D90 (Gy) or V100 (%) between seed migration or the absence thereof in both the PI group and PI + EBRT group

  4. Extraction of (129)I and (127)I via combustion from organic rich samples using (125)I as a quantitative tracer.

    Science.gov (United States)

    Herod, Matthew N; Cornett, R Jack; Clark, Ian D; Kieser, W E; Jean, Gilles St

    2014-12-01

    Iodine-129 ((129)I) is a biophilic, naturally occurring radioisotope (half-life: 1.57 × 10(7) years) that has been released in large quantities by nuclear fuel reprocessing. This iodine has cycled throughout the globe and chiefly the northern hemisphere and can be found in a wide variety of environmental materials, particularly organic rich soil and organic matter. Extracting iodine reliably from solid samples has been done by a variety of methods, however, pyrohydrolysis has been the most widely used. There is a wide variation between existing pyrohydrolysis techniques and this raises questions about the quantitative recovery of iodine from method to method. In order to quantify iodine recovery from pyrohydrolysis we have spiked samples with an iodine-125 radiotracer prior to combustion and trapping in an alkaline solution. Inorganic (125)I tracer was used as well as humic acid labeled with (125)I to simulate the behavior of (129)I and (127)I in complex organic substances and extract iodine regardless of how it is partitioned. Using these tracers we explored the effect on recovery of (125)I under a variety of combustion parameters. These include carrier gas flow rate and iodine volatilization temperature. We observed that the best recoveries of (125)I were at flow rates between 400 and 800 mL/min and most (125)I recoveries were above 85%. The experiment to determine the temperature at which iodine volatilizes from the sample showed two distinct trends for the release of iodine. One trend showed that most iodine is released at approximately 525 °C, while the other trend showed that the samples needed to reach 800 °C and remain there for at least an hour. These findings illustrate the usefulness and importance of using a quantitative recovery tracer for every iodine extraction. We then combusted and precipitated several Atlantic Ocean seaweed and standard reference materials for AMS analysis as AgI. The (129)I concentration of the seaweed ranged between 4

  5. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study

    Energy Technology Data Exchange (ETDEWEB)

    Ohashi, Toshio, E-mail: ohashi@rad.med.keio.ac.jp [Keio University School of Medicine, Tokyo (Japan); Yorozu, Atsunori; Saito, Shiro [National Hospital Organization Tokyo Medical Center, Tokyo (Japan); Tanaka, Nobumichi [Nara Medical University School of Medicine, Nara (Japan); Katayama, Norihisa [Okayama University School of Medicine, Okayama (Japan); Kojima, Shinsuke; Maruo, Shinichiro; Kikuchi, Takashi [Translational Research Informatics Center, Hyogo (Japan); Dokiya, Takushi [Kyoundo Hospital, Tokyo (Japan); Fukushima, Masanori [Translational Research Informatics Center, Hyogo (Japan); Yamanaka, Hidetoshi [Institutes of Preventive Medicine, Kurosawa Hospital, Gunma (Japan)

    2015-09-01

    Purpose: To assess, in a nationwide multi-institutional cohort study begun in 2005 and in which 6927 subjects were enrolled by 2010, the urinary and rectal toxicity profiles of subjects who enrolled during the first 2 years, and evaluate the toxicity profiles for permanent seed implantation (PI) and a combination therapy with PI and external beam radiation therapy (EBRT). Methods and Materials: Baseline data for 2339 subjects out of 2354 patients were available for the analyses. Toxicities were evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, and the International Prostate Symptom Scores were recorded prospectively until 36 months after radiation therapy. Results: Grade 2+ acute urinary toxicities developed in 7.36% (172 of 2337) and grade 2+ acute rectal toxicities developed in 1.03% (24 of 2336) of the patients. Grade 2+ late urinary and rectal toxicities developed in 5.75% (133 of 2312) and 1.86% (43 of 2312) of the patients, respectively. A higher incidence of grade 2+ acute urinary toxicity occurred in the PI group than in the EBRT group (8.49% vs 3.66%; P<.01). Acute rectal toxicity outcomes were similar between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late urinary toxicities were 6.04% versus 4.82% for the PI and the EBRT groups, respectively, with no significant differences between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late rectal toxicities were 0.90% versus 5.01% (P<.01) for the PI and the EBRT groups, respectively. The mean of the postimplant International Prostate Symptom Score peaked at 3 months, but it decreased to a range that was within 2 points of the baseline score, which was observed in 1625 subjects (69.47%) at the 1-year follow-up assessment. Conclusions: The acute urinary toxicities observed were acceptable given the frequency and retention, and the late rectal toxicities were more favorable than those of other

  6. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study

    International Nuclear Information System (INIS)

    Purpose: To assess, in a nationwide multi-institutional cohort study begun in 2005 and in which 6927 subjects were enrolled by 2010, the urinary and rectal toxicity profiles of subjects who enrolled during the first 2 years, and evaluate the toxicity profiles for permanent seed implantation (PI) and a combination therapy with PI and external beam radiation therapy (EBRT). Methods and Materials: Baseline data for 2339 subjects out of 2354 patients were available for the analyses. Toxicities were evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, and the International Prostate Symptom Scores were recorded prospectively until 36 months after radiation therapy. Results: Grade 2+ acute urinary toxicities developed in 7.36% (172 of 2337) and grade 2+ acute rectal toxicities developed in 1.03% (24 of 2336) of the patients. Grade 2+ late urinary and rectal toxicities developed in 5.75% (133 of 2312) and 1.86% (43 of 2312) of the patients, respectively. A higher incidence of grade 2+ acute urinary toxicity occurred in the PI group than in the EBRT group (8.49% vs 3.66%; P<.01). Acute rectal toxicity outcomes were similar between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late urinary toxicities were 6.04% versus 4.82% for the PI and the EBRT groups, respectively, with no significant differences between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late rectal toxicities were 0.90% versus 5.01% (P<.01) for the PI and the EBRT groups, respectively. The mean of the postimplant International Prostate Symptom Score peaked at 3 months, but it decreased to a range that was within 2 points of the baseline score, which was observed in 1625 subjects (69.47%) at the 1-year follow-up assessment. Conclusions: The acute urinary toxicities observed were acceptable given the frequency and retention, and the late rectal toxicities were more favorable than those of other

  7. A new 125I-fibrinogen technique for detection and depth localization of post-operative venous thrombosis

    International Nuclear Information System (INIS)

    The reliability and sensitivity of the 125I-fibrinogen uptake test (FUT) was improved by using an equipment that allowed frequent controls of its sensitivity. A new technique the 125 I-fibrinogen-sum-coincidence method (FSC), which can be used in combination with the conventional FUT for detection deep venous thrombosis (DVT) was developed. With this new method the depths of the fibrin deposits detected by the FUT could be determined. Very good agreement was demonstrated between depth determinations of thrombi by the FSC-technique and by phlebography. The new technique permits differentiation between true DVT and superficial venous thrombosis. Altogether 354 patients subjected to gynecology surgery were studied postoperatively with the improved FUT and 65 of them had signs of lower limb DVT with this test. 41 patients with a positive FUT were investigated with the FSC-technique as well, and in 37 of them the diagnosis of DVT was confirmed. Advanced age, and malignancy were preoperative risk factors for the development of DVT whereas the method of anaesthesia (general or epidural) had no significant influence on the rate of DVT. The five-fold increase in the rate of DVT after preoperative treatment with synthetic oestrogens neccesitated a change in the preoperative administration of such drugs. The new FSC-technique offers the possibilities of both determining the true 125I-activity in athrombosis and of following its course for several weeks. It is recommended that thrombi with a maximum net-activity >2kBq and with no sign of lysis when checked by the FSC-test should be treated. (author)

  8. Novel /sup 125/I radioimmunoassay for the analysis of. delta. /sup 9/-tetrahydrocannabinol and its metabolites in human body fluids

    Energy Technology Data Exchange (ETDEWEB)

    Law, B.; Mason, P.A.; Moffat, A.C.; King, L.J.

    A cannabinoid radioimmunoassay (RIA) that detects some of the major ..delta../sup 9/-THC metabolites is developed and evaluated for use in forensic science. It incorporates a novel /sup 125/I radiotracer, is sensitive, reliable, relatively quick, and simple to use. The RIA uses a commercially available antiserum and detects a number of cannabinoid metabolites, including ..delta../sup 9/-THC-11-oic acid and its glucuronide conjugate in biological fluids. The method was successfully applied to the analysis of blood and urine samples submitted for forensic analysis.

  9. Multigroup discrete ordinates modeling of 125I 6702 seed dose distributions using a broad energy-group cross section representation.

    Science.gov (United States)

    Daskalov, George M; Baker, R S; Rogers, D W O; Williamson, J F

    2002-02-01

    Our purpose in this work is to demonstrate that the efficiency of dose-rate computations in 125I brachytherapy, using multigroup discrete ordinates radiation transport simulations, can be significantly enhanced using broad energy group cross sections without a loss of accuracy. To this end, the DANTSYS multigroup discrete ordinates neutral particle transport code was used to estimate the absorbed dose-rate distributions around an 125I-model 6702 seed in two-dimensional (2-D) cylindrical R-Z geometry for four different problems spanning the geometries found in clinical practice. First, simulations with a high resolution 210 energy groups library were used to analyze the photon flux spectral distribution throughout this set of problems. These distributions were used to design an energy group structure consisting of three broad groups along with suitable weighting functions from which the three-group cross sections were derived. The accuracy of 2-D DANTSYS dose-rate calculations was benchmarked against parallel Monte Carlo simulations. Ray effects were remedied by using the DANTSYS internal first collision source algorithm. It is demonstrated that the 125I primary photon spectrum leads to inappropriate weighting functions. An accuracy of +/-5% is achieved in the four problem geometries considered using geometry-independent three-group libraries derived from either material-specific weighting functions or a single material-independent weighting function. Agreement between Monte Carlo and the three-group DANTSYS calculations, within three standard Monte Carlo deviations, is observed everywhere except for a limited region along the Z axis of rotational symmetry, where ray effects are difficult to mitigate. The three-group DANTSYS calculations are 10-13 times faster than ones with a 210-group cross section library for 125I dosimetry problems. Compared to 2-D EGS4 Monte Carlo calculations, the 3-group DANTSYS simulations are a 100-fold more efficient. Provided that these

  10. Effect of perindopril on myocardial remodeling after permanent pacemaker implantation%培哚普利对置入永久性起搏器后心肌重构的影响

    Institute of Scientific and Technical Information of China (English)

    白静; 陈杰; 王一茹; 刘丽凤; 王禹

    2011-01-01

    目的 评价培哚普利对置入永久性心脏起搏器后心肌重构的影响.方法 连续入选置入永久性起搏器患者112例,随机分为治疗组及对照组,每组56例.治疗组给予口服培哚普利,2~8mg/d,对照组不给予血管紧张素转换酶抑制剂类药物.采用二维超声心动图检测患者置入永久性心脏起搏器前后心脏各参数,随访18个月.结果 与置入前比较,对照组左心室重量指数增加(P<0.05),治疗组LVEF明显增加(P<0.05).18个月时,2组左心室重量指数比较差异有统计学意义(P<0.05),治疗组LVEF显著高于对照组(P<0.05).结论 永久性起搏器置入18个月时,患者心肌重构已出现改变,培哚普利可改善患者心肌重构,但仍需要长期的随访.%Objective To investigate the influence of perindopril on left ventricular remodeling after implantation of permanent pacemaker. Methods 112 cases who received implantation of permanent pacemaker were selected. They were divided into two groups randomly:one group of patients were treated with perindopril 2-8 mg once daily for less than one month after implantation of permanent pacemaker and the other group served as control group. After 18 months,the LVEDD,LA,RV,RA, IVS, LVPW, LVMI were examined and analyzed by echocardiography of GE V7type. Results At baseline before management, the two groups had no significant difference in clinical features and heart morphological images. Eighteen months later, the control group showed increase in LVMI (P < 0. 05). LVEF level was higher in treatment group than in control group (P < 0. 05). Conclusion Early stage of myocardial remodeling has already been observed 18 months after implanting permanent pacemakers. Perindopril can improve myocardial remodeling, but long-term observation is still needed.

  11. Human circulating monocytes internalize 125I-insulin in a similar fashion to rat hepatocytes: relevance to receptor regulation in target and nontarget tissues

    International Nuclear Information System (INIS)

    Circulating monocytes bind 125I-insulin in a specific fashion and have been used to analyze the ambient receptor status in humans. When freshly isolated circulating monocytes are incubated with 125I-insulin and examined by electron microscopic autoradiography, approximately 18% of the labeled material is internalized after 15 minutes at 37 degrees C. By 2 hours at 37 degrees C, approximately one half of the 125I-insulin is internalized. Internalization occurs also at 15 degrees C but at a slower rate. Furthermore, the monocytes bind and internalize 125I-insulin in a manner that mirrors that of major target tissues, such as rat hepatocytes. These data suggest that the insulin receptor of the circulating monocyte might be regulated by adsorptive endocytosis in a manner analogous to that of target tissue, such as the liver

  12. Preparation of 125I-labeled human growth hormone of high quality binding properties endowed with long-term stability

    International Nuclear Information System (INIS)

    125I-labeled human growth hormone (125I-labeled.hGH) was prepared by using two variants of the chloramine T labelling procedure and purified by polyacrylamide gel electrophoresis (PAGE) of the reaction mixture. Variant A produced a tracer with high specific activity (100 +/- 10 microCi/microgram), high maximal binding capacity to antibodies (93%) and long-term stability (at least 150 days at -20/degree/C). No diiodinated tyrosil residues could be detected in this tracer. Variant B was devised to obtain higher yields of labeled hormone. The electrophoresis of the iodination mixture revealed two radioactive components with Rm values of 0.49 and 0.55 which result from the iodination of hGH variants preexisting in the starting material. Both tracers had similar specific activities (70 +/- 10 microCi/microgram), high maximal binding capacity to antibodies or receptors (80-100%, after 80 days of their obtention) and high stability (at least 100 days at -20/degree/C). It is concluded that the iododerivatives of hGH obtained by either method are adequate to perform radioimmunoassay and receptor studies and have long-term stability

  13. Preparation of ( sup 123 I)- and ( sup 125 I)epidepride: a dopamine D-2 receptor antagonist radioligand

    Energy Technology Data Exchange (ETDEWEB)

    Clanton, J.A.; Schmidt, D.E.; Ansari, M.S.; Manning, R.G.; Kessler, R.M. (Vanderbilt Univ., Nashville, TN (United States). School of Medicine); Paulis, T. de (Vanderbilt Univ., Nashville, TN (United States). School of Medicine Vanderbilt Univ., Nashville, TN (United States). Dept. of Chemistry); Baldwin, R.M. (Yale Univ., West Haven, CT (United States). Veterans Administration Medical Center Research)

    1991-07-01

    (S)-(-)-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-({sup 123}I) iodo-2,3-dimethoxybenzamide (TDP 517) (proposed generic name, ({sup 123}I)epidepride) is the iodine-123 substituted analogue of isoremoxipride (FLB 457), both of which are very potent dopamine D-2 antagonists (epidepride K{sub D} 0.024 nM). ({sup 123}I) Epidepride was radioiodinated in 60-70% radiochemical yields in 35 min from the corresponding 5-(tributyltin) derivative using Na{sup 123}I with a specific radioactivity of 3000 Ci/mmol, and oxidized in situ with chloramine-T. The aryltin precursor was prepared from non-labelled epidepride by palladium-catalyzed stannylation using bis(tri-n-butyltin) in triethylamine. Alternatively, using no carrier-added Na{sup 125}I as the radioisotope, ({sup 125}I) epidepride at 2000 Ci/mmol specific radioactivity was prepared in 86% radiochemical yield and 99% radiochemical purity after purification by reverse phase HPLC in ethanolic phosphate buffer. (author).

  14. A sup 125 I-radioimmunoassay for measuring androstenedione in serum and in blood-spot samples from neonates

    Energy Technology Data Exchange (ETDEWEB)

    Thomson, S.; Wallace, A.M.; Cook, B. (Stobhill Hospital, Glasgow (England))

    1989-08-01

    We developed a radioimmunoassay with a gamma-emitting radioligand to measure androstenedione in human serum and in dried blood-spot samples from newborns. Antisera were raised in rabbits against androstenedione linked to bovine serum albumin at positions 3, 6, or 11 on the steroid nucleus. Radioligands were prepared by linking ({sup 125}I)iodohistamine at positions 3, 6, or 11. Linkages were through either carboxymethyloxime or hemisuccinate bridges. All label and antibody combinations were examined, and the most sensitive and specific combination (antiserum raised against androstenedione-3-carboxymethyloxime-bovine serum albumin with an androstenedione-carboxymethyloxime-({sup 125}I)iodohistamine label) was selected for full evaluation. We report the performance of these selected reagents in an immunoassay for androstenedione in both serum and dried blood-spot samples from neonates. We measured concentrations of androstenedione in serum under normal and pathological conditions such as congenital adrenal hyperplasia and polycystic ovarian disease. Diurnal variation in normal men was observed. Androstenedione was measured in blood spots from neonates born at term or prematurely, with respiratory distress syndrome, or with congenital adrenal hyperplasia.

  15. Synthesis and biological evaluation of {sup 125}I-erythropoietin as a potential radiopharmaceutical agent for tumours

    Energy Technology Data Exchange (ETDEWEB)

    Clemente, Goncalo dos Santos, E-mail: goncaloclemente@uc.pt [University of Coimbra (Portugal). Inst. of Nuclear Sciences Applied to Health; Duarte, Vera Lucia Serra [Polytechnical Institute of Lisbon (Portugal). Higher School of Health Technology

    2011-01-15

    Erythropoietin (EPO) is a glycoprotein hormone responsible for regulating erythropoiesis. Expression of EPO and EPO receptors (EPOr) has recently been demonstrated in some neoplastic cell lines and tumours, suggesting a potential new target for therapy. In this work, EPO was labeled with iodine-125 using the lactoperoxidase method, known to prevent damage to protein during radioiodination, and labeling conditions were optimized. In vitro stability studies have shown that {sup 125}I-EPO is radiochemically stable for 20 days after radiolabeling. In vitro cell binding studies have demonstrated very low binding (<2%) of EPO to normal and neoplastic cell lines tested. As expected, the biodistribution in healthy mice exhibited comparatively high rates of fixation in the organs of the excretory system. Thyroid also proved to be a critical organ which may indicate in vivo dissociation of {sup 125}I-EPO. In mice with induced melanoma, only a residual fixation in the tumour was evident. Further studies are warranted on other tumoral cell lines to better understand the binding process and internalization into cells. Studies on EPO labeled with carbon-11 could be valuable, since there is a greater chance of preserving the biological activity of the protein using this method. (author)

  16. Ocular Brachytherapy Dosimetry for 103Pd and 125I in The Presence of Gold Nanoparticles: Monte Carlo Study

    CERN Document Server

    Asadi, S; Vahidian, M; Marghchouei, M; Masoudi, S Farhad

    2015-01-01

    The aim of the present Monte Carlo study is to evaluate the variation of energy deposition in healthy tissues in the human eye which is irradiated by brachytherapy sources in comparison with the resultant dose increase in the gold nanoparticle(GNP)-loaded choroidal melanoma. The effects of these nanoparticles on normal tissues are compared between 103Pd and 125I as two ophthalmic brachytherapy sources. Dose distribution in the tumor and healthy tissues have been taken into account for both mentioned brachytherapy sources. Also, in a certain point of the eye, the ratio of the absorbed dose by the normal tissue in the presence of GNPs to the absorbed dose by the same point in the absence of GNPs has been calculated. In addition, differences observed in the comparison of simple water phantom and actual simulated human eye in presence of GNPs are also a matter of interest that have been considered in the present work. The results show that the calculated dose enhancement factor in the tumor for 125I is higher tha...

  17. Binding and degradation of /sup 125/I-insulin by isolated rat renal brush border membranes: evidence for low affinity, high capacity insulin recognition sites

    Energy Technology Data Exchange (ETDEWEB)

    Meezan, E.; Pillion, D.J.; Elgavish, A.

    1988-10-01

    The kidney plays a major role in the handling of circulating insulin in the blood, primarily via reuptake of filtered insulin at the luminal brush border membrane. 125I-insulin associated with rat renal brush border membrane vesicles (BBV) in a time- and temperature-dependent manner accompanied by degradation of the hormone to trichloroacetic acid (TCA)-soluble fragments. Both association and degradation of 125I-insulin were linearly proportional to membrane protein concentration with virtually all of the degradative activity being membrane associated. Insulin, proinsulin and desoctapeptide insulin all inhibited the association and degradation of 125I-insulin by BBV, but these processes were not appreciably affected by the insulin-like growth factors IGF-I and IGF-II or by cytochrome c and lysozyme, low molecular weight, filterable, proteins, which are known to be reabsorbed in the renal tubules by luminal endocytosis. When the interaction of 125I-insulin with BBV was studied at various medium osmolarities (300-1100 mosM) to alter intravesicular space, association of the ligand with the vesicles was unaffected, but degradation of the ligand by the vesicles decreased progressively with increasing medium osmolarity. Therefore, association of 125I-insulin to BBV represented binding of the ligand to the membrane surface and not uptake of the hormone or its degradation products into the vesicles. Attempts to crosslink 125I-insulin to a high-affinity insulin receptor using the bifunctional reagent disuccinimidyl suberate revealed only trace amounts of an 125I-insulin-receptor complex in brush border membrane vesicles in contrast to intact renal tubules where this complex was readily observed. Both binding and degradation of 125I-insulin by brush border membranes did not reach saturation even at concentrations of insulin approaching 10(-5) M.

  18. Binding and degradation of 125I-insulin by isolated rat renal brush border membranes: evidence for low affinity, high capacity insulin recognition sites

    International Nuclear Information System (INIS)

    The kidney plays a major role in the handling of circulating insulin in the blood, primarily via reuptake of filtered insulin at the luminal brush border membrane. 125I-insulin associated with rat renal brush border membrane vesicles (BBV) in a time- and temperature-dependent manner accompanied by degradation of the hormone to trichloroacetic acid (TCA)-soluble fragments. Both association and degradation of 125I-insulin were linearly proportional to membrane protein concentration with virtually all of the degradative activity being membrane associated. Insulin, proinsulin and desoctapeptide insulin all inhibited the association and degradation of 125I-insulin by BBV, but these processes were not appreciably affected by the insulin-like growth factors IGF-I and IGF-II or by cytochrome c and lysozyme, low molecular weight, filterable, proteins, which are known to be reabsorbed in the renal tubules by luminal endocytosis. When the interaction of 125I-insulin with BBV was studied at various medium osmolarities (300-1100 mosM) to alter intravesicular space, association of the ligand with the vesicles was unaffected, but degradation of the ligand by the vesicles decreased progressively with increasing medium osmolarity. Therefore, association of 125I-insulin to BBV represented binding of the ligand to the membrane surface and not uptake of the hormone or its degradation products into the vesicles. Attempts to crosslink 125I-insulin to a high-affinity insulin receptor using the bifunctional reagent disuccinimidyl suberate revealed only trace amounts of an 125I-insulin-receptor complex in brush border membrane vesicles in contrast to intact renal tubules where this complex was readily observed. Both binding and degradation of 125I-insulin by brush border membranes did not reach saturation even at concentrations of insulin approaching 10(-5) M

  19. Effects of renal shielding on the degradation of 125I-insulin and Na131I in rabbits exposed to X-rays

    International Nuclear Information System (INIS)

    The metabolism of simultaneously injected Na131I and 125I bovine insulin was investigated in 12 rabbits before and after whole-body exposure to 700 R X-rays, with the kidneys shielded by a lead plate. The following parameters were measured: a) Degradation of 131iodide, b) Degradation of the total 125I radioactivity in the blood, c) Degradation in the blood of the 125I radioactivity precipitable with trichloraecetic acid, d) Elimination with urine of 131I and 125I, e) Radioactivity concentrations in the livers, kidneys, spleens, and thyroid glands of irradiated animals only, f) Blood leukocyte count. The following results were obtained: 1) The distribution of Na131I and 125I-insulin between plasma and extravascular space and the cell uptake of these substances remained unchanged on irradiation. 2) The renal insulin catabolism and the renal excretion function for water, iodide, and insulin degradation products remained unchanged while insulin degradation by the other organs was significantly delayed. 3) The delayed insulin catabolism is assumed to be due to radiolesions of the liver. 4) There was no effect of X-ray exposure on the distribution of Na131I and 125I-insulin on the liver, kidneys, and spleen. 5) Blood leukocyte counts decreased rapidly directly after irradiation and had reached a constant 11% of the initial level at four days p.r. on an average. (orig./MG)

  20. An improved analysis of experimental data from 125I hot-line autoradiographs: allowing for the effects of background grains

    International Nuclear Information System (INIS)

    In this paper we suggest a new statistical method of correcting the results of hot-line experiments for the effects of background sources and we use the new method to reassess the adequacy of three probability distributions proposed in the literature for image spread from line sources. The data are from sources labelled with 125I in semi-thin resin sections 0.4-0.8 μm in thickness. The new method reveals that two of the models described the empirical distributions more closely than earlier analysis had suggested, and it confirms an increasing relationship between half distance of image spread and the thickness of the source. However, it also confirms that considerable 'inter hot-line' experimental variation remains, even after background correction. This suggests that multiple experiments are needed to produce reliable estimates of half distance. (Author)

  1. Preparation of (125)I-ricin suitable as a probe for the autoradiographic localization of toxin binding sites

    Energy Technology Data Exchange (ETDEWEB)

    Doebler, J.A.; Mayer, T.W.; Traub, R.K.; Broomfield, C.A.; Calamaio, C.A.

    1993-05-13

    The long term objectives of this research are to identify cellular binding sites for ricin and examine its organ distribution in mice following aerosol inhalation exposure. Preliminary studies relating to the synthesis and evaluation of (125 I)-ricin as an autoradiographic probe have been conducted. Non-radioactive (I)-ricin prepared using the Iodogen method was found to be non-toxic both in vivo and in vitro. Lactose was then added to the Iodogen reaction medium to block galactose-binding site associated tyrosines in an attempt to retain toxicity. However, this did not prevent iodination-induced loss of biological potency. We then switched to the lactoperoxidase method of iodination, which yielded an (I)-ricin preparation with toxicity comparable to that of native toxin.

  2. [125]I-spectramide: A novel benzamide displaying potent and selective effects at the D2 dopamine receptor

    International Nuclear Information System (INIS)

    The new substituted benzamide Spectramide, (N-[2-[4-iodobenzyl-N-methylamino]-2-methoxy-4-ethyl]-5-chloro-methylamine benzamide) labelled with 125I was used as a potent and highly selective dopamine-D2 receptor antagonist in rat striatal homogenates for in vitro receptor binding. Kinetic experiments demonstrated the reversibility of the binding and the estimated Kd from saturation analysis was 25 pM, with a Bmax of 20 pmol/g of tissue. Competition studies showed that spectramide did not interact potently with the D1 or dopamine-uptake site. Drugs known to interact with other receptor system were weak competitors of the binding, while binding was potently inhibited by other D2 antagonists, such as spiperone and eticlopride. These data indicate that Spectramide binds selectively and with high affinity to the dopamine D2 receptors, and may prove to be a useful tool for the study of these receptors in vivo using PET or SPECT

  3. Studies with encapsulated sources of 125I. III. Microdosimetry using a non-metallic wall-less proportional counter

    International Nuclear Information System (INIS)

    A significant problem in measurement of microdosimetric spectra of low energy X rays has been the perturbing influence of the counters used in experiments. The conventional proportional counters used in microdosimetry have employed electrode structures of stainless steel. Since photoelectric cross-sections are highly sensitive to atomic number (approximately proportional to z4), the photoelectrons, emitted from the steel structures, with correspondingly higher energies, may dominate over the softer Compton electrons emitted from the wall and gas. This is more serious for a wall-less type of counter, in which metallic supporting structures may contribute an additional source of photoelectrons entering the sensitive region. In order to perform accurate measurement with 125I photons and other soft X rays having energies less than 100 keV, a special counter was constructed having no metal parts. The construction is of the grid-defined ''wall-less'' type, contained inside a plastic spherical shell. The plastic was chosen to match the energy absorption coefficient of tissue at 25 keV as closely as possible; therefore, conventional tissue-equivalent A-150 was replaced by an ''air-equivalent'' type, C-552, which at 25 keV matches tissue to within a few percent. This material, based on the plastic polyvinylidene fluoride has additional advantages in terms of tensile strength and rigidity, for the purpose of molding delicate structures. The gas used was a propane-based tissue-equivalent type, modified to match the plastic. A human hair, coated with graphite, was used as the central collecting wire. The construction and details of this detector are described, and measurements are reported of 125I and 60 keV photons from 241Am, as well as high energy photons from 137Cs and 60Co

  4. Calculation of DNA strand breakage by neutralisation effect after 125I decays in a synthetic oligodeoxynucleotide using charge transfer theory

    International Nuclear Information System (INIS)

    The decay of the radioisotope 125I into 125Te is typically followed by the emission of two groups of approximately 10 electrons each via Auger processes. In deoxyribonucleic acid (DNA) with 125I incorporated, these electrons produce various types of damage to DNA, e.g. single strand breaks (SSBs) and double strand breaks (DSBs) through direct actions of physical tracks, or indirect actions of radicals produced in water. Among the direct actions one should consider not only the excitation and ionisation of DNA by Auger electrons, but also the neutralisation of highly charged 125mTe ions with electrons from neighbouring molecules. Comparison between experiment and simulation done recently revealed that without including neutralisation effect the simulated yield of SSBs was 50% less than the measured result. In the present work a calculation of DNA strand breakage by the neutralization effect in a 41-mer synthetic oligodeoxynucleotide (oligo-DNA) model was done using the charge transfer theory. Calculation based on transfer rate using the newly evaluated electronic coupling of DNA bases showed that the positive charge (hole) transfer rate is of the order of magnitudes of several 1013s-1, implying that a charge higher than 10 units might not build on a 125mTe atom. The potential energy accumulated on the decay base is transferred to bases along the DNA chain nearby and destroys those bases and ionises the sugar-phosphate group, leading a DNA SSB with a frequency of 0.2% per eV in average. (authors)

  5. Preferential reduction of binding of sup 125 I-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments

    Energy Technology Data Exchange (ETDEWEB)

    Ordway, G.A.; Gambarana, C.; Tejani-Butt, S.M.; Areso, P.; Hauptmann, M.; Frazer, A. (Veterans Affairs Medical Center, Philadelphia, PA (USA))

    1991-05-01

    This study utilized quantitative receptor autoradiography to examine the effects of repeated administration of antidepressants to rats on the binding of the beta adrenoceptor antagonist, {sup 125}I-iodopindolol ({sup 125}I-IPIN) to either beta-1 or beta-2 adrenoceptors in various regions of brain. Antidepressants were selected to represent various chemical and pharmacological classes including tricyclic compounds (desipramine and protriptyline), monoamine oxidase inhibitors (clorgyline, phenelzine and tranylcypromine), atypical antidepressants (mianserin and trazodone) and selective inhibitors of the uptake of serotonin (citalopram and sertraline). Additionally, rats were treated with various psychotropic drugs that lack antidepressant efficacy (cocaine, deprenyl, diazepam and haloperidol). Repeated treatment of rats with desipramine, protriptyline, clorgyline, phenelzine, tranylcypromine or mianserin reduced the binding of {sup 125}I-IPIN to beta-1 adrenoceptors in many brain areas. Only in the basolateral and lateral nuclei of the amygdala did all six of these antidepressants significantly reduce {sup 125}I-IPIN binding to beta-1 adrenoceptors. In these amygdaloid nuclei, the magnitude of the reduction in the binding of {sup 125}I-IPIN caused by each of these drugs was comparable to or greater than the reduction in binding produced in any other region of brain. Reductions of binding of {sup 125}I-IPIN after antidepressant treatments were not consistently observed in the cortex, the area of brain examined most often in homogenate binding studies. Only the monoamine oxidase inhibitors caused reductions in the binding of {sup 125}I-IPIN to beta-2 adrenoceptors, and this effect was generally localized to the amygdala and hypothalamus.

  6. Monte Carlo calculation of dosimetric parameters of a {sup 125}I brachytherapy seed encapsulation with biocompatible polymer and a ceramic matrix as radiographic marker

    Energy Technology Data Exchange (ETDEWEB)

    Reis, Lucas P.; Santos, Adriano M.; Grynberg, Suely E., E-mail: lpr@cdtn.b [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN/CNEN-MG), Belo Horizonte, MG (Brazil). Lab. de Dosimetria e Simulacao Computacional; Facure, Alessandro, E-mail: facure@cnen.gov.b [Comissao Nacional de Energia Nuclear (CNEN), Rio de Janeiro, RJ (Brazil)

    2011-07-01

    For prostate cancer treatments, there is an increasing interest in the permanent radioactive seeds implant technique. Currently, in Brazil, the seeds are imported at high prices, which prohibit their use in public hospitals. One of the seed models that have been developed at CDTN has a ceramic matrix as a radioisotope carrier and a radiographic marker; the seed is encapsulated with biocompatible polymer. In this work, Monte Carlo simulations were performed in order to assess the dose distributions generated by the prototype seed model. The obtained data was assessed as described in the TG-43U1 report by the AAPM. The dosimetric parameters dose rate constant, {Lambda}, radial dose function, g{sub L}(r), and anisotropy function, F(r,{theta}), were derived from simulations using the MCNP5 code. The function g(r) shows that the seed has a lower decrease in dose rate on its transverse axis when compared to the 6711 model (one of the most used seeds in permanent prostate implants). F(r,{theta}) shows that CDTN's seed anisotropy curves are smoother than the 6711 model curves for {theta}{<=}20 deg and 0.25{<=}r{<=}1 cm. As well, the {Lambda} value is 15% lower than the {Lambda} value of 6711. The results show that CDTN's seed model can deposit a more isotropic dose. Because of the model's characteristics, the seeds can be impregnated with iodine of lower specific activity which would help reducing costs. (author)

  7. 125I-induced DNA double strand breaks: use in calibration of the neutral filter elution technique and comparison with X-ray induced breaks

    International Nuclear Information System (INIS)

    The neutral filter elution assay, for measurement of DNA double strand breakage, has been calibrated using mouse L cells and Chinese hamster V79 cells labelled with [125I]dUrd and then held at liquid nitrogen temperature to accumulate decays. The basis of the calibration is the observation that each 125I decay, occurring in DNA, produces a DNA double strand break. Linear relationships between 125I decays per cell and lethal lesions per cell (minus natural logarithm survival) and the level of elution, were found. Using the calibration data, it was calculated that the yield of DNA double strand breaks after X-irradiation of both cell types was from 6 to 9 x 10-12 DNA double strand breaks per Gy per dalton of DNA, for doses greater than 6 Gy. Neutral filter elution and survival data for X-irradiated and 125I-labelled cells suggested that the relationships between lethal lesions and DNA double strand breakage were significantly different for both cell types. An attempt was made to study the repair kinetics for 125I-induced DNA double strand breaks, but was frustrated by the rapid DNA degradation which occurs in cells that have been killed by the freezing-thawing process. (author)

  8. Synthesis and evaluation of an (125)I-labeled azide prosthetic group for efficient and bioorthogonal radiolabeling of cyclooctyne-group containing molecules using copper-free click reaction.

    Science.gov (United States)

    Choi, Mi Hee; Shim, Ha Eun; Nam, You Ree; Kim, Hye Rim; Kang, Jung Ae; Lee, Dong-Eun; Park, Sang Hyun; Choi, Dae Seong; Jang, Beom-Su; Jeon, Jongho

    2016-02-01

    Herein we report the radiosynthesis of a pyridine derived azide prosthetic group for iodine radioisotope labeling of dibenzocyclooctyne (DBCO) conjugated molecules. The radiolabeling of the stannylated precursor 2 was conducted using [(125)I]NaI and chloramine-T to give (125)I-labeled azide ([(125)I]1) with high radiochemical yield (72±8%, n=4) and radiochemical purity (>99%). Using (125)I-labeled azide ([(125)I]1), cyclic RGD peptide and near infrared fluorescent molecule were efficiently labeled with modest to good radiochemical yields. The biodistribution study and SPECT/CT images showed that [(125)I]1 underwent rapid renal clearance. These results clearly demonstrated that [(125)I]1 could be used as an useful radiotracer for in vivo pre-targeted imaging as well as efficient in vitro radiolabeling of DBCO containing molecules. PMID:26748695

  9. Dosimetric studies, spectrometric, radiographic, metallographic of a new argentinean seed of {sup 125} I used in brachytherapy; Estudios dosimetricos, espectrometricos, radiograficos, metalograficos de una nueva semilla argentina de {sup 125}I empleada en braquiterapia

    Energy Technology Data Exchange (ETDEWEB)

    Pirchio, R.; Saravi, M.; Banchik, D.; Munoz, C. [CNEA, Pbro. J. Gonzalez y Aragon No. 15 (B1802AYA), Ezeiza, Buenos Aires (Argentina)]. e-mail: pirchio@cae.cnea.gov.ar

    2006-07-01

    A new source of {sup 125} I model Braquibac{sup TM} has been developed in Argentina for applications in interstitial brachytherapy. The AAPM Task Group 43 (TG-43) recommends that dosimetric characteristics of new sources of brachytherapy of Iodine-125 have been theoretically and experimentally determined before its clinical use. The objectives outlined in this work were the study of the design of the new seed, the calculation of dosimetric parameters and the photons spectra analysis. Its were carried out radiographic and metallographic studies to determine the physical characteristics of the source. For the realization of the dosimetric calculations it was used the Monte Carlo code MCNP5. Values of the radial dose function, g(r), of the constant of dose rate, {lambda}, of the function of anisotropy of two dimensions, F(r, {theta}), of the factor and constant of anisotropy its were obtained simulating the source in water according to the recommended methodology in TG-43. The constant of dose rate is similar to 0,880 {+-} 0,080 c Gy h{sup -1} U{sup -1}. The kerma in air rate of reference, S{sub K}, was calculated as 1,036 c Gy cm{sup 2}h{sup -1} mCi{sup -1} simulating the seed in dry air. Its were carried out spectrometric studies using a semiconductor planar detector of HPGe (high purity germanium). Photons spectra showed characteristic x-rays of {sup 125} I with energies of 27,20 keV, 27,47 keV, 31 keV and 31,70 keV gamma photons of 35,5 keV, and x-ray fluorescent coming from the silver nucleus of 22,10 keV, 24,94 keV and 25,45 keV. The angular dependence of the intensity of photons around the seed and in air it was analyzed with the planar detector. This was carried out to study the anisotropy in the photons flow due to variation in the thickness of the titanium wall and of the welding, movements of the silver tube inside the source and deposition of the radioactive material on the silver tube. (Author)

  10. Monitoring intervals for measurement of the radionuclides {sup 125} I and {sup 129I} in thyroid glands; Intervalos de monitoreo, para la medicion en la glandula tiroides de los radionucleidos {sup 125}I y {sup 1} {sup 29}I

    Energy Technology Data Exchange (ETDEWEB)

    Simanca, Yoan Yera; Bejerano, Gladys M. Lopez, E-mail: yoan@cphr.edu.cu, E-mail: gladys@cphr.edu.cu [Centro de Proteccion e Higiene de las Radiaciones (CPHR), Cuidad de la Habana (Cuba)

    2013-07-01

    This work shows the monitoring interval, which can be implemented in the Laboratorio de Contaminacion Interna del Centro de Proteccion e Higiene de las Radiaciones, for direct measurement in the thyroid gland of radionuclides {sup 125}I and {sup 129}I . Were used two measuring systems, one employing a scintillating detector and the other detector Phoswich. Both detectors were placed inside a depth camera, 2.5 x 2.5 x 2.5m of dimension covered with 15 cm of steel, 3 mm lead, 1.8 mm tin and 1.5 mm of copper. Was calculated for each system, the minimum detectable activity, and based on this, the monitoring interval is determined. Was obtained, for {sup 125}, all tested intervals, 120, 90,60,30 , 14, and 7 days may be implemented with both systems. In the case of the radionuclide {sup 129} I, with the installation of scintillating detector can only be implemented the intervals 120, 90, and 60 days , and for installation with Phoswich, all evaluated.

  11. Binding of immunoglobulin G from patients with autoimmune thyroid diseases to solubilized guinea pig fat cell membranes crosslinked with 125I-TSH

    International Nuclear Information System (INIS)

    Binding of immunoglobulin G (IgG) to Triton-solubilized fat cell membranes crosslinked with 125I-TSH was studied by an indirect immunoprecipitation method. Guinea pig fat cell membranes (FCM) containing TSH receptors with an association constant of 1.92 x 109 M-1 were first reacted with 125I-TSH, then treated with a crosslinker, dissuccinimidyl suberate. The dissociation of 125I-TSH from the crosslinked 125I-TSH-FCM complexes due to the addition of 100 mU/ml unlabeled TSH was 9.0 %, while it was 33 % without the treatment. To the Triton-solubilized FCM crosslinked with 125I-TSH, 50 μg each of IgG from 20 normal controls, 20 patients with Graves' disease and 20 with Hashimoto's disease was added and precipitation was effected by adding antihuman IgG. In patients with Graves' disease, 125I-TSH-FCM complexes immunoprecipitated ranged from 1.10 to 4.18 % with an average of 2.4 ± 0.99 (S. D.) % which was significantly higher than those in normal controls (1.6 ± 0.29 %). The values in the patients with Hashimoto's disease averaged 1.7 ± 0.53 (S. D.) which did not differ significantly from those of controls. The value did not correlate with either TSH-binding inhibiting activities or titers of anti-microsomal antibodies. These data suggest the presence of TSH-receptor antibodies which react with antigens other than TSH-binding sites in the patients with Graves' disease. (author)

  12. Enhanced lysis of (/sup 125/I)5-iodo-2'-deoxyuridine-labeled target cells in the presence of normal macrophages: possible mechanisms of action

    Energy Technology Data Exchange (ETDEWEB)

    Evans, R.; Eidlen, D.M.

    1985-01-01

    The potential mechanisms involved during the faster release of (/sup 125/I)-iodo-2'-deoxyuridine (/sup 125/IdUrd)-labeled target sarcoma cells in the presence of normal C57BL/6J peritoneal macrophages were investigated. Maximum (. 90%) spontaneous release of /sup 125/I from target cells cultured alone occurred over a period of about 10 days. However, after about 3 days, confluent sheets of target cells developed. In the presence of normal macrophages, 90% of the /sup 125/I was released between 3 and 7 days, again with the formation of confluent sheets of target cells. This enhanced /sup 125/I release was not influenced by increasing the relative concentration of IdUrd using the nonradioactive isotope 127IdUrd. Established mechanisms of target cell destruction were investigated but no evidence was found for the involvement of superoxide anion, hydrogen peroxide, or regulation by prostaglandin synthesis. The macrophage-mediated effect was abrogated by incorporating hydrocortisone-acetate (10(-7) to 10(-4) M) into the culture medium but this did not affect target cell proliferation. The use of serum-free culture medium suggested that macrophages secreted a soluble mediator that was not derived from or dependent on the presence of fetal bovine serum. In addition, macrophage-conditioned medium was able to induce the faster /sup 125/I release. The failure to precipitate with 20% trichloroacetic acid the /sup 125/I released from target cells cultured in the presence of macrophages indicated that the radioactive component had been separated from the precipitable DNA. The data are discussed in light of two possible hypotheses: that macrophages recognized subtle changes in IdUrd-labeled cells and exacerbate radiotoxicity, and that the faster release reflected proliferative death caused by stimulated growth.

  13. Quantitative mineral salt evaluation in the calcaneous bone using computed tomography, 125I-photon absorption and chemical analysis to compare the value of the individual methods

    International Nuclear Information System (INIS)

    It was the aim of the study described here to verify the accuracy of two different methods for the quantitative evaluation of mineral salts, which were the 125I-photon absorption technique on the one hand and wholebody CT on the other hand. For this purpose, post-mortem examinations of 31 calcaneous bones were carried out to evaluate their individual mineral salt contents in vitro using either of the above-mentioned methods. The results obtained were subsequently contrasted with calcium concentrations determined by chemical analysis. A comparison of the individual mineral salt evaluations with the results from calcium analyses pointed to a highly significant correlation (p=0.001) for both methods under investigation. The same held for the correlation of findings from CT and the 125I-hydroxylapatite technique, where the level of significance was also p=0.001. The above statements must, however, be modified in as much as the mineral salt values measured by CT were consistently lower than those obtained on the basis of 125I-photon absorption. These deviations are chiefly attributable to the fact that the values provided by CT are more susceptible to influences from the fat contained in the bones. In 125I-photon absorption a special formula may be derived to allow for the bias occurring here, provided that the composition of the bone is known. To summarise, the relative advantages and drawbacks of CT and 125I-photon absorption are carefully balanced. Mineral salt evaluations by CT permit incipient losses to be ascertained even in the trunk. The 125I-photon absorption technique would appear to be the obvious method for any kind of follow-up examination in the peripheral skeleton, as it is easily reproducible and radiation exposure can be kept to minimum. (TRV)

  14. {sup 125}I-BMIPP and {sup 18}F-FDG uptake in a transgenic mouse model of stunned myocardium

    Energy Technology Data Exchange (ETDEWEB)

    Verberne, Hein J.; Sloof, Gerrit W.; Eck-Smit, Berthe L.F. van [Department of Nuclear Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam (Netherlands); Beets, Arnold L.; Knapp, Furn (Russ) F. [Nuclear Medicine Program, Oak Ridge National Laboratory, Oak Ridge, Tennessee (United States); Murphy, Anne M. [Department of Pediatrics and Institute of Molecular Cardiobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland (United States)

    2003-03-01

    Reported metabolic patterns in myocardial stunning are not uniform. We investigated relative myocardial perfusion, glucose and fatty acid uptake using a technetium-99 hexakis-2-methoxyisobutyl-isonitrile (MIBI), fluorine-18 2-fluoro-2-deoxyglucose (FDG) and iodine-125 15-(p-iodo-phenyl)-3(R,S)-methylpentadecanoic acid (BMIPP) mixture, in a recently developed transgenic (TR) mouse model which mimics stunned myocardium. Twenty-seven mice - 14 TR and 13 age-matched wild type controls (C) - were divided into four groups: TR-fed, TR-fasted, C-fed and C-fasted. Animals were sacrificed 2 h after injection, tissue samples counted and percent-injected dose/gram tissue (% id/g) calculated for each radioisotope. Tissues were also Folch extracted and {sup 125}I incorporation into the various lipid pools (TG, triglycerides; DG, diglycerides; FFA, free fatty acids; PL, phospholipids) was determined by thin-layer chromatography (TLC). The pooled data for each of the four groups (TR-fed vs C-fed and TR-fed vs C-fasted) showed no differences in myocardial blood flow (% MIBI id/g), glucose uptake (% FDG id/g) or fatty acid uptake (% BMIPP id/g). Only minor differences were observed in the incorporation of {sup 125}I-BMIPP into the myocardial TG, DG, FFA and PL lipid pools. However, significantly decreased myocardial FDG uptake was observed in a subset of fasted mice - four out of ten TR-fasted mice (3.4% vs 20.5% id/g) and three out of nine C-fasted mice (5.5% vs 30.6% id/g). The transgenic mouse model of stunned myocardium shows normal myocardial perfusion and overall intact myocardial glucose and myocardial fatty acid uptake as determined with clinically applicable radiolabelled analogues. These data are in line with the hypothesis that the contractile inefficiency in stunned myocardium is not linked to metabolic alterations but is associated with an insufficient chemical to mechanical energy coupling. (orig.)

  15. Calculation of excitation functions of proton, alpha and deuteron induced reactions for production of medical radioisotopes {sup 122–125}I

    Energy Technology Data Exchange (ETDEWEB)

    Artun, Ozan, E-mail: ozanartun@yahoo.com; Aytekin, Hüseyin, E-mail: huseyinaytekin@gmail.com

    2015-02-15

    In this work, the excitation functions for production of medical radioisotopes {sup 122–125}I with proton, alpha, and deuteron induced reactions were calculated by two different level density models. For the nuclear model calculations, the Talys 1.6 code were used, which is the latest version of Talys code series. Calculations of excitation functions for production of the {sup 122–125}I isotopes were carried out by using the generalized superfluid model (GSM) and Fermi-gas model (FGM). The results have shown that generalized superfluid model is more successful than Fermi-gas model in explaining the experimental results.

  16. Autoradiographic study of dopamine transporter in rat Model of Parkinson' s disease with 125I-β-CIT

    Institute of Scientific and Technical Information of China (English)

    Liu Zhenguo; Chen Shengdi; Shum Wenshan

    2000-01-01

    Objective To evaluate the value of iaaging for dopamine transpter(DAT) wi th 125I- β-CIT. Methods The partial and complete lesioned rat models of hemiparkinsonism were rendered with 6- hydroxy-dopamine (6-OHDA). Each rat was injected intravenously with 1251-β-CIT containing 40 μ Ci. Coronal t issue sections were imaged by autoradiography. The levets of dopamine (DA)and its metabolites were measured by high performance 1iquid choromatography and electro-chemical detection (HPLC-ECD). The t yros i nc hydroxylase(Tll)-positive cells and fibres in substantia nigra and striatum of the rats were observed by immunohistochemieal staining. Results The radioactivities in the lesioned striatum of both partial and complete lesioned hemiparkinsonian rats were 2.67±0.25 and O. 98±0.29 respectively , and were singificantly decreased by.18% and 72% respectively, as compared with those of unlesioned side. The levels of DA in the lesioned striatum of partial and complete lesioned models were decreased by 39% and 98% respectively. The loss of TH-positive eells and fibres in the substantia nigra and striatum was found in the lesioned striatum of both partial and complete-lesioned models. Conclusion The imaging study of DAT may be helpful for the early diagnosis of Parkinson's disease and for the monitor of the progression of this discaose;.

  17. Erythropoietin messenger RNA levels in developing mice and transfer of /sup 125/I-erythropoietin by the placenta

    Energy Technology Data Exchange (ETDEWEB)

    Koury, M.J.; Bondurant, M.C.; Graber, S.E.; Sawyer, S.T.

    1988-07-01

    Erythropoietin (EP) mRNA was measured in normal and anemic mice during fetal and postnatal development. Normal fetal livers at 14 d of gestation contained a low level of EP mRNA. By day 19 of gestation, no EP mRNA was detected in normal or anemic fetal livers or normal fetal kidneys, but anemic fetal kidneys had low levels of EP mRNA. Newborn through adult stage mice responded to anemia by accumulating renal and hepatic EP mRNA. However, total liver EP mRNA was considerably less than that of the kidneys. Juvenile animals, 1-4 wk old, were hyperresponsive to anemia in that they produced more EP mRNA than adults. Moreover, nonanemic juveniles had readily measured renal EP mRNA, whereas the adult level was at the lower limit of detection. Because of the very low level of fetal EP mRNA, placental transfer of EP was evaluated. When administered to the pregnant mouse, /sup 125/I-EP was transferred in significant amounts to the fetuses. These results indicate that in mice the kidney is the main organ of EP production at all stages of postnatal development and that adult kidney may also play some role in providing EP for fetal erythropoiesis via placental transfer of maternal hormone.

  18. 125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis

    International Nuclear Information System (INIS)

    We studied the incidence and levels of circulating immune complexes by the 125I-Clq-binding assay in patients with cystic fibrosis in relation to clinical respiratory status and specific IgG and IgE antibodies to Pseudomonas aeruginosa. Staphylococcus aureus, Aspergillus fumigatus, and Candida albicans. Overall prevalence of CIC was 43%, but 86% of serially studied patients had evidence of CIC at some time. Patients with acute respiratory exacerbations and deteriorating pulmonary function had a higher incidence of CIC (76%) as compared to stable patients (36%, P less than 0.01), as well as significantly higher levels of CIC. Acute exacerbations were also associated with significant increases in IgG antibody to Pseudomonas (P less than 0.005) but not in other antibodies. CIC did not correlate with Pseudomonas-specific IgG nor with any other specific antibody studied. A variety of age-related differences in specific antibody levels were seen. The episodic appearance of CIC is common in CF and is usually associated with exacerbation of lung disease

  19. Feasibility and impact of the measurement of extracellular fluid volume simultaneous with GFR by 125I-iothalamate.

    Science.gov (United States)

    Visser, Folkert W; Muntinga, Jaap H J; Dierckx, Rudi A; Navis, Gerjan

    2008-09-01

    The feasibility, validity, and possible applications of the assessment of extracellular fluid volume (ECFV) simultaneous with glomerular filtration rate (GFR) were assessed in a series of validation studies using the constant infusion method of (125)I-iothalamate (IOT). In 48 subjects with a broad range of GFR, distribution volume (V(d)) of IOT corresponded well with V(d) bromide (16.71 +/- 3.0 and 16.73 +/- 3.2 l, respectively, not significant), with a strong correlation (r = 0.933, P IOT during strictly standardized (50 mmol Na(+)/d) sodium intake. An increase in dietary sodium intake (200 mmol Na(+)/d) induced a corresponding rise in V(d) IOT of 1.11 +/- 1.5 l (P IOT. After appropriate validation, also other GFR tracers could be used for such a simultaneous estimation, providing a valuable resource of data on ECFV in renal studies and, moreover, allowing GFR to be indexed to the body fluid compartment it clears: the ECFV.

  20. Relato de caso: implante transparietohepático de cateter de longa permanência para diálise Case report: transhepatic insertion of long-term dialysis catheter

    Directory of Open Access Journals (Sweden)

    Felipe Nasser

    2007-12-01

    Full Text Available O implante transhepático de cateteres de diálise de longa permanência é um procedimento de exceção, utilizado para obter um acesso em pacientes com oclusão de veias centrais de membros superiores e inferiores. O caso descrito relata um paciente jovem, com história de 15 anos de diálise, que foi submetido no passado a um transplante renal sem sucesso. Esse paciente encontrava-se em urgência dialítica e oclusão comprovada de veias centrais de membros superiores e de veias ilíacas. Foi realizado o implante do cateter de longa permanência pelo acesso transparietohepático sob anestesia geral. A ponta do cateter foi posicionada ao nível do átrio direito. A diálise foi realizada satisfatoriamente no mesmo dia.Transhepatic insertion of long-term dialysis catheter is an exception procedure used to obtain access in patients with central vein occlusion of lower and upper limbs. We report on a case of a young patient with history of dialysis for 15 years, who was submitted to an unsuccessful renal transplantation. This patient was in dialytic emergency and had confirmed occlusion of upper limb central veins and iliac veins. Transhepatic insertion of a long-term catheter was performed under general anesthesia. The catheter tip was placed at the level of the right atrium. Dialysis was satisfactorily performed on the same day.

  1. Restoration of ankle movements with the ActiGait implantable drop foot stimulator: a safe and reliable treatment option for permanent central leg palsy.

    Science.gov (United States)

    Martin, Klaus Daniel; Polanski, Witold Henryk; Schulz, Anne-Kathrin; Jöbges, Michael; Hoff, Hansjoerg; Schackert, Gabriele; Pinzer, Thomas; Sobottka, Stephan B

    2016-01-01

    OBJECT The ActiGait drop foot stimulator is a promising technique for restoration of lost ankle function by an implantable hybrid stimulation system. It allows ankle dorsiflexion by active peroneal nerve stimulation during the swing phase of gait. In this paper the authors report the outcome of the first prospective study on a large number of patients with stroke-related drop foot. METHODS Twenty-seven patients who experienced a stroke and with persisting spastic leg paresis received an implantable ActiGait drop foot stimulator for restoration of ankle movement after successful surface test stimulation. After 3 to 5 weeks, the stimulator was activated, and gait speed, gait endurance, and activation time of the system were evaluated and compared with preoperative gait tests. In addition, patient satisfaction was assessed using a questionnaire. RESULTS Postoperative gait speed significantly improved from 33.9 seconds per 20 meters to 17.9 seconds per 20 meters (p mobility, social participation, and quality of life was confirmed by 89% to 96% of patients. CONCLUSIONS The ActiGait implantable drop foot stimulator improves gait speed, endurance, and quality of life in patients with stroke-related drop foot. Regarding gait speed, the ActiGait system appears to be advantageous compared with foot orthosis or surface stimulation devices. Randomized trials with more patients and longer observation periods are needed to prove the long-term benefit of this device. PMID:26207599

  2. A facile and improved synthesis of 17α-{2-(E)-[125I]-iodovinyl}-19-nortestosterone, a no-carrier-added ligand for progesterone receptor analyses

    International Nuclear Information System (INIS)

    We have synthesized the no-carrier-added progesterone receptor ligand 17α-{2-(E)-[125I]-iodovinyl}-19-nortestosterone (E-125IVNNT) by a simple and high yielding method, and determined its uptake and specific progesterone receptor binding in vitro using T47D human breast carcinoma cells. (Author)

  3. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide

    NARCIS (Netherlands)

    L.J. Hofland (Leo); P.M. van Koetsveld (Peter); M. Waaijers (Marlijn); J. Zuyderwijk; W.A.P. Breeman (Wouter); S.W.J. Lamberts (Steven)

    1995-01-01

    textabstractRecently, we developed a technique that allows the in vivo visualization in man of somatostatin receptor-positive neuroendocrine tumors after i.v. injection of [125I-Tyr3]octreotide or [111In-DTPA-D-Phe1]octreotide. Radiotherapy of such tumors using somatost

  4. Localization of dopamine receptors in the tree shrew brain using [3H]-SCH23390 and [125I]-epidepride.

    Science.gov (United States)

    Mijnster, M J; Isovich, E; Flügge, G; Fuchs, E

    1999-09-11

    The tree shrew is a mammalian species, which is phylogenetically related to insectivores and primates. The aim of the present study was to investigate the distribution of dopamine receptor D1- and D2-like binding sites in the brain of this non-rodent, non-primate mammal. Using in vitro autoradiography and employing the radioligands [3H]-SCH23390 and [125I]-epidepride, dopamine receptors were mapped and quantified. Significant findings with regard to the D1-like binding pattern include the presence of a "patchy" binding in the striatum. In the cortex, D1-like binding sites were observed in both the superficial and the deep layers. In the hippocampal formation, D1-like binding sites were seen primarily in the CAI region and not in the dentate gyrus. These characteristics of the D1 pattern in the tree shrew brain are shared by cat and monkey and human brain, but not by rodent brain. Significant findings with regard to the D2-like binding pattern include the presence of D2-like binding in the claustrum. In addition, the striatum demonstrated "patchy" D2-like binding. These characteristics of the D2 pattern in the tree shrew brain are shared by cat and monkey and human brain, but not by rodent brain. On the other hand, the significant densities of D2-like binding sites in the glomerular layer of the tree shrew olfactory bulb is a finding that discriminates tree shrews from higher evolutionary species who lack such binding. Overall, the evidence coincides with the view that tree shrews are phylogenetically related to primates. PMID:10546993

  5. Current status of the gyro centrifugal blood pump--development of the permanently implantable centrifugal blood pump as a biventricular assist device (NEDO project).

    Science.gov (United States)

    Nosé, Yukihiko; Furukawa, Kojiro

    2004-10-01

    The New Energy and Industrial Technology Development Organization (NEDO) project was started in 1995. The goal is the development of a multipurpose, totally implantable biventricular assist device (BVAD) that can be used for any patient who suffers from severe heart failure. Our C1E3 (two-week pump) centrifugal pump, called the Gyro pump, has three design characteristics: a magnetic coupling and double pivot bearing system, an eccentric inlet port, and secondary vanes on the bottom of the impeller. The pump was miniaturized. The C1E3 evolved into the NEDO PI-601, a totally implantable centrifugal pump for BVAD. The current NEDO PI-710 pump (five-year pump) system includes a centrifugal pump with pivot bearings, a hydraulically-levitated impeller, an rpm-controlled miniaturized actuator (all-in-one actuator plus controller), an emergency clamp on the left outflow, and a Frank-Starling-type flow control. The final mass production model is now finalized, and the final animal study and two-year endurance studies are ongoing.

  6. Depression and its risk factors after implantation of permanent pacemaker%永久性人工心脏起搏器植入术后抑郁及危险因素分析

    Institute of Scientific and Technical Information of China (English)

    王丽娜; 马娜

    2015-01-01

    Objective To analyze the incidence and risk factors of depression after implantation of artificial permanent pacemaker.Methods The patients (n=40) with implantation of artificial permanent pacemaker were chosen from Sept. 2013 to June 2014. All patients were given 24-item questionnaire of Hamilton Depression Scale (HAMD) before and after implantation, and then divided into depression group (n=15) and non-depression group (n=25) after the implantation. The data of 2 groups were compared including age, sex, marriage, income, degree of education, hypertension, diabetes, arrhythmia, negative life events, 2 or more complications, smoking and implantation time. The risk factors of depression after implantation were analyzed.Results Of 40 patients, 15 had depression and incidence was 37.5%. The comparison in income, negative life events, arrhythmia and 2 or more complications showed statistical difference (allP<0.05) between 2 groups, and then these 4 possible risk factors were given Logistic regression analysis. The results showed that income (OR=62.58, 95%CI: 1.16~3.54), negative life events (OR=218.19, 95%CI: 2.13~4.25) and arrhythmia (OR=62.62, 95%CI: 1.13~2.78) were risk factors of depression after implantation.Conclusion The incidence of depression is 37.5% after implantation of artificial permanent pacemaker, and risk factors are income, negative life events and arrhythmia.%目的:永久性人工心脏起搏器术后抑郁的发生率及危险因素分析。方法入选2013年9月~2014年6月于甘肃省第二人民医院心内科行永久性人工心脏起搏器植入术的患者40例,所有患者术前及术后行汉密尔顿(HAMD)24项抑郁量表问卷调查。术后根据量表评估结果将患者分为抑郁组(n=15)和非抑郁组(n=25)。比较两组患者在年龄、性别、婚姻、经济收入、文化程度、高血压、糖尿病、心律失常、负性生活事件、合并两种或以上疾病、吸烟、植入时间方面的资料

  7. Synthesis and biological evaluation of two new radiolabelled estrogens: [{sup 125}I](E)-3-methoxy-17{alpha}-iodovinylestra-1,3,5(10),6-tetraen-17{beta}-o= l and [{sup 125}I](Z)-3-methoxy-17{alpha}-iodovinylestra-1,3,5(10),6-tetraen-17{beta}-o= l

    Energy Technology Data Exchange (ETDEWEB)

    Melo e Silva, M.C.M. Cristina; Patricio, Luciana E-mail: lucianap@itn1.itn.pt; Gano, Lurdes; Sa e Melo, M. Luisa; Inohae, Eiko; Mataka, Shuntaro; Thiemann, Thies

    2001-02-01

    The synthesis of two novel radiolabelled estrogen derivatives, [{sup 125}I](E)-3-methoxy-17{alpha}-iodovinylestra-1,3,5(10),6-tetraen-17{beta}-o= l (E[{sup 125}I]IVDE) and [{sup 125}I](Z)-3-methoxy-17{alpha}-iodovinylestra-1,3,5(10),6-tetraen-17{beta}-o= l (Z[{sup 125}I]IVDE), was carried out aiming to study the influence of the introduction of a C6-C7 double bond on the biological properties of the estradiol molecule. 3-Methoxyestra-1,3,5(10),6-tetraen-17-one was synthesised starting from a suitably protected estrone and subsequently converted into the 17{alpha}-ethynyl derivative. The radioiodinated derivatives were stereoselectively formed by radioiododestannylation of the corresponding tributylstannyl precursors. The biodistribution of the novel [{sup 125}I]iodovinylestradiol derivatives was evaluated in immature female mice. Biological data indicated that the Z-isomer, owing to its higher in vivo uptake by the target tissue, has the preferable configuration for further development of similar compounds for estrogen receptor detection.

  8. Postoperative [{sup 125}I] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland. With associated risk factors

    Energy Technology Data Exchange (ETDEWEB)

    Mao, Ming-hui; Zhang, Jian-Guo; Zhang, Jie; Zheng, Lei; Liu, Shu-ming; Huang, Ming-wei; Shi, Yan [Peking Univ. School and Hospital of Stomatology, Beijing (China). Dept. of Oral and Maxillofacial Surgery

    2014-11-15

    This retrospective study was undertaken to analyze data from patients receiving iodine-125 ([{sup 125}I]) seed brachytherapy postoperatively for the treatment of acinic cell carcinoma (ACC) of the parotid gland along with the following risk factors: residual tumor, recurrent tumor, facial nerve invasion, positive resection margins, advanced tumor stage, or tumor spillage. Twenty-nine patients with ACC (17 females, 12 males; age range, 13-73 years; median age, 37.3 years) were included. Median follow-up was 58.2 months (range, 14-122 months). Patients received [{sup 125}I] seed brachytherapy (median actuarial D90, 177 Gy) 3-41 days (median, 14 days) following surgery. Radioactivity was 18.5-33.3 MBq per seed, and the prescription dose was 80-120 Gy. The 3-, 5-, and 10-year rates of local control were 93.1, 88.7, and 88.7 %, respectively; overall survival was 96.6, 92, and 92 %; disease-free survival was 93.1, 88.4, and 88.4 %; and freedom from distant metastasis was 96.6, 91.2, and 91.2 %. Lymph node metastases were absent in all patients, although two patients died with distant metastases. Facial nerve recovery was quick, and no severe radiotherapy-related complications were noted. Recurrence history, local recurrence, and distant metastasis significantly affected overall survival. Postoperative [{sup 125}I] seed brachytherapy is effective in treating ACC and has minor complications. Patients with a history of recurrence showed poor prognosis and were more likely to experience disease recurrence and develop metastases. (orig.) [German] Diese retrospektive Studie wurde durchgefuehrt, um die Daten von Patienten zu analysieren, die postoperativ eine Seed-Brachytherapie mit Iod-125 ([{sup 125}I]) zur Behandlung von Azinuszellkarzinomen der Ohrspeicheldruese mit begleitenden Risikofaktoren, wie Residualtumor, Rezidivtumor, Invasion in den N. facialis, positive (= nicht tumorfreie) Resektionsraender, fortgeschrittenes Tumorstadium oder lokale Verbreitung von Tumorzellen

  9. Clinical Observation on the Effect of Xiaoyan Decoction plus 125I and Thermotherapy on the Lung Cancer of late stage%消岩汤联合125I粒子及热疗治疗中晚期肺癌疗效观察

    Institute of Scientific and Technical Information of China (English)

    贾英杰; 张蕴超; 李小江; 方文岩; 陈军; 赵成

    2011-01-01

    Objective To observe the effect of Xiaoyan Decoction (Herbal decoction for cancer) plus 125I particle implantation and high frequency thermotherapy on the lung cancer of late stage. Methods Thirty-nine cases of the late stage lung cancer were divided into 3 groups: Xiaoyan Decoction group, Xiaoyan Decoction plus 125I particle implantation group (oral taking Xiaoyan Decoction for 3 days and then 125I particle implantation), and Xiaoyan Decoction plus 125I particle implantation and high frequency thermotherapy group (oral taking Xiaoyan Decoction for 3 days and then 125I particle implantation, 7 days later high frequency thermotherapy in vitro). After treatment, all patients were re-examined by chest CT to compare the tumor size, and Karnofsky scores, changes of body weight, immune indices (NK cells, T cell subpopulation), and tumor markers (carcinoembryonic antigen, CEA), (cellular cutin fragment-19) were observed. Results In the aspect of tumor size, the comparison with before treatment showed that there was no statistical difference after treatment in all 3 groups (P>0.05). The Xiaoyan Decoction plus 125I particle implantation and high frequency thermotherapy group was effective in decreasing and stabilizing the tumor size.In the aspect of Karnofsky scores, changes of body weight, and immune indices, the comparison with before treatment showed that there was no statistical difference after treatment in all 3 groups (P>0. 05). The Xiaoyan Decoction group and Xiaoyan Decoction plus 125I particle implantation and high frequency thermotherapy group were showing tendency in improving the organism state of patients. Xiaoyan Decoction group presented effect in improving the tiredness, insomnia, and loss of appetite of the patients(P<0. 05). Conclusion Xiaoyan Decoction, 125I particle implantation, and high frequency thermotherapy in vitro used in combination is effective on the lung cancer of late stage and these three method have synergy effect.%目的

  10. Rapid method for the preparation of 125I-labelled human growth hormone for receptor studies, using reverse-phase high performance liquid chromatography

    International Nuclear Information System (INIS)

    Human growth hormone was labelled with 125 Iodine by the stoichiometric modification of the chloramine-T method to a specific activity of 50-80 microCi/microgram, and the iodinated mixture was purified by reverse-phase high performance liquid chromatography using a C18 column (SynChropak RP-P) and a linear gradient. Compared with the usual Sephadex G-100 chromatography, HPLC gave a much better separation, with a higher yield and a considerably reduced analysis time (30 min vs 5 h). The [125I]-labelled preparation had normal binding to IM-9 lymphocyte receptors. The maximum bindability of the HPLC-purified preparation approximated 90%, which is the best value so far reported for human growth hormone. It is concluded that HPLC is a fast, convenient and reproducible method for obtaining an improved [125I]-labelled human growth hormone for receptor studies

  11. (99m) Tc-labelled human serum albumin cannot replace (125) I-labelled human serum albumin to determine plasma volume in patients with liver disease

    DEFF Research Database (Denmark)

    Henriksen, Ulrik Lütken; Henriksen, Jens H; Bendtsen, Flemming;

    2013-01-01

    −1) in liver patients as compared to 260 ml (3·5 ml kg−1) in patients without liver disease (Pdetermination was 1·75% (coefficient of variation) with 99mTc-HSA and 1·71% with 125I-HSA (ns), and similar values were found in patients with and without liver disease......Summary Background and aims Determination of plasma volume (PV) is important in several clinical situations. Thus, patients with liver disease often have augmented PV as part of their sodium–water retention. This study was undertaken to compare PV determination by two indicators: technetium...... In all patients, a close correlation was present between PV determined by the two indicators (r = 0·89, Pdetermined with 99mTc-HSA exceeded PV determined with 125I-HSA by 367 ml (5·2 ml kg...

  12. Binding of (/sup 125/I)-N-(p-aminophenethyl)spiroperidol to the D-2 dopamine receptor in the neurointermediate lobe of the rat pituitary gland: a thermodynamic study

    Energy Technology Data Exchange (ETDEWEB)

    Agui, T.; Amlaiky, N.; Caron, M.G.; Kebabian, J.W.

    1988-02-01

    The novel iodinated ligand (/sup 125/I)-N-(p-aminophenethyl)spiroperidol ((/sup 125/I)NAPS) was used to identify the D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland. The binding of (/sup 125/I)NAPS was of high affinity and saturable, given that the dissociation constant and the maximal binding were 34.7 +/- 4.8 pM and 21.1 +/- 2.5 fmol/mg of protein, respectively. The ability of dopaminergic agonists and antagonists to compete with (/sup 125/I)NAPS varied markedly with incubation temperature. The marked decrease of the molar potency associated with increasing incubation temperature in the competitive displacement curve suggested that the binding of five agonists, dopamine, (-)-apomorphine, (-)-n-propylnorapomorphine, N-0434, and LY-171555, to the D-2 dopamine receptor was enthalpy-driven, with a negative change in entropy. In contrast, the binding of three antagonists, fluphenazine, (+)-butaclamol, and domperidone, was entropy-driven, with positive change in entropy, suggesting less temperature-sensitive change in the molar potency. Several molecules gave unanticipated results; the molar potency of two dopamine agonists, bromocriptine and lisuride, was much less temperature-sensitive than the other agonists used in this study. The thermodynamic parameters for the atypical agonists indicated entropy-driven binding. Conversely, the molar potency of (+)-apomorphine, a dopamine receptor antagonist, was markedly affected by incubation temperature, indicating enthalpy-driven binding. Another antagonist, YM-09151-2, was affected by the inclusion of sodium chloride in the assay system: in the absence of sodium chloride, the drug was relatively weak and displayed enthalpy-driven binding; in the presence of sodium chloride, its molar potency was increased and its binding manner turned into entropy-driven.

  13. Result of oral intake of glucose by healthy subjects and patients with essential hypertension on the binding and degradation of 125I-insulin by erythrocyte receptors

    International Nuclear Information System (INIS)

    The work presents the results of researches of binding and degradation of 125I-insulin by erythrocyte receptors in the patients with essential hypertension and healthy patients after glucose intake. In order to obtain full representation of the pattern of changes the serum IRI and glucose concentrations were assayed. Binding and degradation of 125I-insulin by erythrocyte receptors were determined with the method described by Gambhir (1977), modified by the authors. The modification consisted in usage of constant concentrations of iodized insulin (0.9 pg/0.1 ml) and bovine insulin (2.4 I.U./0.1 ml). Before administration of glucose and in 30, 60 and 120 minutes after, venous blood was collected from ulnar vein. All examined persons were in sitting position during the trial of glucose intake. Obtained results show, that blood insulin level in the patients with essential hypertension is statistically significantly higher than in healthy persons of similar anthropometric characteristics. Binding of 125-I-insulin to erythrocyte receptors in fasting state is statistically significantly lower. Degradation after glucose intake in the patients shows decreasing tendency, while in healthy persons-growing tendency. (author). 19 refs, 4 figs, 3 tabs

  14. The standardization methods of radioactive sources (125I, 131I, 99mTc, and 18F) for calibrating nuclear medicine equipment in Indonesia

    Science.gov (United States)

    Wurdiyanto, G.; Candra, H.

    2016-03-01

    The standardization of radioactive sources (125I, 131I, 99mTc and 18F) to calibrate the nuclear medicine equipment had been carried out in PTKMR-BATAN. This is necessary because the radioactive sources used in the field of nuclear medicine has a very short half-life in other that to obtain a quality measurement results require special treatment. Besides that, the use of nuclear medicine techniques in Indonesia develop rapidly. All the radioactive sources were prepared by gravimetric methods. Standardization of 125I has been carried out by photon- photon coincidence methods, while the others have been carried out by gamma spectrometry methods. The standar sources are used to calibrate a Capintec CRC-7BT radionuclide calibrator. The results shows that calibration factor for Capintec CRC-7BT dose calibrator is 1,03; 1,02; 1,06; and 1,04 for 125I, 131I, 99mTc and 18F respectively, by about 5 to 6% of the expanded uncertainties.

  15. Use of DCE-MRI for evaluating the efficacy of 125I seed interstitial brachytherapy for pancreatic carcinoma%动态对比增强磁共振成像在125I粒子治疗胰腺癌疗效评估中的实验研究

    Institute of Scientific and Technical Information of China (English)

    宋琦; 刘玉; 胡曙东; 黄蔚; 王忠敏; 陈克敏; 严福华; 田建明

    2012-01-01

    8-10 mm. A total of 16 nude mice were studied,in which 8 nude mice were implanted interstitially with 125I seeds and 8 were implanted with blank seeds. Conventional MRI scans and DCE-MRI were performed before and 2 weeks,2 months after seeds implantation. Tumor samples were studied by histopathological examination. Results Obvious tumor necrosis could be seen in 125I seeds implantation group,while no obvious necrosis was seen in control group. Heart,liver,lung,kidney and spleen of nude mice showed no significant radiological inflammation. Conventional MRI imaging had limited value for evaluating the efficacy of 125I seeds brachytherapy for pancreatic cancer. The Ktrans value of the boundary zone between tumor parenchyma and necrosis area was the highest,followed by Ktrans values of the entire tumor tissue,the tumor parenchyma,and finally the tumor necrosis. The Ktrans values of entire tumor 2 weeks and 2 months after 125I seeds implantation were lower than that before implantation. The Ktrans of entire tumor had some negative correlation with tumor necrosis (r =-0.518,P - 0.01),and tumor necrosis had some positive correlation with tumor volume (r = 0.641,P = 0.001). Conclusions 125I interstitial brachytherapy is effective for treating human pancreatic cancer xenografts in nude mice. 125I seeds implantation is safe for nearby organs. Conventional MRI imaging has limited value for evaluating the efficacy of 125I seeds brachytherapy for human pancreatic cancer xenograft,while DCE-MR1 imaging could quantitatively analyze the vascular perfusion changes of tumor after 125I seeds brachytherapy and had substantial value for the evaluation of its efficacy.

  16. Utilização da veia ilíaca externa recanalizada para implante de cateter de longa permanência para hemodiálise Using recanalized external iliac vein for tunneled hemodialysis catheter insertion

    Directory of Open Access Journals (Sweden)

    Ricardo Wagner da Costa Moreira

    2008-06-01

    Full Text Available O uso de cateteres venosos cervicais para hemodiálise leva freqüentemente à oclusão dessas veias. Como alternativa, os acessos venosos femorais são válidos, porém o seu uso também está associado à oclusão dessas veias e a um maior índice de infecção. Vias alternativas são cada vez mais utilizadas na impossibilidade dos acessos previamente mencionados. Descrevemos neste relato de caso uma alternativa para o implante de cateter de longa permanência para hemodiálise usando a veia ilíaca externa recanalizada. Comentamos os detalhes da técnica utilizada, suas vantagens e desvantagens.The frequent insertion of cervical venous catheters for hemodialysis is closely related to venous stenosis or occlusion. As an alternative, femoral catheter insertions are helpful but are also associated with femoral vein occlusion and an even higher infection rate. Alternative venous accesses have been increasingly used when the aforementioned accesses are not feasible. We report a case in which a recanalized external iliac vein was used for hemodialysis tunneled catheter insertion. The technique approach is discussed, focusing on its advantages and disadvantages.

  17. 125I-Labelled 2-Iodoestrone-3-sulfate: synthesis, characterization and OATP mediated transport studies in hormone dependent and independent breast cancer cells

    International Nuclear Information System (INIS)

    Introduction: Organic Anion Transporting Polypeptides (OATP) are a family of membrane associated transporters that facilitate estrone-3-sulphate (E3S) uptake by hormone dependent, post-menopausal breast cancers. We have established E3S as a potential ligand for targeting hormone dependent breast cancer cells, and in this study sought to prepare and investigate radioiodinated E3S as a tool to study the OATP system. Methods: 2- and 4-Iodoestrone-3-sulfates were prepared from estrone via aromatic iodination followed by a rapid and high yielding sulfation procedure. The resulting isomers were separated by preparative HPLC and verified by 1H NMR and analytical HPLC. Transport studies of 2- and 4-[125I]-E3S were conducted in hormone dependent (i.e. MCF-7) and hormone independent (i.e. MDA-MB-231) breast cancer cells in the presence or absence of the specific transport inhibitor, bromosulfophthalein (BSP). Cellular localization of OATP1A2, OATP2B1, OATP3A1 and OATP4A1 were determined by immunofluorescence analysis using anti-Na+/K+ ATPase-α (1:100 dilution) and DAPI as plasma membrane and nuclear markers, respectively. Results: Significantly (p < 0.01) higher total accumulation of 2-[125I]-E3S was observed in hormone dependent MCF-7 as compared to hormone independent MDA-MB-231 breast cancer cells. In contrast 4-[125I]-E3S did not show cellular accumulation in either case. The efficiency of 2-[125I]-E3S transport (expressed as a ratio of Vmax/Km) was 2.4 times greater in the MCF-7 as compared to the MDA-MB-231 breast cancer cells. OATP1A2, OATP3A1 and OATP4A1 expression was localized in plasma membranes of MCF-7 and MDA-MB-231 cells confirming the functional role of these transporters in radioiodinated E3S cellular uptake. Conclusion: An efficient method for the preparation of 2- and 4-[125I]-E3S was developed and where the former demonstrated potential as an in vitro probe for the OATP system. The new E3S probe can be used to study the OATP system and as a platform to

  18. Experimental studies for immunoscintigraphy of adenocarcinoma of the prostate with [sup 125]I-labeled monoclonal antibody to [gamma]-seminoprotein

    Energy Technology Data Exchange (ETDEWEB)

    Fujino, Awato; Suyama, Kazuho; Shidara, Toshiya; Ao, Teruaki; Ishibashi, Akira; Koshiba, Ken (Kitasato Univ., Sagamihara, Kanagawa (Japan). School of Medicine)

    1994-02-01

    We established LNCaP tumor in male nude mice after inoculation of LNCaP cells. The tumor produces the organ-specific glycoproteins in the human prostate, [gamma]-seminoprotein ([gamma]-Sm). The LNCaP tumor is composed of fluid and solid portions. The fluid portion contains much more [gamma]-Sm than the solid part. Monoclonal antibody against [gamma]-Sm (murine IgG[sub 1], K) was radiolabeled with iodine-125 by lactoperoxidase method followed by passage over column chromatography. Finally the conjugates with specific activity of 49.8-56.6 KBq/[mu]g were obtained. Biodistribution of [sup 125]I- labeled monoclonal antibody to [gamma]-Sm ([sup 125]I-[gamma]MAb) was evaluated by whole-body autoradiography (ARG) and by determination of label uptake (DLU) by the LNCaP tumor using the well type gamma counter. The ARG were obtained 1-9 days after intravenous administration of 32-38 [mu]g of [sup 125]I-[gamma]MAb to 12 nude mice bearing LNCaP tumor. The DLU were evaluated 3, 4 and 7 days after intravenous administration of 18-25 [mu]g of [sup 125]I- [gamma]MAb to 9 nude mice bearing LNCaP tumor. The DLU by organs (fluid portion, solid portion, liver, kidney, spleen, lung, etc.) were expressed as F-values (%) which were calculated by the following formula: F=radioactivity per gram of tissue (dpm/g) / injected dose per gram of animal (dpm/g)x100 and tissue-to-blood ratios (T/B). The specific uptake by the LNCaP tumors, especially in the fluid portion, was observed on ARG, with optimal images of the tumor evaluated 4-7 days after administration. The F-values and T/B of the LNCaP tumors were always higher than those of other organs. Especially T/B of fluid portion were of 6.7 and 6.3, evaluated 4 and 7 days after administration of [sup 125]I-[gamma]MAb respectively. These results suggest that the radiolabeled [gamma] MAb is applicable for immunoscintigraphy of adenocarcinoma of the prostate. (author).

  19. 心脏起搏器围术期预防性应用抗生素现状调查%Current status of perioperative antibiotic prophylaxis for permanent pacemaker implantation

    Institute of Scientific and Technical Information of China (English)

    陈柯萍; 樊晓寒; 华伟; 张澍

    2013-01-01

    Objective The aim of this survey was to describe the current status of perioperative antibiotic prophylaxis for permanent pacemaker (PPM) implantation in our clinical practice.Methods From January to March in 2012,questionnaires were sent by e-mails to directors of PPM implanting hospitals,for clinical details with respect to use of antibiotics around implantation.Data would be verified via telephone,e-mail or follow-up if no response or some doubts existed.Results Available questionnaires were returned from135 hospitals.Before or during procedure,112 of the 135 centers (82.9%) gave prophylactic antibiotics to patients,while 14 hospitals (10.4%) used postoperative antibiotics and 9 (6.7%) with no prescription of antibiotics.The first/second generation cephalosporins or penicillins were used in significant proportion (79.2%) of hospitals.Other options included the third generation cephalosporins (6.7%) and quinolones (2.2%).As for the onset time,in 74.1% of the hospitals antibiotics were administered 0.5 to 2.0 hours prior to implantation,with 5.2% 3 to 6 hours before procedure,3.7% at implantation,10.3% post operation.The duration also showed great variation in different hospitals.Single dose of antibiotics prescription before or during procedure was given in 10 centers (7.9%).The duration was over 72 hours in seventeen hospitals and ranged from 24 to 72 hours in the rest hospitals.Intra-pocket antibiotic infusion at implantation was used in forty-eight centers (35.6%),and most (81.3%) were gentamicin.Conclusion There are no guidelines on the antibiotics prophylaxis in PPM implantation,such as indication,choice,timing and duration,resulting in wide variation in practice.In majority of the hospitals prophylactic antibiotics were used prior to implantation and β-lactam antibiotic for a board antibacterial spectrum was selected which covering staphylococcus aureus.However,further studies are required to determine the duration of antibiotics

  20. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors

    International Nuclear Information System (INIS)

    Epidepride, (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxybenzamide, the iodine analogue of isoremoxipride (FLB 457), was found to be a very potent dopamine D2 receptor antagonist. Optimal in vitro binding required incubation at 25C for 4 h at pH 7.4 in a buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 1 nM MgCl2. Scatchard analysis of in vitro binding to striatal, medical frontal cortical, hippocampal and cerebellar membranes revealed a KD of 24 pM in all regions, with Bmax's of 36.7, 1.04, 0.85, and 0.37 pmol/g tissue, respectively. The Hill coefficients ranged from 0.91-1.00 in all four regions. The IC50's for inhibition of [125I]epidepride binding to striatal, medial frontal cortical, and hippocampal membranes for SCH 23390, SKF 83566, serotonin, ketanserin, mianserin, naloxone, QNB, prasozin, clonidine, alprenolol, and norepinephrine ranged from 1 μM to >10 μM. Partial displacement of [125I]epidepride by nanomolar concentrations of clonidine was noted in the frontal cortex and hippocampus, but not in the striatum. Scatchard analysis of epidepride binding to α2 noradrenergic receptors in the frontal cortex and hippocampus revealed an apparent KD of 9 nM. At an epidepride concentration equal to the KD for the D2 receptor, i.e., 25 pM, no striatal α2 binding was seen and only 7% of the specific epidepride binding in the cortex or hippocampus was due to binding at the α2 site. Correlation of inhibition of [3H]spiperone and [125I]epidepride binding to striatal membranes by a variety of D2 ligands revealed a correlation coefficient of 0.99, indicating that epidepride labels a D2 site

  1. Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain

    International Nuclear Information System (INIS)

    The distribution and pharmacology of the binding of 125I-epidepride, a substituted benzamide with high affinity and selectivity for dopamine (DA) D2 receptors in rat brain is described in human brain. Saturation analysis of the binding of 125I-epidepride to membranes derived from striatum and regions of cortex demonstrated similar Kd values (34 and 28-33 pM, respectively) but differing maximum density of binding site values (152 and 3-8 fmol/mg of protein, respectively). The pharmacological profile of binding in cortex was also similar to striatum (epidepride greater than spiperone greater than butaclamol = flupenthixol greater than clozapine) except that an additional low-affinity site, blocked by the alpha-2 adrenergic antagonist idazoxan, was present in cortex. Quantification by autoradiography also demonstrated the greatest binding in the basal ganglia, with the striatum exhibiting greater binding than the pallidal complex or midbrain regions. For the pallidum, binding in the external segment was higher than the internal segment. Within the midbrain the binding of 125I-epidepride correlated well with the known distribution of DA-containing cell bodies, with the substantia nigra (pars compacta and pars lateralis) and ventral tegmental area (A10) higher than area A8 and central gray. Binding in frontal and parietal cortex was highest in the internal layers (layers V and VI). Temporal cortex showed a 2-fold higher density of binding than other cortical regions and a trilaminar pattern; binding was greater in the external (layers I and II) and internal layers than in the middle layers (III and IV). This pattern changed in the parahippocampal complex. Within the lateral occipitotemporal cortex, binding was densest in layers I to III and very low in layers IV to VI, but binding was almost nonexistent in the adjacent entorhinal cortex

  2. Characterization and distribution of (125I)epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain

    Energy Technology Data Exchange (ETDEWEB)

    Joyce, J.N.; Janowsky, A.; Neve, K.A. (Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia (USA))

    1991-06-01

    The distribution and pharmacology of the binding of {sup 125}I-epidepride, a substituted benzamide with high affinity and selectivity for dopamine (DA) D2 receptors in rat brain is described in human brain. Saturation analysis of the binding of {sup 125}I-epidepride to membranes derived from striatum and regions of cortex demonstrated similar Kd values (34 and 28-33 pM, respectively) but differing maximum density of binding site values (152 and 3-8 fmol/mg of protein, respectively). The pharmacological profile of binding in cortex was also similar to striatum (epidepride greater than spiperone greater than butaclamol = flupenthixol greater than clozapine) except that an additional low-affinity site, blocked by the alpha-2 adrenergic antagonist idazoxan, was present in cortex. Quantification by autoradiography also demonstrated the greatest binding in the basal ganglia, with the striatum exhibiting greater binding than the pallidal complex or midbrain regions. For the pallidum, binding in the external segment was higher than the internal segment. Within the midbrain the binding of {sup 125}I-epidepride correlated well with the known distribution of DA-containing cell bodies, with the substantia nigra (pars compacta and pars lateralis) and ventral tegmental area (A10) higher than area A8 and central gray. Binding in frontal and parietal cortex was highest in the internal layers (layers V and VI). Temporal cortex showed a 2-fold higher density of binding than other cortical regions and a trilaminar pattern; binding was greater in the external (layers I and II) and internal layers than in the middle layers (III and IV). This pattern changed in the parahippocampal complex. Within the lateral occipitotemporal cortex, binding was densest in layers I to III and very low in layers IV to VI, but binding was almost nonexistent in the adjacent entorhinal cortex.

  3. Production of {sup 125}I from amorphous films of Si doped with {sup 124}Xe and evaluation of its potential use in brachytherapy

    Energy Technology Data Exchange (ETDEWEB)

    Leal, Alexandre S., E-mail: asleal@cdtn.br [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN/CNEN-MG), Belo Horizonte, MG (Brazil); Viana, Gustavo A., E-mail: gviana@eletronuclear.gov.br [Universidade Estadual de Campinas (UNICAMP), SP (Brazil). Instituto de Fisica Gleb Wataghin; Siqueira, Paulo T.D.; Saiki, Mitiko, E-mail: mitiko@ipen.br [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2015-07-01

    This work describes the simulation of a new material that can be used in the brachytherapy treatment. The material consists of xenon-incorporated amorphous silicon (Xe@a-Si). The irradiated {sup 124}Xe atoms of the samples are converted into {sup 125}Xe, according to the reaction: {sup 124}Xe (n,γ) {sup 125}Xe that, in turn, decays to the radioisotope {sup 125}I. A set of simulations performed using the MCNP5 code, shows that, in principle, the material proposed can be used in the seed of brachytherapy in the clinical treatment. (author)

  4. Synthesis and evaluation of [{sup 125}I]I-TSA as a brain nicotinic acetylcholine receptor {alpha}{sub 7} subtype imaging agent

    Energy Technology Data Exchange (ETDEWEB)

    Ogawa, Mikako [Laboratory of Genome Bio-Photonics, Photon Medical Research Center, Hamamatsu Medical University, Hamamatsu 431-3192 (Japan); Tatsumi, Ryo [Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Yokohama 227-0033 (Japan); Fujio, Masakazu [Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Yokohama 227-0033 (Japan); Katayama, Jiro [Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Yokohama 227-0033 (Japan); Magata, Yasuhiro [Laboratory of Genome Bio-Photonics, Photon Medical Research Center, Hamamatsu Medical University, Hamamatsu 431-3192 (Japan)]. E-mail: magata@hama-med.ac.jp

    2006-04-15

    Introduction: Some in vitro investigations have suggested that the nicotinic acetylcholine receptor (nAChR) {alpha}{sub 7} subtype is implicated in Alzheimer's disease, schizophrenia and others. Recently, we developed (R)-3'-(5-bromothiophen-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-[1',3'] oxazolidin]-2'-one (Br-TSA), which has a high affinity and selectivity for {alpha}{sub 7} nAChRs. Therefore we synthesized (R)-3'-(5-[{sup 125}I]iodothiophen-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'- [1',3']oxazolidin]-2'-one ([{sup 125}I]I-TSA) and evaluated its potential for the in vivo detection of {alpha}{sub 7} nAChR in brain. Methods: In vitro binding affinity of I-TSA was measured in rat brain homogenates. Radioiodination was accomplished by a Br-I exchange reaction. Biodistribution studies were undertaken in mice by tail vein injection of [{sup 125}I]I-TSA. In vivo receptor blocking studies were carried out by treating mice with methyllycaconitine (MLA; 5 nmol/5 {mu}l, i.c.v.) or nonradioactive I-TSA (50 {mu}mol/kg, i.v.). Results: I-TSA exhibited a high affinity and selectivity for the {alpha}{sub 7} nAChR (K {sub i} for {alpha}{sub 7} nAChR=0.54 nM). Initial uptake in the brain was high (4.42 %dose/g at 5 min), and the clearance of radioactivity was relatively slow in the hippocampus ({alpha}{sub 7} nAChR-rich region) and was rather rapid in the cerebellum ({alpha}{sub 7} nAChR poor region). The hippocampus to cerebellum uptake ratio was 0.9 at 5 min postinjection, but it was increased to 1.8 at 60 min postinjection. Although the effect was not statistically significant, administration of I-TSA and MLA decreased the accumulation of radioactivity in hippocampus. Conclusion: Despite its high affinity and selectivity, [{sup 125}I]I-TSA does not appear to be a suitable tracer for in vivo {alpha}{sub 7} nAChR receptor imaging studies due to its high nonspecific binding. Further structural optimization is needed.

  5. Early detection of degraded A14-125I-insulin in human fibroblasts by the use of high performance liquid chromatography

    International Nuclear Information System (INIS)

    We studied the metabolism of A14-125I-insulin in intact human fibroblasts using high performance liquid chromatography (HPLC) to detect and separate its early degradation products. The high resolving power of HPLC enabled us to separate what has been considered ''intact insulin'' by Sephadex G-50 chromatography or TCA precipitability into two additional peaks that had decreased biochemical properties with respect to immunoprecipitability and receptor binding but not decreased TCA precipitability. We conclude that human fibroblast is capable of metabolizing insulin within 2 min at 37 degrees C into intermediate molecules that can be detected by HPLC but not by TCA precipitability or molecular sieve chromatography

  6. Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate membranes for the cocaine analog [125I]RTI-55.

    Science.gov (United States)

    Rothman, R B; Cadet, J L; Akunne, H C; Silverthorn, M L; Baumann, M H; Carroll, F I; Rice, K C; de Costa, B R; Partilla, J S; Wang, J B

    1994-07-01

    The drug 3 beta-[4'-iodophenyl]tropan-2 beta-carboxylic acid methyl ester (RTI-55) is a cocaine congener with high affinity for the dopamine transporter (Kd < 1 nM). The present study characterized [125I]RTI-55 binding to membranes prepared from rat, monkey and human caudates and COS cells transiently expressing the cloned rat dopamine (DA) transporter. Using the method of binding surface analysis, two binding sites were resolved in rat caudate: a high-capacity binding site (site 1, Bmax = 11,900 fmol/mg of protein) and a low-capacity site (site 2, Bmax = 846 fmol/mg of protein). The Kd (or Ki) values of selected drugs at the two sites were as follows: (Ki for high-capacity site and Ki for low-capacity site, respectively): RTI-55 (0.76 and 0.21 nM), 1-[2-diphenyl-methoxy)ethyl]-4-(3-phenylpropyl)piperazine (0.79 and 358 nM), mazindol (37.6 and 631 nM), 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane (45.0 and 540 nM) and cocaine (341 and 129 nM). Nisoxetine, a selective noradrenergic uptake blocker, had low affinity for both sites. Serotonergic uptake blockers had a high degree of selectivity and high affinity for the low-capacity binding site (Ki of citalopram = 0.38 nM; Ki of paroxetine = 0.033 nM). The i.c.v. administration of 5,7-dihydroxytryptamine to rats pretreated with nomifensine (to protect dopaminergic and noradrenergic nerve terminals) selectively decreased the Bmax of site 2, strongly supporting the idea that site 2 is a binding site on the serotonin (5-HT) transporter. This serotonergic lesion also increased the affinity of [125I]RTI-55 for the DA transporter by 10-fold. The ligand selectivity of the caudate 5-HT transporter was different from the [I125]RTI-55 binding site on the 5-HT transporter present in membranes prepared from whole rat brain minus caudate. The [125I]RTI-55 binding to the DA transporter was further resolved into two components, termed sites 1a and 1b, by using human and monkey (Macaca mulatta) caudate membranes but not the

  7. In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [{sup 125}I]MRK-16 monoclonal antibody

    Energy Technology Data Exchange (ETDEWEB)

    Scott, Andrew M.; Rosa, Eddie; Mehta, Bippin M.; Divgi, Chaitanya R.; Finn, Ronald D.; Biedler, June L.; Tsuruo, Takashi; Kalaigian, Hovannes; Larson, Steven M

    1995-05-01

    Multidrug resistance (MDR) in tumors is associated with P-glycoprotein (Pgp) expression. In vivo quantitation of Pgp may allow MDR to be evaluated noninvasively prior to treatment planning. The purpose of this study was to radiolabel MRK-16, a monoclonal antibody that targets an external epitope of P-glycoprotein, and perform in vivo quantitation of P-glycoprotein in a MDR xenograft nude mouse model. MRK-16 was labeled with {sup 125}I by the iodogen method, with subsequent purification by size exclusion chromatography. Groups of 10 Balb/c mice were each xenografted with colchicine-resistant or -sensitive neuroblastoma cell lines, respectively. Whole body clearance and tumor uptake over time was quantitated by gamma camera imaging, and biodistribution studies were performed with [{sup 125}]MRK-16 and an isotype matched control antibody, A33. Quantitative autoradiography and immunohistochemistry analysis of tumors was also evaluated to confirm specific targeting of [{sup 125}I]MRK-16. Peak tumor uptake was at 2-3 days post-injection, and was significantly greater in resistance compared to sensitive tumors (mean % injected dose/g {+-} SD) (18.76 {+-} 2.94 vs 10.93 {+-} 0.96; p < 0.05). Quantitative autoradiography verified these findings (19.13 {+-} 0.622 vs 12.08 {+-} 0.38, p < 0.05). Specific binding of [{sup 125}I]MRK-16 was confirmed by comparison to [{sup 131}I]A33 in biodistribution studies, and localized to cellular components of tissue stroma by comparison of histologic and autoradiographic sections of sensitive and resistant tumors. Immunoblot analysis demonstrated a 4.5-fold difference in P-glycoprotein expression between sensitive and resistant cell lines without colchicine selective pressure. We conclude that in vivo quantitation of P-glycoprotein in MDR tumors can be performed with [{sup 125}I]MRK-16. These findings suggest a potential clinical application for radiolabeled MRK-16 in the in vivo evaluation of multidrug resistance in tumors.

  8. 永久性可植入式搏动流叶轮型人工心脏的探索与研究%A Permanent Implantable Pulsatile Impeller Heart with a Specially Devised Needle Bearing

    Institute of Scientific and Technical Information of China (English)

    钱坤喜; 曾培; 茹伟民; 袁海宇; 封志刚; 李岚

    2001-01-01

    我们研制的可植入式搏动流叶轮型人工心脏可辅助试验小牛 血液循环数个 月。试验终止大多由于机械轴承磨损,导致转子振动,直至血泵运行出现故障。若轴承不发 生故障,试验可一直进行下去。试验中动物状况良好,所有血液生化数据均处于正常范围。 为解决轴承磨损问题,我们研制了一种特殊的滚针轴承,其中滚针由超高分子量聚乙烯制成 ,磨损寿命在一年以上。这种新型的叶轮型人工心脏有望用于长期或永久性辅助循环。%The author's implantable pulsatile impeller pump can assist the circulation of the calves for several months. The termination of the experiments was related to wear of the mechanical bearing, which resulted in vibration of the rotor and pump failure. It seemedas if the experiments could have lasted inde finitelyif the bearing had not failed. To solve the problem of bearing wear, a specially devised rolling bearing was investigated and applied to the impellerp ump. Its service life is more than 10 years due to the wear-proof roller made of ultra-high-molecular weight polythene. This newly devised impeller heart promises to have long-term and permanent applications. Compared with the magnetic bearing, the rolling bearing has the advantages of simpler construction and control, no consumption of energy, and better reliability.

  9. 永久起搏器植入术后谵妄的危险因素研究%Incidence and risk factors of delirium in patients post permanent pacemaker implantation

    Institute of Scientific and Technical Information of China (English)

    朱孔博; 叶行舟; 陈龙; 智宏; 任利群; 马根山

    2016-01-01

    目的 探讨永久起搏器植入术后谵妄的危险因素.方法 入选2013年9月至2015年2月期间我院行永久起搏器植入术的患者,收集临床资料和实验室检查数据,术后当天及第1、2、3天用谵妄评定法进行谵妄评估.根据术后是否发生谵妄将患者分为术后谵妄组和对照组,通过单因素及多因素分析研究术后谵妄危险因素.结果 225例患者入选,术后谵妄组12例(5.3%),对照组213例(94.7%).与对照组比较,术后谵妄组年龄更高[(83±5)岁比(74±11)岁,P=0.002],术前血压显著异常者比例更高[58.3% (7/12)比4.7%(10/213),P<0.001],收缩压较高[(157±35)mmHg比(136±22) mmHg,1 mmHg=0.133 kPa,P=0.007],低钠血症发生率较高[25.0% (3/12)比5.2% (11/213),P=0.030],术前平均心率较慢[(47±18)次/min比(58±15)次/min,P=0.007].采用前进逐步法将年龄、术前血压显著异常、低钠血症、术前平均心率、陈旧性脑梗死作为自变量纳入logistic回归模型分析显示,高龄(OR=2.984,95%CI1.226 ~7.624,P=0.016)、术前血压显著异常(OR=27.393,95%CI6.735 ~ 111.417,P<0.001)与术后谵妄相关.结论 高龄和术前血压显著异常是永久起搏器植入术后谵妄的危险因素.%Objective To evaluate the incidence and risk factors of postoperative delirium in patients post permanent pacemaker implantation.Methods Patients underwent permanent pacemaker implantation in our department from September 2013 to February 2015 were included in this study.Delirium was measured by the confusion assessment method on the first three postoperative days.All the patients were divided into the postoperative delirium group and the non-delirium control group according to whether new onset delirium was diagnosed.Risk factors significantly associated with postoperative delirium detected by univariate analysis were entered into multivariable analysis to define the independent predictors of postoperative delirium.Results A total of

  10. (R)-N-Methyl-3-(3-{sup 125}I-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters

    Energy Technology Data Exchange (ETDEWEB)

    Lakshmi, Balagopal; Kung, M.-P.; Lieberman, Brian [Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104 (United States); Zhao Jun; Waterhouse, Rikki [Department of Psychiatry, Columbia University, New York City, NY 10032 (United States); Kung, Hank F. [Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104 (United States); Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104 (United States)], E-mail: kunghf@sunmac.spect.upenn.edu

    2008-01-15

    Alterations in serotonin and norepinephrine neuronal functions have been observed in patients with major depression. Several antidepressants bind to both serotonin transporters and norepinephrine transporters (NET). The ability to image NET in the human brain would be a useful step toward understanding how alterations in NET relate to disease. In this study, we report the synthesis and characterization of a new series of derivatives of iodonisoxetine, a known radioiodinated probe. The most promising, (R)-N-methyl-3-(3-iodopyridin-2-yloxy)-3-phenylpropylamine (PYINXT), displayed a high and saturable binding to NET, with a K{sub d} value of 0.53{+-}0.03 nM. Biodistribution studies of (R)-N-methyl-3-(3-{sup 125}I-pyridin-2-yloxy)-3-phenylpropan-1-amine in rats showed moderate initial brain uptake (0.54% dose/organ at 2 min) with a relatively fast washout from the brain (0.16% dose/organ at 2 h) as compared to [{sup 125}I]INXT. The hypothalamus (a NET-rich region)-to-striatum (a region devoid of NET) ratio was found to be 2.14 at 4 h after intravenous injection. Preliminary results suggest that this improved iodinated ligand, when labeled with {sup 123}I, may be useful for mapping NET-binding sites with single photon emission computed tomography in the living human brain.

  11. Synthesis of 16α-[125I]iodo-5α-dihydrotestosterone and evaluation of its affinity for the androgen receptor

    International Nuclear Information System (INIS)

    Analogs of 5α-dihydrotestosterone, halogenated at carbon 11, were synthesized as potential gamma-emitting ligands for the androgen receptor. These compounds, were chosen for synthesis because estradiol, similarly substituted, is strongly bound to the estrogen receptor, and both androgen and estrogen receptors have generally similar structural requirements for the D-ring. The 16α-halogenated steroids, including 16α-[125I]iodo-5α-dihydrotestosterone were synthesized from 16β-bromo-5α-dihydrotestosterone by halogen exchange. The cis-β-bromohydrin substrate was synthesized from 5α-androstane-3,17-dione by selective ketalization, dibromination at C-16 and stereoselective reduction. 16α-iodo dihydrotestosterone was devoid of androgen activity in vivo at concentrations at which 5α-dihydrotestosterone was fully stimulatory. The 16α-iodo, 16α-bromo, and 16β-bromo analogs were allowed to compete with [3H]-dihydrotestosterone for binding to the androgen receptor; the 16α-iodo compound had a relative binding affinity 1/100th and both bromo compounds 1/30th that of dihydrotestosterone. In addition, no specific binding was detected when the 16α-[125I]iodo analog was incubated with prostatic cytosol. (author)

  12. 125I-fibrinogen scanning, perfusion/ventilation scintigraphy and prophylaxis with low-dosage heparin therapy in acute medical conditions

    International Nuclear Information System (INIS)

    The diagnostic specificity of 125I-fibrinogen scanning ranges between 0.69 and 0.93. Patients with a deep-venous thrombosis diagnosed by this method have a significantly increased incidence of a perfusion/ventilation scintigrafically verified pulmonary embolism. The diagnostic specificity of a perfusion/ventilation scintigrafy ranges between 0.76 and 1.00. However, what is the clinical significance of a positive perfusion/ventilation scintigrafy, when used as a screening procedure. In patients with myocardial infarction, low-dose heparin results in reduced incidence of 125I-fibrinogen scan diagnosed deep-venous thrombosis. However, most recent papers do not show any significant reduction. Clinical trials with randomizaton according to different risk groups are required in order to clarify whether these groups will benefit from prophylaxis with low-dose heparin. As low-dose heparin has resulted in significantly increased incidence of wound-haematomas in surgical patients, we do not find the treatment advisible in patients with acute stroke, as long as one can not distinguish between haemorrhagic and thrombotic vascular insult, even though the prophylaxis reduces the incidence of deep-venous thrombosis significantly. Patient-groups with other acute internal medical diseases are not yet adequatly investigated. (author)

  13. Radiolabelling of 4-iodo-N-(2-morpholinoethyl)benzamide with Na{sup 123}I and Na{sup 125}I

    Energy Technology Data Exchange (ETDEWEB)

    Tsopelas, C

    1999-07-01

    4-Iodo-N-(2-morpholinoethyl)benzamide (1) is a new benzamide that is an analogue of the antidepressant moclobemide. The synthesis of (1) is described and the radiolabelling conditions with Na{sup 123}I and Na{sup 125}I were optimized using the Cu(I)-added exchange labelling reaction. The reaction was found to perform best in the presence of Cu{sup +} and a stannous reducing agent, in the absence of Cu{sup 2+} and potassium iodide, and at [H{sup +}] = 1.8-7.9 mM with a ligand (1) concentration = 2.6-5.6 mg/mL cold kit. Above a [H{sup +}] of 7.9 mM, the hydrolysis of (1) gave 4-iodo[{sup 125}I]benzoic acid in high amounts. The radiochemical conversion was routinely >95% and >98% after anion exchange Sep-Pak treatment. The radiolabelled product is stable at room temperature for at least 4 h.

  14. Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with {sup 125}I seeds (model I25.S16)

    Energy Technology Data Exchange (ETDEWEB)

    Acar, Hilal; Chiu-Tsao, Sou-Tung; Oezbay, Ismail; Kemikler, Goenuel; Tuncer, Samuray [Istanbul University Medicine Faculty, Oncology Institute, Fatih, Istanbul 34093 (Turkey); Quality MediPhys LLC, 17 Jade Lane, Denville, New Jersey 07834 (United States); Istanbul University Medicine Faculty, Oncology Institute, Fatih, Istanbul 34093 (Turkey); Istanbul University Medicine Faculty, Eye Department, Fatih, Istanbul 34093 (Turkey)

    2013-01-15

    Purpose: (1) To measure absolute dose distributions in eye phantom for COMS eye plaques with {sup 125}I seeds (model I25.S16) using radiochromic EBT film dosimetry. (2) To determine the dose correction function for calculations involving the TG-43 formalism to account for the presence of the COMS eye plaque using Monte Carlo (MC) method specific to this seed model. (3) To test the heterogeneous dose calculation accuracy of the new version of Plaque Simulator (v5.3.9) against the EBT film data for this seed model. Methods: Using EBT film, absolute doses were measured for {sup 125}I seeds (model I25.S16) in COMS eye plaques (1) along the plaque's central axis for (a) uniformly loaded plaques (14-20 mm in diameter) and (b) a 20 mm plaque with single seed, and (2) in off-axis direction at depths of 5 and 12 mm for all four plaque sizes. The EBT film calibration was performed at {sup 125}I photon energy. MC calculations using MCNP5 code for a single seed at the center of a 20 mm plaque in homogeneous water and polystyrene medium were performed. The heterogeneity dose correction function was determined from the MC calculations. These function values at various depths were entered into PS software (v5.3.9) to calculate the heterogeneous dose distributions for the uniformly loaded plaques (of all four sizes). The dose distributions with homogeneous water assumptions were also calculated using PS for comparison. The EBT film measured absolute dose rate values (film) were compared with those calculated using PS with homogeneous assumption (PS Homo) and heterogeneity correction (PS Hetero). The values of dose ratio (film/PS Homo) and (film/PS Hetero) were obtained. Results: The central axis depth dose rate values for a single seed in 20 mm plaque measured using EBT film and calculated with MCNP5 code (both in ploystyrene phantom) were compared, and agreement within 9% was found. The dose ratio (film/PS Homo) values were substantially lower than unity (mostly between 0

  15. Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with 125I seeds (model I25.S16)

    International Nuclear Information System (INIS)

    Purpose: (1) To measure absolute dose distributions in eye phantom for COMS eye plaques with 125I seeds (model I25.S16) using radiochromic EBT film dosimetry. (2) To determine the dose correction function for calculations involving the TG-43 formalism to account for the presence of the COMS eye plaque using Monte Carlo (MC) method specific to this seed model. (3) To test the heterogeneous dose calculation accuracy of the new version of Plaque Simulator (v5.3.9) against the EBT film data for this seed model. Methods: Using EBT film, absolute doses were measured for 125I seeds (model I25.S16) in COMS eye plaques (1) along the plaque's central axis for (a) uniformly loaded plaques (14–20 mm in diameter) and (b) a 20 mm plaque with single seed, and (2) in off-axis direction at depths of 5 and 12 mm for all four plaque sizes. The EBT film calibration was performed at 125I photon energy. MC calculations using MCNP5 code for a single seed at the center of a 20 mm plaque in homogeneous water and polystyrene medium were performed. The heterogeneity dose correction function was determined from the MC calculations. These function values at various depths were entered into PS software (v5.3.9) to calculate the heterogeneous dose distributions for the uniformly loaded plaques (of all four sizes). The dose distributions with homogeneous water assumptions were also calculated using PS for comparison. The EBT film measured absolute dose rate values (film) were compared with those calculated using PS with homogeneous assumption (PS Homo) and heterogeneity correction (PS Hetero). The values of dose ratio (film/PS Homo) and (film/PS Hetero) were obtained. Results: The central axis depth dose rate values for a single seed in 20 mm plaque measured using EBT film and calculated with MCNP5 code (both in ploystyrene phantom) were compared, and agreement within 9% was found. The dose ratio (film/PS Homo) values were substantially lower than unity (mostly between 0.8 and 0.9) for all four

  16. Implantation of iodine-125 seed for head and neck carcinoma

    International Nuclear Information System (INIS)

    Objective: To investigate the technological feasibility, efficacy and morbidity of 125I-seed implantation for head and neck cancer. Methods: Forty patients with head and neck cancer were treated with 125I-seed intersitial brachytherapy guided by uhrasound or CT. Among them thirty-six patients were performed under local anesthesia and four were under general anesthesia. Thirty-six patients were treated with 125I-seed implantation under ultrasound guidance and four cases under CT guidance. Seed needles were implanted in parallel with each other, 1-1.5 cm apart. Mick applicator was used to each needle to implant seed. The radioactive activity ranged 0.40-0.70 mCi, and the matched peripheral doses were 90-145 Gy. The mean number of 125I-seed was 3-84. Five cases received external beam irradiation one week after seed implantation, and the total doses were 45-50 Gy(200 cGy/f). All the cases were examined by X-ray or CT after implantation for quality evaluation and by routine chest X ray within twenty-four to forty-eight hours after seed implantation. Results: These patients were followed-up for 3-33 months. In 10 tongue carcinoma patients, complete response was shown in 3 cases, partial response in three cases, no change in three cases and progressive disease in one case. The local control rate was 60%, the median survival time was 11 monthes, and the one-year and two year survival rates were 87.50% and 35%, respectively. In 14 patients with recurrent cancer of head and neck the local control rate was 76.47% ,the one-year and two-year survival rates were 66.08% and 24%, respectively, and the median survival time was 9 months. In 16 patients with metastatic cancer of head and neck the local control rate was 95.23%, the one-year and two-year survival rates were 54.55% and 32.73%, and the median survival time was 9 months. One seed migrated to the maxilla and loss of seeds happened in two cases, but there was no clinically related mobidity. Conclusion: 125I

  17. Monte Carlo dosimetry for {sup 103}Pd, {sup 125}I, and {sup 131}Cs ocular brachytherapy with various plaque models using an eye phantom

    Energy Technology Data Exchange (ETDEWEB)

    Lesperance, Marielle; Martinov, M.; Thomson, R. M., E-mail: rthomson@physics.carleton.ca [Carleton Laboratory for Radiotherapy Physics, Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6 (Canada)

    2014-03-15

    Purpose: To investigate dosimetry for ocular brachytherapy for a range of eye plaque models containing{sup 103}Pd, {sup 125}I, or {sup 131}Cs seeds with model-based dose calculations. Methods: Five representative plaque models are developed based on a literature review and are compared to the standardized COMS plaque, including plaques consisting of a stainless steel backing and acrylic insert, and gold alloy backings with: short collimating lips and acrylic insert, no lips and silicone polymer insert, no lips and a thin acrylic layer, and individual collimating slots for each seed within the backing and no insert. Monte Carlo simulations are performed using the EGSnrc user-code BrachyDose for single and multiple seed configurations for the plaques in water and within an eye model (including nonwater media). Simulations under TG-43 assumptions are also performed, i.e., with the same seed configurations in water, neglecting interseed and plaque effects. Maximum and average doses to ocular structures as well as isodose contours are compared for simulations of each radionuclide within the plaque models. Results: The presence of the plaque affects the dose distribution substantially along the plaque axis for both single seed and multiseed simulations of each plaque design in water. Of all the plaque models, the COMS plaque generally has the largest effect on the dose distribution in water along the plaque axis. Differences between doses for single and multiple seed configurations vary between plaque models and radionuclides. Collimation is most substantial for the plaque with individual collimating slots. For plaques in the full eye model, average dose in the tumor region differs from those for the TG-43 simulations by up to 10% for{sup 125}I and {sup 131}Cs, and up to 17% for {sup 103}Pd, and in the lens region by up to 29% for {sup 125}I, 34% for {sup 103}Pd, and 28% for {sup 131}Cs. For the same prescription dose to the tumor apex, the lowest doses to critical

  18. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom

    International Nuclear Information System (INIS)

    Purpose: To investigate dosimetry for ocular brachytherapy for a range of eye plaque models containing103Pd, 125I, or 131Cs seeds with model-based dose calculations. Methods: Five representative plaque models are developed based on a literature review and are compared to the standardized COMS plaque, including plaques consisting of a stainless steel backing and acrylic insert, and gold alloy backings with: short collimating lips and acrylic insert, no lips and silicone polymer insert, no lips and a thin acrylic layer, and individual collimating slots for each seed within the backing and no insert. Monte Carlo simulations are performed using the EGSnrc user-code BrachyDose for single and multiple seed configurations for the plaques in water and within an eye model (including nonwater media). Simulations under TG-43 assumptions are also performed, i.e., with the same seed configurations in water, neglecting interseed and plaque effects. Maximum and average doses to ocular structures as well as isodose contours are compared for simulations of each radionuclide within the plaque models. Results: The presence of the plaque affects the dose distribution substantially along the plaque axis for both single seed and multiseed simulations of each plaque design in water. Of all the plaque models, the COMS plaque generally has the largest effect on the dose distribution in water along the plaque axis. Differences between doses for single and multiple seed configurations vary between plaque models and radionuclides. Collimation is most substantial for the plaque with individual collimating slots. For plaques in the full eye model, average dose in the tumor region differs from those for the TG-43 simulations by up to 10% for125I and 131Cs, and up to 17% for 103Pd, and in the lens region by up to 29% for 125I, 34% for 103Pd, and 28% for 131Cs. For the same prescription dose to the tumor apex, the lowest doses to critical ocular structures are generally delivered with plaques

  19. Studies of the biogenic amine transporters. V. Demonstration of two binding sites for the cocaine analog [125I]RTI-55 associated with the 5-HT transporter in rat brain membranes.

    Science.gov (United States)

    Silverthorn, M L; Dersch, C M; Baumann, M H; Cadet, J L; Partilla, J S; Rice, K C; Carroll, F I; Becketts, K M; Brockington, A; Rothman, R B

    1995-04-01

    Earlier work characterized the binding of the high-affinity cocaine analog 3 beta-(4-125iodophenyl)-tropane-2-carboxylic acid methyl ester ([125I]RTI-55) to membranes prepared from rat caudate. That investigation demonstrated that [125I]RTI-55-labeled serotonin (5-HT) transporters in addition to dopamine (DA) transporters and resolved [125I]RTI-55 binding to 5-HT transporters into two distinct components. In the present study, we characterized [125I]RTI-55 binding to membranes prepared from whole rat brain minus caudate. The first series of experiments established that [125I]RTI-55 labels both DA and 5-HT transporters and that 50 nM paroxetine and either 1000 nM 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)homopiperazine (LR1111) or 500 nM (RTI-120) could be used to block [125I]RTI-55 binding to the 5-HT and DA transporters, thereby generating selective assay conditions for the DA and 5-HT transporters, respectively. Selective lesioning of dopaminergic and serotonergic neurons with intracerebroventricular 6-hydroxydopamine and 5,7-dihydroxytryptamine selectively decreased [125I]RTI-55 binding to DA and 5-HT transporters, respectively, thereby confirming the selectivity of the assay conditions. The ligand-selectivity pattern of the whole brain minus caudate 5-HT transporter correlated significantly with that of the caudate 5-HT transporter, although there were some striking differences for selected test agents. Additional experiments resolved [125I]RTI-55 binding to the 5-HT transporter into two components. A ligand-selectivity analysis of the two components failed to identify a highly selective test agent. In summary, the major findings of the present study are that [125I]RTI-55 labels both DA and 5-HT transporters in membranes prepared from whole brain minus caudate, that 50 nM paroxetine and either 1000 nM LR1111 or 500 nM RTI-120 can be used as a blocking agent to generate selective assay conditions for the DA and 5-HT transporters, respectively, and that [125

  20. Effects of radioactive 125I seeds on A549 cell line and human embryonic lung diploid cell line 2BS cultivated in vitro and assessment of its clinical safety dose

    International Nuclear Information System (INIS)

    Objective: To observe the cell count changes of A549 cell line and human embryonic lung diploid cell line 2BS after irradiated by 125I seeds with different doses, and to study the growth inhibition of 125I on this two kinds of cell lines, and to determine its clinical safety dose in treatment of non-small cell lung. Methods: 125I seeds with different doses (low dose: 0.2 mCi, mediate dose: 0.4 mCi, high dose: 0.8 mCi) were chosen and put into A549 cells and human embryonic lung diploid cell line 2BS in vitro, the cells on the 2nd, 4th, 6th and 8th days after irradiation were collected, the alive cells were counted by cells dyeing experiments, then the growth curves were drawn, and the IC50 of the radioactive 125I seeds to both two cell lines were calculated. Results: Compared with blank and control groups, the cell proliferation trend of A549 cells in low dose group was not significantly influenced (P>0.05), but the growth of A549 cells in mediate and high dose groups were inhibited in a time-dependent manner, there were significant differences (P<0.05), the most obvious change was on the 6th day. The IC50 of the radioactive 125I seeds to A549 cells was about .04 mCi. While the growth inhibition of 125I 2BS had no statistically significant differences between various dose groups (P>0.05), and the IC50 of the radioactive 125I seeds to 2BS cell line was about 1.65 mCi. Conclusion: 0.4 mCi of radioactive 125I seeds has already had the obvious damage effect on A549 cell, 0.8 mCi of radioactive 125I seeds has the stronger effect. The IC50 of the radioactive 125I seeds to 2BS cells is about 1.65 mCi, so the clinical safety dosage is 0.4-0.8 mCi. (authors)

  1. Preparation of biologically intact radioiodinated hyaluronan of high specific radioactivity: coupling of /sup 125/I-tyramine-cellobiose to amino groups after partial N-deacetylation

    Energy Technology Data Exchange (ETDEWEB)

    Dahl, L.B.; Laurent, T.C.; Smedsrod, B.

    1988-12-01

    Hyaluronan was substituted with tyramine-cellobiose on amino residues exposed after hydrazinolytic N-deacetylation of the polysaccharide. Nonsubstituted amino groups were reacetylated, and the carboxylic hydrazides were removed by treatment with HIO/sub 3/. The adduct was labeled with /sup 125/I before or after coupling to hyaluronan. N-deacetylation increased with prolonged pretreatment with hydrazine, which also reduced the chain length of hyaluronan. Hydrazinolysis for 30 min produced hyaluronan with Mr 2.2-2.9 x 10(5). This material was substituted with varying amounts of tyramine-cellobiose (from 1 per 20 to 1 per 130 disaccharides). Hyaluronan labeled in this way was recognized by Streptomyces hyaluronidase, hyaluronan affinity protein of cartilage proteoglycan, and receptors for specific endocytosis of hyaluronan in liver endothelial cells. Since tyramine-cellobiose is nondegradable and therefore is arrested intralysosomally at the site of uptake, turnover studies of hyaluronan can be easily carried out with this ligand.

  2. Quality control of insulin radioreceptor assay for human erythrocytes. Effect of ageing of mono-125I-Tyr-A14-insulin preparation

    International Nuclear Information System (INIS)

    The quality control of insulin radioreceptor assay for human erythrocytes is based on the storage of erythrocyte preparations in Hepes buffer of pH 8.0, containing 10 g/l of albumin and 20 mmol/l of glucose. The change of erythrocytes into spherocytes and crenated cells reduces the apparent number of insulin receptors in a relatively constant way by less than 8% a week after 10 days of storage. At the same time the dissociation constants of the insulin-receptor complex increase rapidly. Thus the use of a preparation must be limited to controlling the determination of the insulin binding sites of erythrocytes, and not to the measurement of the affinities of the receptors. When mono-125I-Tyr-A14-insulin gets old, a slow decrease in the insulin binding sites can be measured, but the dissociation constants of the insulin receptor complex are not affected. (author)

  3. Autoradiographic quantitation of. beta. -adrenergic receptors on neural cells in primary cultures. 1. Pharmacological studies of (/sup 125/I)pindolol binding of individual astroglial cells

    Energy Technology Data Exchange (ETDEWEB)

    Burgess, S.K.; McCarthy, K.D. (North Carolina Univ., Chapel Hill (USA). School of Medicine)

    1985-05-27

    The current investigation was undertaken to determine whether the binding of (/sup 125/I)pindolol (*IPIN) to immunocytochemically stained cultured cells, as measured by quantitative autoradiography, would fulfill the usual pharmacological criteria for specific ..beta..-adrenergic receptor binding. *IPIN binding experiments were carried out on individual astroglia obtained from neonatal rat cerebral cortex and grown as primary cultures on polylysine-coated glass slides. Autoradiographic silver grains on cells which stained for the intracellular astroglial marker, glial fibrillary acidic protein (GFAP), were quantified by a microcomputer-based video digitizing system. This study is a demonstration of receptor binding parameters derived from single cells in a known population, and represents a novel approach to the problem of assessing cell-type specific receptors on neural cells in mixed primary cultures.

  4. Peptide mapping of /sup 125/I-labelled membrane protein of influenza viruses by reverse-phase high-performance liquid chromatography

    Energy Technology Data Exchange (ETDEWEB)

    Darveau, A.; Lecomte, J. (Centre de Recherche en Virologie, Institut Armand-Frappier, Laval, Quebec (Canada)); Seidah, N.G.; Chretien, M. (Institut de Recherches Cliniques de Montreal, Montreal (Canada))

    1982-03-01

    The resolution potential of reverse-phase high-performance liquid chromatography (HPLC) for peptide analysis of hydrophobic viral membranes has been investigated, using as a model the membrane (M) protein of influenza virus. Proteolytic digests of /sup 125/I-labelled M protein CNBr fragments, extracted from radioiodinated whole virus, have been separated on a uBondapak C/sub 18/ column with an isopropanol or acetonitrile solvent system. Peptide mapping of trypsin digests of M protein from A/PR/8/34 (H1N1) and A/chicken/Germany/N/49 (H10N7) viruses was identical, whereas Staphylococcus aureus V8 protease digests showed minor differences in at least two peptides. The results also show that HPLC is a powerful tool for the separation of proteolytic digests of viral proteins, since the peptide maps are highly reproducible and recovery was always greater than 85%.

  5. Monte Carlo study of LDR seed dosimetry with an application in a clinical brachytherapy breast implant

    Energy Technology Data Exchange (ETDEWEB)

    Furstoss, C.; Reniers, B.; Bertrand, M. J.; Poon, E.; Carrier, J.-F.; Keller, B. M.; Pignol, J. P.; Beaulieu, L.; Verhaegen, F. [Medical Physics Unit, McGill University, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4 (Canada); Medical Physics Unit, McGill University, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4 (Canada) and Department of Radiation Oncology (MAASTRO), GROW, University Hospital Maastricht, Maastricht 6202 AZ (Netherlands); Medical Physics Unit, McGill University, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4 (Canada); Departement de Radio-Oncologie et Centre de Recherche du CHUM, Hopital Notre-Dame, 1560 rue Sherbrooke Est, Montreal, Quebec H2L 4M1 (Canada); Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5 (Canada); Departement de Radio-Oncologie et Centre de Recherche en Cancerologie, CHUQ Pavillon L' Hotel-Dieu de Quebec, 11 Cote du Palais, Quebec G1R 2J6 (Canada) and Departement de Physique, de Genie Physique et d' Optique, Universite Laval, Quebec G1K 7P4 (Canada); Medical Physics Unit, McGill University, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4 (Canada) and Department of Radiation Oncology (MAASTRO), GROW, University Hospital Maastricht, Maastricht 6202 AZ (Netherlands)

    2009-05-15

    A Monte Carlo (MC) study was carried out to evaluate the effects of the interseed attenuation and the tissue composition for two models of {sup 125}I low dose rate (LDR) brachytherapy seeds (Medi-Physics 6711, IBt InterSource) in a permanent breast implant. The effect of the tissue composition was investigated because the breast localization presents heterogeneities such as glandular and adipose tissue surrounded by air, lungs, and ribs. The absolute MC dose calculations were benchmarked by comparison to the absolute dose obtained from experimental results. Before modeling a clinical case of an implant in heterogeneous breast, the effects of the tissue composition and the interseed attenuation were studied in homogeneous phantoms. To investigate the tissue composition effect, the dose along the transverse axis of the two seed models were calculated and compared in different materials. For each seed model, three seeds sharing the same transverse axis were simulated to evaluate the interseed effect in water as a function of the distance from the seed. A clinical study of a permanent breast {sup 125}I implant for a single patient was carried out using four dose calculation techniques: (1) A TG-43 based calculation, (2) a full MC simulation with realistic tissues and seed models, (3) a MC simulation in water and modeled seeds, and (4) a MC simulation without modeling the seed geometry but with realistic tissues. In the latter, a phase space file corresponding to the particles emitted from the external surface of the seed is used at each seed location. The results were compared by calculating the relevant clinical metrics V{sub 85}, V{sub 100}, and V{sub 200} for this kind of treatment in the target. D{sub 90} and D{sub 50} were also determined to evaluate the differences in dose and compare the results to the studies published for permanent prostate seed implants in literature. The experimental results are in agreement with the MC absolute doses (within 5% for EBT

  6. The interaction of /sup 125/I-insulin with cultured 3T3-L1 adipocytes: quantitative analysis by the hypothetical grain method

    Energy Technology Data Exchange (ETDEWEB)

    Fan, J.Y.; Carpentier, J.L.; Van Obberghen, E.; Blackett, N.M.; Grunfeld, C.; Gorden, P.; Orci, L.

    1983-07-01

    The murine 3T3-L1 fibroblast under appropriate incubation conditions differentiates into an adipocyte phenotype. This 3T3-L1 adipocyte exhibits many of the morphologic, biochemical, and insulin-responsive features of the normal rodent adipocyte. Using quantitative electron microscopic (EM) autoradiography we find that, when /sup 125/I-insulin is incubated with 3T3-L1 adipocytes, the ligand at early times of incubation localizes to the plasma membrane of the cell preferentially to microvilli and coated pits. When the incubation is continued at 37 degrees C, /sup 125/I-insulin is internalized by the cells and preferential binding to the villous surface is lost. With the internalization of the ligand, two intracellular structures become labeled, as determined by the method of hypothetical grain analysis. These include large clear, presumably endocytotic, vesicles and multivesicular bodies. Over the first hour of incubation the labeling of these structures increases in parallel, but in the second hour they diverge: the labeling of multivesicular bodies and other lysosomal forms continuing to increase and the labeling of large clear vesicles decreasing. At 3 hours limited but significant labeling occurs in small Golgi-related vesicles that have the typical distribution of GERL. The distinct morphologic features of this cell make it ideal for a quantitative morphologic analysis and allow for an unambiguous view of the sequence of events involved in receptor-mediated endocytosis of a polypeptide hormone. These events are likely to be representative of the processing of insulin by the mature rodent adipocyte.

  7. The angiotensin hexapeptide 3-8 fragment potently inhibits [125I]angiotensin II binding to non-AT1 or -AT2 recognition sites in bovine adrenal cortex.

    Science.gov (United States)

    Jarvis, M F; Gessner, G W; Ly, C Q

    1992-08-25

    In the present studies, ligand competition experiments were conducted to examine the ability of angiotensin II peptide agonists and nonpeptide AT1- and AT2-selective receptor antagonists to inhibit the binding of [125I]angiotensin II to bovine adrenal cortical membranes. Angiotensin II, angiotensin III, the All-(3-8) hexapeptide fragment of angiotensin II, and the AT1-selective receptor antagonist L-158,809, inhibited [125I]angiotensin II binding in a biphasic fashion indicative of a ligand interaction at more than one recognition site. Approximately 20% of low affinity [125I]angiotensin II binding was inhibited only by high micromolar concentrations of L-158,809. RG 13647 (1(-1,4-benzodioxan-2-methyl)-5-diphenylacetyl-4,5,6,7-tetra hydro-1H-imidazo- [4,5,c]-pyridine-6-carboxylic acid) represents a potent and AT2-selective analog of PD 123177 and showed weak activity in competing for [125I]angiotensin II binding with an IC50 value of 100 microM. When subsequent competition studies were conducted in the presence of 1 microM L-158,809 to block [125I]angiotensin II to the AT1 receptor subtype, the angiotensin II agonists produced monophasic inhibition curves with AII-(3-8) showing the greatest activity (IC50 = 6 nM) followed by angiotensin III (IC50 = 15 nM) much greater than angiotensin II (IC50 = 110 nM). RG 13647 was not found to significantly inhibit this portion of [125I]angiotensin II binding. These data demonstrate that bovine adrenal cortex contains both the AT1 receptor subtype, as well as, a novel class of [125I]angiotensin II recognition sites which may be analogous to the recently described angiotensin IV (AT4) receptor.

  8. A modern Monte Carlo investigation of the TG-43 dosimetry parameters for an {sup 125}I seed already having AAPM consensus data

    Energy Technology Data Exchange (ETDEWEB)

    Aryal, Prakash; Molloy, Janelle A. [Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky 40536 (United States); Rivard, Mark J., E-mail: mark.j.rivard@gmail.com [Department of Radiation Oncology, Tufts University School of Medicine, Boston, Massachusetts 02111 (United States)

    2014-02-15

    Purpose: To investigate potential causes for differences in TG-43 brachytherapy dosimetry parameters in the existent literature for the model IAI-125A{sup 125}I seed and to propose new standard dosimetry parameters. Methods: The MCNP5 code was used for Monte Carlo (MC) simulations. Sensitivity of dose distributions, and subsequently TG-43 dosimetry parameters, was explored to reproduce historical methods upon which American Association of Physicists in Medicine (AAPM) consensus data are based. Twelve simulation conditions varying{sup 125}I coating thickness, coating mass density, photon interaction cross-section library, and photon emission spectrum were examined. Results: Varying{sup 125}I coating thickness, coating mass density, photon cross-section library, and photon emission spectrum for the model IAI-125A seed changed the dose-rate constant by up to 0.9%, about 1%, about 3%, and 3%, respectively, in comparison to the proposed standard value of 0.922 cGy h{sup −1} U{sup −1}. The dose-rate constant values by Solberg et al. [“Dosimetric parameters of three new solid core {sup 125}I brachytherapy sources,” J. Appl. Clin. Med. Phys. 3, 119–134 (2002)], Meigooni et al. [“Experimental and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE™ {sup 125}I brachytherapy source,” Med. Phys. 29, 2152–2158 (2002)], and Taylor and Rogers [“An EGSnrc Monte Carlo-calculated database of TG-43 parameters,” Med. Phys. 35, 4228–4241 (2008)] for the model IAI-125A seed and Kennedy et al. [“Experimental and Monte Carlo determination of the TG-43 dosimetric parameters for the model 9011 THINSeed™ brachytherapy source,” Med. Phys. 37, 1681–1688 (2010)] for the model 6711 seed were +4.3% (0.962 cGy h{sup −1} U{sup −1}), +6.2% (0.98 cGy h{sup −1} U{sup −1}), +0.3% (0.925 cGy h{sup −1} U{sup −1}), and −0.2% (0.921 cGy h{sup −1} U{sup −1}), respectively, in comparison to the proposed standard

  9. Analysis of Permanent Pacemaker Implantation in Patients with Emotional State Survey and the Effect of Psychological Intervention%永久性起搏器植入患者情绪状态调查与心理干预的效果分析

    Institute of Scientific and Technical Information of China (English)

    李瑶; 解涛

    2015-01-01

    目的:分析永久性起搏器植入患者情绪状态调查和心理干预的效果。方法回顾性分析我院2011年7月-2014年5月收治的47例永久性起搏器植入患者临床资料,调查其情绪状态,借助于焦虑自评量表和抑郁自评量表观察比较干预前后患者情绪状态。结果干预前后患者情绪状态所存差异明显,有统计学意义(P<0.05)。结论永久起搏器植入患者易出现焦虑和抑郁等不良情绪,合理的心理干预可有效缓解和消除患者所存不良情绪。%Objective To analyze the emotional state of patients with permanent pacemaker implantation of investigation and the effect of psychological intervention. Methods A retrospective analysis of our hospital in 2011 July -2014 year in May admitted 47 cases of permanent pacemaker implantation in patients with clinical data,to investigate their emotional state,with the help of the self rating Anxiety Scale and self rating Depression Scale were observed and compared before and after the intervention of the emotional state of patients. Results Before and after the intervention in patients with emotional state stored differences,with statistical significance (P<0.05). Conclusion The permanent pacemaker implantation in patients prone to anxiety and depression and other negative emotions,psychological intervention is reasonable can effectively al eviate and eliminate the bad mood of patients with deposit.

  10. Auger electron emitter against multiple myeloma - targeted endo-radio-therapy with {sup 125}I-labeled thymidine analogue 5-iodo-4'-thio-2'-deoxyuridine

    Energy Technology Data Exchange (ETDEWEB)

    Morgenroth, Agnieszka, E-mail: amorgenroth@ukaachen.de [Nuclear Medicine Clinic, University Ulm, Albert-Einstein-Allee 23, D-89081 Ulm (Germany); Nuclear Medicine Clinic, University Aachen, RWTH, Pauwelsstrasse 30, D-52074 Aachen (Germany); Dinger, Cornelia; Zlatopolskiy, Boris D.; Al-Momani, Ehab; Glatting, Gerhard [Nuclear Medicine Clinic, University Ulm, Albert-Einstein-Allee 23, D-89081 Ulm (Germany); Mottaghy, Felix M. [Nuclear Medicine Clinic, University Aachen, RWTH, Pauwelsstrasse 30, D-52074 Aachen (Germany); Reske, Sven N. [Nuclear Medicine Clinic, University Ulm, Albert-Einstein-Allee 23, D-89081 Ulm (Germany)

    2011-10-15

    Introduction: Multiple myeloma (MM) is a plasma cell malignancy characterized by accumulation of malignant, terminally differentiated B cells in the bone marrow. Despite advances in therapy, MM remains an incurable disease. Novel therapeutic approaches are, therefore, urgently needed. Auger electron-emitting radiopharmaceuticals are attractive for targeted nano-irradiation therapy, given that DNA of malignant cells is selectively addressed. Here we evaluated the antimyeloma potential of the Auger electron-emitting thymidine analogue {sup 125}I-labeled 5-iodo-4'-thio-2'-deoxyuridine ([{sup 125}I]ITdU). Methods: Cellular uptake and DNA incorporation of [{sup 125}I]ITdU were determined in fluorodeoxyuridine-pretreated KMS12BM, U266, dexamethasone-sensitive MM1.S and -resistant MM1.R cell lines. The effect of stimulation with interleukin 6 (IL6) or insulin-like growth factor 1 (IGF1) on the intracellular incorporation of [{sup 125}I]ITdU was investigated in cytokine-sensitive MM1.S and MM1.R cell lines. Apoptotic cells were identified using Annexin V. Cleavage of caspase 3 and PARP was visualized by Western blot. DNA fragmentation was investigated using laddering assay. Therapeutic efficiency of [{sup 125}I]ITdU was proven by clonogenic assay. Results: [{sup 125}I]ITdU was shown to be efficiently incorporated into DNA of malignant cells, providing a promising mechanism for delivering highly toxic Auger radiation emitters into tumor DNA. [{sup 125}I]ITdU had a potent antimyeloma effect in cell lines representing distinct disease stages and, importantly, in cell lines sensitive or resistant to the conventional therapeutic agent, but was not toxic for normal plasma and bone marrow stromal cells. Furthermore, [{sup 125}I]ITdU abrogated the protective actions of IL6 and IGF1 on MM cells. [{sup 125}I]ITdU induced massive damage in the DNA of malignant plasma cells, which resulted in efficient inhibition of clonogenic growth. Conclusion: These studies may provide a

  11. The clinical application of CT-guided argon-helium cryoablation combined with 125 I radioactive particle in treating liver cancer located under the diaphragm%CT 导引下氩氦冷冻消融联合125I 放射粒子植入治疗膈顶部肝癌的临床应用

    Institute of Scientific and Technical Information of China (English)

    左太阳; 杨卫国; 张忠涛; 咸利军; 张秀亮; 马群; 王松

    2015-01-01

    Objective To evaluate the method of CT‐guided argon‐helium cryoablation combined with 125 I radioactive particle in treating liver cancer located under the diaphragm and to discuss the efficacy of this technique .Methods We se‐lected 16 cases of liver cancer located under the diaphragm .All the cases had been diagnosed by 3‐stage CT scanning and confirmed pathologically .The cancer had been treated by argon‐helium cryoablation combined with 125 I radioactive parti‐cle .Results The rate of the decline in serum AFP level and the efficiency after 3‐ ,6‐ ,12‐ ,24‐month treatment were 100% (16/16) ,100% (16/16) ,93 .8% (15/16) ,87 .5% (14/16) and 100% (16/16) ,100% (16/16) ,87 .5% (14/16) , 87.5% (14/16) .The 3‐ ,6‐ ,12‐ ,24‐month survival rates were 100% (16/16) ,100% (16/16) ,100% (16/16) ,93 .8%(15/16) .Conclusion CT‐guided argon‐helium cryoablation combined with 125 I radioactive particle in treating liver cancer located under the diaphragm is an efficient method for increasing the part control and survival rate for liver cancer located under the diaphragm .%目的:探讨 CT 引导下氩氦冷冻消融联合125 I 放射粒子治疗膈顶部肝癌的方法、疗效。方法选择通过3期CT 增强扫描并经穿刺活检病理证实的膈顶部肝癌16例,行 CT 导引下氩氦冷冻消融联合125 I 放射粒子治疗。结果16例膈顶部肝癌患者治疗后3个月、6个月、12个月、24个月 AFP 下降率依次是100%(16/16),100%(16/16),93.8%(15/16),87.5%(14/16),肿瘤局部控制率依次是100%(16/16),100%(16/16),87.5%(14/16),87.5%(14/16)。结论 CT引导下氩氦冷冻消融联合125 I 放射粒子治疗膈顶部肝癌,疗效可靠,是提高治疗局部控制率和生存率的有效方法。

  12. Monte Carlo simulation of the dose distribution around the {sup 125}I model 6711 seed as function of radius of the silver cylinder using the Penelope code; Simulacion por el Metodo de Monte Carlo de la distribucion de dosis alrededor de la semilla de {sup 125}I modelo 6711 en funcion del radio del cilindro de plata usando el codigo Penelope

    Energy Technology Data Exchange (ETDEWEB)

    Nerio, U. [Universidad de Cordoba, Monteria (Colombia); Instituto Nacional de Cancerologia, Bogota (Colombia); Chica, L. [Universidad Nacional de Colombia, Bogota (Colombia); Paul, A. [Universite de la Mediterranee, Marseille (France)

    2004-07-01

    The Monte Carlo method is applied to find the dose rates distribution in tissue around {sup 125} I seeds model 6711 as a function of the silver cylinder radius, R{sub sc} (0.017, 0.021, 0.025, 0.029 and 0.033) cm are used as radius values. It is found here that the dose rate at any point within the tissue decreases as R{sub sc} increases. The relative difference of dose rate that produced by the standard R{sub sc} seed, is less than 5%, for seeds with Rsc between 0.017 and 0.033 cm. (author)

  13. Estimation of anti-D IgG in red blood cell eluates using the specific radioactivity of 125I-labeled IgG: effect of unlabeled, cytophilic IgG

    Energy Technology Data Exchange (ETDEWEB)

    Masouredis, S.P.; Mahan, L.C.; Sudora, E.J.; Langley, J.W.; Victoria, E.J.

    1981-01-01

    The specific radioactivity of conventionally prepared 125I IgG anti-D eluates is significantly less (from 1/5 to 1/20) than that of the 125I IgG fraction used to prepare the eluate. This discrepancy is due to the release of unlabeled, cytophilic IgG from normal red blood cells during eluate preparation and does not represent an underestimation of the eluate anti-D IgG content. Cytophilic IgG content of eluates plays an important role in reducing the nonimmunologic binding of labeled antibody IgG. The results justify the assumption used in numerous studies that the specific radioactivity of 125I IgG fractions can be used to provide a valid estimate of the anti-D IgG content of eluates.

  14. Differential effects of acute and repeated electrically and chemically induced seizures on ( sup 3 H)Nimodipine and ( sup 125 I)omega-conotoxin GVIA binding in rat brain

    Energy Technology Data Exchange (ETDEWEB)

    Gleiter, C.H.; Cain, C.J.; Weiss, S.R.; Post, R.M.; Marangos, P.J. (National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD (USA))

    1989-07-01

    ({sup 3}H)Nimodipine and high-affinity ({sup 125}I)omega-conotoxin GVIA (CgTX) binding were investigated in membranes from rat cerebral cortex, cerebellum, and hippocampus after electrically and chemically induced seizures. Animals were decapitated 30 min after a single electroconvulsive shock (ECS) or lidocaine-induced seizure and 24 h after the last of 10 once-daily ECS or six once-daily lidocaine-induced seizures. After a single ECS, ({sup 3}H)nimodipine and ({sup 125}I)CgTX binding sites decreased in cerebral cortex (by 10% and 17%, respectively). A downregulation of ({sup 3}H)nimodipine binding sites in hippocampus occurred after single and repeated lidocaine-induced seizures (by 24% and 11%, respectively), whereas ({sup 125}I)CgTX binding remained unaltered. An earlier report on changes in ({sup 3}H)nitrendipine binding after chronic ECS in cortex and hippocampus was not confirmed.

  15. Determination of the intrinsic energy dependence of LiF:Mg,Ti thermoluminescent dosimeters for {sup 125}I and {sup 103}Pd brachytherapy sources relative to {sup 60}Co

    Energy Technology Data Exchange (ETDEWEB)

    Reed, J. L., E-mail: jlreed2@wisc.edu; Micka, J. A.; Culberson, W. S.; DeWerd, L. A. [Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin 53705 (United States); Rasmussen, B. E. [Department of Radiation Oncology, UP Health System Marquette, 580 West College Avenue, Marquette, Michigan 49855 (United States); Davis, S. D. [Department of Medical Physics, McGill University Health Centre, Montreal General Hospital (L5-112), 1650 Cedar Avenue, Montreal, Quebec H3G 1A4 (Canada)

    2014-12-15

    Purpose: To determine the intrinsic energy dependence of LiF:Mg,Ti thermoluminescent dosimeters (TLD-100) for {sup 125}I and {sup 103}Pd brachytherapy sources relative to {sup 60}Co. Methods: LiF:Mg,Ti TLDs were irradiated with low-energy brachytherapy sources and with a {sup 60}Co teletherapy source. The brachytherapy sources measured were the Best 2301 {sup 125}I seed, the OncoSeed 6711 {sup 125}I seed, and the Best 2335 {sup 103}Pd seed. The TLD light output per measured air-kerma strength was determined for the brachytherapy source irradiations, and the TLD light output per air kerma was determined for the {sup 60}Co irradiations. Monte Carlo (MC) simulations were used to calculate the dose-to-TLD rate per air-kerma strength for the brachytherapy source irradiations and the dose to TLD per air kerma for the {sup 60}Co irradiations. The measured and MC-calculated results for all irradiations were used to determine the TLD intrinsic energy dependence for {sup 125}I and {sup 103}Pd relative to {sup 60}Co. Results: The relative TLD intrinsic energy dependences (relative to {sup 60}Co) and associated uncertainties (k = 1) were determined to be 0.883 ± 1.3%, 0.870 ± 1.4%, and 0.871 ± 1.5% for the Best 2301 seed, OncoSeed 6711 seed, and Best 2335 seed, respectively. Conclusions: The intrinsic energy dependence of TLD-100 is dependent on photon energy, exhibiting changes of 13%–15% for {sup 125}I and {sup 103}Pd sources relative to {sup 60}Co. TLD measurements of absolute dose around {sup 125}I and {sup 103}Pd brachytherapy sources should explicitly account for the relative TLD intrinsic energy dependence in order to improve dosimetric accuracy.

  16. Degradation of insulin and insulin-like growth factors by enzyme purified from human erythrocytes. Comparison of degradation products observed with A14- and B26-[125I]monoiodoinsulin

    International Nuclear Information System (INIS)

    An insulin-degrading enzyme has been purified from human erythrocytes. This enzyme degraded 125I-labeled insulin-like growth factor I (IGF-I) more slowly than 125I-IGF-II and degraded IGF-II more slowly than 125I-insulin. The time course of 125I-insulin degradation suggested the presence of intermediates, each of which was itself shown to be a substrate for the enzyme. One of these intermediates appeared to be made up entirely of B-chain residues and had HisB10 as its NH2-terminal. The final major radiolabeled degradation product of A14-[125I]monoiodoinsulin was a peptide with TyrA14 at the A-chain NH2 terminal. This peptide could be reduced with dithiothreitol, suggesting that it contained amino acid residues from both A- and B-chains. It was partially precipitated by trichloroacetic acid and anti-insulin antibody but bound poorly to IM-9 lymphocytes. The final major degradation product of B26-[125I]monoiodoinsulin was a peptide whose NH2-terminal was TyrB26 and could not be reduced by dithiothreitol. It was partially precipitated by anti-insulin antibody but was precipitated poorly, if at all, by trichloroacetic acid and bound poorly to IM-9 lymphocytes. The results show that this enzyme degraded insulin by sequential cleavage of peptide bonds on both A- and B-chains. We identified LeuA13-TyrA14, SerB9-HisB10, and PheB25-TyrB26 as three of the bonds that are cleaved

  17. Translocation of 125I, 75Se and 36Cl to edible parts of radish, potato and green bean following wet foliar contamination under field conditions

    International Nuclear Information System (INIS)

    Specific translocation factor values (ftr) for 129I, 79Se and 36Cl following foliar transfer are still missing from the IAEA reference databases. The translocation of the short-lived isotopes, 125I, 75Se, and 36Cl, to radish, potato and green bean edible parts was measured under field conditions following acute and chronic wet foliar contamination at various plant growth stages in the absence of leaching caused by rain. The translocation factors obtained for 125I ranged from 0.8 to 2.6% for radish, from 0.1 to 2.3% for potato and from 0.1 to 2.6% for bean. The translocation factors obtained for 75Se ranged from 6.3 to 21% for radish, from 1.6 to 32.6% for potato and from 7.7 to 22.8% for bean (values similar to Cs or even higher). The translocation factors obtained for 36Cl were close to those for 75Se and ranged from 4.3 to 28.8% for radish, from 0.5 to 31.5% for potato and from 4.3 to 16.3% for bean. Iodide showed the lowest apparent mobility because of its preferential fixation in or on the leaves and a significant amount was probably volatilized. Selenite internal transfer was significant and possibly followed the sulfur metabolic pathway. Chloride was very mobile and quickly diffused throughout the plant. The translocation factors varied with the growth stage and depended on the development state of the edible tissue and its associated sink strength for nutrients and assimilates. For radish, translocation was high during the early vegetative stages. For potato, wheat and bean, a major peak in translocation was seen during the flowering growth stage and the concomitant growth of potato tubers. An additive effect of successive contamination events on translocated elements was shown in radish but not in bean and potato. The highest translocation value obtained for an acute contamination event was shown to be an adequate, conservative indicator of chronic contamination in absence of specific values. Due to the absence of rain leaching during the experiment this

  18. Synthesis of unlabelled, {sup 3}H- and {sup 125}I-labelled {beta}-CIT and its {omega}-fluoroalkyl analogues {beta}-CIT-FE and {beta}-CIT-FP, including synthesis of precursors

    Energy Technology Data Exchange (ETDEWEB)

    Swahn, C.-G.; Halldin, Christer [Karolinska Inst., Clinical Neuroscience Dept., Stockholm (Sweden); Guenther, Ilonka; Patt, Joerg; Ametamey, Simon [Karolinska Inst., Clinical Neuroscience Dept., Stockholm (Sweden)]|[Paul Scherrer Inst., Villigen (Switzerland)

    1996-07-01

    The full synthesis of the cocaine congener 2{beta}-carbomethoxy-3{beta}-(4-iodophenyl)(tropane {beta}-CIT) and its N-fluoroalkyl analogues, fluoroethyl- and fluoropropyl-nor-{beta}-CIT ({beta}-CIT-FE and {beta}-CIT-FP) starting from cocaine is described. The synthetic routes include the preparation of precursors for labelling with radionuclides such as {sup 11}C, {sup 18}F, {sup 76}Br, {sup 123}I, {sup 125}I and {sup 3}H. Here we also report the labelling with {sup 125}I or {sup 3}H for use in autoradiographic examination of human brain sections. (author).

  19. Uptake of 3-[125I]iodo-α-methyl-L-tyrosine into colon cancer DLD-1 cells: characterization and inhibitory effect of natural amino acids and amino acid-like drugs

    International Nuclear Information System (INIS)

    Introduction: We examined 3-[123I]iodo-α-methyl-L-tyrosine ([123I]IMT) uptake and inhibition by amino acids and amino acid-like drugs in the human DLD-1 colon cancer cell line, to discuss correlation between the inhibition effect and structure. Methods: Expression of relevant neutral amino acid transporters was examined by real-time PCR with DLD-1 cells. The time course of [125I]IMT uptake, contributions of transport systems, concentration dependence and inhibition effects by amino acids and amino acid-like drugs (1 mM) on [125I]IMT uptake were examined. Results: Expression of system L (4F2hc, LAT1 and LAT2), system A (ATA1, ATA2) and system ASC (ASCT1) was strongly detected; system L (LAT3, LAT4) and MCT8 were weakly detected; and B0AT was not detected. [125I]IMT uptake in DLD-1 cells involved Na+-independent system L primarily and Na+-dependent system(s). Uptake of [125I]IMT in Na+-free buffer followed Michaelis-Menten kinetics, with a Km of 78 μM and Vmax of 333 pmol/106 cells per minute. Neutral D- and L-amino acids with branched or aromatic large side chains inhibited [125I]IMT uptake. Tyrosine analogues, tryptophan analogues, L-phenylalanine and p-halogeno-L-phenylalanines, and gamma amino acids [including 3,4-dihydroxy-L-phenylalanine (L-DOPA), DL-threo-β-(3,4-dihydroxyphenyl)serine (DOPS), 4-[bis(2-chloroethyl)amino]-L-phenylalanine and 1-(aminomethyl)-cyclohexaneacetic acid] strongly inhibited [125I]IMT uptake, but L-tyrosine methyl ester and R(+)/S(-)-baclofen weakly inhibited uptake. The substrates of system ASC and A did not inhibit [125I]IMT uptake except L-serine and D/L-cysteine. Conclusions: [125I]IMT uptake in DLD-1 cells involves mostly LAT1 and its substrates' (including amino acid-like drugs derived from tyrosine, tryptophan and phenylalanine) affinity to transport via LAT1. Whether transport of gamma amino acid analogues is involved in LAT1 depends on the structure of the group corresponding to the amino acid residue. Beta-hydroxylation may

  20. Studies of the biogenic amine transporters. VI. Characterization of a novel cocaine binding site, identified with [125I]RTI-55, in membranes prepared from whole rat brain minus caudate.

    Science.gov (United States)

    Rothman, R B; Silverthorn, M L; Baumann, M H; Goodman, C B; Cadet, J L; Matecka, D; Rice, K C; Carroll, F I; Wang, J B; Uhl, G R

    1995-07-01

    Previous studies showed that the cocaine analog [125I]RTI-55 labels dopamine and serotonergic (5-HT) biogenic amine transporters (BATs) with high affinity. Here we characterized [125I]RTI-55 binding to membranes prepared from whole rat brain minus the caudate nuclei. Paroxetine (50 nM) was used to block [125I]RTI-55 binding to 5-HT transporter sites. Initial experiments identified drugs that displaced [125I]RTI-55 binding with moderately low slope factors. Binding surface analysis of the interaction of 3 beta-(4-chlorophenyl)tropan-2 beta-carboxylic acid phenyl ester hydrochloride (RTI-113) and 3 beta-(4-iodophenyl)tropan-2 beta-carboxylic acid phenyl ester hydrochloride (RTI-122) with [125I]RTI-55 binding sites readily resolved two binding sites for [125I]RTI-55 with Kd values of 0.44 nM and 17 nM and Bmax values of 31 and 245 fmol/mg protein. Potent 5-HT and noradrenergic uptake inhibitors had low affinity for both sites. Whereas cocaine, CFT and WIN35,065-2 were 6.0-, 25- and 14-fold selective for the first site, benztropine, PCP and the novel pyrrole, (+-)-(2RS,3aSR,8bRS)-1,2,3,3a,4,8b-hexahydro- 2-benzyl-1-methylindeno-[1,2-b]pyrrole resorcylate [(+-)-HBMP, formerly called (+-)-RTI-4793-14], were moderately selective for the second site. A single binding site with the characteristics of site 1 was resolved using COS cells transiently expressing the cloned rat dopamine transporter. Lesion studies with 6-hydroxydopamine and 5,7-dihydroxytryptamine were conducted to test the hypothesis that site 1 and site 2 are physically distinct. The data showed that these neurotoxins differentially decreased [125I]RTI-55 binding to sites 1 and 2. The differential distribution of sites 1 and 2 in rat brain provides further support for this hypothesis. Viewed collectively, these data show that [125I]RTI-55 labels a novel binding site in rat brain membranes, termed DATsite2, which is not associated with the classic dopamine, serotonin or norepinephrine transporters.

  1. Uptake of 3-[{sup 125}I]iodo-{alpha}-methyl-L-tyrosine into colon cancer DLD-1 cells: characterization and inhibitory effect of natural amino acids and amino acid-like drugs

    Energy Technology Data Exchange (ETDEWEB)

    Shikano, Naoto [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan)], E-mail: sikano@ipu.ac.jp; Ogura, Masato [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Okudaira, Hiroyuki [School of Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa 920-0942 (Japan); Nakajima, Syuichi; Kotani, Takashi [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Kobayashi, Masato [School of Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa 920-0942 (Japan); Nakazawa, Shinya [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Baba, Takeshi; Yamaguchi, Naoto [Center for Medical Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Kubota, Nobuo [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Iwamura, Yukio [Center for Humanities and Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Kawai, Keiichi [School of Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa 920-0942 (Japan)

    2010-02-15

    Introduction: We examined 3-[{sup 123}I]iodo-{alpha}-methyl-L-tyrosine ([{sup 123}I]IMT) uptake and inhibition by amino acids and amino acid-like drugs in the human DLD-1 colon cancer cell line, to discuss correlation between the inhibition effect and structure. Methods: Expression of relevant neutral amino acid transporters was examined by real-time PCR with DLD-1 cells. The time course of [{sup 125}I]IMT uptake, contributions of transport systems, concentration dependence and inhibition effects by amino acids and amino acid-like drugs (1 mM) on [{sup 125}I]IMT uptake were examined. Results: Expression of system L (4F2hc, LAT1 and LAT2), system A (ATA1, ATA2) and system ASC (ASCT1) was strongly detected; system L (LAT3, LAT4) and MCT8 were weakly detected; and B{sup 0}AT was not detected. [{sup 125}I]IMT uptake in DLD-1 cells involved Na{sup +}-independent system L primarily and Na{sup +}-dependent system(s). Uptake of [{sup 125}I]IMT in Na{sup +}-free buffer followed Michaelis-Menten kinetics, with a K{sub m} of 78 {mu}M and V{sub max} of 333 pmol/10{sup 6} cells per minute. Neutral D- and L-amino acids with branched or aromatic large side chains inhibited [{sup 125}I]IMT uptake. Tyrosine analogues, tryptophan analogues, L-phenylalanine and p-halogeno-L-phenylalanines, and gamma amino acids [including 3,4-dihydroxy-L-phenylalanine (L-DOPA), DL-threo-{beta}-(3,4-dihydroxyphenyl)serine (DOPS), 4-[bis(2-chloroethyl)amino]-L-phenylalanine and 1-(aminomethyl)-cyclohexaneacetic acid] strongly inhibited [{sup 125}I]IMT uptake, but L-tyrosine methyl ester and R(+)/S(-)-baclofen weakly inhibited uptake. The substrates of system ASC and A did not inhibit [{sup 125}I]IMT uptake except L-serine and D/L-cysteine. Conclusions: [{sup 125}I]IMT uptake in DLD-1 cells involves mostly LAT1 and its substrates' (including amino acid-like drugs derived from tyrosine, tryptophan and phenylalanine) affinity to transport via LAT1. Whether transport of gamma amino acid analogues is

  2. Increase in brain /sup 125/I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesions

    Energy Technology Data Exchange (ETDEWEB)

    Chang, R.S.L.; Lotti, V.J.; Martin, G.E.; Chen, T.B.

    1983-02-21

    Specific /sup 125/I-CCK receptor binding was significantly increased in brain tissue taken from guinea pig or mouse following chronic (2-3 week) daily administration of haloperidol (2-3 mg/kg/day). Scatchard analysis indicated the increase in CCK binding was due to an increased receptor number (B max) with no change in affinity (Kd). In guinea pigs, the increased CCK binding was observed in the mesolimbic regions and frontal cortex, but not in striatum, hippocampus nor posterior cortex. In mice, however, the increases occurred in both pooled cerebral cortical-hippocampal tissue, and in the remainder of the brain. Enhanced CCK receptor binding was also observed in membranes prepared from whole brain of mice one month following intracisternal injection of 6-hydroxydopamine. Additionally, an increase in CCK binding was observed in mesolimbic regions and frontal cortex, but not striatum or hippocampus, of guinea pigs 3 weeks after an unilateral radiofrequency lesions of the ipsilateral ventral tegmentum. The present studies demonstrate that three different procedures which reduce dopaminergic function in the brain enhance CCK receptor binding. The data provide further support for a functional interrelationship between dopaminergic systems and CCK in some brain regions and raise the possibility that CCK may play a role in the antipsychotic action of neuroleptics.

  3. Altered binding of 125I-labeled calmodulin to a 46.5-kilodalton protein in skin fibroblasts cultured from patients with cystic fibrosis

    International Nuclear Information System (INIS)

    The levels of calmodulin and calmodulin-binding proteins have been determined in cultured skin fibroblasts from patients with cystic fibrosis (CF) and age- and sex-matched controls. Calmodulin ranged from 0.20 to 0.76 microgram/mg protein; there was no difference between calmodulin concentration in fibroblasts from CF patients and controls. Calmodulin-binding proteins of 230, 212, 204, 164, 139, 70, 59, 46.5, and 41 kD were identified. A protein with a mobility identical to the 59-kD calmodulin-binding protein was labeled by antiserum against calmodulin-dependent phosphatase. Although Ca2+/calmodulin-dependent phosphatase activity was detected, there was no different in activity between control and CF fibroblasts or in the level of phosphatase protein as determined by radioimmunoassay. Lower amounts of 125I-calmodulin were bound to the 46.5-kD calmodulin-binding protein in CF fibroblasts as compared with controls. The 46.5-kD calmodulin-binding protein may be reduced in CF fibroblasts or its structure may be altered resulting in a reduced binding capacity and/or affinity for calmodulin and perhaps reflecting, either directly or indirectly, the genetic defect responsible for cystic fibrosis

  4. Proliferation kinetics of early hemopoietic precursor cells with self sustaining capacity in the mouse, studied with 125-I-labeled iodo-deoxyuridine

    International Nuclear Information System (INIS)

    With a new labelling technique in radiation chimeras, an attempt was made to determine the duration of the phases of the stem cell cycle including shortest and mean generation time and to estimate the number of hemopoietic stem cells per unit of bone marrow cellularity. The DNA of bone marrow cells in DNA synthesis was labeled with 5-125I-2'- deoxyuridine. The labeled cells were followed after being transfused into fatally irradiated mice. The stem cells were found to have a half-time of about 4.3 days in the donor mice. The average time in the population, i.e. the turnover time of the stem cells, was 6.2 days. The half-time did not change significantly even after transfusion of bone marrow into lethally irradiated recipient mice. Tritiated thymidine (3H-TdR) suicide technique revealed that bone marrow stem cells seeding to the spleens and to the femurs of lethally irradiated recipients behaved differently - S-phase in cells seeding to femurs being shorter. The radiosensitivity of stem cells in S-phase had a D0 of 80 rad whereas stem cells distributed throughout the whole cell cycle had a D0 of 185 rad. The respective extrapolation numbers were 1.23 and 1.14. It is calculated that 2-7% of all nucleated bone marrow cells belong to self renewing stem cell populations. The method described provides a new approach for the study of hematological stem cells. (author)

  5. Determination of the bone-mineral content of the peripheral skeleton (ulna and calcaneus) in chronic renal failure patients on maintenance dialysis using 125 I-photon absorptiometry

    International Nuclear Information System (INIS)

    The bone-mineral content (BMC) of the peripheral skeleton was measured in 53 chronic renal-failure patients on maintenance dialysis using the 125 I photon absorptiometry according to Cameron. 39.6% of the patients were found to have a clearly pathological calcium content in calcaneus and ulna (33%). In total BMC assessments 43.4% of the patients examined showed strongly reduced BMC values at two measurement sites at least. Average bone-mineral content was below the value of the corresponding normal groups in all age groups of the dialysis patients. In addition, a significant correlation was verified to exist between the calcium contents of calcaneus and ulna. A significant correlation was found as well between reduced BMC values and dialysis duration. The correlation between the increased serum level of alkaline phosphatase and the reduced mineral content of the skeleton was significant as well. A minor but not significant correlation existed between the increase of the parathormone (PTH) level in the serum and the decrease of calcium content in calcaneus and ulna. A good correlation was found when contrasting the results of visual roentgenography and the BMC values established by photodensitometry: the median BMC value of patients with clear pathological X-ray findings was significantly below the one of patients without pathological X-ray findings. However, photon absorptiometry is superior to the subjective evaluation of X-ray pictures in the early diagnosis of bone diseases involving bone-mineral loss. (orig.)

  6. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation

    International Nuclear Information System (INIS)

    Purpose: To assess the urinary morbidity experienced by patients undergoing ultrasound-guided, permanent transperineal seed implantation for adenocarcinoma of the prostate. Methods and Materials: Between September 1992 and September 1997, 693 consecutive patients presented with a diagnosis of clinically localized adenocarcinoma of the prostate, and were treated with ultrasound-guided transperineal interstitial permanent brachytherapy (TPIPB). Ninety-three patients are excluded from this review, having received neoadjuvant antiandrogen therapy. TPIPB was performed with 125I in 165 patients and with 103Pd in 435 patients. Patients treated with implant alone received 160 Gy with 125I (pre TG43) or 120 Gy with 103Pd. One hundred two patients received preimplant, pelvic external beam radiation (XRT) to a dose of either 41.4 or 45 Gy because of high-risk features including PSA ≥ 10 and/or Gleason score ≥ 7. Combined modality patients received 120 Gy and 90 Gy, respectively for 125I or 103Pd. All patients underwent postimplant cystoscopy and placement of an indwelling Foley catheter for 24-48 h. Follow-up was at 5 weeks after implant, every 3 months for the first 2 years, and then every 6 months for subsequent years. Patients completed AUA urinary symptom scoring questionnaires at initial consultation and at each follow-up visit. Urinary toxicity was classified by the RTOG toxicity scale with the following adaptations; grade 1 urinary toxicity was symptomatic nocturia or frequency requiring none or minimal medical intervention such as phenazopyridine; grade 2 urinary toxicity was early obstructive symptomatology requiring alpha-blocker therapy; and grade 3 toxicity was considered that requiring indwelling catheters or posttreatment transurethral resection of the prostate for symptom relief. Log-rank analysis and Chi-square testing was performed to assess AUA score, prostate size, isotope selection, and the addition of XRT as possible prognosticators of postimplant

  7. Marxism as permanent revolution

    NARCIS (Netherlands)

    E. van Ree

    2013-01-01

    This article argues that the 'permanent revolution' represented the dominant element in Karl Marx and Friedrich Engels' political discourse, and that it tended to overrule considerations encapsulated in 'historical materialism'. In Marx and Engels's understanding, permanent revolution did not repres

  8. Effect of pH and lysosomotropic agents on membrane-associated and internalized 125I-iodinated human growth hormone in cultured human lymphocytes: a quantitative biochemical and electron microscopic study

    International Nuclear Information System (INIS)

    When 125I-iodinated human GH ([125I]iodo-hGH) interacts with cultured human lymphocytes at 15 C, the reaction is reversible, but at 37 C the reaction becomes less dissociable as a function of incubation time. Acidification of the incubation medium results in rapid ligand dissociation at 15 C, but at 37 C the acid-dissociable component decreases as a function of incubation time. Under conditions where approximately 50% of the ligand is internalized by the cell, 90% is nondissociable. When the 37 C incubation is carried out in the presence of 25 mM NH4Cl, cell-associated radioactivity is increased. Under these conditions approximately 90% of cell-associated radioactivity also is nondissociable. Using quantitative electron microscopic autoradiography, the proportion of [125I]iodo-hGH associated with the plasma membrane and internalized by the cell is indistinguishable in the presence or absence of NH4Cl. Irreversible [125I]iodo-hGH association with cultured human lymphocytes is due to time- and temperature-dependent effects in the plasma membrane of the cell. These effects cannot be distinguished from internalization by acidification. Furthermore, lysosomotropic agents increase cell-associated radioactivity, but the proportion internalized is not increased

  9. Staff dose of hospitalization in the treatment of patients in ophthalmic brachytherapy with 125 I; Dosis al personal de hospitalizacion en el tratamiento de pacientes de braquiterapia oftalmica con I-125

    Energy Technology Data Exchange (ETDEWEB)

    Terron Leon, J. A.; Gomez Palacios, M.; Moreno Reyes, J. C.; Perales Molina, A.

    2013-07-01

    The objective of this work, therefore, has been the evaluation of the dose levels which nursing staff can receive in care for ophthalmic brachytherapy patients treated with 125 I from measurements made on the same, evaluating, in an experimental way, job security following the PR rules laid down for these treatments. (Author)

  10. Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of /sup 75/Se-, /sup 111/In-, and /sup 125/I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice

    Energy Technology Data Exchange (ETDEWEB)

    Koizumi, M.; Endo, K.; Watanabe, Y.; Saga, T.; Sakahara, H.; Konishi, J.; Yamamuro, T.; Toyama, S.

    1989-04-01

    In order to know the true biodistribution of anti-tumor monoclonal antibodies, three monoclonal antibodies (OST6, OST7, and OST15) against human osteosarcoma and control antibody were internally labeled with 75Se by incubating (75Se)methionine and hybridoma cells. 75Se-labeled monoclonal antibodies were evaluated both in vitro and in vivo using the human osteogenic sarcoma cell line KT005, and the results were compared with those of 125I- and 111In-labeled antibodies. 75Se-, 125I- and 111In-labeled monoclonal antibodies had identical binding activities to KT005 cells, and the immunoreactivity was in the decreasing order of OST6, OST7, and OST15. On the contrary, in vivo tumor uptake (% injected dose/g) of 75Se- and 125I-labeled antibodies assessed using nude mice bearing human osteosarcoma KT005 was in the order of OST7, OST6, and OST15. In the case of 111In, the order was OST6, OST7, and OST15. High liver uptake was similarly seen with 75Se- and 111In-labeled antibodies, whereas 125I-labeled antibodies showed the lowest tumor and liver uptake. These data indicate that tumor targeting of antibody conjugates are not always predictable from cell binding studies due to the difference of blood clearance of labeled antibodies. Furthermore, biodistribution of both 111In- and 125I-labeled antibodies are not identical with internally labeled antibody. Admitting that internally labeled antibody is a ''gold standard'' of biodistribution of monoclonal antibody, high liver uptake of 111In-radiolabeled antibodies may be inherent to antibodies. Little, if any, increase in tumor-to-normal tissue ratios of antibody conjugates will be expected compared to those of 111In-labeled antibodies if stably coupled conjugates are administered i.v.

  11. Hereditary orotic aciduria, Lesch-Nyhan syndrome, and xeroderma pigmentosum probed by herpes simplex virus: 125I-iododeoxycytidine incorporation as an assay for viral growth

    International Nuclear Information System (INIS)

    125I-Iododeoxycytidine (125IdC) incorporation into acid-insoluble material was a sensitive, rapid, and quantitative assay for the growth of herpes simplex virus type 1 (HSV-1) in human fibroblasts. Cellular utilization of the isotope was 10 to 25% of the incorporation by infected cells and could be 80% inhibited by tetrahydrouridine (THU). Viral utilization was inhibited by acycloguanosine, thioguanine (TG), and cytosine arabinoside. Isotope was incorporated equally well by growing or quiescent infected cells. HSV-1 was used to probe the metabolic capabilities of three mutant human fibroblast strains. 125IdC incorporation quantitatively measured the ability of the virus to grow in these cells. Viral 125IdC incorporation was sensitive to TG in normal fibroblasts but showed a 8- to 10-fold greater resistance to TG in fibroblasts derived from patients with Lesch-Nyhan syndrome (LN). Similarly, the growth of ultraviolet irradiated HSV-1 in normal fibroblasts was 5-fold greater than in fibroblasts derived from patients with xeroderma pigmentosum. In fibroblasts derived from patients with hereditary orotic aciduria, viral 125IdC incorporation was sensitive to adenosine (AD) at concentrations which were slightly stimulatory in normal fibroblasts. This was a 2-fold difference in AD sensitivity, which the radioassay reliably and quantitatively documented. HSV-1 infected cells could be individually identified by their incorporated 125IdC; such cells had blackened nuclei in autoradiograms prepared 12 hr after infection. Normal cells infected in the presence of TG had many fewer labeled nuclei than LN cells similarly infected in the presence of the drug

  12. Diagnosis-specific serum 17 beta-estradiol (E2) upper limits for treatment with menotropins using a 125I direct E2 assay.

    Science.gov (United States)

    Haning, R V; Boehnlein, L M; Carlson, I H; Kuzma, D L; Zweibel, W J

    1984-12-01

    Statistical evaluation of 133 cycles of induction of ovulation using generalized linear models demonstrated that the occurrence and severity of ovarian hyperstimulation was influenced by the serum 17 beta-estradiol (E2) concentration (P less than 0.001), conception (P less than 0.001), and the endocrinologic diagnosis, polycystic ovary syndrome (PCO) or hypothalamic amenorrhea (HA) (P less than 0.01). When menotropins were administered between 5:00 P.M. and 8:00 P.M. and blood was drawn at 8:00 A.M., an upper limit for serum E2 in patients with HA of 2417 pg/ml or an upper limit for patients with PCO of 3778 pg/ml gave an approximate 5% risk of severe ovarian hyperstimulation in conception cycles and a 1.3% risk of severe hyperstimulation in nonconception cycles. Comparison of our E2 radioimmunoassay involving extraction and chromatography to the Pantex immunodirect Estradiol 125I kit (Pantex, Santa Monica, CA) demonstrated no detectable systematic error, allowing the use of these limits with either assay. The ovulating injection of human chorionic gonadotropin was given at 5:00 P.M. to 8:00 P.M. on the evening of blood drawing as soon as the first follicle reached an average diameter of 14 mm or greater. The ultrasound parameters allow the chance of pregnancy to be optimized and the chance of multiple gestation to be minimized. Serum E2 monitoring indicates when the risk of ovarian hyperstimulation is too great for human chorionic gonadotropin to be given. PMID:6437878

  13. Suppression of 125I-uptake in mouse thyroid by seaweed feeding: possible preventative effect of dietary seaweed on internal radiation injury of the thyroid by radioactive iodine.

    Science.gov (United States)

    Maruyama, H; Yamamoto, I

    1992-12-01

    We conducted an animal experiment to determine how dietary seaweeds rich in iodine and dietary fibers suppress radioactive iodine uptake by the thyroid, using mice and four kinds of experimental diets, three with 1% or 2% powdered fronds of the kelp Laminaria religiosa and 2% powdered laver Porphyra yezoensis, and one with cellulose. Iodine content of a hot-water extract of the kelp was 0.530 +/- 0.001%, and its dietary fiber (DF) values were 52.8 +/- 1.2%. Iodine in an extract of the laver was 0.008 +/- 0.001%, and its DF values were 41.4% +/- 0.7%. A statistically significant reduction of 125I uptake by the thyroid, 3 hours after intragastric administration of the radionuclide at a dosage of 18.5 kBq or 185 kBq in 0.3 ml aqueous solution per mouse, was observed in mice previously fed the experimental diets containing 1% and 2% kelp during periods varying from 24 hours to 7 days. The degree of the suppression was observed to depend on the amount of iodine in the diet or in the injected sample, no matter whether organic or inorganic, judging from the results of an additional experiment. Thus, we conclude that previously fed iodine-rich material, especially dietary seaweeds rich in iodine and other minerals, vitamins, and beta-carotene, such as kelps or laver supplemented with inorganic iodine, may be effective in prevention of internal radiation injury of the thyroid. PMID:1344008

  14. Autoradiographical detection of cholecystokinin-A receptors in primate brain using sup 125 I-Bolton Hunter CCK-8 and 3H-MK-329

    Energy Technology Data Exchange (ETDEWEB)

    Hill, D.R.; Shaw, T.M.; Graham, W.; Woodruff, G.N. (Merck Sharp and Dohme Research Laboratories, Harlow, Essex (England))

    1990-04-01

    In vitro autoradiography was performed in order to visualize cholecystokinin-A (CCK-A) receptors in sections of Cynomolgus monkey brain. CCK-A receptors were defined as those which displayed high affinity for the selective non-peptide antagonist MK-329 (L-364,718) and were detected in several regions by selective inhibition of 125I-Bolton Hunter CCK using MK-329 or direct labeling with 3H-MK-329. In the caudal medulla, high densities of CCK-A sites were present in the nucleus tractus solitarius, especially the caudal and medial aspects, and also the dorsal motor nucleus of the vagus. CCK-A sites were localized to a number of hypothalamic nuclei such as the supraoptic and paraventricular nuclei, the dorsomedial and infundibular nuclei as well as the neurohypophysis. The mammillary bodies and supramammillary nuclei also contained CCK-A receptor sites. High concentrations of CCK-A receptors were present in the substantia nigra zona compacta and also the ventral tegmental area and may be associated with dopamine cell bodies. Binding of 3H-MK-329 was also detected in parts of the caudate nucleus and ventral putamen. The detection, by autoradiographical means, of CCK-A receptors throughout the Cynomolgus monkey brain contrasts with similar studies performed using rodents and suggests differences in the density and, perhaps, the importance of CCK-A receptors in the primate as opposed to the rodent. The data suggest the possibility that CCK-A receptors may be involved in a number of important brain functions as diverse as the processing of sensory information from the gut, the regulation of hormone secretion, and the activity of dopamine cell activity.

  15. 个性化护理对老年永久性人工起搏器置入患者生活质量的影响%The influence of individual care on life quality of elderly pafients with permanent pace-maker implantation

    Institute of Scientific and Technical Information of China (English)

    张娜; 张成芳; 甄莉莉

    2008-01-01

    Objective To investigate the influence of individual care on life quality of elderly patients with permanent pace-maker implantation. Methods Sixty-two old patients who experienced permanent pace-maker implantation in our hospital were randomly divided into the treatment group and the control group. Traditional peri-operative and post-operative nursing were performed among patients of the control group,but intensively individual nursing Was performed among patients of the treatment group in addition to traditional nursing. The outcomes were evaluated by WHOQOL on the third day and the forth week after the operation. Results The significant difference was observed between the two groups. After the individual nursing intervention,there were significant improvements of life quality in the treatment group but spirit support,religion and personal belief(P>0.05).Conclusions Individual nursing can markedly improve the life quality of patients with permanent pace-maker implantation. Nurses should understand the necessity and importance of individual nursing.%目的 探讨个性化护理干预对老年永久性人工起搏器置入患者生活质量的影响.方法 对行永久人工心脏起搏器置入术的62例老年患者,随机分为干预组和对照组,每组31例.对照组进行常规术前术后护理,干预组在进行常规护理的同时,针对患者的不同情况加强个性化的护理干预.在术后3 d及4周末,应用世界卫生组织生存质量测定量表(WHOQOL)进行测评.结果患者生活质量(QOL)的各维度在实施个性化护理干预后,除精神支柱/宗教/个人信仰维度外,其余各维度差异有统计学意义,干预组生活质量明显高于对照组(P<0.05).结论 个性化护理干预可以明显提高老年永久性人工起搏器置入患者的生活质量,护理人员要重视对老年患者进行个性化护理的必要性和重要性.

  16. Application of clinical nursing pathway combined with individual case management model in permanent cardiac pacemaker implantation patients%临床护理路径结合个案管理模式在永久性起搏器植入患者中的应用

    Institute of Scientific and Technical Information of China (English)

    熊敏; 许少娜; 郭维英; 林宇洵

    2016-01-01

    Objective To investigate the effect of clinical nursing pathway combinied with individual case management model in permanent cardiac pacemaker implantation patients. Methods A total of 60 patients with perma-nent cardiac pacemaker implantation was selected and divided into an observation group and a control group, with 30 cases in each group. The observation group carried out clinical nursing pathway combined with individual case maneg-ment model, and the control group acceptted the traditional nursing model. The hospitalization days, cases of happening complications, score of disease knowledge questionnaire, patient s' satisfaction and anxiety level of the two groups were compared. Results Compared to the control group, the observation group had fewer hospitalization days and complica-tions, higher score of disease knowledge questionnaire and higher patient satisfaction level (P0. 05), but the anxiety level of observation group obviously lower than that of the control group when discharged from hospital (P0.05),出院时两组比较差异均有统计学意义(P<0.05)。结论在永久性起搏器植入患者中实施临床护理路径与个案管理相结合的模式,可以明显缩短住院天数,减少并发症,提高患者疾病知识掌握程度,提高患者满意度,减轻患者焦虑水平。

  17. Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, l-methionine, {sup 67}Ga-citrate, and {sup 125}I-HSA

    Energy Technology Data Exchange (ETDEWEB)

    Sugawara, Y.; Gutowski, T.D.; Fisher, S.J.; Brown, R.S. [Michigan Univ., Ann Arbor (United States). Medical Center; Wahl, R.L. [Michigan Univ., Ann Arbor (United States). Medical Center]|[Department of Radiology, University of Michigan Medical Center, Ann Arbor (United States)

    1999-04-29

    The purpose of this study was to evaluate the localization of positron emission tomography (PET) tracers [2-deoxy-2-fluoro-d-glucose (FDG), thymidine, and l-methionine] in sites of bacterial infection, and to contrast this with that of other tracers. The left calf muscles of rats were infected with a suspension of Escherichia coli and the biodistribution of {sup 18}F- or {sup 3}H-FDG, {sup 3}H-thymidine, l-{sup 11}C- or {sup 3}H-methionine, gallium-67 citrate ({sup 67}Ga-citrate) and iodine-125 human serum albumin ({sup 125}I-HSA) was determined in these animals. {sup 3}H-FDG uptake in the infectious foci was evaluated by autoradiography of histological sections. Although {sup 18}F-FDG, {sup 67}Ga-citrate, and {sup 125}I-HSA showed comparatively high uptake in the infected muscle [the percentage activity of injected dose (ID) per gram of tissue normalized for rat weight in kilogram (%ID/g) x kg at 2 h postinjection was as follows: {sup 18}F-FDG, 0.184{+-}0.026 to 0.218{+-}0.046; {sup 67}Ga-citrate, 0.221{+-}0.016; {sup 125}I-HSA, 0.198{+-}0.019], the infected muscle to blood ratio was much higher for {sup 18}F-FDG than for {sup 67}Ga-citrate or {sup 125}I-HSA ({sup 18}F-FDG, 10.31{+-}0.76 to 14.89{+-}2.26; {sup 67}Ga-citrate, 1.24{+-}0.67; {sup 125}I-HSA, 0.20{+-}0.02). The draining reactive lymph nodes also showed higher accumulation of {sup 18}F-FDG than of {sup 67}Ga-citrate or {sup 125}I-HSA. The uptake of {sup 3}H-thymidine and l-{sup 11}C- or {sup 3}H-methionine in the infected muscle was lower than that of {sup 18}F- or {sup 3}H-FDG at 2 h postinjection, {sup 3}H-thymidine = 0.039{+-}0.005 and L-{sup 3}H-methionine = 0.063{+-}0.007 (%ID/g) x kg. Autoradiographs showed that the highest {sup 3}H-FDG uptake was seen in the area of inflammatory cell infiltration surrounding the necrotic region. In conclusion, {sup 18}F-FDG, which rapidly accumulates in sites of bacterial infection and in reactive lymph nodes with a high target to background ratio, appears to be

  18. A comparison of the biological effects of 125I seeds continuous low-dose-rate radiation and 60Co high-dose-rate gamma radiation on non-small cell lung cancer cells.

    Directory of Open Access Journals (Sweden)

    Zhongmin Wang

    Full Text Available To compare the biological effects of 125I seeds continuous low-dose-rate (CLDR radiation and 60Co γ-ray high-dose-rate (HDR radiation on non-small cell lung cancer (NSCLC cells.A549, H1299 and BEAS-2B cells were exposed to 125I seeds CLDR radiation or 60Co γ-ray HDR radiation. The survival fraction was determined using a colony-forming assay. The cell cycle progression and apoptosis were detected by flow cytometry (FCM. The expression of the apoptosis-related proteins caspase-3, cleaved-caspase-3, PARP, cleaved-PARP, BAX and Bcl-2 were detected by western blot assay.After irradiation with 125I seeds CLDR radiation, there was a lower survival fraction, more pronounced cell cycle arrest (G1 arrest and G2/M arrest in A549 and H1299 cells, respectively and a higher apoptotic ratio for A549 and H1299 cells than after 60Co γ-ray HDR radiation. Moreover, western blot assays revealed that 125I seeds CLDR radiation remarkably up-regulated the expression of Bax, cleaved-caspase-3 and cleaved-PARP proteins and down-regulated the expression of Bcl-2 proteins in A549 and H1299 cells compared with 60Co γ-ray HDR radiation. However, there was little change in the apoptotic ratio and expression of apoptosis-related proteins in normal BEAS-2B cells receiving the same treatment.125I seeds CLDR radiation led to remarkable growth inhibition of A549 and H1299 cells compared with 60Co HDR γ-ray radiation; A549 cells were the most sensitive to radiation, followed by H1299 cells. In contrast, normal BEAS-2B cells were relatively radio-resistant. The imbalance of the Bcl-2/Bax ratio and the activation of caspase-3 and PARP proteins might play a key role in the anti-proliferative effects induced by 125I seeds CLDR radiation, although other possibilities have not been excluded and will be investigated in future studies.

  19. Investigation of the effects of long-term infusion of 125I-iododeoxyuridine on tumor growth in mice (solid mouse tumor sarcoma-180)

    International Nuclear Information System (INIS)

    The present experiments were designed to test the therapeutic qualification of 125I incorporated in DNA of tumor cells. The tumor-host system used was the solid mouse tumor sarcoma-180 growing on female albino mice (NMRI). A device was built which makes it possible to intravenously infuse tumor bearing mice with solutions of 125IUdR for several weeks. Three or, respectively, 5 days before the onset of the infusions the mice were inocculated into the right hind leg with 3x105 tumor cells in 0.1 ml physiological salt solution. The total activity administered per mouse was 100 μCi infused during a period of 10 days. After termination of the infusions tumor sizes and retained radioactivities were measured every 5 days until death of the animals occured. In comparison with tumors of control animals tumors of mice infused with 125IUdR showed a mean retardation in growth of about 27% of the volumes of control tumors during the total period of post-infusion observation (25 days). Extension of life expectancy and an increase of the rate of final tumor regression did not occur. Likewise, no significant differences were observed between tumors which were 3 or 5 days old on the first day of infusion. After termination of the infusions the residual whole-body radioactivity per mouse was about 1% of the total activity infused per animal. This was in good agreement with calculations considering rates of incorporation and excretion and confirmed earlier assumptions that only about 5% of the administered IUdR is incorporated initially. The number further confirmed that, during the first 10 days after incorporation, the daily loss of activity - due to cell death - is about 30%. Control animals without tumors showed a faster decrease of incorporated activity or, respectively, loss of cells than tumor bearing mice. This difference could in part be explained by an exhaution of the short-lived cell populations of the reticulo-endothelial system of tumor bearing animals. (orig./MG)

  20. 永久性心脏起搏器植入术后患者发生深静脉血栓的影响因素分析%Influencing factors on deep venous thrombosis in patients with permanent pacemaker implantation after operation

    Institute of Scientific and Technical Information of China (English)

    段霞; 龚美芳

    2013-01-01

    目的:探讨永久性心脏起搏器植入术后患者发生深静脉血栓( DVT)的预测因素及预防性护理措施。方法采用回顾性调查法,查阅2009年1月至2011年12月住院行永久性起搏器植入术的425例患者的住院病历,共发生DVT 32例,对永久性心脏起搏器术后发生DVT的影响因素进行单因素分析与多因素Logistic回归分析。结果单因素方差分析结果表明,年龄、BMI指数、吸烟史、术后制动时间、DVT病史、糖尿病、高血压病、冠心病、房颤、房扑病史为心脏起搏器术后发生 DVT的影响因素(χ2值分别为8.43,5.30,11.86,5.09,17.66,22.36,4.69,12.78,32.52;P<0.05)。多因素Logistic回归分析结果表明,年龄(OR=3.463)、肥胖(OR=3.584)、吸烟史(OR=2.785)、术后制动时间(OR=4.844)、DVT病史(OR=7.605)、各种基础疾病( OR=4.052)为永久心脏起搏器植入术后发生DVT 的影响因素( P均<0.05)。结论应针对预测影响因素,及时采取护理措施,预防和减少永久性心脏起搏器植入术后DVT的发生。%Objective To explore the predictive factors and preventive nursing measures on deep venous thrombosis ( DVT) in patients with permanent pacemaker implantation after operation .Methods Four hundreds and twenty-five patients with permanent pacemaker implantation from January 2009 to December 2011 were retrospectively investigated , of which 32 patients suffered from DVT .The influencing factors on DVT in patients with permanent pacemaker implantation after operation were tested by the One -Way ANOVA analysis and multivariate logistic regression analysis .Results One-way ANOVA analysis showed that the age , BMI index, history of smoking, braking time after operation, history of DVT, diabetes, hypertension, coronary heart disease, atrial fibrillation, atrial flutter were all the risk factors on DVT in

  1. Expansão rápida da maxila ancorada em implantes: uma nova proposta para expansão ortopédica na dentadura permanente Rapid maxillary expansion anchored by implants: a new proposal to orthopedic expansion in the permanent dentition

    OpenAIRE

    Daniela Gamba Garib; Ricardo de Lima Navarro; Carlos Eduardo Francischone; Paula Vanessa Pedron Oltramari

    2007-01-01

    OBJETIVO: este trabalho apresenta um método para expansão ortopédica da maxila, na dentadura permanente, utilizando implantes como ancoragem. METODOLOGIA: detalharam-se os procedimentos cirúrgicos e laboratoriais da confecção de um expansor com ancoragem dento-óssea em crânio seco humano. Dois implantes de titânio foram colocados na região anterior do palato, e o parafuso Hyrax adaptado de modo que a expansão ancorou-se nos implantes e nos primeiros molares permanentes. RESULTADOS: o experime...

  2. Serving Deaf Students Who Have Cochlear Implants. PEPNet Tipsheet

    Science.gov (United States)

    Searls, J. Matt, Comp.

    2010-01-01

    Cochlear implants (CIs) are complex electronic devices surgically implanted under the skin behind the ear. These devices utilize electrodes placed in the inner ear (the cochlea) to stimulate the auditory nerve of individuals with significant permanent hearing loss. Cochlear implants may not be suitable for everyone. They are designed to provide…

  3. 1251 seed calibration using afterloading equipment Seed Selectron. Practical solution to meet the recommendations of the AAPM; Calibracion de semillas de {sup 1}25I usando el equipo de carga difereida SeedSelectron. Solucion practica para cumplir las recomendaciones de la AAPM

    Energy Technology Data Exchange (ETDEWEB)

    Perez-Calatayud, J.; Richart, J.; Perez-Garcia, J.; Guirado, D.; Ballester, F.; Rodriguez, S.; Santos, M.; Depiaggio, M.; Carmona, V.; Lliso, F.; Camacho, C.; Pujades, M. C.

    2011-07-01

    Seed Selectron is a system used in the after loader permanent implant brachytherapy seeds 1-125 interstitial prostate. Two aspects are critical when you can meet the recommendations of the AAPM: a practical difficulty to check the quantity of seed required, and the great uncertainty of all measured diodes. The purpose of this paper is to present a practical solution that has been adopted to implement the recommendations of the AAPM.

  4. {sup 125}I-iomazenil binding shows stress- and/or diazepam-induced reductions in mouse brain. Supporting data for {sup 123}I-iomazenil SPECT study of anxiety disorders

    Energy Technology Data Exchange (ETDEWEB)

    Takahashi, Makoto; Odano, Ikuo [Niigata Univ. (Japan). School of Medicine; Fujita, Shozo; Ohkubo, Masaki

    1997-08-01

    Effects of repeated swim stress on the binding of {sup 125}I-iomazenil were examined in the brains of diazepam-treated and non-treated mice. The mice were orally administered diazepam or vehicle (0.5% ethylene glycol) and subjected to daily swim stress (at 20degC for 10 min) for seven consecutive days. The distribution and the amount of {sup 125}I-iomazenil binding were analyzed autoradiographically after in vivo and in vitro binding experiments. Repeated swim stress decreased the in vivo binding in the hippocampus (p<0.05) and cerebral cortex (p<0.05) of vehicle-treated mice but caused no significant changes in diazepam-treated mice. Subchronic treatment with diazepam decreased the in vivo binding approximately 50% in all brain regions examined (p<0.01). The in vitro experiment, however, revealed no significant changes except in the hippocampus, where a small but significant decrease in the binding was observed after subchronic treatment with diazepam (p<0.01). The stress- or diazepam-induced reductions seem to represent alterations in the in vivo environment related to {sup 125}I-iomazenil binding. These results suggest that we can investigate the pathophysiology of stress and anxiety with {sup 123}I-iomazenil SPECT. Care must be taken concerning the effects of benzodiazepines. (author)

  5. 125I标记雄激素受体TFO抗前列腺癌细胞增殖的研究%The effect of 125I labeled anti-androgen receptor agent on the proliferation of prostate cancer cells

    Institute of Scientific and Technical Information of China (English)

    张勇; 陈维真; 梁昌盛; 刘长征

    2007-01-01

    目的 探讨反基因放射治疗对雄激素受体(AR)表达和前列腺癌细胞增殖的影响.方法 用Iodogen法对AR三螺旋形成寡核苷酸(TFO)进行直接125I标记,经脂质体介导转染LNCaP前列腺癌细胞株,于转染后24和48 h分别采用四甲基偶氮唑蓝(MTT)方法测定癌细胞增殖活性,RT-PCR方法检测AR mRNA表达,免疫组织化学方法检测AR蛋白表达.结果 125I-TFO的标记率为63.7%,放化纯为95.6%,比活度为80.1jBq/μg.相同TFO浓度下,125I-TFO组LNCaP细胞的AR表达水平显著低于TFO组(P<0.01),125I-TFO对LNCaP细胞增殖的抑制率显著高于TFO(P<0.01).结论 反基因放射治疗对AR表达和前列腺癌细胞增殖的抑制作用明显强于单纯的反基因治疗.

  6. Evaluation of the Coat-A-Count sup 125 I fentanyl RIA: Comparison of sup 12 5I RIA and GC/MS-SIM for quantification of fentanyl in case urine specimens

    Energy Technology Data Exchange (ETDEWEB)

    Watts, V.W.; Caplan, Y.H. (Mesa Police Crime Laboratory, AZ (USA))

    1990-09-01

    The Coat-A-Count solid phase {sup 125}I Fentanyl Radioimmunoassay was evaluated with respect to linearity and precision using equine urine fortified with fentanyl and then compared with a gas chromatographic/mass spectrometric method for quantification of fentanyl in urine. The RIA assay was found to be linear over the urine fentanyl concentration range of 0.25 to 7.5 ng/mL and precise with coefficients of variation (CV) ranging from 9.6 to 19.3%. The RIA calibrators, ranging in fentanyl concentrations from 0.25 to 7.5 ng/mL, and controls, at mean fentanyl concentrations of 0.46 and 1.32 ng/mL, were compared by both the RIA and GC/MS methods. The cross-reactivity with the {sup 125}I RIA test was determined for the fentanyl metabolites, norfentanyl and hydroxyfentanyl, and found to be 5% and 35%, respectively. The illicit fentanyl analogs were found to show significant cross-reactivity, ranging from 20 to 100%. The {sup 125}I RIA was compared to GC/MS quantifications of fentanyl in 35 positive and 20 negative case urine specimens.

  7. Treatment of portal vein tumor thrombus using ~(125)Iodine seed implantation brachytherapy

    Institute of Scientific and Technical Information of China (English)

    2010-01-01

    We reported two cases of liver metastasis with portal vein tumor thrombus that developed after liver transplantation for hepato cellular carcinoma (HCC). Both the patients were women aged 43 and 55 years, who had liver metastasis and portal vein tumor thrombus formation after liver transplantations for HCC. For the treatment of portal vein tumor thrombus, 125I seeds were implanted into the hepatic tissue under the guidance of preoperative computed tomography (CT) images with a total radiation dose of 130 Gy...

  8. 125I标记三链形成寡核苷酸对肝癌细胞生长的抑制作用%Inhibition effects of 125I-triplex forming oligonucleotide to hepatoma cells

    Institute of Scientific and Technical Information of China (English)

    吕中伟; 侯敏; 何俊民; 蔡海东; 袁雪宇; 杨越华; 袁世栋

    2007-01-01

    目的 探讨125I标记的三链形成寡核苷酸(TFO)对肝癌细胞的抑制作用,为HBV相关肝细胞癌(HCC)的基因治疗提供实验依据.方法 合成能与HBV前S基因特异结合的TFO,并以125I标记(125I-TFO);分125I-TFO、等量TFO、相同活度125I和空白对照4组与HepG2.2.15细胞共同培养,通过ELISA法检测培养前后各组细胞上清中乙型肝炎e抗原(HBeAg)和乙型肝炎表面抗原(HBsAg)含量的变化,以四甲基偶氮唑蓝(MTT)比色法检测各组细胞存活率.结果 125I-TFO标记率>93%,稳定性较好,37℃放置12 h放化纯90.8%,48 h 81.1%,72 h 73.2%;125I-TFO组在转染48 h对HepG2.2.15细胞合成HBeAg及HBsAg的抑制作用最强,对HBeAg和HBsAg表达的抑制率(74.5%和45.2%)及细胞杀伤率[72 h田胞增殖抑制率为(31.6±2.5)%]高于其他实验组(P<0.01).结论 125I-TFO可以抑制HBV抗原表达,杀伤肝癌细胞,为制备抗HBV、抗HCC的放射性基因治疗药物提供依据.

  9. Permanences GAG-EPA

    CERN Multimedia

    GAC-EPA

    2015-01-01

    Le GAC organise chaque mois des permanences avec entretiens individuels. La prochaine permanence se tiendra le : Mardi 5 mai de 13 h 30 à 16 h 00 Salle de réunion de l’Association du personnel Les permanences suivantes auront lieu les mardis 2 juin, 1er septembre, 6 octobre, 3 novembre et 1er décembre 2015. Les permanences du Groupement des Anciens sont ouvertes aux bénéficiaires de la Caisse de pensions (y compris les conjoints survivants) et à tous ceux qui approchent de la retraite. Nous invitons vivement ces derniers à s’associer à notre groupement en se procurant, auprès de l’Association du personnel, les documents nécessaires.

  10. Permanent neonatal diabetes mellitus

    OpenAIRE

    Al-Matary, Abdulrahman; Hussain, Mushtaq; Nahari, Ahmed; Ali, Jaffar

    2012-01-01

    Summary Background: Neonatal diabetes is a rare cause of hyperglycemia, affecting 1: 500,000 births, with persistent hyperglycemia occurring in the first months of life lasting more than 2 weeks and requiring insulin. This condition in infants less than 6 months of age is considered as permanent neonatal diabetes mellitus. Case Report: A rare case of permanent neonatal diabetes mellitus presented with intrauterine growth retardation (IUGR; birth weight: 1460 grams; female), hyperglycemia, gly...

  11. Carmustine Implant

    Science.gov (United States)

    Carmustine implant is used along with surgery and sometimes radiation therapy to treat malignant glioma (a certain type of ... Carmustine implant comes as a small wafer that is placed in the brain by a doctor during surgery to ...

  12. Goserelin Implant

    Science.gov (United States)

    Goserelin implant is used in combination with radiation therapy and other medications to treat localized prostate cancer and is ... treatment of abnormal bleeding of the uterus. Goserelin implant is in a class of medications called gonadotropin- ...

  13. 移动电话对埋藏式永久起搏器干扰的临床研究%Interference of cellular phones on implanted permanent pacemaker

    Institute of Scientific and Technical Information of China (English)

    刘芳; 吕宝经; 陆尚彪; 徐惠芬; 舒红; 方祖祥

    2001-01-01

    目的:研究移动电话对埋藏式永久起搏器的干扰情况。方法:用自身对照法,将国内常用的2种移动电话分别放在3种不同位置及处于不同工作状态下,检测其对埋藏式起搏器的干扰情况。结果:对110例患者共进行1 857次测试,仅1例(0.9%)Biotronic Ergos-01 VVI型起搏器依赖型患者22次(1.2%)出现干扰。干扰只发生在移动电话处于起搏器上,且多出现于铃响阶段。数字机干扰大于模拟机。当移动电话处在正常耳旁位置时未见干扰。结论:目前的埋藏式心脏起搏器对移动电话具有一定的抗干扰能力;起搏器患者在通常耳旁位置使用移动电话是安全的;起搏器依赖型患者最好选用模拟式移动电话。%Objective:To investigate the interference of cellular phones on implanted permannet pacemaker.Mothod:By self-contrasted method,110 patients with implanted pacemakers were interfered by two types of cellular phones in vivo. Each phone was placed at three different position and was in different state of work.Result:Among 1 857 interference tests, which were determined in 110 patients, 22 (1.2%) episodes were demonstrated in only one pacemaker-dependent patient with Biotronic Ergos-01 VVI type. All interference occurred only when the cellular phone was positioned above the pacemaker pocket.The most interference was observed during and before the ringing. Both the digital and analog cellular phone can lead to interference, but the former predominated the latter. No interference was seen when the cellular phone was placed on the ear. Conclusion:It is suggested that the new-generated implanted pacemaker could protect interference from cellular phone, but few patient may be interfered. When they use the cellular phone on one ear in the normal position, patients would be considerably safe.It is better for pacemaker-dependent patients to select the analog cellular phone.

  14. Radiation exposure to operating room staff during prostate brachytherapy using iodine-125 seeds; Exposition radiologique de l'equipe operatoire au cours de curietherapies de prostate par implants permanents d'iode-125

    Energy Technology Data Exchange (ETDEWEB)

    Gagna, G.; Amabile, J.C.; Laroche, P. [Service de protection radiologique des armees (SPRA), 1 bis rue du Lieutenant Raoul Batany, 92141 Clamart Cedex (France); Gauron, C. [Institut national de recherche et de securite (INRS), Departement Etudes et Assistance Medicales, 30 rue Olivier Noyer, 75680 Paris Cedex 14 (France)

    2011-04-15

    The French defense radiation protection service (SPRA) and the French national institute for research and safety (INRS) conducted a joint study to assess the radiation exposure to operating room staff during prostate brachytherapy using iodine-125 seeds at the Val-de-Grace military hospital. The purpose of the study was the assessment of the effective doses, the equivalent doses to the extremities and lens received by a novice team, the different ambient dose equivalent rates measurements and the delineation of areas. After six brachy-therapies, all the recorded doses with whole-body InLight{sup R} OSL and nanoDot{sup R} dosimeters remained below the detection limit for the whole staff. The dose rate measured at the end of implantation by an AT1123{sup R} survey meter is about 170 {mu}Sv/h at the perineum of the patient. The controlled area limit is estimated to be about 20 cm from the patient perineum. From these results, the authors propose recommendations for the categorization of workers, the delineation of areas and the dose monitoring procedures. This study demonstrates that real-time ultrasound-guided trans-perineal prostate brachytherapy delivers low dose to the operators because of the radioactive source characteristics and the instrumentation providing an effective radiation protection for the surgical team. (authors)

  15. The Labeling of [Tyr3]-Octreotide with 125 I and Its Biodistribution and Pharmacokinetic%125I标记的[Tyr3]-Octreotide在小鼠体内的分布及其药代动力学研究

    Institute of Scientific and Technical Information of China (English)

    朱然; 范我; 许玉杰; 张友九; 胡明江; 朱本兴

    2006-01-01

    目的探讨125I Ch-T法标记生长抑素类似物奥曲肽的方法,观察其在小鼠体内的生物学分布.方法用Ch-T法进行[Tyr3]-octreotide的125I标记,标记完成后加入NH4HAc以防止标记物的再氧化.Sephadex G-10分离纯化,纸层析测定放化纯,并行小鼠体内分布和药代实验.结果 125I-[Tyr3]-octreotide比活度为5.92 TBq/mmol,标记率为76%,放化纯为95%.注射后1.0 h血液中放射性下降了90%,肠道、肝脏和肾脏中均有浓集,标记物24 h内排出体外.结论 125I的Ch-T法标记[Tyr3]-octreotide放化纯高,方法简便,标记物的稳定性尚可.125I-[Tyr3]-octreotide在小鼠体内血液清除快,药代动力学符合二室开放模型,T(1)/(2)α为5.28 min,T(1)/(2)β为141.3 min,经肠-肝途径和泌尿系统排除.

  16. Studies of the biogenic amine transporters. VII. Characterization of a novel cocaine binding site identified with [125I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate.

    Science.gov (United States)

    Rothman, R B; Silverthorn, M L; Glowa, J R; Matecka, D; Rice, K C; Carroll, F I; Partilla, J S; Uhl, G R; Vandenbergh, D J; Dersch, C M

    1998-04-01

    [125I]RTI-55 is a cocaine analog with high affinity for dopamine (DA) and serotonin (5-HT) transporters. Quantitative ligand binding studies revealed a novel high affinity [125I]RTI-55 binding site assayed under 5-HT transporter (SERT) conditions which has low affinity for almost all classic biogenic amine transporter ligands, including high affinity 5-HT transporter inhibitors such as paroxetine, but which retains high affinity for cocaine analogs. This site, termed SERT(site2) for its detection under 5-HT transporter conditions (not for an association with the SERT) occurs in monkey caudate, human caudate, and guinea pig caudate membranes, but not in rat caudate membranes. SERT(site2) is distinguished from the DA transporter (DAT) and SERT by several criteria, including a distinct ligand-selectivity profile, the inability to detect SERT(site2) in cells stably expressing the cloned human DAT, and insensitivity to irreversible ligands which inhibit [125I]RTI-55 binding to the DAT and SERT. Perhaps the most striking finding about SERT(site2) is that a wide range of representative antidepressant agents have very low affinity for SERT(site2). The affinity of cocaine for this site is not very different from the concentration cocaine achieves in the brain at pharmacological doses. Viewed collectively with the observation that ligands with high affinity for SERT(site2) are mostly cocaine analogs, these data lead us to speculate that actions of cocaine which differ from those of classic biogenic amine uptake inhibitors may be mediated in part via SERT(site2).

  17. Differential cytotoxicity of [123I]IUdR, [125I]IUdR and [131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire.

    OpenAIRE

    Neshasteh-Riz, A.; Mairs, R. J.; Angerson, W J; Stanton, P D; Reeves, J. R.; Rampling, R.; Owens, J.; Wheldon, T E

    1998-01-01

    Radioiodinated iododeoxyuridine (IUdR) is a novel, cycle-specific agent that has potential for the treatment of residual malignant glioma after surgery. As only cells in S-phase incorporate IUdR into DNA, a major limitation to this therapy is likely to be proliferative heterogeneity of the tumour cell population. Using a clonogenic end point, we have compared the toxicities of three radioiodoanalogues of IUdR--[123I]IUdR, [125I]IUdR and [131I]IUdR--to the human glioma cell line UVW, cultured ...

  18. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer

    OpenAIRE

    Christensen, T. B.; Engbaek, F; Marqversen, J; Nielsen, S I; Kamby, C.; Maase, H von der

    1999-01-01

    The rate of reduction in the concentration of serum human chorionic gonadotrophin (hCG) following chemotherapy for germ cell tumours may follow a complex pattern, with longer apparent half-life during later stages of chemotherapy, even in patients treated successfully. The commonly used half-life of less than 3 days for hCG to monitor the effect of chemotherapy in patients with germ cell tumours of the testis may represent too simple a model. 125I-labelled hCG was injected intravenously in 27...

  19. Co-localization of 125I-epidermal growth factor and ferritin-low density lipoprotein in coated pits: a quantitative electron microscopic study in normal and mutant human fibroblasts

    OpenAIRE

    1982-01-01

    Low density lipoprotein (LDL) and epidermal growth factor (EGF) bind to receptors on the surface of human fibroblasts and are internalized in coated vesicles. Each of the ligands has been studied separately by electron microscopy in human fibroblasts using ferritin-LDL as one visual probe and 125I-EGF as a second visual probe. A mutant strain of human fibroblasts (J.D.) has been described in which LDL does not localize to coated pits and hence is not internalized. Because LDL and EGF do not c...

  20. Reuse of Occluded Veins During Permanent Pacemaker Lead Extraction: A New Indication for Femoral Lead Extraction

    OpenAIRE

    Staniforth, Andrew D; Schilling, Richard J

    2002-01-01

    Objectives: This study examined the utility of a novel technique for reuse of thrombosed veins when extracting permanent pacemaker leads via a femoral vein approach. Background: Although lead extraction permanent pacemaker using a femoral approach has advantages over the subclavian approach, it cannot be used to provide access for a new lead using currently employed techniques. This is important because up to 23% of patients have occluded veins after permanent pacemaker implantation. M...

  1. Alkaline "Permanent" Paper.

    Science.gov (United States)

    Pacey, Antony

    1991-01-01

    Discussion of paper manufacturing processes and their effects on library materials focuses on the promotion of alkaline "permanent" paper, with less acid, by Canadian library preservation specialists. Standards for paper acidity are explained; advantages of alkaline paper are described, including decreased manufacturing costs; and recyclability is…

  2. CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC).

    Science.gov (United States)

    Martínez-Monge, Rafael; Pagola, María; Vivas, Isabel; López-Picazo, José María

    2008-08-01

    Seven patients with early stage T1N0M0 NSCLC who had medical contraindications for surgical resection were treated with CT-guided percutaneous implantation of (103)Pd or (125)I seeds. After the procedure, two patients developed pneumothorax and hemo/pneumothorax that was managed with aspirative drainage. One patient developed a focal pneumonitis 3 months after the procedure. After a median follow-up of 13 months (4.6-41.0+ months), no patient has developed local or regional failure. PMID:18243409

  3. A Experimental Study on the Treatment of Hepatoma by the Implanted 125I Radion%125I放射粒子治疗兔肝VX2肿瘤的实验研究

    Institute of Scientific and Technical Information of China (English)

    娄明武; 范义; 梁冰; 胡卫东

    2009-01-01

    目的 探讨组织间插植125I放射粒子对兔肝VX2肿瘤的治疗作用.方法 选健康成年新西兰白兔30只随机分为2组,分别为对照组和治疗组(每组各15只).所有动物采用CT引导下经皮穿刺法制作兔肝VX2肿瘤模型.于模型制作后14 d,治疗组在肿瘤近中心位置植入125I放射粒子,对照组不予处理.各组动物分别于动物模型制作后14 d、21 d、28 d进行MR扫描观察肿瘤生长情况,并检验肝功能.结果 与对照组相比,治疗组动物肿瘤生长有所延缓,动物模型制作后14 d肿瘤体积无明显变化(P>0.05),21 d、28 d体积缩小(P<0.05)且平均存活期延长(P<0.05).结论 组织间植入125I放射粒子可抑制肝肿瘤生长、延长动物生存期.

  4. Safety of 125iodine and 192iridium implants to the canine carotid artery: preliminary report

    International Nuclear Information System (INIS)

    Thirty-nine healthy dogs underwent a simulated radical neck dissection followed by implantation of either 125Iodine or 192Iridium in various dose regimes randomized prospectively from 3,000 to 30,000 rad. Bilateral selective carotid angiography was performed immediately postoperatively and at six months and one year. No significant effects occurred to the animals who received 15,000 rad 125I or 6,000 rad 192Ir. In the higher dosed animals the 125I treated group fared better than the 192Ir treated group, probably due to the lower dose rate delivery. All surviving animals will be maintained an additional year to determine the late effects of brachytherapy irradiation to the carotid artery

  5. Magnesium as Biodegradable Implant Material

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    Drawbacks associated with permanent metallic implants lead to the search for degradable metallic biomaterials. Magnesium alloys have been highly considered as Mg has a high biocorrosion potential and is essential to bodies. In this study, corrosion behaviour of pure magnesium and magnesium alloy AZ31 in both static and dynamic physiological conditions (Hank's solution) has been investigated. It is found that the materials degrade fast at beginning, then stabilize after 5 days of immersion. High purity in th...

  6. Variable Permanent Magnet Quadrupole

    Energy Technology Data Exchange (ETDEWEB)

    Mihara, T.; Iwashita, Y.; /Kyoto U.; Kumada, M.; /NIRS, Chiba; Spencer, C.M.; /SLAC

    2007-05-23

    A permanent magnet quadrupole (PMQ) is one of the candidates for the final focus lens in a linear collider. An over 120 T/m strong variable permanent magnet quadrupole is achieved by the introduction of saturated iron and a 'double ring structure'. A fabricated PMQ achieved 24 T integrated gradient with 20 mm bore diameter, 100 mm magnet diameter and 20 cm pole length. The strength of the PMQ is adjustable in 1.4 T steps, due to its 'double ring structure': the PMQ is split into two nested rings; the outer ring is sliced along the beam line into four parts and is rotated to change the strength. This paper describes the variable PMQ from fabrication to recent adjustments.

  7. Percutaneous implantation of (125)iodine seeds for treatment of portal vein tumor thrombosis in hepatocellular carcinoma.

    Science.gov (United States)

    Liu, Yan; Liu, Ruibao; Wang, Ping; Li, Shijie; Shen, Haiyang

    2015-08-01

    The aim of the study is to evaluate the practicability and therapeutic efficacy of (125)iodine seeds implantation percutaneously for portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC). Nineteen patients with HCC accompanied with PVTT received ultrasound-guided implantation of 8-30 (125)iodine seeds, 8 mm apart within the portal vein tumor thrombi. The patients were followed up postoperatively for a period of 3-22 months. The successful rates of the procedure, postoperative changes of liver and renal function, hemogram, complications and therapeutic response were monitored. (125)I seeds were successfully implanted in the portal veins in all patients without serious complications. During the follow-up period, the portal vein tumor thrombi all shrunk obviously. Percutaneous implantation of (125)iodine seeds into the portal vein is an effective and safe treatment for PVTT accompanying HCC.

  8. Lawful Permanent Residents - Annual Report

    Data.gov (United States)

    Department of Homeland Security — A lawful permanent resident (LPR) or 'green card' recipient is defined by immigration law as a person who has been granted lawful permanent residence in the United...

  9. High affinity dopamine D2 receptor radioligands. 2. ( sup 125 I)epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors

    Energy Technology Data Exchange (ETDEWEB)

    Kessler, R.M.; Ansari, M.S.; Schmidt, D.E.; de Paulis, T.; Clanton, J.A.; Manning, R.G.; Gillespie, D. (Vanderbilt Univ., Nashville, TN (United States)); Innis, R.; Al-Tikriti, M. (Yale Univ., New Haven, CT (United States))

    1991-01-01

    Epidepride, (S)-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-iodo-2,3-dimethoxybenzamide, the iodine analogue of isoremoxipride (FLB 457), was found to be a very potent dopamine D2 receptor antagonist. Optimal in vitro binding required incubation at 25C for 4 h at pH 7.4 in a buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl{sub 2} and 1 nM MgCl{sub 2}. Scatchard analysis of in vitro binding to striatal, medical frontal cortical, hippocampal and cerebellar membranes revealed a K{sub D} of 24 pM in all regions, with Bmax's of 36.7, 1.04, 0.85, and 0.37 pmol/g tissue, respectively. The Hill coefficients ranged from 0.91-1.00 in all four regions. The IC{sub 50}'s for inhibition of ({sup 125}I)epidepride binding to striatal, medial frontal cortical, and hippocampal membranes for SCH 23390, SKF 83566, serotonin, ketanserin, mianserin, naloxone, QNB, prasozin, clonidine, alprenolol, and norepinephrine ranged from 1 {mu}M to >10 {mu}M. Partial displacement of ({sup 125}I)epidepride by nanomolar concentrations of clonidine was noted in the frontal cortex and hippocampus, but not in the striatum. Scatchard analysis of epidepride binding to {alpha}{sub 2} noradrenergic receptors in the frontal cortex and hippocampus revealed an apparent K{sub D} of 9 nM. At an epidepride concentration equal to the K{sub D} for the D2 receptor, i.e., 25 pM, no striatal {alpha}{sub 2} binding was seen and only 7% of the specific epidepride binding in the cortex or hippocampus was due to binding at the {alpha}{sub 2} site. Correlation of inhibition of ({sup 3}H)spiperone and ({sup 125}I)epidepride binding to striatal membranes by a variety of D2 ligands revealed a correlation coefficient of 0.99, indicating that epidepride labels a D2 site.

  10. Computed tomographic-guided iodine-125 interstitial implants for malignant thoracic tumors

    Energy Technology Data Exchange (ETDEWEB)

    Huang, Qiming [The Department of Radiology, First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou 350005 (China); The Department of Radiology, Second Affiliated Hospital of Fujian Medical University, 34 Zhongshan Bei Road, Quanzhou 362000 (China); Chen, Jin; Chen, Qunlin [The Department of Radiology, First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou 350005 (China); Lai, Qingquan; Cai, Siqing [The Department of Radiology, Second Affiliated Hospital of Fujian Medical University, 34 Zhongshan Bei Road, Quanzhou 362000 (China); Luo, Kaidong [The Department of Radiology, Longyan Hosptial of Traditional Chinese Medical, 59 Longteng Middle Road, Longyan 364000 (China); Lin, Zhengyu, E-mail: linsinlan@yahoo.com.cn [The Department of Radiology, First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou 350005 (China)

    2013-11-01

    Purpose: To evaluate the feasibility and efficacy of percutaneous interstitial brachytherapy using iodine-125 ({sup 125}I) radioactive seeds under computed tomographic (CT) guidance for malignant thoracic tumors. Materials and methods: Forty-one patients (34 males, 7 females; 18–90 years; mean, 63.7 years) with 77 lesions (3 in the mediastinum, 7 in the chest wall, 67 in the lung) underwent percutaneous interstitial implantation of {sup 125}I radioactive seeds under CT guidance. A treatment planning system (TPS) was employed to calculate the number and distribution of seeds preoperatively. An 18-G needle was inserted into the lesions under CT guidance and send the seeds according to TPS. Two patients with mediastinal lesions undergoing seed implantation received an artificial pneumothorax. One patient with lung carcinoma adjacent to the anterior mediastinum underwent seed implantation through the sternum. Follow-up CT was done every 2 months postoperatively. Results: The procedure was successful in all patients. No major procedure-associated death occurred. The mean duration of follow-up was 19.4 ± 1.3 months (3–49 months). A complete response (CR) was seen in 49 lesions (63.6%), partial response (PR) in 9 lesions (11.7%), stable disease (SD) in 12 lesions (12.8%), and progressive disease (PD) in 7 lesions (7.4%). The overall response rate (CR + PR) was 75.3%; the local control rate (CR + PR + SD) was 90.9%. The 1-, 2- and 3-year progression-free rates for local tumors were 91%, 88% and 88%, respectively. The 1-, 2- and 3-year survival rates were 87%, 74% and 68%, respectively. Conclusion: Implantation of CT-guided {sup 125}I seeds is feasible and effective for patients with malignant thoracic tumors.

  11. Pathophysiologic effects of stable iodine used as a thyroidal blocking agent to reduce thyroid radiation exposure. Progress report, November 1, 1975--October 31, 1976. [/sup 125/I tracer technique

    Energy Technology Data Exchange (ETDEWEB)

    Becker, D.V.; Hurley, J.R.

    1976-01-01

    In an effort to determine whether iodide administration in man can induce injury to thyroid follicular cells similar to that demonstrated in lower animals, this study measures thyroglobulin, thyroxine and triiodothyronine and thyroid autoantibodies in the serum before and after administration of iodine in a variety of patients. In the last eight months primary efforts have been devoted to the development of a high specificity and sensitivity radioimmunoassay of thyroglobulin and its preliminary clinical application. Human thyroglobulin obtained from operative specimens was purified and its identity and purity established. Rabbits were injected with thyroglobulin for 30 weeks with the appearance of significant titres of antibodies within 6 weeks. The antibody developed was examined for immunological purity and used in a radioimmunoassay system with thyroglobulin labeled in this Laboratory with /sup 125/I.

  12. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer

    DEFF Research Database (Denmark)

    Christensen, T B; Engbaek, F; Marqversen, J;

    1999-01-01

    days (3.6-6.8 days), whereas four out of five patients not achieving long-term remission had half-lives shorter than 3 days. After the third treatment cycle, eight patients who achieved long-term remission had hCG half-lives longer than 3 days (7.4-17.0 days). In these patients, the plasma...... disappearance of [125I]hCG was equivalent to that of hCG. Thus, the slow decline of hCG represented a slow plasma disappearance rather than a hCG production from vital tumour cells and could, consequently, not be used to select patients for additional or intensified chemotherapy. The concept of a fixed half...

  13. Liquids with permanent porosity

    Science.gov (United States)

    Giri, Nicola; Del Pópolo, Mario G.; Melaugh, Gavin; Greenaway, Rebecca L.; Rätzke, Klaus; Koschine, Tönjes; Pison, Laure; Gomes, Margarida F. Costa; Cooper, Andrew I.; James, Stuart L.

    2015-11-01

    Porous solids such as zeolites and metal-organic frameworks are useful in molecular separation and in catalysis, but their solid nature can impose limitations. For example, liquid solvents, rather than porous solids, are the most mature technology for post-combustion capture of carbon dioxide because liquid circulation systems are more easily retrofitted to existing plants. Solid porous adsorbents offer major benefits, such as lower energy penalties in adsorption-desorption cycles, but they are difficult to implement in conventional flow processes. Materials that combine the properties of fluidity and permanent porosity could therefore offer technological advantages, but permanent porosity is not associated with conventional liquids. Here we report free-flowing liquids whose bulk properties are determined by their permanent porosity. To achieve this, we designed cage molecules that provide a well-defined pore space and that are highly soluble in solvents whose molecules are too large to enter the pores. The concentration of unoccupied cages can thus be around 500 times greater than in other molecular solutions that contain cavities, resulting in a marked change in bulk properties, such as an eightfold increase in the solubility of methane gas. Our results provide the basis for development of a new class of functional porous materials for chemical processes, and we present a one-step, multigram scale-up route for highly soluble ‘scrambled’ porous cages prepared from a mixture of commercially available reagents. The unifying design principle for these materials is the avoidance of functional groups that can penetrate into the molecular cage cavities.

  14. Diffusion of HTO, {sup 36}Cl{sup -}, {sup 125}I{sup -} and {sup 22}Na{sup +} in Opalinus Clay: Effect of Confining Pressure, Sample Orientation, Sample Depth and Temperature

    Energy Technology Data Exchange (ETDEWEB)

    Van Loon, L.R.; Soler, J.M

    2004-02-01

    Effective diffusion coefficients (D{sub e}), rock capacity factors ({alpha}) and diffusion-accessible porosities ({epsilon}) were measured using the through-diffusion technique. Transport (diffusion) was measured both perpendicular and parallel to the bedding. Special cells that allowed the application of an axial confining pressure were designed. The pressures applied ranged from 1 to 5 MPa for Mont Terri samples and between 4 and 15 MPa for Benken samples, the upper values representing the in-situ confining pressure at both locations. The test solutions used in the experiments were synthetic Opalinus Clay pore water, which has Na and Cl as main components (Mont Terri: I = 0.39 M; Benken: I = 0.20 M). Pressure only had a small effect on the value of the effective diffusion coefficients. In the case of Mont Terri samples, increasing the pressure from 1 to 5 MPa resulted in a decrease of the effective diffusion coefficient of 20% for HTO, 27% for {sup 36}Cl{sup -}, 29% for {sup 125}I{sup -} and 17 % for {sup 22}Na{sup +}. In the case of Benken samples, increasing the pressure from 4 to 15 MPa resulted in a decrease of D{sub e} of 17% for HTO, 22% for {sup 36}Cl{sup -}, 32% for {sup 125}I{sup -} and 17 % for {sup 22}Na{sup +}. Moreover, the effective diffusion coefficients for for {sup 36}Cl{sup -}are smaller than for HTO, which is consistent with an effect arising from anion exclusion. This ion exclusion effect is smaller in samples from Mont Terri than in samples from Benken, which can be explained by the higher ionic strength of the Mont Terri water used in the experiments. The diffusion of {sup 22}Na{sup +} is similar to that of HTO in the case of Mont Terri OPA. For Benken OPA, the D{sub e} value of {sup 22}Na{sup +} is a factor of 2 higher than that of HTO. This last observation cannot be explained so far but is comparable to experimental data from ANDRA (1999) on Callovo-Oxfordian claystones from the Meuse/Haute Same site. {sup 125}I{sup -} is retarded with

  15. Pulsars: Cosmic Permanent 'Neutromagnets'?

    CERN Document Server

    Hansson, Johan

    2011-01-01

    We argue that pulsars may be spin-polarized neutron stars, i.e. cosmic permanent magnets. This would simply explain several observational facts about pulsars, including the 'beacon effect' itself i.e. the static/stable misalignment of rotational and magnetic axes, the extreme temporal stability of the pulses and the existence of an upper limit for the magnetic field strength - coinciding with the one observed in "magnetars". Although our model admittedly is speculative, this latter fact seems to us unlikely to be pure coincidence.

  16. Diagnostic Imaging for Dental Implant Therapy

    Directory of Open Access Journals (Sweden)

    Aishwarya Nagarajan

    2014-01-01

    Full Text Available Dental implant is a device made of alloplastic (foreign material implanted into the jaw bone beneath the mucosal layer to support a fixed or removable dental prosthesis. Dental implants are gaining immense popularity and wide acceptance because they not only replace lost teeth but also provide permanent restorations that do not interfere with oral function or speech or compromise the self-esteem of a patient. Appropriate treatment planning for replacement of lost teeth is required and imaging plays a pivotal role to ensure a satisfactory outcome. The development of pre-surgical imaging techniques and surgical templates helps the dentist place the implants with relative ease. This article focuses on various types of imaging modalities that have a pivotal role in implant therapy.

  17. Diagnostic imaging for dental implant therapy.

    Science.gov (United States)

    Nagarajan, Aishwarya; Perumalsamy, Rajapriya; Thyagarajan, Ramakrishnan; Namasivayam, Ambalavanan

    2014-01-01

    Dental implant is a device made of alloplastic (foreign) material implanted into the jaw bone beneath the mucosal layer to support a fixed or removable dental prosthesis. Dental implants are gaining immense popularity and wide acceptance because they not only replace lost teeth but also provide permanent restorations that do not interfere with oral function or speech or compromise the self-esteem of a patient. Appropriate treatment planning for replacement of lost teeth is required and imaging plays a pivotal role to ensure a satisfactory outcome. The development of pre-surgical imaging techniques and surgical templates helps the dentist place the implants with relative ease. This article focuses on various types of imaging modalities that have a pivotal role in implant therapy. PMID:25379354

  18. Cochlear Implants

    Science.gov (United States)

    ... on this topic can be found in our Audiology Information Series [PDF]. How does a cochlear implant ... speech-language pathologists; speech, language, and hearing scientists; audiology and speech-language pathology support personnel; and students. ...

  19. Optimization of permanent breast seed implant dosimetry incorporating tissue heterogeneity

    Science.gov (United States)

    Mashouf, Shahram

    Seed brachytherapy is currently used for adjuvant radiotherapy of early stage prostate and breast cancer patients. The current standard for calculation of dose around brachytherapy sources is based on the AAPM TG43 formalism, which generates the dose in homogeneous water medium. Recently, AAPM task group no. 186 (TG186) emphasized the importance of accounting for heterogeneities. In this work we introduce an analytical dose calculation algorithm in heterogeneous media using CT images. The advantages over other methods are computational efficiency and the ease of integration into clinical use. An Inhomogeneity Correction Factor (ICF) is introduced as the ratio of absorbed dose in tissue to that in water medium. ICF is a function of tissue properties and independent of the source structure. The ICF is extracted usi